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GENERAL INTRODUCTION
This thesis comprises studies on two important health problems that people may experi-
ence in the aŌ ermath of the large Q-fever epidemic in the Netherlands: chronic Q-fever and 
persistent faƟ gue aŌ er a Coxiella burneƟ i (C. burneƟ i) infecƟ on. These studies are described 
from a public health perspecƟ ve.
It is well established that screening for IgG anƟ bodies against phase I of C. burneƟ i is the 
main strategy for early detecƟ on of chronic Q-fever. However, there are important unan-
swered quesƟ ons that are addressed in this thesis:
1. What serological follow-up did Q-fever paƟ ents in part of Noord Brabant receive?
2. What is the best screening regimen for Ɵ mely idenƟ ﬁ caƟ on of chronic Q-fever?
3. Is screening of the general populaƟ on for chronic Q-fever years aŌ er a Q-fever outbreak 
useful?
In contrast to chronic Q-fever, persisƟ ng faƟ gue aŌ er acute Q-fever, also referred to as the 
Q-fever FaƟ gue Syndrome (QFS), is not a life threatening condiƟ on. As post infecƟ ous faƟ gue 
aﬀ ects a large proporƟ on of Q-fever paƟ ents it is an important public health problem. The 
following quesƟ ons pertain to an impaired health status, especially faƟ gue aŌ er Q-fever are 
addressed in this thesis:
1. What is the occurrence at populaƟ on level?
2. What are the consequences for daily acƟ viƟ es and ability to work?
3. What is the current knowledge base with respect to the deﬁ niƟ on, diagnosis, aeƟ ology, 
prognosis and best treatment for QFS?
Seeking answers to these quesƟ ons, while working at the Municipal Health Service (MHS) 
Hart voor Brabant in the epicentre of this vast Q-fever outbreak, was the main inspiraƟ on 
to conduct these studies. Findings are considered relevant to paƟ ents, clinicians, medical 
microbiologists, the MHS and policy makers dealing with C. burneƟ i.
The outbreak
From December 2006 unƟ l spring 2007, ﬁ ve Q-fever cases were noƟ ﬁ ed by the MHS Hart 
voor Brabant. As no cases had been noƟ ﬁ ed by this MHS, in the previous 7 years, this was 
unusual. Clusters of paƟ ents with pneumonia, in May and June 2007, in two rural villages, 
Herpen and St. Oedenrode, were iniƟ ally aƩ ributed to respecƟ vely Mycoplasma pneumoniae 
(M. pneumoniae) and C. burneƟ i [1]. As the clinical presentaƟ on of cases from both villages 
was similar, samples from Herpen were weeks later also tested for C. burneƟ i anƟ bodies. 
Test results indicated that the outbreak in Herpen was not caused by M. pneumoniae but 
C. burneƟ i.
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To facilitate control measures, the MHS focused on the idenƟ ﬁ caƟ on of the cause of 
the outbreak and the aﬀ ected geographical area/populaƟ on. QuesƟ onnaires were used to 
idenƟ fy a common alimentary or animal source. The rural outbreak region was doƩ ed with 
animal husbandry enterprises in close proximity to human seƩ lements. The Animal Health 
Service (GD) revealed that since 2005 [2] C. burneƟ i caused aborƟ on storms in some dairy 
goat farms. The goat and sheep density in Noord Brabant was with 43 per km2 the highest 
in the Netherlands (10 per km2 )[3]. Similar outbreaks implicaƟ ng goats as the source had 
occurred in other countries such as Bulgaria [4] and Canada [5], but most Q-fever outbreaks 
for example in Germany [6] and the UK [7] were associated with sheep. Although not formally 
proven in 2007, goats seemed the likely source of this Dutch outbreak [8]. The 2007 outbreak 
was, at the Ɵ me, considered a rare and one oﬀ  event. However, the following years ever 
bigger seasonal annual outbreaks in a larger geographical area occurred with the MHS Hart 
voor Brabant at the epicentre.
Despite the implementaƟ on of veterinary control measures from 2008 onwards, includ-
ing vaccinaƟ on of dairy goats and dairy sheep, and hygiene measures, naƟ onal noƟ ﬁ caƟ ons 
had increased to 4,026 cases by 2010 [9]. As the number of paƟ ents increased, so did the 
concerns of local professionals and the public. In November 2009, Q-uesƟ on, a Q-fever pa-
Ɵ ent organisaƟ on was founded [10]. Their agenda was to; inform Q-fever aﬀ ected individuals 
on the infecƟ on, sƟ mulate interacƟ on between paƟ ents, promote research on long-term 
eﬀ ects of C. burneƟ i infecƟ ons and represent the interests of Q-fever paƟ ents in the poliƟ cal 
arena. The Q-fever outbreak received naƟ onal aƩ enƟ on in 2009 and culminated in a naƟ on-
ally broadcasted television program on the 6th of December 2009 [11]. Notwithstanding the 
veterinary measures taken, the large outbreak in 2009 indicated that these were insuﬃ  cient. 
In order to prevent an even larger outbreak in 2010, in December 2009 the culling of more 
than 58,000 dairy goats [12] started on farms that tested Q-fever posiƟ ve in a mandatory bulk 
tank milk monitoring programme.
Although the outbreak stopped, public concern did not. The Q-fever saga is ongoing, the 
Commission van Dijk presented an invesƟ gaƟ ve report [13], the naƟ onal ombudsman held a 
public hearing in 2012 [14] and Q-fever paƟ ents started a court case to seek compensaƟ on 
from goat farmers and the State [15].
Between 2008 and 2010 the MHS Hart voor Brabant noƟ ﬁ ed 2,753 Q-fever cases, which 
was 40-53% of all their infecƟ ous diseases noƟ ﬁ caƟ ons which doubled their noƟ ﬁ caƟ on work-
load. During the same period 2,267 incoming Q-fever related telephone calls represented up 
to 36% of all received phone calls. These telephone calls from paƟ ents, occupaƟ onal physi-
cians, general pracƟ Ɵ oners (GPs), medical specialists, the press, and municipaliƟ es touched 
on aspects of chronic Q-fever and serological follow-up, the consequences of Q-fever on the 
general health status, in parƟ cularly faƟ gue and the eﬀ ect on the ability to work.
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Although the outbreak stopped ﬁ ve years ago, chronic Q-fever and the health status, es-
pecially faƟ gue post Q-fever remain important problems, with many unanswered yet relevant 
public health quesƟ ons such as; is the follow-up aŌ er acute Q-fever adequate, is screening 
of the exposed general populaƟ on indicated to idenƟ fy chronic Q-fever? Can one develop a 
chronic infecƟ on aŌ er an asymptomaƟ c Q-fever infecƟ on and how big a problem is Q-fever 
related impaired health status, especially faƟ gue?
Sequels of infecƟ on
Chronic Q-fever and the Q-fever faƟ gue syndrome (QFS) as sequels of infecƟ on.
1. CHRONIC Q-FEVER
Between 2 [16] and 5% of acute Q-fever paƟ ents develop chronic Q-fever [17, 18, 19]. As the 
then most recent arƟ cle, the European Centre for Disease PrevenƟ on and Control (ECDC) 
risk assesment [16], stated 2% this percentage is used here in further calculaƟ ons. Chronic 
Q-fever mainly presents as an endocardiƟ s or a vascular infecƟ on with a high morbidity and 
mortality [20]. In the internaƟ onal literature, endocardiƟ s is most oŌ en described but in this 
outbreak in the Netherlands, vascular infecƟ ons are more common [21]. Among those most 
at risk to develop chronic Q-fever are individuals with cardiac valve pathology, aneurysms, 
vascular graŌ s and the immunocompromised [22]. The diagnosis is based on a combinaƟ on 
of serology and clinical ﬁ ndings; a posiƟ ve C. burneƟ i PCR analysis but not during acute infec-
Ɵ on, an IgG phase I anƟ body Ɵ tre ≥1:1,024, presence of clinical risk factors and radiological 
imaging results including echocardiography and positron emission tomography-computed 
tomography (PET-CT) [23]. In order to detect chronic Q-fever (serological) follow-up is needed. 
Follow-up is especially important for the above menƟ oned paƟ ents with an increased risk to 
develop chronic Q-fever. The internaƟ onal literature, advised a follow-up strategy of three 
serological tests and echocardiography [24] for acute Q-fever paƟ ents. Part of the 2007-2008 
cohorts of acute Q-fever paƟ ents were followed up accordingly but as no chronic infecƟ ons 
were detected [25] the general echocardiographic screening was stopped. Raoult et al. [26] 
considered that decision premature because some heart valve defects are clinically silent 
(can only be detected with echocardiography) yet predispose paƟ ents for chronic Q-fever for 
at least 10 years post infecƟ on.
The approximately 300 voluntarily registered chronic Q-fever paƟ ents far exceeded the 
80 (2% of 4,000 symptomaƟ c noƟ ﬁ ed Q-fever cases) expected cases. This would suggest 
that this sequel also occurred in the not noƟ ﬁ ed C. burneƟ i infected individuals that had mild 
symptoms or were asymptomaƟ c. The esƟ maƟ on was that every noƟ ﬁ ed Dutch Q-fever case 
stood for 12.6 infecƟ ons [27]. This would bring the total number of infecƟ ons to approxi-
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mately 50,000 (12.6 X 4,000) and the number of expected chronic Q-fever cases to 1,000 (2% 
of 50,000). If 2% chronicity is correct, this would suggest that many chronic Q-fever cases 
are not yet idenƟ ﬁ ed, or alternaƟ vely, that transiƟ on rates from acute to chronic infecƟ on 
are lower for the asymptomaƟ c C. burneƟ i infected than for those with clinical acute Q-fever.
2. THE HEALTH STATUS, ESPECIALLY FATIGUE AND THE ABILITY TO WORK POST 
C. BURNETII INFECTION
In 1960 Powell [28] was the ﬁ rst to publishdata on long-term faƟ gue aŌ er Q-fever but it 
was Shannon [29] who introduced the term post Q-fever chronic faƟ gue syndrome in 1992. 
Syndrome, because the undue faƟ gue is accompanied [30] by many other nonspeciﬁ c symp-
toms such as headache, disturbed sleep, night sweats, myalgia, arthralgia and blurred vision. 
The majority of internaƟ onal studies on QFS were small and follow-up was limited. In iniƟ al 
studies in the Netherlands, 52% of paƟ ents suﬀ ered from severe faƟ gue one year aŌ er the 
onset of Q-fever [31] and 37% aŌ er 2 years [32]. Important limitaƟ ons of Dutch studies were 
the small sample size, control groups that were not serologically tested for Q-fever, were 
healthier than the general populaƟ on, and the sole use of noƟ ﬁ ed, symptomaƟ c C. burneƟ i 
infected or MHS registered individuals.
The impaired health status and increased faƟ gue of Q-fever paƟ ents have a signiﬁ cant 
societal impact as work and private life are aﬀ ected as a consequence [33, 34]. PaƟ ents, 
occupaƟ onal physicians, GPs and the paƟ ent’s organisaƟ on had many quesƟ ons on how to 
interpret and deal with faƟ gue aŌ er Q-fever. This became such an important issue that the 
Ministry of Health requested the Dutch Centre for InfecƟ ous disease control (CIb) to write a 
naƟ onal QFS guideline [35] that was ﬁ nalised in 2012.
The outline of this thesis
Chapter 2 sketches the outbreak from 2007 to 2010, provides broad informaƟ on on C. burneƟ i 
including diagnosis, veterinary measures and the general problems that paƟ ents with Q-fever 
might experience.
Part I. Studies on screening for chronic Q-fever. These are presented in chapters 3-5. 
Chapter 3 depicts diﬀ erent follow-up strategies of three laboratories aŌ er an acute Q-fever 
infecƟ on, the knowledge of pracƟ Ɵ oners regarding serological follow-up of Q-fever, and the 
diﬀ erences in follow-up rates. Due to the many Q-fever noƟ ﬁ caƟ ons in the Netherlands, the 
quesƟ on arose what the best pracƟ ce of follow-up screening for detecƟ on of chronic Q-fever 
could be. Therefore, a systemaƟ c review was conducted, see chapter 4. Was screening of the 
general populaƟ on in a high prevalence area for chronic Q-fever indicated? Such a populaƟ on 
screening was conducted in 2014 in the village Herpen and is described in chapter 5.
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Part II. Studies on health status, especially faƟ gue and work. These are presented in 
chapter 6-9. Chapter 6 provides informaƟ on on the occurrence and impact of long-term 
complaints and absence from work whilst in chapter 7 diﬀ erent aspects of the health status 
of noƟ ﬁ ed Q-fever paƟ ents one to two years aŌ er noƟ ﬁ caƟ on are described. The health 
status of parƟ cipants of a populaƟ on survey in Herpen seven years aŌ er the start of the 
Q-fever outbreak is presented in chapter 8. QuesƟ ons regarding the deﬁ niƟ on, aeƟ ology, 
prognosis, prevenƟ on and treatment of faƟ gue or QFS aŌ er an infecƟ on with C. burneƟ i led 
to a systemaƟ c review chapter 9. The thesis is ﬁ nalized with a summarising discussion in 
chapter 10.
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ABSTRACT
In 2005, Q-fever was diagnosed on two dairy goat farms and 2 years later it emerged 
in the human populaƟ on in the south of the Netherlands. From 2007 to 2010, more 
than 4,000 human cases were noƟ ﬁ ed with an annual seasonal peak. The outbreaks 
in humans were mainly restricted to the south of the country in an area with intensive 
dairy goat farming. In the most aﬀ ected areas, up to 15% of the populaƟ on may have 
been infected. The epidemic resulted in a serious burden of disease, with a hospitalisa-
Ɵ on rate of 20% of noƟ ﬁ ed cases and is expected to result in more cases of chronic 
Q-fever among risk groups in the coming years. The most important risk factor for 
human Q-fever is living close (<5 km) to an infected dairy goat farm. OccupaƟ onal 
exposure plays a much smaller role. In 2009 several veterinary control measures were 
implemented including mandatory vaccinaƟ on of dairy goats and dairy sheep, improved 
hygiene measures, and culling of pregnant animals on infected farms. The introducƟ on 
of these drasƟ c veterinary measures has probably ended the Q-fever outbreak, for 
which the Netherlands was ill-prepared.
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INTRODUCTION
Since its ﬁ rst descripƟ on in abaƩ oir workers in Australia in 1935, Q-fever has been consid-
ered primarily an occupaƟ onal disease for abaƩ oir workers, sheep shearers, farmers, and 
veterinarians. Occasional outbreaks among the general populaƟ on have been described in 
diﬀ erent countries but these were mostly conﬁ ned to small areas and were of short dura-
Ɵ on. The 2007–2010 epidemic of Q-fever in the Netherlands with more than 4,000 noƟ ﬁ ed 
human cases was unique. We describe the diﬀ erent aspects of this excepƟ onally large epi-
demic, primarily from the human health perspecƟ ve, and provide details of ongoing research 
that will add considerably to the global knowledge base of Q-fever. Topics covered are the 
surveillance of acute Q-fever before and during the epidemic; the challenges in laboratory 
diagnosƟ cs; the long-term eﬀ ects of Q-fever; prevenƟ on of severe disease by vaccinaƟ on; 
risks for pregnant women; and the drasƟ c veterinary measures on dairy goat and dairy sheep 
farms that were implemented from 2009 and that have probably played a major role in stop-
ping the epidemic.
2. SURVEILLANCE OF ACUTE Q-FEVER AND DIAGNOSTIC CRITERIA
2.1 Q-fever as a rarity before 2007
The diagnosis of Q-fever was very rare in the Netherlands before 1977, despite increasing 
numbers of reported cases from other countries. Extensive studies were carried out between 
1951 and 1956 on caƩ le (n = 524) and on paƟ ents with atypical pneumonia (n = 6,000). 
These studies tested serum samples using complement ﬁ xaƟ on test (CFT) and used animal 
(guinea pig) cultures. None of them revealed a posiƟ ve result [1]. Then in 1956, just as these 
studies were being phased out, the ﬁ rst three human cases of Q-fever were diagnosed in the 
Netherlands [2, 3]. One paƟ ent worked at a slaughterhouse, one was thought to have been 
infected in Switzerland, and a third had spent Ɵ me living near sheep. When 28 of these sheep 
were serologically analysed, one tested posiƟ ve.
2.2 An increase in reported cases
In 1976 Q-fever was added to the list of noƟ ﬁ able diseases in the Netherlands. This was 
quickly followed by a rise in the number of reported cases – an average of 2–3 a year be-
tween 1977 and 1980, and an average of 20 a year up unƟ l 2007. Thirty-three Q-fever cases 
diagnosed between 1979 and 1983 have been described in more detail [4]. An in-house 
developed immunoﬂ uorescence assay (IFA) was used and IgM phase II ≥1:16 was considered 
reacƟ ve. Apart from the usual clinical presentaƟ on, epidemiological analysis to idenƟ fy pos-
sible sources showed that 67% of these paƟ ents had acquired Q-fever in the Netherlands, 
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while the rest were probably infected in a variety of other European countries. However, a 
reanalysis of the data shows that the serologic proﬁ les described in the paƟ ents diagnosed 
with acute Q-fever were quite heterogeneous, with mismatches of CFT and IFA results. There-
fore, the group of paƟ ents described was a heterogeneous group with acute, past resolved 
and chronic infecƟ ons.
2.3 Early seroprevalence studies
Within the context of increasing number of cases, extensive serologic studies were con-
ducted in the Netherlands in the period between 1982 and 1985 [5-7], using CFT and IFA 
with Coxiella burneƟ i anƟ gen phase II from Virion (Virion Ltd., Zurich, Switzerland). For IFA, 
IgG anƟ bodies were tested to the phase II anƟ gen, with a cut-oﬀ  of ≥1:16. The study tested 
a selecƟ on of serum samples from groups of people considered to be at high risk of infec-
Ɵ on. This approach showed very high seroposiƟ ve rates among veterinarians working with 
large domesƟ cated animals (84%) and with small domesƟ cated animals (77%), as well as 
taxidermists (70%) and wool spinners (58%). However, a range of high seroposiƟ vity rates 
(14–73%) was also found in the control groups. The authors suggest that these high rates 
were achieved because the IFA used in their study was more sensiƟ ve than the CFT used in 
previous studies. No control experiments with CFT were performed in this study, and the IFA 
results were not conﬁ rmed with addiƟ onal Ɵ traƟ ons.
Unfortunately, the original data are not available for staƟ sƟ cal reanalysis. If transmission 
rates in the 1970s and 1980s were high, then serologic evidence of this should be evident in 
older age groups in recent serological surveys. We speculate that the lack of speciﬁ city in the 
in-house IFA, combined with a low cut-oﬀ  may have inﬂ uenced the seroprevalence rates of 
this study.
2.4 The need for clearer analysis before the 2007 epidemic
When the Dutch Q-fever epidemic began in 2007, some speculated that the disease may 
have been previously overlooked because of under-diagnosis and misclassiﬁ caƟ on, and 
that increased awareness had created a pseudo-epidemic through the misclassiﬁ caƟ on of 
acute infecƟ ons (Van Knapen, personal communicaƟ on). Indeed, a considerable amount of 
misclassiﬁ caƟ on is possible if diagnosis relies on detecƟ on of IgM phase II, which can persist 
for months or even years. Clearly, the pre-epidemic situaƟ on needed analysis. In addiƟ on a 
change in laws and regulaƟ ons regarding infecƟ ous diseases in the Netherlands also started 
to have an impact.
2.5 Changing laws and regulaƟ ons
The analysis of naƟ onal data regarding disease incidence relies on noƟ ﬁ caƟ ons. RegulaƟ ons 
that control noƟ ﬁ caƟ on are important as regulatory changes can inﬂ uence epidemiological 
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curves. When Q-fever was added to the list of noƟ ﬁ able diseases in 1976, clinicians were 
legally required to noƟ fy public health authoriƟ es of Q-fever paƟ ents, and municipaliƟ es (ad-
vised by municipal health services) were obliged to enforce legal acƟ ons to curb epidemics 
when necessary. The use of the Q-fever noƟ ﬁ caƟ on system was analysed in 2002 [8]. Ag-
gregated data from between 1988 and 2002, retrieved from laboratories, hospital admis-
sions and discharge records, were compared to the naƟ onal data set of Q-fever noƟ ﬁ caƟ ons. 
This analysis showed that only 50% of diagnosed cases were reported by clinicians because 
laboratories were not required to provide noƟ ﬁ caƟ on at that Ɵ me. In 2008, a new law was 
introduced in the Netherlands to comply with internaƟ onal health regulaƟ ons. According to 
this law, laboratories were also obliged to provide noƟ ﬁ caƟ on. This approach was expected 
to improve noƟ ﬁ caƟ on records – as each case would be noƟ ﬁ ed by both the laboratory and 
the consulƟ ng clinician.
2.6 Possible Q-fever clusters before 2007 detected retrospecƟ vely
Clinical Q-fever in animals was diagnosed in the Netherlands in 2005 in two dairy goat herds 
with high aborƟ on rates [9]. Van den Wijngaard et al. [10] speculated that unrecognised 
outbreaks might have preceded the ﬁ rst recognised outbreak in 2007. With this in mind, 
they used space-Ɵ me scan staƟ sƟ cs and syndromic surveillance to search for hidden Q-fever 
clusters before and during 2007. HospitalisaƟ on data for lower respiratory, hepaƟ Ɵ s and en-
docardiƟ s infecƟ ons occurring between 2005 and 2008 were aggregated by week, age group 
and postal codes. AlternaƟ ve causes of outbreaks were excluded by reviewing all mandatory 
noƟ ﬁ ed diseases with similar clinical presentaƟ on in the same period. Surveillance data on 
inﬂ uenza-like illness were also included to assess whether clusters of hospital admissions for 
lower respiratory tract infecƟ ons could be due to inﬂ uenza. From 2005 to 2008, a total of 
20 lower respiratory tract infecƟ on clusters and two hepaƟ Ɵ s clusters were detected. Scan 
staƟ sƟ cs for space-Ɵ me clusters detected one speciﬁ c cluster - the Q-fever epidemic in 2007. 
However, ten other clusters were also detected that could be due to other causes, includ-
ing a major conﬁ rmed Legionella outbreak. Three clusters which occurred earlier than the 
recorded outbreak – two in 2005 and one 2006- could be due to Q-fever because there was 
a Q-fever-aﬀ ected farm nearby and there was no alternaƟ ve explanaƟ on for the cluster. In 
2007, a number of clusters of lower respiratory tract infecƟ on and one hepaƟ Ɵ s cluster were 
also found, and could be aƩ ributed to the actual Q-fever epidemic. Three clusters in 2007 
could not be aƩ ributed to Q-fever, because they could not be linked to Q-fever aborƟ on 
waves on farms.
In conclusion, Q-fever may have spread unnoƟ ced among humans before 2007, and rou-
Ɵ ne cluster scanning may facilitate earlier detecƟ on of comparable epidemics in the future. 
There is indeed circumstanƟ al evidence of limited clustered spreading of C. burneƟ i among 
humans before 2007, but this analysis also conﬁ rms that the major outbreak started in 2007. 
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However, once the Q-fever epidemic was established, it may have resulted in an increased 
number of diagnoses, inﬂ uencing epidemic curves [11].
2.7 Recent serosurveillance: The PIENTER Study
In 2006, a populaƟ on-based seroprevalence study was carried out by the NaƟ onal InsƟ tute for 
Public Health and the Environment to evaluate the Dutch NaƟ onal ImmunisaƟ on Programme. 
This programme (PIENTER) has been described in detail by van der Klis et al. [12]. It was a 
naƟ onal survey in which parƟ cipants were asked to donate blood and complete a quesƟ on-
naire on demographics, health percepƟ on and acƟ viƟ es related to infecƟ ous diseases. Data 
and sample collecƟ on was ﬁ nalised in June 2007, aŌ er which the stored serum samples were 
used to screen for the presence of C. burneƟ i anƟ bodies [13].
Given the screening consideraƟ ons described above, this study used a combined test 
strategy to measure seroprevalence, using an enzyme-linked immunosorbent assay (ELISA) 
IgG phase II (Serion ImmundiagnosƟ ca, Würzburg, Germany) on the study group of 5,654 
samples, followed by a conﬁ rmaƟ on of posiƟ ves by IFA (Focus DiagnosƟ cs, Cypress, Califor-
nia, USA). IFA was also used to esƟ mate the ELISA’s false negaƟ ve rates on 504 randomly 
chosen ELISA negaƟ ve samples.
Of the 5,654 samples tested, 85 were posiƟ ve with the ELISA IgG phase II. Of these, 47 
had borderline levels and 15 were negaƟ ve in an IFA IgG phase II screened with 1:32. This 
resulted in a seroprevalence of 1.5% using ELISA to screen and IFA to conﬁ rm. In the 504 
ELISA negaƟ ve samples tested in IFA, six (1.2%) had Ɵ tres ranging from 1:32 to 1:128. Using 
IFA as the ‘agreed standard’, the adjusted seroprevalence esƟ mate was 2.4%. These results 
underscore the problems encountered while comparing diﬀ erent seroprevalence studies.
The results from this study yielded a low seroprevalence in the Netherlands before 2007, 
but the low numbers sƟ ll represent a considerable amount of exposure. SeroposiƟ vity in 
males was higher than in females and increased with age. No regional diﬀ erences were 
observed, even when sheep, goat and caƩ le densiƟ es were examined. However, higher 
seroprevalence was associated with increasing age, being born abroad (speciﬁ cally in Tur-
key), keeping ruminants and having occupaƟ onal contact with animals. In conclusion, this 
study supports the concept of the massive localised introducƟ on of C. burneƟ i in the human 
populaƟ on from 2007 onwards [13].
Clearly, Q-fever has been circulaƟ ng at a low level in the Netherlands since the 1950s. 
There may have been a temporary increase in exposure during the 1980s, but data from 
older sero-surveys and noƟ ﬁ caƟ ons may lack accuracy. Recent studies conﬁ rmed a massive 
exposure of Q-fever in the Netherlands from 2007 onwards.
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3. THE DUTCH EPIDEMIC FROM 2007 TO 2010
3.1 Concerns rise in 2007
Between March and June 2007, six cases of acute Q-fever were noƟ ﬁ ed by regional 
microbiology laboratories to public health authoriƟ es in the province of North Brabant in 
the south of the Netherlands. These paƟ ents were admiƩ ed with atypical pneumonia to a 
number of hospitals in the province. Concerned, the regional Municipal Health Service (MHS) 
analysed the cases in detail, but could not link them epidemiologically. Then a general prac-
Ɵ Ɵ oner from a nearby village reported an excess of paƟ ents with pneumonia at his pracƟ ce. 
IniƟ ally, these paƟ ents were mistakenly thought to have Mycoplasma pneumoniae infecƟ on 
due to serologic cross-reacƟ ons, but they were eventually conﬁ rmed as having acute Q-fever 
in July 2007 [14; 15].
Eventually, a total of 168 human cases were noƟ ﬁ ed in North Brabant in 2007. Dairy 
goats were idenƟ ﬁ ed as the source of the human Q-fever cases in North Brabant - the Animal 
Health Service conﬁ rmed a considerable number of Q-fever- induced aborƟ ons at several 
farms in the region. The unusually hot and dry weather in the spring of 2007 may have caused 
airborne transmission of contaminated dust parƟ cles. The outbreak seemed to have been 
concentrated around a single village, but a speciﬁ c point source could not be idenƟ ﬁ ed. A 
case-control study was performed in the village [16] and contact with manure, hay and straw 
were shown to be risk factors. It was shown that people living in the eastern part of the 
village close to ruminant farms (one of which had a recent history of aborƟ on problems) 
were at a higher risk than people living in other parts of the village. Contact with animals and 
the consumpƟ on of raw milk products were not signiﬁ cant risk factors in the mulƟ variable 
analysis. In general, acute Q-fever seemed not to be related to the working environment 
but there were reports of incidental cases that occurred aŌ er visits to dairy goat farms with 
aborƟ on problems.
3.2 Source of epidemiological data
The source of epidemiological data is the naƟ onal registry of noƟ ﬁ able infecƟ ous diseases. At-
tending physicians and heads of microbiology laboratories have a legal obligaƟ on to noƟ fy the 
diagnosis of human Q-fever to the MHS, which enters the cases into an anonymous naƟ onal 
electronic database (‘Osiris’) monitored by the Centre for InfecƟ ous Disease Control. Since the 
beginning of 2007, noƟ ﬁ caƟ on criteria for acute Q-fever in Osiris have been a combinaƟ on of 
clinical presentaƟ on matching Q-fever, with either a four-fold IgG Ɵ tre rise or a posiƟ ve IgM 
phase II anƟ body test measured by IFA, ELISA, or CFT. During the course of the outbreaks, certain 
adaptaƟ ons were made to the noƟ ﬁ caƟ on criteria. In July 2008, a clinical presentaƟ on matching 
Q-fever was further deﬁ ned as fever, or pneumonia, or hepaƟ Ɵ s. In February 2010, an addiƟ onal 
laboratory criterion was the detecƟ on by polymerase chain reacƟ on (PCR) of C. burneƟ i DNA in 
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serum or respiratory material. However, diagnoses based on PCR were already accepted before 
that Ɵ me. Given the above criteria, misclassiﬁ caƟ on was possible when isolated IgM was used 
as a sole measure, since IgM can be a false posiƟ ve, or persist for months aŌ er a past resolved 
infecƟ on. Moreover, clinical symptoms may be nonspeciﬁ c.
Another important source of epidemiological data was a quesƟ onnaire rouƟ nely dis-
patched to noƟ ﬁ ed acute Q-fever cases by the MHS, which included quesƟ ons about envi-
ronmental risk factors and clinical characterisƟ cs. This quesƟ onnaire was received from 74% 
of noƟ ﬁ ed cases with onset of illness in 2007 and from 93% of noƟ ﬁ ed cases with onset of 
illness in 2008.
3.3 2007–2010 Overview: not an isolated incident
As the number of noƟ ﬁ caƟ ons increased from May 2008, it became evident that the 2007 
outbreak was not an isolated incident. A total of 3,489 Q-fever paƟ ents who experienced 
onset of disease between 2007 and 2009 were noƟ ﬁ ed. Of these, 194 cases had a date of 
onset in 2007, 982 in 2008, and 2,313 in 2009. The epidemic curve (Fig.1) shows a seasonal 
paƩ ern, with most cases occurring in spring and early summer. The highest incidences were 
seen in the south of the country, mainly in the province of North Brabant; the aﬀ ected area 
expanded to the north and the south during the epidemic (Fig.2). PaƟ ent characterisƟ cs from 
2007 to 2009 were presented by Schneeberger et al. [17]. The median age of the conﬁ rmed 
noƟ ﬁ ed paƟ ents was 50 years, and > 60% were male.
The addiƟ onal MHS quesƟ onnaires showed that only a small proporƟ on of paƟ ents lived 
on a farm or worked in the agriculture or meat processing sectors. However, noƟ ﬁ ed paƟ ents 
frequently reported that they had been in contact with a diverse number of animals and 
animal products.
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Fig. 1 Number of noƟ ﬁ ed acute Q fever paƟ ents from 1 January 2007 to 23 March 2011 with known day of 
onset of illness
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Fig. 2 Annual incidence of acute Q fever by municipality and locaƟ on of infected farms. Incidence is 
based on year of onset of illness of noƟ ﬁ ed acute Q fever paƟ ents
In 2007, the percentage of hospitalized paƟ ents (50%) was largely inﬂ uenced by acƟ ve case 
ﬁ ndings in a retrospecƟ ve survey among hospitalised cases [18]. In 2008 and 2009 it was 
20%, sƟ ll much higher than the 2-5% hospitalisaƟ on rate reported in the literature [19]. Fever 
was the most frequently reported symptom (92%), followed by faƟ gue (78%) and headache 
(69%). Pneumonia was diagnosed in 62% of paƟ ents, while endocardiƟ s (3%) and hepaƟ Ɵ s 
(<1%) were relaƟ vely rare. Underlying diseases were frequently reported. Almost 49% of 
paƟ ents smoked, which is relaƟ vely high compared to percentages in the general populaƟ on 
(30% for males and 24% for females, according to StaƟ sƟ cs Netherlands).
3.4 DiagnosƟ c delay and inﬂ uence of inﬂ uenza A (H1N1)
All noƟ ﬁ ed paƟ ents in 2007 for whom addiƟ onal laboratory data was available were diag-
nosed either by IFA or CFT. In 2008, 3% of cases were diagnosed by PCR. The most popular 
method in 2008 was sƟ ll IFA (75%), although CFT, ELISA, PCR and other methods were also 
used. In 2009, 79% of noƟ ﬁ ed paƟ ents were diagnosed serologically and 20% by PCR. IFA was 
used in more than half of the cases in 2009, CFT was used in more than a quarter of the cases 
and ELISA was used in 14% of cases.
The median diagnosƟ c delay (the delay between the date of onset of illness and the date 
of C. burneƟ i diagnosis) decreased from 82 days in 2007, to 28 days in 2008, to 20 days in 
2009 [11]. The diagnosƟ c delay was due to lack of awareness by medical staﬀ  and the delay 
in making a deﬁ niƟ ve diagnosis, as rouƟ ne diagnosƟ cs mainly relied on seroconversion in 
convalescent serum. Increased awareness and improved rouƟ ne laboratory services, such as 
the introducƟ on of IFA, ELISA, and in 2009 PCR, have reduced this diagnosƟ c delay.
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Under condiƟ ons of high incidence, the posiƟ ve predicƟ ve values of tests are very high. In 
the autumn of 2009, pandemic inﬂ uenza A (H1N1) 2009 with more or less similar symptoms 
interfered with the analysis of the Q-fever epidemic. In this third year of the Q-fever outbreak, 
a high background prevalence of anƟ bodies to C. burneƟ i, speciﬁ cally posiƟ ve IgM Ɵ tres, 
were common in most of the aﬀ ected areas. This made it much more diﬃ  cult to determine 
the exact start of an acute Q-fever episode, thus making noƟ ﬁ caƟ ons less reliable. In fact, 
many paƟ ents diagnosed in the laboratory in 2010 had probably experienced clinical signs 
of acute Q-fever much earlier. Under these circumstances, the persistence of IgM makes it 
diﬃ  cult to measure the actual decline of the incidence of the disease.
3.5 A link with goats and sheep
In May 2008, an outbreak of Q-fever occurred in a psychiatric care insƟ tuƟ on in Nijmegen 
near the 2007 outbreak area [20]. At least 28 in-paƟ ents, staﬀ , and visitors had laboratory 
conﬁ rmed Q-fever illness and several paƟ ents in the insƟ tuƟ on developed atypical pneu-
monia. It was discovered that these paƟ ents had been in close contact with lambs as part of 
their therapy sessions. Then a large number of goats unexpectedly aborted their oﬀ spring on 
a farm close by, and Q-fever was conﬁ rmed in the farmer and his wife living there [14]. An 
urban cluster idenƟ ﬁ ed in 2008 was found to be related to a goat farm with high aborƟ on 
rates in the area. PaƟ ents lived downwind of the goat farm and a house located <2 km from 
the farm was associated with a higher risk of Q-fever infecƟ on, compared to a house located 
at ≥ 5 km [21]. In 2009, 59% of noƟ ﬁ ed human cases lived within a 5 km zone of a bulk tank 
milk-posiƟ ve dairy goat or sheep farm, and 12% (roughly one million people) of the Dutch 
populaƟ on lived within such zones [14;18]. The available evidence in the Netherlands points 
to dairy goat farms with Q-fever-induced aborƟ on problems as the main source of the human 
outbreaks with a smaller role for dairy sheep and non-dairy sheep.
3.6 Transmission from animals to humans
InfecƟ on of humans is caused by inhalaƟ on of contaminated aerosols that can spread over 
some distance. Especially when infected pregnant small ruminants abort, billions of C. burneƟ i 
end up in the environment while fewer than 10 organisms are suﬃ  cient to seed an infecƟ on 
[22]. The organism’s ability to persist in the environment may result in a conƟ nued risk for 
infecƟ on weeks to months aŌ er the birthing event.
The size of the community outbreak in the Netherlands suggests that transmission 
predominantly takes place through wide-scale environmental contaminaƟ on or mulƟ ple 
point-source contaminaƟ on sites. There is strong epidemiological evidence that most human 
cases are caused by aborƟ on waves on dairy goat farms. People living close to such farms are 
at risk. Infected farms that have no aborƟ on waves can sƟ ll be infecƟ ous when there is close 
contact with animals. The transmission route is the same, through inhalaƟ on of contaminated 
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aerosols, but the dose is much lower, hence closer contact is required for infecƟ on. Based on 
detailed informaƟ on from noƟ ﬁ ed paƟ ents, occupaƟ onal exposure can explain only a small 
proporƟ on of the acute Q-fever cases in the Netherlands.
Despite the evidence poinƟ ng towards dairy goat farms with Q-fever-induced aborƟ on 
problems, there were a number of such farms without any human cases in the surrounding 
populaƟ on. In the 5 km areas around 27 farms with clinical aborƟ on problems, environmen-
tal data sets were collected. This showed clear diﬀ erences between areas with and without 
transmission to humans in vegetaƟ on density and in average groundwater condiƟ ons [23]. 
Areas without transmission had higher vegetaƟ on densiƟ es, based on remotely sensed 
satellite imagery, and relaƟ vely shallow groundwater condiƟ ons suggesƟ ng that vegetaƟ on 
and soil moisture are relevant factors in the transmission of C. burneƟ i from infected small 
ruminant farms to humans.
AlternaƟ ve routes of transmission are unlikely to have played an important role. Q-fever is 
a zoonoƟ c disease with no convincing evidence for human-to-human transmission. Informa-
Ɵ on from noƟ ﬁ ed acute Q-fever paƟ ents makes it very unlikely that consumpƟ on of unpas-
teurised dairy products has played an important role. In 2008 the manure streams from dairy 
goat farms were invesƟ gated in some detail. Manure was oŌ en transported to other parts 
of the country to be used for example in ﬂ ower bulb culƟ vaƟ on but in the recipient areas no 
Q-fever cases were reported (unpublished data). It was therefore concluded that manure did 
not play an important role. More than 2000 Ɵ cks have been collected from sheep and the 
environment but no C. burneƟ i was detected. Dairy goats in the Netherlands are kept indoors 
in deep liƩ er stables and are not aﬀ ected by Ɵ cks.
4. VETERINARY CONTROL MEASURES
4.1 The Veterinary situaƟ on at the beginning of the outbreak
The world’s largest Q-fever epidemic recorded to date occurred in an area densely populated 
with people and domesƟ cated animals, suggesƟ ng that animal farming in such areas poses a 
risk for zoonoƟ c diseases such as Q-fever in humans. IniƟ ally, the evidence to link the outbreak 
to goat farming was largely circumstanƟ al, in the absence of DNA ﬁ ngerprinƟ ng techniques 
for C. burneƟ i that could have matched bacteria from human and animal samples. While 
there was no sound evidence base for control measures, the subsequent rapid expansion 
in the scale of the epidemic was unforeseen. NaƟ onal and regional public health authoriƟ es 
were largely unprepared for an outbreak of this magnitude, and internaƟ onal literature on 
smaller outbreaks provided insuﬃ  cient guidance on several key issues - such as appropri-
ate control measures, the possible eﬀ ects of the epidemic on pregnant women, the most 
adequate therapy for acute Q-fever, the idenƟ ﬁ caƟ on and classiﬁ caƟ on of chronic Q-fever, 
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and the use of the Australian human vaccine for Q-fever. The most aﬀ ected province, North 
Brabant, has a surface area of 5,100 km2 and currently houses 2.4 million people and 6.4 
million livestock (80,000 sheep, 135,000 goats, 660,000 cows and 5.5 million pigs) [24], with 
a goat density that increased ﬁ ve-fold between 1990 and 2007. In retrospect, aborƟ on waves 
due to C. burneƟ i infecƟ on among the goat populaƟ on were reported from 2005 onwards, 
although they were not recognized as such at that Ɵ me.
4.2 Veterinary measures in response to the 2008 outbreak
The widespread paƩ ern of the outbreak in 2008 was alarming and pointed to several clusters 
with mulƟ ple sources. In June 2008, the government announced the mandatory noƟ ﬁ caƟ on 
of Q-fever on dairy goat and sheep farms with >5% aborƟ ons due to C. burneƟ i infecƟ on, 
and introduced appropriate hygiene measures [25]. During a period of 90 days following the 
detecƟ on of Q-fever at a farm, a manure removal ban and visiƟ ng restricƟ ons were imple-
mented [25].However, no restricƟ ons on the trans- port of animals from infected farms were 
imposed, and other possible veterinary measures to contain the outbreak, such as a breeding 
ban, were not included.
Then, in October 2008, the Dutch government authorised the voluntary vaccinaƟ on 
of animals on large dairy goat and sheep and recreaƟ onal farms using the non-registered 
Coxevac® vaccine (Ceva Santé Animale, France). From November 2008, goat and sheep at 
smaller farms were also vaccinated. However because of limited vaccine availability – just 
80,000 doses – vaccinaƟ ons could only be provided within a 45 km radius of the outbreak 
source. In February 2009, a naƟ onwide hygiene protocol became mandatory for all dairy goat 
and sheep farms, whether infected or not [25]. The eradicaƟ on of vermin became compul-
sory, the cleaning of stables during lambing season and for 30 days aŌ erwards was forbidden, 
and manure had to be stored and covered for at least 90 days before use.
4.3 VETERINARY MEASURES IN RESPONSE TO THE 2009 OUTBREAK
Despite these measures, the outbreak was sƟ ll far from contained. Over 2,000 new human 
acute Q-fever cases were noƟ ﬁ ed from late March 2009 onwards, in a larger area than in 
2008. In response, in April 2009, the government extended the vaccinaƟ on campaign to 
include a compulsory vaccinaƟ on programme [25]. Farms with a public funcƟ on and dairy 
goat and sheep farms with more than 50 animals in the epidemic centre had to vaccinate 
their animals before 2010. All Q-fever infected farms outside of the area were also obliged 
to vaccinate their animals. VaccinaƟ on of animals on farms in the rest of the Netherlands 
was sƟ ll on a voluntary basis. In July 2009, the pasteurizaƟ on of manure for a minimum of 1 
hour at 70°C was permiƩ ed instead of a decomposiƟ on period of 90 days [25]. RestricƟ ons 
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on incoming and outgoing animal transport on C. burneƟ i infected farms were imposed from 
October 2009 onwards [25].
4.4 Bulk tank milk monitoring
Also from October 2009 onwards, the government set out a new strategy to idenƟ fy infected 
farms that did not have an aborƟ on rate above 5%. Farms with more than 50 dairy goats or 
sheep were obliged to parƟ cipate in Q-fever bulk tank milk monitoring [25]. Bulk milk tanks 
were sampled once every 2 months (and later on once every 2 weeks) and tested for the 
presence of C. burneƟ i DNA using a real- Ɵ me PCR by the Animal Health Service. To separate 
infected farms from non- infected farms, a cycle threshold (Ct) of 36 as detected by a-real-
Ɵ me PCR test targeƟ ng IS1111 was used. This threshold, which was set arbitrarily, is close to 
the detecƟ on limit of real-Ɵ me PCR tests, implying that the outcome of the test in the lower 
range (from Ct 34 to 36) is determined stochasƟ cally. PosiƟ ve samples were forwarded for 
conﬁ rmatory tesƟ ng to the Central Veterinary InsƟ tute, and conﬁ rmed farms were declared 
infected. Infected farms were idenƟ ﬁ ed on the basis of a posiƟ ve PCR outcome only, as in-
formaƟ on on background values of C. burneƟ i DNA load in goat bulk tank milk samples was 
unavailable. This approach may well have resulted in farms being declared infected when 
they posed no threat to human health.
4.5 DrasƟ c veterinary measures
In December 2009, Zembla, a current aﬀ airs television programme co-produced by the Dutch 
BroadcasƟ ng AssociaƟ on and a Dutch public newscaster, raised criƟ cal concerns about the 
role of the Dutch government in containing the Q-fever outbreak. The Dutch government 
responded to the increasing concerns by administrators, professionals, and the public by 
making the locaƟ on of the 55 C. burneƟ i-infected farms public, announcing a breeding ban 
on infected farms, and increasing the frequency of tank milk monitoring from bi-monthly to 
bi-weekly [25]. The decision was taken to implement the most radical measure possible, the 
pre-empƟ ve culling of all pregnant goats on infected farms [25]. Male goats on infected farms 
were also culled, as they could supposedly transmit the disease via semen.
A total of 50,355 goats and sheep were culled from 21 December 2009 to June 2010 on 
89 bulk tank milk posiƟ ve farms. Of 517 culling-workers, involved, 17.5% seroconverted for 
anƟ bodies to C. burneƟ i despite use of personal protecƟ ve equipment [26]. Seroprevalence 
of C. burneƟ i in workers before the culling acƟ vity was 13%, which is similar to ﬁ ndings among 
blood donors residing in the high-incidence area in the Netherlands in 2009 and in similar 
high-risk occupaƟ onal groups internaƟ onally [27]. SymptomaƟ c infecƟ on was recorded in 
31% of the seroconverters. A strong dose-response relaƟ onship was shown between risk 
of seroconversion and number of hours worked on the farms and working inside the stable 
(in close proximity to the animals). In other seƫ  ngs internaƟ onally, a risk-gradient has also 
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been shown with close direct and indirect animal contact over Ɵ me [28; 29]. Given the high 
risk of infecƟ on during culling acƟ viƟ es, addiƟ onal prevenƟ ve measures should be taken. 
The Health Council of the Netherlands (2010) [30] has already issued a ﬁ rst advice on risk 
groups suitable for human vaccinaƟ on against Q-fever. However this advice does not extend 
to culling workers.
4.6 Eﬀ ect of veterinary measures in 2010
ExponenƟ al spread of Q-fever did not occur during the spring of 2010, as feared. SƟ ll, almost 
400 new Q-fever paƟ ents were diagnosed during that year. By June 2010, all dairy goats and 
sheep had been vaccinated twice with Coxevac, and on July 15th the breeding ban for non-
infected farms was liŌ ed. The reason for the approximately ﬁ ve-fold decrease in the number 
of human infecƟ ons between 2009 and 2010 is mainly aƩ ributed to the culling of pregnant 
goats and sheep, and the vaccinaƟ on programme. Other factors could have contributed such 
as hygiene measures, climate, and increasing immunity among the general populaƟ on.
4.7 IdenƟ ﬁ caƟ on of the source of the outbreak
Recent genotyping studies point to a mulƟ -strain bacterium in both livestock and humans 
[31] as the cause of the Dutch Q-fever outbreak and not simply one highly virulent C. burneƟ i 
strain. Several condiƟ ons may have favoured the introducƟ on and rapid spread of C. burneƟ i 
among livestock in the Netherlands since 2005. In general, goats are kept in large herds in 
‘deep liƩ er stables’ - stables on concrete ﬂ oors with pits. Straw is regularly added to these 
deep liƩ er stables, which allows for relaƟ vely unhygienic condiƟ ons as potenƟ ally infected 
excreta such as urine, faeces and birth products are not regularly removed. Furthermore, the 
straw is oŌ en bought from countries such as France and Germany, which might be a source of 
C. burneƟ i. RelaƟ vely high quanƟ Ɵ es of C. burneƟ i DNA were measured in samples of stocked 
straw that had not yet been used in deep liƩ er stables (unpublished observaƟ on of MHA 
Hermans and PC Wever).
New-born goats are oŌ en fed raw cow colostrum. Colostrum is the highly nutriƟ ous milk 
produced by mammals just before giving birth, and cow colostrum may contain large quanƟ -
Ɵ es of C. burneƟ i DNA (unpublished observaƟ ons of MHA Hermans and PC Wever). Therefore, 
the role of straw and colostrum are interesƟ ng for further invesƟ gaƟ on as potenƟ al sources 
of mulƟ -strain C. burneƟ i infecƟ on in goats.
When the pits in deep liƩ er stables are full – which happens two or three Ɵ mes a year – 
everything (including manure and birth products) is removed and spread over the ﬁ elds or 
transported elsewhere. Furthermore, the open air stables allow wind to blow through and 
carry C. burneƟ i-infected dust into the environment. April 2007, May and June of 2008, and 
April 2009 were unusually dry by Dutch standards – this type of weather condiƟ on combined 
with wind has been documented to play an important role in other Q-fever outbreaks [32].
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5. LABORATORY ISSUES
5.1 The opƟ mizaƟ on of acute Q-fever diagnosƟ cs in the Netherlands during an 
outbreak
Prior to recogniƟ on of the Q-fever outbreak in 2007, Q-fever diagnosƟ cs were performed 
by a limited number of Dutch microbiology laboratories. The NaƟ onal InsƟ tute for Public 
Health and the Environment funcƟ oned as a reference laboratory using the IFA as a reference 
method, while other regional microbiology laboratories used the CFT. Following recogniƟ on 
of the scale of the outbreak, mid 2007, a number of microbiology laboratories in the epi-
demic area began to oﬀ er Q-fever diagnosƟ cs. The laboratories chose to use either IFA or 
CFT, depending in part on the type of serologic assays already in use by them. Seroconversion 
can be detected earlier by IFA compared to CFT (between 10 and 15 days aŌ er infecƟ on, 
versus 2–3 weeks, respecƟ vely). In addiƟ on, IFA allows the separate analysis of IgM and IgG 
anƟ bodies against C. burneƟ i phase II and phase I anƟ gens (IgM-II, IgG-II, IgM-I and IgG-I 
anƟ bodies). Analysis of these four anƟ bodies makes it possible to idenƟ fy various stages in 
the acute Q-fever infecƟ on. The presence of solitary IgM-II anƟ bodies – the ﬁ rst anƟ body to 
appear in the serologic response – indicates early acute infecƟ on, whereas the presence of 
IgG-II, IgM-I and IgG-I anƟ bodies reﬂ ects a later stage of acute infecƟ on. CFT, in contrast, has 
been reported to be less prone to false posiƟ ve results than IFA, especially with detecƟ on of 
IgM-II anƟ bodies. Both methods are labour-intensive, non-automated and subject to inter- 
and intra-observer variaƟ on [33; 34].
An important drawback to the serological diagnosis of acute Q-fever is the lag phase in 
anƟ body response of up to 3 weeks aŌ er the onset of clinical symptoms. In 2008, the ongoing 
outbreak resulted in the development of real-Ɵ me PCR assays targeƟ ng the mulƟ  copy IS1111 
inserƟ on element by several microbiology laboratories. These assays were used for the detec-
Ɵ on of C. burneƟ i DNA in serum, respiratory samples, urine specimens, Ɵ ssues and amnioƟ c 
ﬂ uids. Subsequently, an inter laboratory evaluaƟ on of diﬀ erent DNA extracƟ on and real Ɵ me 
PCR methods for the detecƟ on of C. burneƟ i DNA in serum was conducted. Overall, a low 
degree of variaƟ on was observed in the sensiƟ vity of the evaluated real Ɵ me PCR assays, al-
though assays amplifying short DNA fragments yielded beƩ er results than those producing a 
large DNA fragment [35]. Next, performance of one of the PCR was evaluated retrospecƟ vely 
on serum samples of acute Q-fever paƟ ents at various stages of the serological response. 
C. burneƟ i DNA was detected in serum from 98% of seronegaƟ ve acute Q-fever paƟ ents and 
in 90% of paƟ ents with solitary IgM-II anƟ bodies. UlƟ mately, the PCR became negaƟ ve as the 
serological response to C. burneƟ i further developed, with subsequent appearance of IgG-II, 
IgM-I and IgG-I anƟ bodies [36].
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5.2 Increasing diagnosƟ c demands
To cope with the surge in diagnosƟ c demands, which occurred during 2009 (e.g. over 18,000 
requests for Q-fever diagnosƟ cs were received by one single laboratory), several microbiology 
laboratories in the epidemic area began using algorithms to provide accurate, fast, cost-eﬀ ec-
Ɵ ve and standardized acute Q-fever diagnosƟ cs. One such algorithm used an ELISA for IgM-II 
anƟ bodies, performed on an automated processing system as an iniƟ al screening step. In the 
case of a posiƟ ve or dubious ELISA result, IFA was performed as a conﬁ rmaƟ on step. PCR was 
performed aŌ er a negaƟ ve ELISA result and when the serum sample was either acquired ≤14 
days aŌ er onset of disease or referred by a hospital physician (noted for their lack in providing 
a date of onset of disease). When acute Q-fever diagnosƟ cs on the ﬁ rst serum sample were 
non-conclusive, a second serum sample was requested aŌ er 14 days. Overall, this diagnosƟ c 
approach led to a signiﬁ cant reducƟ on in the number of labour-intensive, non-automated 
IFA tests performed, with an increased diagnosƟ c yield on ﬁ rst serum samples due to the 
introducƟ on of PCR techniques. Likewise, an algorithm was introduced using the ELISA for 
IgM-II anƟ bodies as a screening step followed by CFT as a conﬁ rmaƟ on step [37].
5.3 A consensus on Q-fever diagnosis
In 2010, the NaƟ onal InsƟ tute for Public Health and the Environment and the Dutch Society 
for Medical Microbiology formed a working group to develop a consensus on the microbio-
logical diagnosis of acute Q-fever. In September 2010, a consensus document was published 
recommending the use of algorithms in which PCR, ELISA for IgM-II anƟ bodies and either IFA 
or CFT were incorporated [34]. The diagnosis ‘conﬁ rmed acute Q-fever’ is established by a 
single posiƟ ve PCR result with an appropriate clinical presentaƟ on or an IgG-II seroconversion 
or a four-fold or higher increase in IgG-II Ɵ tre detected by IFA or CFT (requiring mulƟ ple 
serum samples). The diagnosis of ‘possible acute Q-fever’ is made by a posiƟ ve IgM-II result 
(in the presence or absence of IgG-II, IgM-I, IgG-I anƟ bodies) in a single serum sample with an 
appropriate clinical presentaƟ on and should be conﬁ rmed by either an IgG-II seroconversion 
or a four-fold or higher increase in IgG-II Ɵ tre in a follow-up serum sample. The introducƟ on 
of the term ‘possible acute Q-fever’ was the result of an increasing number of paƟ ents with 
past resolved Q-fever and persisƟ ng anƟ body Ɵ tres against phase II anƟ gens in parƟ cular, as 
well as reported false-posiƟ ve IgM-II results from IFA and ELISA.
5.4 Cross-reacƟ ons in serologic tests for Coxiella burneƟ i
While screening methods should be very sensiƟ ve and can be less speciﬁ c, several screen-
ing methods for infecƟ ous diseases have shown cross-reacƟ ons with other infecƟ ons. For 
Q-fever, most cross-reacƟ ons described in the literature are those with other agents, which 
cause pulmonary infecƟ ons such as Legionella pneumophila [38; 39].
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In the Netherlands, paƟ ents with a pulmonary infecƟ on are usually screened for several 
pathogens. This approach recognises cross-reacƟ ons with other agents that cause pulmonary 
infecƟ ons. The Q-fever epidemic in the Netherlands was ﬁ rst thought to be caused by Myco-
plasma pneumoniae, because CFT results of several paƟ ents showed low Ɵ tres against this 
organism. Therefore, we invesƟ gated cross- reacƟ ons between sera from paƟ ents with high 
Mycoplasma Ɵ tres and the ELISA screening assay for Q-fever. No cross-reacƟ ons were found.
Cross-reacƟ ons with other pathogens are less likely to be recognised. We invesƟ gated 
cross-reacƟ vity in sera taken from paƟ ents with recent Epstein-Barr virus (EBV) and Cytomeg-
alo virus (CMV) infecƟ ons (IgM posiƟ ve with low avidity). In a Coxiella screening ELISA (IgM 
phase II), 16/72 EBV IgM posiƟ ve sera reacted while 7/33 CMV IgM posiƟ ve sera reacted. In 
both EBV IgM- and CMV IgM-posiƟ ve paƟ ents, the results in the Q-fever ELISA were generally 
low posiƟ ve. When performing an IFA phase I and II assay on the ELISA posiƟ ve samples, 
all EBV IgM posiƟ ve paƟ ents became negaƟ ve. However, 40% of CMV IgM posiƟ ve paƟ ents 
also had posiƟ ve IFA tests and we concluded that these paƟ ents probably had two infecƟ ons 
going on at around the same Ɵ me.
When screening paƟ ents with a proven seroconversion for C. burneƟ i, we found very 
few cross-reacƟ ons in tests for EBV IgM (2%) but somewhat more in tests for CMV IgM (8%). 
Unfortunately, we were unable to follow these paƟ ents up to see if these were true double 
infecƟ ons or not. We concluded that recent EBV and CMV infecƟ ons can cause cross-reacƟ ve 
anƟ bodies against C. burneƟ i in ELISA tests, but not in IFA tests. It is possible that a recent 
Q-fever infecƟ on can also cause cross- reacƟ ons in the test for CMV IgM. Therefore, screen-
ing with ELISA, followed by conﬁ rmaƟ on with IFA, is a good way to exclude false posiƟ ve tests 
for C. burneƟ i due to recent EBV and CMV infecƟ ons.
5.5 Seroprevalence surveys
Strategies for diagnosing acute and chronic Q-fever in individual paƟ ents diﬀ er from 
populaƟ on-based seroprevalence surveys. Acute Q-fever is diagnosed mainly by the detec-
Ɵ on of anƟ bodies of IgM and IgG subclasses against phase II of C. burneƟ i. The diagnosis of 
chronic Q-fever relies on high Ɵ tres of phase I IgG anƟ bodies; the sole presence of phase II 
IgG anƟ bodies against C. burneƟ i indicates a previous infecƟ on [40; 41]. IgG-II anƟ body levels 
remain constantly high for almost a year and then slowly decrease, remaining detectable for 
years aŌ er ﬁ rst detecƟ on [42]. Therefore, the study of seroprevalence relies on the detecƟ on 
of IgG-anƟ bodies against phase II of C. burneƟ i in serum samples– anƟ bodies can be detected 
by CFT, IFA or ELISA. What we need to establish is: which test works best?
5.6 The IFA/ELISA debate: the need for a standard
Studies in the late 1980s and early 1990s reported that the ELISA was a more sensiƟ ve and 
speciﬁ c method than either the IFA or CFT [43 - 45] evaluated the performance of an ELISA 
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IgG kit (Panbio) against an in-house IFA. The two tests had moderate (53%) agreement; the 
ELISA had a sensiƟ vity of 71% and a speciﬁ city of 96%. A number of diﬀ erent in-house IFAs 
were evaluated against ELISA, using diﬀ erent methods and cut-oﬀ s [46 - 47] and the results 
are illustraƟ ve of the diﬃ  culƟ es in comparing studies of the serodiagnosis and seropreva-
lence of Q-fever. Nevertheless, IFA has been proclaimed the gold standard reference method 
in the literature [48], although this method is laborious when compared to the ELISA (which 
is easier to automate and more suitable for tesƟ ng large sample numbers). Commercial ELISA 
and IFA tests are both in current use for the diagnosis of acute and chronic Q-fever and in 
seroprevalence studies globally [49 - 51]. The uncertainty regarding a valid standardised test, 
coupled with insuﬃ  cient knowledge about the speciﬁ c fate of anƟ bodies against C. burneƟ i 
makes the sero-epidemiology of Q-fever a diﬃ  cult undertaking.
Serum samples from a case-control study conducted in 2007 in the Netherlands to 
invesƟ gate the source and routes of transmission in this outbreak were used to evaluate 
the performance of one commercially available ELISA (Serion ImmundiagnosƟ ca, Würzburg, 
Germany) and one IFA (Focus DiagnosƟ cs, Cypress, California, USA). Four hundred and 
eighty-seven human sera were evaluated in terms of sensiƟ vity, speciﬁ city and kappa value. 
The sensiƟ vity and speciﬁ city of ELISA for the detecƟ on of IgG phase II anƟ bodies were 59% 
and 97%, respecƟ vely [52]. Seroprevalence varied depending on the method used; it was 
12.7% when tested with IFA and 6.2% when tested with the ELISA. When measuring IgM 
anƟ bodies to phase II Coxiella anƟ gen, the two tests were comparable, with a kappa value of 
0.89. SensiƟ vity was 82% and speciﬁ city 100%. These results sup-port the concept that the 
ELISA performs reasonably well when diagnosing acute Q-fever. However, in past infecƟ ons, 
as deﬁ ned by the sole presence of IgG anƟ bodies, low posiƟ ve samples have been missed 
by ELISA. More longitudinal studies using diﬀ erent test systems are needed to measure the 
levels of anƟ bodies to C. burneƟ i in human serum. A single standard must be agreed on and 
deﬁ ned in order to be able to easily compare results from various sero-surveys.
6. Q-FEVER AND PREGNANCY DURING THE 2007–2010 Q-FEVER OUTBREAKS IN 
THE NETHERLANDS
6.1 The internaƟ onal literature
When it became apparent that Q-fever had become a major problem in the Netherlands 
from 2007 onwards, discussion arose about the health threat to pregnant women [18; 53]. 
An esƟ mated 90% of acute Q-fever infecƟ ons in pregnancy present without clinical signs, 
which is much higher than among non-pregnant persons. InternaƟ onal literature suggests 
that untreated acute Q-fever infecƟ on during pregnancy may result in adverse pregnancy 
outcomes in up to 81% of cases [54 - 56]. These outcomes include aborƟ on or intra-uterine 
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foetal death and pre- mature delivery or low birth weight. Furthermore, the risk of develop-
ing chronic Q-fever infecƟ on is reported to be higher in pregnant women [33; 57]. The only 
way to detect subclinical Q-fever is through screening of serum for anƟ bodies to C. burneƟ i.
6.2 The ﬁ rst year of the epidemic
In 2007 the Q-fever outbreak was conﬁ ned to a relaƟ vely small area. In July 2007, the Out-
break Management Team of the Netherlands decided to oﬀ er all pregnant women living 
in that area a screening test for Q-fever. This decision was based on the fact that a policy 
based on signs and or symptoms was not possible [58] as asymptomaƟ c infecƟ ons could 
carry the same risk for adverse pregnancy outcome and chronic infecƟ on as symptomaƟ c 
cases. TesƟ ng of all pregnant women in outbreak situaƟ ons was also common policy in other 
countries. In France, the recommendaƟ on was to treat pregnant women tesƟ ng posiƟ ve and 
for those tesƟ ng negaƟ ve, to repeat tesƟ ng on a monthly basis unƟ l delivery [54]. Public 
health pracƟ Ɵ oners in the south of the Netherlands tried to idenƟ fy all women who were 
pregnant or who had recently delivered in the aﬀ ected area. They were contacted by leƩ er 
and oﬀ ered the test. Out of 29 women idenƟ ﬁ ed through midwives and obstetricians work-
ing in the area, 19 responded, were interviewed and underwent serological tesƟ ng with IFA 
(Focus DiagnosƟ cs) in which a Ɵ tre of 1:64 was considered posiƟ ve. None of these women 
experienced or had experienced signs or symptoms of Q-fever. Two women however had 
serological evidence of a recent infecƟ on and one of an older infecƟ on [59]. The two women 
with serological evidence of recent infecƟ on were treated with cotrimoxazole for the dura-
Ɵ on of the pregnancy, as recommended in the literature [55]. Both delivered under strict 
hygiene measures and both pregnancies and deliveries were without complicaƟ ons. Birth 
products tested by PCR all were negaƟ ve. In none of the neonates there was serological or 
PCR evidence of verƟ cal transmission of Q-fever.
6.3 2008–2010
In the following years, the epidemic spread to a much larger geographical area with a popula-
Ɵ on of almost two million people. This raised the quesƟ on whether screening of pregnant 
women for acute Q-fever infecƟ on was necessary or feasible. The adverse eﬀ ects from 
untreated Q-fever infecƟ ons were compared with the possible side eﬀ ects of long-term 
anƟ bioƟ c treatment during pregnancy. In July 2008 an internaƟ onal meeƟ ng organized by 
the Centre for InfecƟ ous Disease Control and the Health Council of the Netherlands met to 
discuss the feasibility of screening all pregnant women for a recent Q-fever infecƟ on.
In all reported studies, there are a limited number of pregnant women with Q-fever for 
whom pregnancy outcomes (adverse or otherwise) have been reported (<100 women for all 
studies combined). Most reports concern retrospecƟ vely collected data, which don’t allow 
quanƟ ﬁ caƟ on of the risk for an adverse outcome of an infecƟ on during pregnancy. Based 
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on this informaƟ on and the fact that the epidemic had spread to a larger geographical area, 
the recommendaƟ on was that screening of all pregnant women for recent Q-fever was not 
recommended [60] by the Health Council of the Netherlands 2008. Several retrospecƟ ve and 
prospecƟ ve studies were set up in response to the urgent need for beƩ er quanƟ ﬁ caƟ on of 
the risk of adverse pregnancy outcome among pregnant women with acute Q-fever in early 
pregnancy.
6.4 A populaƟ on-based retrospecƟ ve follow-up study
In a retrospecƟ ve study, the presence of anƟ bodies against C. burneƟ i during pregnancy 
was determined by tesƟ ng sera that had rouƟ nely been collected in the Prenatal Screen-
ing for InfecƟ ous Diseases and Erythrocyte ImmunizaƟ on (PSIE) programme (hƩ p://www.
rivm.nl/pns_en/). This screening programme for hepaƟ Ɵ s B, syphilis, and HIV is oﬀ ered to all 
pregnant women in the Netherlands at around the 12th week of pregnancy. Samples were 
available in a high percentage of pregnancies as they are oŌ en stored for a period of 1 year 
aŌ er iniƟ al analysis. Sera were analysed using an IFA for detecƟ on of IgG and IgM anƟ bodies. 
A recent infecƟ on was deﬁ ned as the presence of anƟ -phase II IgM and anƟ -phase II IgG 
anƟ bodies with a Ɵ tre of ≥1:64. A possible infecƟ on was deﬁ ned as a solitary IgM II ≥ 1:64 
and a past infecƟ on as the presence of anƟ -phase I and II IgG anƟ bodies without IgM being 
present. InformaƟ on on pregnancy outcome was obtained from the Netherlands Perinatal 
Registry (PRN) – a database that represents the joint eﬀ orts of the professional organizaƟ ons 
of midwives, gynaecologists, obstetrically-trained general pracƟ Ɵ oners and paediatricians in 
the Netherlands. The PRN contains perinatal data from 16 weeks of gestaƟ on onwards for 
96% of all births in the Netherlands. It was esƟ mated that 60% of pregnant women were 
included in the study during the study period, based on the registered number of births. In 
this study, almost 4.5% of women had a recent or past infecƟ on. The presence of anƟ bodies 
against C. burneƟ i was not signiﬁ cantly associated with an adverse pregnancy outcome as 
measured by: preterm delivery (gestaƟ onal age below 37 weeks), low birth weight <2,500 
g, birth weight for gestaƟ onal age <10th percenƟ le, foetal or neonatal mortality, congenital 
malformaƟ on and 5-min Apgar score <7 [61].
6.5 A ProspecƟ ve screen and treat study
In 2010 a clustered randomized controlled trial among pregnant women within the area 
of high transmission was started in the Netherlands [62]. The study parƟ cipants were re-
cruited by midwives in these high risk areas. The midwife centres were randomized to recruit 
pregnant women from the control group or the intervenƟ on group. When taking part in the 
intervenƟ on group, blood samples were taken and tested immediately for Q-fever. PaƟ ents 
were referred to a hospital for further pregnancy monitoring and long-term bacteriostaƟ c 
treatment, if found posiƟ ve for acute or chronic Q-fever. In the control arm, blood samples 
Epidemic Q-fever in humans in the Netherlands  |  39
2
were stored and analysed for Q-fever only aŌ er delivery. If tested posiƟ ve for Q-fever aŌ er 
pregnancy, anƟ bioƟ cs were started if needed as part of regular health care. The objecƟ ve of 
the study was to measure diﬀ erences in obstetric or maternal complicaƟ ons in Q-fever posi-
Ɵ ve women between the screened and control group. Because the outbreak of Q-fever in the 
Netherlands was successfully managed, relaƟ vely few pregnant women included in this study 
experienced a recent infecƟ on with C. burneƟ i. By September 2010, 815 samples had been 
examined, showing an overall seroprevalence of 15%, but with only 4% having a serologic 
proﬁ le suggesƟ ng recent infecƟ on [63]. The ﬁ nal results of this study are not yet available.
6.6 No evidence of adverse eﬀ ects on pregnancy outcome in the Netherlands
Data from the literature on the eﬀ ects of a Q-fever infecƟ on in pregnant women are limited. 
Currently the best available evidence with regard to adverse pregnancy outcomes comes 
from a large case series and from several case reports documenƟ ng one to two cases [55; 64; 
67]. Case reports and case series have methodological limitaƟ ons and selecƟ ve publicaƟ on 
of severe outcomes cannot be ruled out. In contrast, in the Dutch outbreak the presence of 
anƟ bodies against C. burneƟ i in early pregnancy was not associated with adverse pregnancy 
outcome. This might be explained by a possible diﬀ erence in pathogenicity of diﬀ erent bacte-
rial strains or because we were not able to include early miscarriages in the study. We have 
to conclude that in the Dutch Q-fever outbreak, no evidence was found for adverse eﬀ ects on 
pregnancy outcome among pregnant women with an asymptomaƟ c Q-fever infecƟ on in early 
pregnancy. Based on this, there is insuﬃ  cient basis for recommending large-scale screening 
of pregnant women in high incidence areas.
7. LONG-TERM EFFECTS OF ACUTE Q-FEVER
7.1 From acute to chronic illness
According to the literature, 60% of infected Q-fever paƟ ents are asymptomaƟ c, while 20% of 
paƟ ents develop mild symptoms [68]. The remaining 20% present with more severe symp-
toms including high fever, severe headache, night sweaƟ ng, nausea, diarrhoea, pneumonia, 
hepaƟ Ɵ s, pericardiƟ s, myocardiƟ s, neuro- logical symptoms and weight loss [69]. The acute 
illness spontaneously resolves aŌ er 2–6 weeks [70]. However, the organism or its partly 
degraded remains can persist in bone marrow, which can cause future episodes. Chronic 
illness aŌ er acute Q-fever can express itself in diﬀ erent forms [71; 72]. Classic Q-fever endo-
cardiƟ s may take 10–15 years to develop and presents with cardiac vegetaƟ ons that contain 
viable Coxiella bacteria. Recrudescent granulomatous infecƟ ons can also occur. PaƟ ents with 
these two forms present with elevated levels of anƟ bodies and persistent presence of viable 
C. burneƟ i. Another long-term eﬀ ect of Q-fever is QFS (post-Q-fever faƟ gue syndrome). Con-
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trary to the ﬁ rst two forms, QFS may present while there are no viable Coxiella and anƟ body 
levels are low or negligible. This is confusing for clinicians and paƟ ents alike.
7.2 Laboratory Diagnosis of Chronic Q-Fever
Acute Q-fever may develop into chronic Q-fever in 2% of paƟ ents, a potenƟ ally lethal 
disease with endocardiƟ s as the main presentaƟ on [73]. PaƟ ents with previous cardiac valve 
pathology, aneurysms or vascular graŌ s, the immuno- compromised and women who are 
infected during pregnancy are at risk of chronic Q-fever [33]. An IFA IgG phase I anƟ body Ɵ tre 
≥1:800 is considered highly predicƟ ve for chronic Q-fever [40; 54; 74]. The ﬁ nal diagnosis 
of chronic Q-fever is made when a suspect serologic proﬁ le is combined with a posiƟ ve PCR 
[75]. However, considerable uncertainƟ es exist about the value of serology to idenƟ fy chronic 
cases, and the value of a posiƟ ve PCR is not completely clear. At the regional laboratory of 
Jeroen Bosch Hospital (‘s-Hertogenbosch, the Netherlands), located at the epicentre of the 
Dutch outbreak, we evaluated the serologic proﬁ les of 686 paƟ ents diagnosed with acute 
Q-fever in 2007 and 2008 at 3, 6 and 12 months aŌ er diagnosis [76]. Our results diﬀ er from 
data provided by others, as high IgG phase I anƟ body Ɵ tres at a 3-month follow-up were 
not predicƟ ve for chronic Q-fever and IgG phase I anƟ body Ɵ tres greater than IgG phase II 
anƟ body Ɵ tres were rarely seen. An IgG phase I ≥1:1,024 at 6 months seemed to have the 
highest sensiƟ vity for detecƟ ng chronic Q-fever, but the probability that cases with this proﬁ le 
actually had chronic Q-fever is low. Chronic Q-fever cases show a persistently high (≥1:1,024) 
or increasing IgG phase I anƟ body Ɵ tre, combined with a persistently high (≥1:4,096) IgG 
phase II anƟ body Ɵ tre. A serologic cut-oﬀ  at ≥1:1,024 (or at the previously proposed ≥1:800) 
provides adequate sensiƟ vity and posiƟ ve predicƟ ve value. The study conﬁ rmed that IgG 
phase I is a good screening test, in our case with a cut-oﬀ  of ≥1:1,024, at a follow- up of be-
tween 6 and 12 months aŌ er the acute Q-fever episode. A more stringent follow-up scheme 
is required for paƟ ents with clinical risk factors. Based on the experience gained since 2007, 
the serologic follow-up strategy is now one analysis at 9 months aŌ er an episode of acute 
Q-fever. For paƟ ents with speciﬁ c risk factors, the serological follow-up strategy at 3, 6 and 
12 months is maintained, combined with a PCR test. The diagnosis of chronic Q-fever and 
the decisions about treatment were made by a mulƟ disciplinary team of medical specialists, 
based on serologic proﬁ le, PCR results, the presence of clinical risk factors, clinical presenta-
Ɵ on, and other paƟ ent characterisƟ cs. Of the 686 acute Q-fever cases that were followed up, 
1.6% converted to a classic chronic case with microbiological evidence [76]. In the epidemic 
in the Netherlands, we found that the anƟ body Ɵ tre of IgG phase I ≥1:1,024 is not useful for 
immuno- compromised paƟ ents and every follow-up serum sample must be tested by PCR 
independently of the serological proﬁ le. In endocardiƟ s paƟ ents, we concluded that the PCR 
in a minority of paƟ ents is negaƟ ve despite having vegetaƟ on’s on echocardiography. Almost 
every vascular paƟ ent has a chronic serological proﬁ le and a posiƟ ve PCR.
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A Dutch consensus on chronic Q-fever was recently formulated [77]. A disƟ ncƟ on is made 
between ‘proven’, ‘probable’, and ‘possible’ chronic Q-fever. Proven chronic Q-fever requires 
(1) a posiƟ ve PCR in Ɵ ssue or blood in the absence of an acute Q-fever infecƟ on; or (2) an IFA 
phase I IgG Ɵ tre ≥1:1,024 and evidence of endocardiƟ s; or (3) an IFA phase I IgG Ɵ tre ≥1:1,024 
and evidence of vascular infecƟ on by radiologic imaging.
7.3 FaƟ gue in Q-fever paƟ ents
Following acute Q-fever, up to 60% of paƟ ents may experience post-infecƟ on faƟ gue symp-
toms. These symptoms can persist for 6–12 months, aŌ er which they spontaneously resolve 
[78]. Post-infecƟ on faƟ gue also occurs aŌ er other infecƟ ous diseases such as Lyme disease 
[79]. In 10–15% of Q-fever paƟ ents, faƟ gue can last from 5 to 10 years [80] and is then oŌ en 
referred to as QFS, with a symptom presentaƟ on similar to chronic faƟ gue syndrome (CFS). 
Some studies state that cytokine deregulaƟ on and immuno- modulaƟ on due to the persis-
tence of C. burneƟ i may be responsible for prolonged faƟ gue, but others contradict this [81]. 
An impaired or deregulated immune response or the long-term persistence of the bacteria 
or its anƟ gens and the immune response may also play a role.
7.4 A typical Q-fever paƟ ent
‘Jan Verkerk’ is a 48-year-old self-employed male. He ran a small, family-owned bicycle shop 
and did most of the work himself. He was also an acƟ ve sportsman, running 15 km three Ɵ mes 
a week and cycling daily. He had no known underlying physical or psychological diseases. In 
May 2007 he developed Q-fever and visited his general pracƟ Ɵ oner (GP) for the ﬁ rst Ɵ me in 
years, presenƟ ng with high fever and pneumonia. These acute symptoms disappeared during 
ensuing weeks, but 1 year later and despite his best eﬀ orts, he sƟ ll hadn’t resumed running at 
his normal level. He was feeling constantly Ɵ red and was struggling to manage his business. 
He did not sleep well due to night sweaƟ ng, was unable to concentrate, and suﬀ ered muscle 
and joint pains. He visited his GP many Ɵ mes, but several blood tests revealed nothing. He 
felt misunderstood by his GP, who seemed unable to help him, and he worried that if he did 
not recover he might not be able to manage his shop any longer. AŌ er speaking with other 
paƟ ents who told a similar story, he called the Department of InfecƟ ous Diseases of the 
Municipal Health Service to ﬁ nd out if this was a normal experience, whether others had 
similar problems, what further invesƟ gaƟ ons could be done, and how he could be treated for 
his persisƟ ng symptoms.
7.5 The health status of Q-fever paƟ ents aŌ er Long-term follow-up
In response to the many signals and quesƟ ons about persisƟ ng symptoms, parƟ cularly 
faƟ gue in Q-fever paƟ ents from the 2007 cohort, the collaboraƟ ve mulƟ disciplinary study 
Q-Quest I was started in 2008 [82]. A validated quesƟ onnaire, the Nijmegen Clinical Screen-
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ing Instrument (NCSI), was used to obtain a detailed assessment of the health status in 
Q-fever paƟ ents 12–26 months aŌ er the onset of their illness. This study is the largest and 
longest follow-up study of Dutch Q-fever paƟ ents from the 2007 and 2008 outbreaks. In 
2009, 870 Q-fever paƟ ents from the 2007 and 2008 outbreaks were asked to complete the 
quesƟ onnaire based on an empirical deﬁ niƟ on of health status [83], covering physiological 
funcƟ oning, symptoms, funcƟ onal impairment and quality of life as the main domains. These 
domains were subdivided into eight sub-domains: subjecƟ ve symptoms, dyspnoea emoƟ ons, 
faƟ gue, behavioural impairment, subjecƟ ve impairment, general quality of life, health related 
quality of life, and saƟ sfacƟ on with relaƟ ons [84]. We compared the NCSI scores of these 
Q-fever paƟ ents with normal data from healthy individuals and paƟ ents with severe chronic 
obstrucƟ ve pulmonary disease (COPD).
Our ﬁ ndings demonstrate that in comparison to healthy individuals, Q-fever paƟ ents – es-
pecially those that were hospitalised – present 12 to 26 months aŌ er the onset of illness with 
more severe clinically relevant subjecƟ ve symptoms, funcƟ onal impairment and impaired 
quality of life. The long-term health status of two-thirds of Q-fever paƟ ents was severely 
aﬀ ected for at least one sub-domain. Year of illness onset, level of educaƟ on and smoking 
behaviour had no signiﬁ cant inﬂ uence on sub-domain mean scores. Published data on the 
health status and its sub-domains of Q-fever paƟ ents are scarce. HatcheƩ e et al. (2003) 
[85] reported that 52% of Q-fever paƟ ents were symptomaƟ c and had an impaired quality 
of life 27 months aŌ er infecƟ on, using the 36-Item Short Form Health Survey (SF-36), with 
signiﬁ cantly lower scores, compared to non-infected controls in the domains of physical pain, 
funcƟ on and role, emoƟ onal role and social funcƟ on.
In Q-Quest I, the sub-domains ‘general quality of life’ and ‘faƟ gue’ measured with the 
NCSI were severely and clinically impaired, compared to the reference group. More than half, 
59% of paƟ ents had abnormal (mild to severe) faƟ gue, similar to other publicaƟ ons, which 
indicate that 60% of paƟ ents reported protracted faƟ gue [68] and up to 69% faƟ gue [78] 5 
years aŌ er infecƟ on. A small study on Dutch paƟ ents that measured a 1-year follow-up and 
also used the NCSI reported a higher rate of 53% of paƟ ents with severe faƟ gue [86], whereas 
the Q-Quest I study reported 44%.
The health status can be impaired aŌ er pneumonia regardless of the causaƟ ve organism. 
Dutch pneumonia paƟ ents had signiﬁ cantly aﬀ ected SF-36 scores 18 months aŌ er pneumo-
nia on the subscales ‘physical funcƟ on’ and ‘general health status’ [87]. Survivors of a Le-
gionnaire’s Disease outbreak in the Netherlands 17 months aŌ er infecƟ on reported severely 
impaired SF-36 domains: ‘physical role funcƟ on’, ‘general health’ and ‘vitality’ [88]. Up to 75% 
of paƟ ents reported faƟ gue. In Q-Quest I hospitalizaƟ on in the acute phase was signiﬁ cantly 
related to long-term behavioural impairment [82], poor health-related quality of life [82] 
and subjecƟ ve symptoms [82]. Severity of iniƟ al illness generally has a negaƟ ve inﬂ uence on 
the long-term quality of life [89; 90]. Similarly, the severity of the acute Q-fever symptoms 
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predicts long-term symptoms [91]. HospitalisaƟ on can be seen as an indicator of the severity 
of the iniƟ al infecƟ on. We conclude that Q-fever paƟ ents with severe acute illness are more 
likely to experience a long-term impaired quality of life. Lung or heart disease, depression 
and arthriƟ s also signiﬁ cantly aﬀ ected the long-term health status of Q-fever paƟ ents. Other 
authors state that underlying heart [92; 93] or lung disease [94], arthriƟ s [95], depression 
[96] and diabetes [97] all have a negaƟ ve eﬀ ect on diﬀ erent sub-domains of the health status. 
In Q-Quest I this eﬀ ect was also found for all underlying condiƟ ons, except for diabetes. It was 
not possible to compare data with exisƟ ng studies as most of these studies focus on speciﬁ c 
diseases (such as COPD) and grades of severity.
7.6 THE Q-FEVER PATIENT SOCIETY
In 2007 and 2008 the Q-fever outbreaks in the province of North Brabant did not receive 
much media aƩ enƟ on. In 2009, the outbreaks expanded to a larger area outside Brabant 
and paƟ ent numbers rose to over 2,000. The number of paƟ ents presenƟ ng with long-term 
eﬀ ects grew, the precauƟ onary veterinary measures were stepped up and media aƩ enƟ on 
increased as a result. This fed the public interest. Then, at the height of the Q-fever epidemic 
in 2009, most of the media aƩ enƟ on switched to the inﬂ uenza pandemic. Some general prac-
Ɵ Ɵ oners and other medical doctors and public health oﬃ  cials felt that the concurrent Q-fever 
outbreak received insuﬃ  cient aƩ enƟ on. At the same Ɵ me, GPs and paƟ ents increasingly 
reported long-term complaints. In November 2009, with help and ﬁ nancial support from 
the Province of North Brabant, a Q-fever PaƟ ent’s Society was founded. This society oﬀ ers 
paƟ ents a plaƞ orm to meet and express concerns and needs such as on treatment opƟ ons.
Several hospitals now run Q-fever out-paƟ ent departments for follow-up of Q-fever 
paƟ ents but care in these centres is not standardized. In June 2010, the PaƟ ent’s Society 
requested the Minister of Health to focus aƩ enƟ on on paƟ ents with long-term complaints 
aŌ er acute Q-fever infecƟ on. The NaƟ onal InsƟ tute for Public Health and the Environment 
was asked to draŌ  guidelines on the treatment of long-term complaints aŌ er acute Q-fever, 
and the product of a mulƟ disciplinary working group is expected in 2012.
7.7 An opportunity for more research and understanding
Many quesƟ ons on the late eﬀ ects of Q-fever remain unanswered, such as the eﬀ ecƟ veness 
of treatment of QFS [98] with cogniƟ ve behavioural treatment and graded exercise therapy. 
The outbreaks in the Netherlands oﬀ er a unique opportunity for prospecƟ ve research (the 
Q-Quest II study) on the long-term health outcomes in Q-fever paƟ ents. With more than 
4,000 acute Q-fever cases reported up to November 2010 and symptoms that can last for 
10 years or more, a considerable burden of disease in coming years is expected for paƟ ents 
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and the aﬀ ected communiƟ es. GPs and other medical doctors should be aware that Q-fever 
paƟ ents may present with long-term symptoms, especially if they have been hospitalised or 
have co-morbidity (heart or lung disease, or depression). Ongoing research on the treatment 
and recovery of Q-fever paƟ ents should oﬀ er a beƩ er understanding of the delayed and long-
term eﬀ ects of this zoonosis. There is a parƟ cular need for randomised clinical trials to test 
the eﬀ ecƟ veness of treatment opƟ ons.
8. Q-FEVER VACCINATION IN THE NETHERLANDS
8.1 VaccinaƟ on decisions during the Q-fever epidemic
The annual Q-fever epidemics that began in 2007 prompted Dutch policy makers to consider 
introducing a human vaccinaƟ on programme to protect people at risk for severe outcomes of 
the disease. However, early live aƩ enuated and sub-unit vaccines were abandoned because 
of low eﬃ  cacy and safety concerns, leaving just one human Q-fever vaccine. This whole-cell 
vaccine was developed and registered in Australia and is licensed under the name Q-vax. It is 
not registered in the Netherlands or in any other European country. There were logisƟ cal and 
legal constraints to introducing a non-registered vaccine that required extensive tesƟ ng of 
subjects before vaccinaƟ on. Human vaccinaƟ on can play no role in controlling the epidemic 
but the increasing number of reports of long-term eﬀ ects in paƟ ents with chronic Q-fever 
eventually caused both professionals and decision makers to reconsider the introducƟ on of 
the vaccine in the Netherlands. At the same Ɵ me, hospitals and public health services were 
confronted with an increasing number of worried Q-fever paƟ ents, both acute and chronic, 
some of whom travelled to Australia at their own expense to be vaccinated. In 2010, the 
Government asked the Health Council of the Netherlands to advice on the possible use of 
the vaccine.
8.2 The Q-vax vaccine
Q-vax consists of formalin inacƟ vated C. burneƟ i and was developed by CSL limited (CLS 
Biotherapies). It has been licensed in Australia to protect at-risk slaughterhouse employees 
and veterinary professionals [99]. In this respect, the vaccine was quite successful and is sƟ ll 
in use [100; 101].
Analysis of the vaccine’s eﬃ  cacy in selected groups of professionals with a potenƟ ally high 
aƩ ack rate shows a protecƟ on rate of 97% [102]. VaccinaƟ ng subjects without a measurable 
immune response to C. burneƟ i is safe, but does commonly result in mild local reacƟ ons 
(33–48%) or mild systemic reacƟ ons (9%) such as headache [103]. Between 2002 and 2006, 
a large campaign in Australia saw the vaccinaƟ on of 50,000 paƟ ents, resulƟ ng in eight serious 
adverse events requiring hospital admission and one life-threatening event. No deaths have 
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ever been recorded aŌ er vaccinaƟ on [104]. It is noteworthy that this data comes from a spe-
ciﬁ c group of young and predominantly healthy males, the vaccine is only given to subjects 
over 15 years of age, and it is not administered to pregnant women.
Data is not available on the eﬀ ecƟ veness of the vaccine in persons other than healthy 
workers. Furthermore, the vaccine can only be given to those not previously in contact with 
C. burneƟ i, as vaccinaƟ ng subjects that have already mounted an immunological response 
may lead to serious adverse reacƟ ons such as sterile abscesses and systemic symptoms of 
inﬂ ammaƟ on. To prevent this, serology and skin tesƟ ng must be performed to idenƟ fy those 
who have previously had contact with C. burneƟ i. Although these tests are not complicated 
per se, they can be diﬃ  cult to organise and require speciﬁ c skills such as administering and 
interpreƟ ng of the skin test. To further complicate maƩ ers, laboratory tests are not stan-
dardised, and diﬀ erent serologic tests systems and cut-oﬀ  values are used.
8.3 Target Groups for VaccinaƟ on
PaƟ ents aﬀ ected with Q-fever come mainly from speciﬁ c areas in the south of the Nether-
lands. However, considerable diﬀ erences occur within the aﬀ ected area, and people living 
near aﬀ ected farms may be especially aﬀ ected. Nevertheless, localised mass vaccinaƟ on has 
never been considered.
Preliminary data indicate that high numbers of professionals have been infected with 
C. burneƟ i – studies performed among goat and sheep farmers and veterinarians showed 
seroprevalence ﬁ gures of up to 80%. Since the majority of these risk groups had already been 
exposed with a limited burden of disease, it was decided not to vaccinate them. However, 
those just starƟ ng out in a high-risk career, such as veterinarians, could be considered as 
candidates for vaccinaƟ on.
The Q-fever vaccine could be of use for populaƟ on groups with underlying disease that 
make them at risk for long-term eﬀ ects. Although these long-term eﬀ ects are quite rare, they 
can be very serious and include endocardiƟ s and the infecƟ on of large blood vessels [74; 
105]. The treatment of chronic Q-fever requires long-term (>1.5 years) anƟ bioƟ c treatment 
and someƟ mes cardiovascular surgical intervenƟ ons.
PaƟ ents with pathologic heart valves or blood vessels are parƟ cularly at risk. However, 
most of the studies in this area have been performed retrospecƟ vely and suﬀ er from con-
siderable selecƟ on bias. This means that the true contribuƟ on and magnitude of the risk 
associated with pre-existent factors is not known. It is also unclear whether minor valve or 
vessel pathology could develop into serious pathology during chronic Q-fever. Furthermore, 
liƩ le is known about the incubaƟ on period of serious long-term eﬀ ects of chronic Q-fever.
Once the decision has been made to vaccinate paƟ ents at risk, these uncertainƟ es maƩ er 
and must be considered. For example, the screening of all acute Q-fever paƟ ents for heart 
defects with echocardiography (as advised in the internaƟ onal literature) was not feasible 
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during the large-scale Dutch outbreak [86; 105]. Similar screening opƟ ons for aneurysms in a 
given populaƟ on may also not be feasible.
For these reasons, deﬁ ning and selecƟ ng paƟ ent groups for vaccinaƟ on is not a simple 
maƩ er. In 2010, the Health Council of the Netherlands (2010) [30] idenƟ ﬁ ed the following 
groups as eligible for vaccinaƟ on:
• PaƟ ents who have had endocardiƟ s in the past
• PaƟ ents with arƟ ﬁ cial heart valves
• PaƟ ents with signiﬁ cant congenital heart anomalies, including those that required repair 
with
• PaƟ ents with structural defects of the aorƟ c or mitral valve
• PaƟ ents with known aneurysm of the aorta
• PaƟ ents with vascular graŌ s
• PaƟ ents with severe peripheral vascular disease (such as Buerger’s disease).
8.4 Deciding to vaccinate
Even though the use of the vaccine in certain groups has been advocated, this vaccine is not 
licensed in the Netherlands and its administraƟ on will not be part of a naƟ onally steered 
programme. However, it is considered part of health care under the responsibility of the 
treaƟ ng physician. Together with the paƟ ent, the physician must weigh the potenƟ al beneﬁ ts 
and disadvantages of vaccine administraƟ on. These decisions need to be made with full 
awareness of the medical and the epidemiological risks involved.
Vaccine administraƟ on can only be carried out aŌ er a professional skin test reading and 
serology result analysis. This requires a standardised process with similar cut-oﬀ  Ɵ tres and 
speciﬁ city tests, as well as centralised vaccinaƟ on to realise standardised quality of care. 
Therefore, even though the vaccine has not been added to the naƟ onal vaccine programme, 
its introducƟ on in 2011 was coordinated by the NaƟ onal InsƟ tute of Public Health and the 
Environment, in collaboraƟ on with a commercial partner, regional public health departments 
and local physicians. In the vaccinaƟ on campaign, early 2011, 1,354 people were vaccinated, 
all from the deﬁ ned high risk groups.
CONCLUSIONS
Between 2007 and 2009, the Netherlands experienced an unprecedented series of seasonal 
outbreaks of Q-fever. Dairy goats are clearly implicated in these outbreaks. In 2010 there 
were a much lower number of noƟ ﬁ ed acute Q-fever cases than in 2009, probably due to the 
drasƟ c veterinary intervenƟ ons such as culling of pregnant goats on infected farms, vaccina-
Ɵ on, and hygiene measures. But the risk of Q-fever outbreaks and possibly other zoonoƟ c 
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diseases remains high because of the cohabitaƟ on of 2.4 million inhabitants with 6.4 million 
animals in the province of North Brabant. A great deal of knowledge has been generated in 
the past few years but many quesƟ ons remain. Ongoing research, including 20 PhD projects, 
is expected to signiﬁ cantly advance the knowledge base. AƩ enƟ on is now shiŌ ing from acute 
Q-fever to the problem of long-term eﬀ ects of Q-fever, the extent of which is not yet known 
and which poses important challenges for diagnosis and treatment.
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ABSTRACT
Background
During the Dutch Q-fever epidemic more than 4,000 Q-fever cases were noƟ ﬁ ed. This 
provided logisƟ cal challenges for the organisaƟ on of serological follow-up, which is con-
sidered mandatory for early detecƟ on of chronic infecƟ on. The aim of this study was to 
invesƟ gate the proporƟ on of acute Q-fever paƟ ents that received serological follow-up, 
and to idenƟ fy regional diﬀ erences in follow-up rates and contribuƟ ng factors, such as 
knowledge of medical pracƟ Ɵ oners.
Methods
Serological datasets of Q-fever paƟ ents diagnosed between 2007 and 2009 (n=3,198) 
were obtained from three Laboratories of Medical Microbiology (LMM) in the province 
of Noord-Brabant. One LMM oﬀ ered an acƟ ve follow-up service by approaching pa-
Ɵ ents; the other two only tested on physician’s request. The medical microbiologist 
in charge of each LMM was interviewed. In December 2011, 240 general pracƟ ces 
and 112 medical specialists received quesƟ onnaires on their knowledge and pracƟ ces 
regarding the serological follow-up of Q-fever paƟ ents.
Results
Ninety-ﬁ ve percent (2,226/2,346) of the Q-fever paƟ ents diagnosed at the LMM with a 
follow-up service received at least one serological follow-up within 15 months of diag-
nosis. For those diagnosed at a LMM without this service, this was 25% (218/852) (OR 
54, 95% CI: 43−67). Although 80% (162/203) of all medical pracƟ Ɵ oners with Q-fever 
paƟ ents reported informing paƟ ents of the importance of serological follow-up, 33% 
(67/203) never requested it.
Conclusions
Regional diﬀ erences in follow-up are substanƟ al and range from 25% to 95%. In areas 
with a low follow-up rate the proporƟ on of missed chronic Q-fever is potenƟ ally higher 
than in areas with a high follow-up rate. Medical pracƟ Ɵ oners lack knowledge regard-
ing the need, Ɵ ming and implementaƟ on of serological follow-up, which contributes 
to paƟ ents receiving incorrect or no follow-up. Therefore, this informaƟ on should be 
incorporated in naƟ onal guidelines and paƟ ent informaƟ on forms.
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INTRODUCTION
In the Netherlands, more than 4,000 paƟ ents were noƟ ﬁ ed with acute Q-fever during sea-
sonal outbreaks between 2007 and 2010 [1, 2]. However, at least ten Ɵ mes as many people 
might have been infected with Coxiella burneƟ i in this period and had either asymptomaƟ c 
or non-diagnosed infecƟ ons [3, 4]. Acute Q-fever may progress to chronic Q-fever in about 
2% of cases [5]. Chronic Q-fever is not noƟ ﬁ able. There are no esƟ mates for the proporƟ on of 
asymptomaƟ c acute C. burneƟ i infecƟ ons that develop into chronic infecƟ on. The most com-
mon presentaƟ ons of chronic Q-fever are endocardiƟ s and vascular infecƟ ons, condiƟ ons 
with high morbidity and mortality [6]. The diagnosis of chronic Q-fever is based on clinical 
presentaƟ on, presence of risk factors, diagnosƟ c imaging techniques, detecƟ on of C. burneƟ i 
DNA in blood or Ɵ ssue, and serological test results. DetecƟ on of an IgG anƟ body Ɵ tre against 
phase I of C. burneƟ i of ≥1:1,024 in a commercially available immunoﬂ uorescence assay 
during follow-up screening is considered an important marker of chronic infecƟ on [7]. Sero-
logical follow-up of acute Q-fever paƟ ents is advised in order to idenƟ fy and ensure Ɵ mely 
treatment of chronic Q-fever [8−10]. Follow-up is especially important for paƟ ents with val-
vulopathy, vascular prosthesis/abnormaliƟ es, pregnant women, and immunocompromised 
paƟ ents, as they have a higher risk of developing chronic Q-fever aŌ er acute infecƟ on [9, 11].
A common but non-validated recommendaƟ on in the internaƟ onal literature was to oﬀ er 
all paƟ ents at least two serologic tests (at three and six months) in the ﬁ rst year aŌ er the 
diagnosis of acute Q-fever [12, 13]. In 2008 the advice to test all Q-fever paƟ ents at three, six, 
and twelve months aŌ er diagnosis was published in a Dutch microbiology journal [10]. Two 
years later, in 2010, new advice was published in another Dutch medical journal proposing 
one follow-up serologic test at nine months for low-risk paƟ ents, while the recommendaƟ on 
for high-risk paƟ ents was to test at three, six, nine, and twelve months [7]. During the Dutch 
Q-fever epidemic, apart from these recommendaƟ ons in scienƟ ﬁ c journal arƟ cles, there 
were no naƟ onal guidelines on the serological follow-up of Q-fever paƟ ents.
In the province of Noord-Brabant, one Laboratory of Medical Microbiology (LMM) used 
an automaƟ c paƟ ent recall system for the serological follow-up of paƟ ents with acute Q-fever. 
The other two LMMs depended on medical pracƟ Ɵ oners to request serological Q-fever 
follow-up. The Municipal Health Service (MHS) Hart voor Brabant received informaƟ on from 
both paƟ ents and health professionals that indicated poor serological follow-up of Q-fever 
paƟ ents with regional diﬀ erences. Therefore the quesƟ on arose, if and to what extent the 
serological follow-up rates of Q-fever paƟ ents diﬀ ered per LMM catchment area. Are chronic 
Q-fever cases potenƟ ally missed due to a lack of proper follow-up? The aim of this study 
was to invesƟ gate the extent to which acute Q-fever paƟ ents received serological follow-up, 
idenƟ fy regional diﬀ erences and contribuƟ ng factors and study the diﬀ erences in knowledge 
and pracƟ ces regarding serological follow-up among medical pracƟ Ɵ oners.
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MATERIALS AND METHODS
Ethics Statement
According to Dutch legislaƟ on, wriƩ en consent from paƟ ents for the use of anonymized 
informaƟ on from laboratory databases is not necessary; therefore ethical review was not 
required.
Study populaƟ on and data collecƟ on
Laboratories of Medical Microbiology (LMMs)
Three LMMs (A, B, and C, see Figure 1) performed the majority of Q-fever serology in the 
province of Brabant. LMM-A in ’s-Hertogenbosch provided acƟ ve follow-up by contacƟ ng 
every diagnosed Q-fever paƟ ent for serological follow-up through an automated system. All 
paƟ ents received an explanatory leƩ er and a laboratory form. The other two LMMs, LMM-B 
in Tilburg and LMM-C in Veldhoven, performed serological follow-up only upon request of a 
medical pracƟ Ɵ oner.
All three LMMs provided anonymous serological datasets from all paƟ ents that were diag-
nosed with acute Q-fever between January 2007 and December 2009. Follow-up samples up 
to 15 months aŌ er diagnosis of Q-fever were analysed for Ɵ ming and frequency. Samples that 
were taken within 60 days of diagnosis were not considered as follow-up samples. Follow-
up periods were divided into 60−135 days (2−4.5 months), 136−255 days (4.5−8.5 months) 
and 256−450 days (8.5−15 months) in order to include the three-, six-, and twelve-month 
follow-up, respecƟ vely. The nine-month follow-up started in 2010; therefore these data are 
not presented as a separate follow-up moment in this study but are included in the follow-up 
period 256−450 days (8.5−15 months). PaƟ ents that were present in the dataset of more 
than one LMM were only included once by checking gender, date of birth and the postal 
code. These paƟ ents were then allocated to the LMM that requested the Q-fever serology. 
We conducted semi-structured interviews with the head medical microbiologist of each labo-
ratory regarding perceived role and responsibility of serological follow-up of Q-fever paƟ ents.
InformaƟ on from general pracƟ Ɵ oners and medical specialists
In December 2011, quesƟ onnaires were posted to all 240 general pracƟ ces (with 501 general 
pracƟ Ɵ oners) and all internists (n=42), cardiologists (n=46), and pulmonologists (n=24) from 
all hospitals (n=6) in the MHS region Hart voor Brabant (MHS HvB), the epicentre of the 
Q-fever epidemic (see Figure 1). We used the term medical pracƟ Ɵ oners to refer to both 
general pracƟ Ɵ oners (GPs) and medical specialists. Non-responders received a reminder 
aŌ er two and four weeks. Reminders were not sent to GPs when one out of three GPs from 
the medical pracƟ ce responded.
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The quesƟ ons posed were: work locaƟ on (postal code), LMM used, the number of 
Q-fever paƟ ents treated and the knowledge and pracƟ ces regarding serological follow-up 
of Q-fever paƟ ents. PracƟ ce quesƟ ons included informing the paƟ ent about the importance 
of serological follow-up (never/someƟ mes/oŌ en/always); requesƟ ng Q-fever follow-up se-
rology for paƟ ents (never/someƟ mes/oŌ en/always); and diﬀ erenƟ aƟ ng between high- and 
low-risk paƟ ent groups when oﬀ ering follow-up (never/someƟ mes/oŌ en/always). Never and 
someƟ mes were regarded as inadequate pracƟ ce. Knowledge quesƟ ons (mulƟ ple-choice) 
focused on idenƟ ﬁ caƟ on of high-risk groups for developing chronic Q-fever i.e., “people with 
valvulopathy, vascular prosthesis/ abnormaliƟ es, pregnant women, and the immunocompro-
mised”. The possibility to add another perceived risk group was oﬀ ered as an open quesƟ on. 
The same method was used for the follow-up, Ɵ ming and diﬀ erences in follow-up between 
high- and low-risk group paƟ ents. Not being able to idenƟ fy three high-risk groups, and mak-
ing no disƟ ncƟ on in frequency or Ɵ ming of serological follow-up between high- and low-risk 
groups were regarded as incorrect answers.
Medical pracƟ Ɵ oners were divided in groups with zero, few (≤10) and many (>10) Q-fever 
paƟ ents and the Q-fever incidence area where they worked. These Q-fever incidence areas 
were based on the cumulaƟ ve Q-fever noƟ ﬁ caƟ on data from 2007 up to December 2010 
in the area of the MHS HvB and were deﬁ ned as low (<150 cases per 100,000 residents), 
medium (150−300/100,000) and high (>300 up to 2,425/100,000) (see Figure 1).
Data analysis
All data were analysed using SPSS StaƟ sƟ cs version 19.0.0 (SPSS Inc.). ProporƟ ons were 
compared with the Mantel-Haenszel chi-square and Fisher’s exact test. P-values were based 
on two-tailed tests, deﬁ ning p<0.05 as signiﬁ cant.
RESULTS
Laboratories of Medical Microbiology
We received serological datasets of 3,198 paƟ ents diagnosed by three LMMS between 2007 
and 2009 with serology indicaƟ ve of acute Q-fever (Figure 1). The diﬀ erence in percentage 
of paƟ ents without serological follow-up within 15 months of diagnosis, diﬀ ered greatly be-
tween LMMs with an acƟ ve or passive follow-up approach (Table 1); 5% (120/2,346) versus 
74% (634/852) respecƟ vely (OR 54, 95% CI: 43−67). The percentage of paƟ ents that did not 
receive serological follow-up was comparable for the two LMMs without acƟ ve follow-up 
(74%). Overall, 24% (754/3,198) of Q-fever paƟ ents did not receive any follow-up.
During the interviews, one of the heads of an LMM (without a follow-up service) stated 
that both the medical pracƟ Ɵ oner and the MHS were responsible for the serological follow-up 
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of Q-fever paƟ ents. The other two microbiologists perceived this to be a shared responsibility 
between medical pracƟ Ɵ oners, paƟ ents, and the LMM. The microbiologist in charge of LMM-
A, the LMM that provided acƟ ve follow-up, chose a proacƟ ve approach at the beginning 
of the epidemic. The heads of the two LMMs without acƟ ve follow-up stated that in their 
opinion an acƟ ve recall of paƟ ents by an LMM was not an opƟ on because they regarded this 
as interfering with the responsibility of the medical pracƟ Ɵ oner.
Response quesƟ onnaires and interviews medical pracƟ Ɵ oners
The response rate of general pracƟ ces was 70% (167/240), and included 42% (209/501) 
of GPs. The response rate of specialists was 29% (32/112); highest for pulmonologists 37% 
(9/24) and internists 33% (14/42), and lowest for cardiologists 15% (6/46). The most fre-
quently menƟ oned reasons for not parƟ cipaƟ ng in the study by non-responders who gave 
reasons (n=70) were no Q-fever paƟ ents (38%) or Ɵ me constraints (25%).
Response quesƟ onnaires and interviews medical pracƟ Ɵ oners
The response rate of general pracƟ ces was 70% (167/240), and included 42% (209/501) 
of GPs. The response rate of specialists was 29% (32/112); highest for pulmonologists 37% 
(9/24) and internists 33% (14/42), and lowest for cardiologists 15% (6/46). The most fre-
quently menƟ oned reasons for not parƟ cipaƟ ng in the study by non-responders who gave 
reasons (n=70) were no Q-fever paƟ ents (38%) or Ɵ me constraints (25%).
Figure 1. CumulaƟ ve Q-fever incidence in the Netherlands from 2007 up to and including 2010, mark-
ing the Municipal Health Service regions, highlighƟ ng the Municipal Health Service region Hart voor 
Brabant and the Laboratories of Medical Microbiology, A in ’s-Hertogenbosch, B in Tilburg, and C in 
Veldhoven.
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Table 1. Diagnosis and serological follow-up up to 15 months (450 days) aŌ er diagnosis of Q-fever for 
three Laboratories of Medical Microbiology (LMM).
 
 
 
 
Provision follow-up service and locaƟ on LMM  
Yes No No Total
’s-Hertogenbosch Veldhoven Tilburg All LMM
n (%) n (%) n (%) n (%)
Total diagnosis Q-fever 2,346 (100) 527 (100) 325 (100) 3,198 (100)
Diagnosis by
 GP 1,786 (76.2) 320 (60.7)  91 (28.0) 2,197 (68.7)
 Specialist  536 (22.8) 207 (39.3) 137 (42.1)  880 (27.5)
 Unspeciﬁ ed  24 (1.0)  0 (0.0)  97 (29.8)  121 (3.8)
No follow-up  120 (5.1) 392 (74.4) 242 (74.5)  754 (23.6)
Received follow-up in days aŌ er diagnosis
 60−135 a 2,077 (88.5)  67 (12.7)  47 (14.5) 2,191 (68.5)
 136−255 2,015 (85.9)  57 (10.8)  40 (12.3) 2,112 (66.0)
 256−450 1,926 (82.1)  61 (11.6)  24 (7.4) 2,011 (62.9)
Follow-up requested by
 GP NA  86 (46.5)  43 (43.9)  129 (45.6)
 Specialist NA  99 (53.5)  55 (56.1)  154 (54.4)
Total NA 185 (100)  98 (100)b  283 (100)
GP: general pracƟ Ɵ oner; LMM: Laboratory of Medical Microbiology; NA: not applicable.
a A sample taken within 60 days aŌ er diagnosis was not considered as a follow-up sample.
b For 13 samples the applicant was unknown (request by an external laboratory).
Knowledge and behaviour of medical pracƟ Ɵ oners regarding serological follow-up
Although 80% (162/203) of all medical pracƟ Ɵ oners with Q-fever paƟ ents reported informing 
paƟ ents of the importance of serological follow-up, 33% (67/203) stated never to request 
follow-up. InformaƟ on on knowledge and pracƟ ce quesƟ ons for medical pracƟ Ɵ oners with 
Q-fever paƟ ents that do (someƟ mes/oŌ en/always) oﬀ er follow-up is provided in Table 2. 
Outcomes were comparable for diﬀ erent incidence areas and type of medical pracƟ Ɵ oner 
(GP or medical specialist). Medical pracƟ Ɵ oners with one to ﬁ ve Q-fever paƟ ents (mainly 
found in the low and middle incidence areas) seemed less likely to request serological follow-
up, as 47% (27/58) stated never. There was no signiﬁ cant diﬀ erence compared to those with 
more paƟ ents. Overall, there was no diﬀ erence in reported pracƟ ce of requesƟ ng follow-up 
serology between GPs in an area with or without an automaƟ c recall-system (Table 3). GPs 
with many paƟ ents (>10) and working in the catchment area of a LMM without acƟ ve follow-
up requested follow-up signiﬁ cantly more oŌ en than those with few paƟ ents (≤10).
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The ability to diﬀ erenƟ ate between high- and low-risk paƟ ent groups was comparable for 
GPs and specialists. The knowledge quesƟ on; “are paƟ ents with a heart valve defect a high-
risk group for chronic Q-fever” was answered ‘yes’ by 88% of GPs and 100% of specialists. 
For stents and vascular abnormaliƟ es this was 85% and 86%, for the immune compromised 
85% and 79%, and for pregnant during the iniƟ al infecƟ on 74% and 61%, respecƟ vely. When 
looking at individual medical pracƟ Ɵ oners, 67% correctly idenƟ ﬁ ed all high-risk groups. When 
oﬀ ering serological follow-up, 35% of GPs and 22% of medical specialists never consider the 
risk category of the paƟ ent. Medical pracƟ Ɵ oners with many (>10) paƟ ents scored signiﬁ cantly 
worse for idenƟ ﬁ caƟ on of the correct high-risk groups, discussing the importance of serological 
follow-up with the paƟ ent, and requesƟ ng follow-up serology for high-risk groups (Table 2).
Both GPs (63%) and specialists (45%) assumed that the LMM requests follow-up. GPs 
with few Q-fever paƟ ents indicated that they were not acquainted with the procedure and 
referred paƟ ents to specialists. The main reason for not requesƟ ng serological follow-up, 
menƟ oned by GPs with many Q-fever paƟ ent cases, was the assumpƟ on that the LMM or the 
MHS would take this responsibility.
Table 2. Answers to knowledge and pracƟ ce quesƟ ons of medical pracƟ Ɵ oners (MPs) comparing those 
with few (≤10) and many (>10) Q-fever paƟ ents.
 
 
 
 
Number of Q-fever paƟ ents per medical pracƟ Ɵ onera  
>10 ≤10 Total  
Answered 
Yes
Total MPs
Answered 
Yes
Total MPs
Answered 
Yes
Total MPs OR (95% CI)
n  (%) n  (100%) n  (%) n  (100%) n  (%) n  (100%)  
Knowledge quesƟ ons
Makes disƟ ncƟ on of risk 
groups for chronic infecƟ on
35 (50.7) 69 (100) 33 (53.2) 62 (100) 68 (51.9) 131 (100) 0.9 (0.4−1.8)
IdenƟ ﬁ es all high-risk 
groups for chronic infecƟ on
28 (41.1) 68 (100) 16 (24.6) 65 (100) 44 (33.1) 133 (100) 2.1 (1.0−4.5)
PracƟ ce quesƟ ons
Discusses importance of 
follow-up with paƟ ent
66 (94.2) 70 (100) 55 (82.1) 67 (100) 121 (88.3) 137 (100) 3.6 (1.1−11.8)
Requests follow-up 
Q-fever paƟ ents without 
disƟ ncƟ on of risk groups
32 (45.7) 70 (100) 31 (49.2) 63 (100)  63 (47.4) 133 (100) 0.8 (0.4−1.7)
Requests serology at least 
once for low-risk groups
34 (52.2) 65 (100) 36 (59.0) 61 (100)  65 (51.5) 126 (100) 0.7 (0.4−1.5)
Requests serology at least 
three Ɵ mes for high-risk 
groups
34 (57.6) 59 (100) 18 (30.5) 59 (100)  52 (44.1) 118 (100) 3.3 (1.4−5.0)
95% CI: conﬁ dence interval; MPs: medical pracƟ Ɵ oners; OR: odds raƟ o.a Excluded are medical pracƟ -
Ɵ oners without Q-fever paƟ ents (n=30), those who never request serological follow-up (n=70) or gave 
not applicable (NA) answers.
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DISCUSSION
Laboratory follow-up
AŌ er diagnosing acute Q-fever, serologic follow-up is considered essenƟ al for early detecƟ on 
and treatment of chronic Q-fever. During the Dutch Q-fever epidemic there was no naƟ onal 
consensus or guidelines on serological follow-up of acute Q-fever paƟ ents. In an aƩ empt to 
comply with the changing recommendaƟ ons, LMMs and clinicians improvised. This led to an ac-
Ɵ ve recall of paƟ ents by one LMM, while in other regions medical pracƟ Ɵ oners had to organise 
this follow-up themselves. In this study we analysed the outcome of these two approaches. An 
acƟ ve follow-up approach by a LMM led to a much higher follow-up rate compared to follow-up 
by medical pracƟ Ɵ oners only (OR 54, 95% CI: 43−67). When the responsibility of follow-up lies 
with medical pracƟ Ɵ oners, the outcome is poor. Overall, 1,187 (37%) paƟ ents received incom-
plete or no (24%; n=754) follow-up. Ideally, the percentage of chronic Q-fever cases found in 
the group of paƟ ents that did receive follow-up would be known, based on the conversion 
rate to chronic Q-fever. However, the diagnosis of chronic Q-fever is a combinaƟ on of; an IgG 
phase I anƟ body Ɵ tre against C. burneƟ i of ≥1:1,024 in immunoﬂ uorescence assay in a follow-
up sample [7], the detecƟ on of C. burneƟ i DNA in blood or Ɵ ssue, clinical ﬁ ndings, the presence 
of risk factors, and diagnosƟ c imaging techniques. This addiƟ onal informaƟ on was unavailable. 
Chronic Q-fever is not noƟ ﬁ able and therefore we lacked accurate data on the occurrence of 
chronic Q-fever. We were unable to retrieve accurate data on chronic Q-fever from paƟ ents 
that were lost to follow-up, as paƟ ent’s personal details were removed from the LMM database 
Table 3. Regional diﬀ erences in reported serological follow-up pracƟ ces by GPs in regions with a Labora-
tory of Medical Microbiology (LMM) with or without an automaƟ c follow-up system.
Number of GPs by LMM region
LMM with automaƟ c follow-upa; 
GPs n=123 (100%)
LMM without automaƟ c follow-up B; 
GPs n=47 (100%)
Few 
paƟ ents ≤10
Many 
paƟ ents >10
Total OR (CI) Few 
paƟ ents ≤10
Many 
paƟ ents >10
Total OR (95% CI)
n  (%) n  (%) n  (%)  n  (%) n  (%) n  (%)  
Frequency serology 
request GP
0.6 (0.2−1.2) 4.8 (1.1−22.1)
Mostly/always 23 (44.2) 22 (30.9) 45 (36.6) 12 (32.4) 7 (70.0) 19 (40.4)
SomeƟ mes/ never 29 (55.8) 49 (69.1) 78 (63.4) 25 (67.6) 3 (30.0) 28 (59.6)
Total 52 (100) 71 (100) 123 (100)  37 (100) 10 (100) 47 (100)  
95% CI: 95% conﬁ dence interval; GPs: general pracƟ Ɵ oners; LMM: Laboratory of Medical Microbiology; 
OR: odds raƟ o.
a MunicipaliƟ es in the service area of a LMM with follow-up: Heusden, Oss, Maasdonk, Uden, Bernheze, 
Lith, Landerd, Vught, ’s-Hertogenbosch (Den Bosch), Sint Michielsgestel, Veghel, Schijndel, Boekel, Boxtel.
B MunicipaliƟ es in the service area of a LMM without follow-up: Dongen, Waalwijk, Tilburg, Oisterwijk, 
Gilze Rijen, Loon op Zand, Sint Oedenrode, Cuijk, Boxmeer, Mill en Sint Hubert, Hilvarenbeek, Sint An-
thonis, Haaren, Grave.
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for reasons of anonymity. We do however know that up to the beginning of 2013 a total of 
3% (71/2,226) of paƟ ents of the LMM that provided acƟ ve follow-up service had an anƟ body 
response (IgG phase I) suspect for a possible, probable or proven chronic Q-fever (personal 
communicaƟ on, unpublished data Nicole H.M. Renders, Medical Microbiologist). However, 
new chronic cases are sƟ ll being idenƟ ﬁ ed, as the average incubaƟ on period of chronic Q-fever 
may be long and deﬁ niƟ ve idenƟ ﬁ caƟ on and characterizaƟ on of chronic Q-fever paƟ ents is 
complicated. Based on an esƟ mated 1−5% conversion rate to chronic Q-fever, we calculate 
that approximately 12 to 59 (1−5% of 1,187 paƟ ents without or with incomplete follow-up) 
chronic Q-fever paƟ ents might have been missed because of inadequate follow-up. Now that 
it is known that this many traceable paƟ ents received no or improper follow-up, the discussion 
arises whether oﬀ ering serological tesƟ ng years aŌ er the iniƟ al infecƟ on would be beneﬁ cial to 
paƟ ents. At the same Ɵ me the current screening recommendaƟ ons [14] are quesƟ oned. What 
percentage of chronic Q-fever might we expect to ﬁ nd per risk category and how should these 
categories be deﬁ ned? Should all 1,187 Q-fever paƟ ents need to be recalled or only a selecƟ on 
of high-risk paƟ ents? What percentage of chronic Q-fever paƟ ents diagnosed several years 
aŌ er acute Q-fever would jusƟ fy such a recall? Should one incorporate a Ɵ me limit for follow-up 
for paƟ ents aŌ er an acute infecƟ on that do not belong to a risk category? Other important 
issues are the cut-oﬀ  value of the immunoﬂ uorescence assay, and the duraƟ on and frequency 
of follow-up. In the Netherlands, several follow-up studies are currently being conducted that 
may answer some of these quesƟ ons.
One would assume that paƟ ent compliance is the same regardless of the system. However, 
computer generated systems are known to improve paƟ ent compliance [15] and a diagnosis of 
acute Q-fever made by a laboratory with an acƟ ve recall-system provides the best guarantee for 
receiving follow-up. The downsides of such a system are the unnecessary exposure of paƟ ents 
to blood tests and the overburdening of laboratory faciliƟ es. To prevent overburdening, the 
LMM needs clinical informaƟ on from the medical pracƟ Ɵ oner to disƟ nguish between acute and 
old infecƟ ons [16] and risk categories, but this informaƟ on is oŌ en not provided.
Response rate, knowledge and pracƟ ces of medical pracƟ Ɵ oners
The response rate of the general pracƟ ces was good (70%), and we consider our sample to 
be representaƟ ve for GPs in the MHS region as the proporƟ ons of responding pracƟ ces were 
comparable for the diﬀ erent incidence areas. We used the number of Q-fever paƟ ents per GP 
rather than incidence area because all GPs stated the number of Q-fever paƟ ents.
Approximately half of the medical pracƟ Ɵ oners lacked knowledge on high-risk groups, 
disƟ ncƟ on between low- and high-risk paƟ ents, and the need to request serological follow-up 
for all acute Q-fever paƟ ents. A high proporƟ on of medical pracƟ Ɵ oners (88%) reported that 
they discussed the importance of serological follow-up with the paƟ ent but it might be that 
an expected correct answer was given [17].
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Barriers to behavioural change by GPs’ and specialists’ relate to knowledge, aƫ  tude and 
external factors [18, 19]. Although many diﬀ erent parƟ es play a role in serological follow-up, 
correct informaƟ on and knowledge [19] is the ﬁ rst step to compliance. During the epidemic, 
the MHS HvB regularly advised medical pracƟ Ɵ oners to contact a microbiologist for speciﬁ c 
advice on follow-up and dispersed general informaƟ on on the importance of follow-up in 
update leƩ ers and in every noƟ ﬁ caƟ on report leƩ er (following the noƟ ﬁ caƟ on of a Q-fever 
paƟ ent). LMM-A and LMM-C menƟ oned the required serological follow-up on each Q-fever 
posiƟ ve laboratory report while LMM-B discussed this with the medical pracƟ Ɵ oner by tele-
phone. The lack of knowledge amongst medical pracƟ Ɵ oners may be due to a combinaƟ on 
of changing recommendaƟ ons on Q-fever follow-up [10, 12−14] combined with a lack of 
naƟ onal guidelines (to this date) and general informaƟ on overload [20].
Conclusion and recommendaƟ ons
The serological follow-up of Q-fever paƟ ents poses logisƟ cal challenges. Our results clearly 
indicate that a LMM based follow-up system with acƟ ve paƟ ent approach achieves high pa-
Ɵ ent compliance compared with systems that rely on referral by medical pracƟ Ɵ oners. Also, 
the current registraƟ on systems of medical pracƟ Ɵ oners are not suited to follow-up Q-fever 
paƟ ents. Medical pracƟ Ɵ oners hold others, including the paƟ ent, responsible for follow-up 
and oŌ en lack knowledge on the indicaƟ on for and implementaƟ on of serological follow-up 
of Q-fever. A lesson learned from this epidemic, is that recommendaƟ ons on best pracƟ ces 
regarding the serological follow-up of acute Q-fever paƟ ents should be translated into pracƟ -
cal guidelines for medical pracƟ Ɵ oners early on during an epidemic. The recommendaƟ on 
on serological follow-up should also be incorporated in paƟ ent informaƟ on leaﬂ ets. Recalling 
selected high risk paƟ ents that received incomplete or no serological follow-up should be 
considered. AddiƟ onal informaƟ on, on conversion to chronic Q-fever per paƟ ent category in 
Ɵ me, is needed in order to decide which paƟ ent groups should be recalled and up to what 
Ɵ me aŌ er iniƟ al infecƟ on. Organising such a recall needs to be a joint acƟ on by medical 
pracƟ Ɵ oners, the LMM, the Q-fever paƟ ent associaƟ on and the MHS.
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ABSTRACT
Background
Chronic Q-fever, a condiƟ on with high morbidity and mortality, may develop aŌ er an 
acute infecƟ on with Coxiella burneƟ i (acute Q-fever). Several strategies have been sug-
gested for early detecƟ on of chronic Q-fever, focusing on follow-up of known acute 
Q-fever paƟ ents and detecƟ on of asymptomaƟ c or unknown chronic infecƟ ons. As 
there is no internaƟ onal standard or consensus, the aims of this study were to sum-
marise the available literature and assess the evidence for diﬀ erent follow-up and 
screening strategies.
Design
We conducted a systemaƟ c review by searching PubMed and Embase. Twenty arƟ cles 
were included, of which fourteen only provided informaƟ on on follow-up of known 
acute Q-fever cases, four presented data on idenƟ ﬁ caƟ on of previously unknown 
C. burneƟ i infecƟ ons, and two had informaƟ on on both topics.
Results
The conversion rate of acute to chronic Q-fever ranged from 0.0% to 5.0%. Most studies 
advised serological follow-up of acute Q-fever paƟ ents, but without consistent advice 
on opƟ mum Ɵ ming and duraƟ on. The recommendaƟ on to use echocardiography for 
all acute Q-fever paƟ ents to detect valvular damage remains controversial. Screening 
of high-risk paƟ ents in an outbreak seƫ  ng is advised by studies invesƟ gaƟ ng such a 
strategy.
Conclusions
There is suﬃ  cient evidence to support serological follow-up of all known acute Q-fever 
paƟ ents at least once during the ﬁ rst year following the acute infecƟ on, and more 
frequently in paƟ ents with known risk factors for chronic disease, such as heart valve- 
or vascular prosthesis. Screening of risk groups should be considered in outbreaks of 
Q-fever.
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INTRODUCTION
Q-fever is a zoonoƟ c disease caused by the intracellular bacterium Coxiella burneƟ i [1]. The 
acute infecƟ on can remain asymptomaƟ c or present as a ﬂ u-like illness, pneumonia or hepa-
Ɵ Ɵ s [1, 2]. Approximately 2% of symptomaƟ c acute Q-fever cases progress to chronic Q-fever 
[3], a potenƟ ally lethal disease that can become apparent years aŌ er iniƟ al infecƟ on [4]. 
Most at risk for a chronic infecƟ on are paƟ ents with pre-exisƟ ng valvular disease, aneurysms, 
vascular graŌ s, immunocompromised paƟ ents, and pregnant women [1]. The most common 
presentaƟ ons of chronic Q-fever are endocardiƟ s and vascular infecƟ ons [5, 6].
C. burneƟ i has two anƟ genic phases: anƟ bodies against phase II anƟ gens (IgG phase II) 
predominate during acute Q-fever, whereas persisƟ ng high Ɵ tres of IgG anƟ bodies against 
phase I anƟ gens (IgG phase I) are indicaƟ ve for chronic Q-fever [7–10].
As chronic Q-fever has a high morbidity and mortality, early detecƟ on and treatment is 
important. Therefore, serological follow-up aŌ er an acute Q-fever infecƟ on is advocated to 
idenƟ fy paƟ ents, although criteria for diagnosing chronic Q-fever are poorly deﬁ ned. How-
ever, as most acute C. burneƟ i infecƟ ons remain undetected, paƟ ents at risk for a chronic 
infecƟ on are unaware of their risk. In addiƟ on, determining the moment of the acute Q-fever 
infecƟ on is hampered by non-speciﬁ c clinical symptoms and the limited accuracy of labora-
tory tests due to the long-term persistence of IgM phase II anƟ bodies [11].
The main strategies to idenƟ fy paƟ ents with chronic Q-fever infecƟ on are serological 
follow-up of known acute Q-fever paƟ ents and detecƟ on of asymptomaƟ c or unknown infec-
Ɵ ons [3, 12–16]. Furthermore, echocardiography is someƟ mes recommended to exclude 
hitherto unknown heart valve disease [2, 3, 17, 18]. To detect asymptomaƟ c or unknown 
C. burneƟ i infecƟ ons, paƟ ents at high risk for chronic Q-fever can be screened by serological 
tesƟ ng [3, 8, 10, 16, 19–21] or a general populaƟ on study can be performed in an outbreak 
area. Other issues that need to be considered are inclusion criteria for those at risk, frequency, 
opƟ mum Ɵ ming, intervals and duraƟ on of follow-up aŌ er diagnosis, analysis of risk factors, 
and serological and clinical case deﬁ niƟ ons of chronic cases. These decisions may depend 
on epidemiological criteria, such as epidemic versus endemic situaƟ on, and the number of 
exposed persons at risk for developing chronic Q-fever. Here, we review the strategies for 
early idenƟ ﬁ caƟ on of chronic Q-fever infecƟ ons as published in the internaƟ onal literature.
DESIGN
Search strategy and selecƟ on criteria
Relevant arƟ cles were idenƟ ﬁ ed by a systemaƟ c literature search of two major scienƟ ﬁ c 
databases, PubMed and Embase. Table 1 shows the search strategies used per database. 
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Search terms were categorised into; Q-fever; chronic disease; and follow-up/screening (Table 
1). Terms referring to cost-eﬀ ecƟ veness were also included. No limits were used for year of 
publicaƟ on or language. Case reports were excluded in the search strings.
In selecƟ on step 1, abstracts and Ɵ tles retrieved from the search strategies were indepen-
dently assessed by two invesƟ gators (CW and WvdH).
Table 1. Search strategy used in PubMed and Embase.
Search string PubMed search terms
Q fever ((Q fever[Mesh]) OR (coxiella burneƟ i[Mesh]) OR (Q fever[tw]) OR (coxiella[tw]) 
OR (Q-fever[tw]) OR (rickeƩ sia burneƟ i[tw]) OR (rickeƩ sia burneƟ i infecƟ on[tw]) 
OR (rickeƩ sia burneƫ  [tw]) OR (rickeƩ siosis infecƟ on[tw]) OR (rickeƩ siosis 
rickeƩ sia[tw]) OR (australian Q fever[tw]))
AND
Chronic disease ((Chronic Disease[Mesh]) OR (chronic[tw]))
AND
Follow-up/screening ((Follow-up Studies[Mesh]) OR (follow-up[tw]) OR (follow up[tw]) OR 
(screening[tw]) OR (screen*[tw]) OR (idenƟ f*[tw]) OR (reexaminat*[tw]) OR (long-
term[tw]) OR (long term[tw]) OR (review[tw]) OR (strateg*[tw]) OR (check*[tw]) 
OR (general populaƟ on[tw]) OR (populaƟ on-based[tw]) OR (populaƟ on based[tw]) 
OR (costs*[tw]) OR (cost eﬀ ect*[tw]) OR (cost-eﬀ ect*[tw]) OR (Cost-Beneﬁ t 
Analysis[Mesh]))
NOT
Case reports (case study) OR (case studies) OR (case report*)
Embase search terms
Q fever (exp Q fever/ OR exp Coxiella burneƟ i/ OR exp Coxiella/ OR (Q fever OR coxiella 
OR Q-fever OR rickeƩ sia burneƟ i OR rickeƩ sia burneƟ i infecƟ on OR rickeƩ sia 
burneƫ   OR rickeƩ siosis infecƟ on OR rickeƩ siosis rickeƩ sia OR australian Q fever).
ab. OR (Q fever OR coxiella OR Q-fever OR rickeƩ sia burneƟ i OR rickeƩ sia burneƟ i 
infecƟ on OR rickeƩ sia burneƫ   OR rickeƩ siosis infecƟ on OR rickeƩ siosis rickeƩ sia 
OR australian Q fever).Ɵ .)
AND
Chronic disease (exp chronic disease/ OR chronic.ab. OR chronic.Ɵ .)
AND
Follow-up/screening (exp screening/ OR exp follow-up/ OR exp cost/ OR (follow-up OR follow up OR 
screening OR screen* OR idenƟ f* OR reexaminat* OR long-term OR long term OR 
review OR strateg* OR check* OR general populaƟ on OR populaƟ on-based OR 
populaƟ on based OR cost* OR cost eﬀ ect* OR cost-eﬀ ect*).ab. OR (follow-up OR 
follow up OR screening OR screen* OR idenƟ f* OR reexaminat* OR long-term OR 
long term OR review OR strateg* OR check* OR general populaƟ on OR populaƟ on-
based OR populaƟ on based OR cost* OR cost eﬀ ect* OR cost-eﬀ ect*).Ɵ .)
NOT
Case reports (case study OR case studies OR case report*).ab. OR (case study OR case studies 
OR case report*).Ɵ .
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Selected were all arƟ cles that could provide informaƟ on on the previously deﬁ ned topics: 
serological follow-up of known acute Q-fever paƟ ents, tesƟ ng known acute Q-fever paƟ ents 
with echocardiography for valvular lesions, detecƟ on of asymptomaƟ c or unknown C. burneƟ i 
infecƟ ons (screening of paƟ ents at high risk for chronic Q-fever by serological tesƟ ng [i.e., 
paƟ ents with known valvular disease, aneurysms, vascular graŌ s, immunocompromised pa-
Ɵ ents, and pregnant women] or conducƟ ng a general populaƟ on study in an outbreak area). 
ArƟ cles were included for full-text assessment when selected by one of the invesƟ gators, 
when considered uncertain to have relevant informaƟ on, or when there was no abstract 
available with a Ɵ tle suggesƟ ng relevance.
In selecƟ on step 2, full-text arƟ cles were checked for relevant informaƟ on, and CocanCPG 
(CoordinaƟ on of Cancer Clinical PracƟ ce Guidelines) checklists [22] were used to assess the 
quality (CW and WvdH). These checklists are designed for cancer research, but are also appli-
cable to other research areas. However, for cross-secƟ onal studies and case series, no check-
lists are available. Therefore, relevant criteria for these types of studies were determined, that 
is, addressing an appropriate and clearly focused quesƟ on, representaƟ ve populaƟ on, survey 
method or data collecƟ on described, outcome measures deﬁ ned and clearly described, 
response rate reported, and results relevant for the objecƟ ves of this review. The quality of 
guidelines was assessed with the AGREE II instrument [23], a validated instrument developed 
for this purpose. The reference lists of selected arƟ cles were checked for addiƟ onal relevant 
publicaƟ ons that were missed by searching in PubMed and Embase. During full-text appraisal, 
we excluded reviews that were not systemaƟ c and did not present relevant data, studies that 
did not present original or relevant data, and case reports with less than ﬁ ve paƟ ents, as case 
reports were sƟ ll present among the search results despite the exclusion with search terms. 
Selected conference abstracts without a full-text arƟ cle, were also excluded, as were arƟ cles 
that could not be retrieved from three diﬀ erent libraries. Finally, the Newcastle OƩ awa Scale 
(NOS), as recommended by the Cochrane Non-Randomized Studies Methods Working Group, 
was used to assess and report the quality of the included studies [24].
Data extracƟ on
Two invesƟ gators (CW and WvdH) extracted data from the included papers and summarised 
relevant data in a table (S.Table 1), which included: country, start study period and duraƟ on, 
epidemiological situaƟ on (outbreak/endemic), and study type; total number of C. burneƟ i 
infecƟ ons and sampling procedure; number of paƟ ents/populaƟ on, development of chronic 
Q-fever or high IgG phase I Ɵ tres, and co-morbidiƟ es or pre-exisƟ ng disease; conclusion/
recommendaƟ on by authors of the arƟ cle; and addiƟ onal comments/interpretaƟ on by the 
authors of this review. For screening studies, we also summarised the categories of high-risk 
paƟ ents included and the total number of paƟ ents screened.
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Case deﬁ niƟ ons and origin of cases (inclusion data)
To place the diﬀ erent studies in the appropriate context, we made a disƟ ncƟ on between studies 
executed during an outbreak or in an endemic situaƟ on. The variaƟ on of case deﬁ niƟ ons of 
acute, past-resolved, and chronic Q-fever is large, as is the deﬁ niƟ on of high Ɵ tres. Therefore, 
inclusion criteria and deﬁ niƟ ons of cases or populaƟ ons are summarised in S.Table 2.
RESULTS
Inclusion of arƟ cles
The online database search was performed on 3 August 2012, and updated with the most 
recent publicaƟ ons on 17 October 2012. The search yielded 394 arƟ cles, of which 259 were 
unique (Figure 1). During abstract assessment, 183 arƟ cles were excluded. Seventy-six arƟ cles 
were idenƟ ﬁ ed as potenƟ ally relevant, and were screened full-text. In the reference lists of 
these arƟ cles, we idenƟ ﬁ ed another twelve references as possibly relevant. AddiƟ onally, one 
not yet cited arƟ cle that did not show up in the search strategy was added to the full-text as-
sessment step [25]. Five full-text arƟ cles (two French, two Japanese, and one Ukrainian) could 
not be retrieved from three diﬀ erent libraries. Overall, 84 full-text arƟ cles were screened, 
and 64 were excluded because of diﬀ erent criteria as detailed in Figure 1. The remaining 
twenty arƟ cles, including one guideline, met the inclusion criteria and were included in this 
systemaƟ c review (fourteen found in PubMed, two in Embase, three from checking reference 
lists, and the one addiƟ onally added arƟ cle). Fourteen arƟ cles only provided informaƟ on 
on the follow-up of known acute Q-fever cases, four presented data on the idenƟ ﬁ caƟ on 
of previously unknown C. burneƟ i infecƟ ons, and two full-texts provided informaƟ on on 
both topics. The sixteen arƟ cles with informaƟ on on follow-up of known acute Q-fever cases 
contained nine outbreak-related arƟ cles, and seven studies performed in an endemic situa-
Ɵ on, of which four were descripƟ ons of (reference) laboratory cohorts. The six arƟ cles that 
described detecƟ on of asymptomaƟ c infecƟ ons consisted of ﬁ ve outbreak-related arƟ cles 
and one study in an endemic area. No cost-eﬀ ecƟ veness study was found.
Inclusion of cases
All nine studies with follow-up of known acute Q-fever cases performed during an epidemic 
had well deﬁ ned inclusion criteria [8, 13, 15, 16, 25–29]. For studies of endemic cases and 
arƟ cles describing a (reference) laboratory cohort, the inclusion of cases was well deﬁ ned in 
four studies [12, 14, 30, 31], while in three studies it was unclear where cases were derived 
from [7, 32, 33]. All sixteen studies with follow-up of known acute cases, independent of 
the epidemiological seƫ  ng, included serology in their inclusion criteria [7, 8, 12–16, 25–33], 
while clinical characterisƟ cs were menƟ oned in ten studies only [7, 13, 25–27, 29–33].
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259 unique articles (394 hits in total) 
168 unique to PubMed 
91 unique to Embase 
84 unique articles were screened full-text 
Step 1: Assessment title and abstract 
183 unique articles excluded 
Step 2: Screened full-text 
64 unique articles excluded 
     30 no relevant data for review 
     12 no systematic review and  
          no relevant data for review 
       6 case report (<5 cases) 
       4 no original and no relevant     
          data for review 
       4 no relevant data for review and   
          case report (<5 cases) 
       4 conference abstract, no full- 
          text published yet 
       2 no original data 
       1 conference abstract, full-text     
          is already included 
       1 conference abstract, full-text         
          has no relevant data  
20 articles included in this review 
76 unique articles identified as potentially 
relevant 
5 unavailable due to language 
12 additional articles identified through 
checking reference lists 1 additional 
article (not yet cited) 
Figure 1. Flowchart of idenƟ ﬁ ed arƟ cles.
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Chronic Q-fever was mostly well deﬁ ned; fourteen studies based their deﬁ niƟ on on serol-
ogy in combinaƟ on with clinical characterisƟ cs [7, 10, 12, 13, 15, 20, 21, 25–27, 29–32]; ﬁ ve 
studies only used serology, clinical data or cause of death as case deﬁ niƟ on [8, 14, 16, 28, 33]; 
one study did not describe the development of chronic Q-fever as outcome [19].
Quality of studies included
The NOS scores are presented in S.Table 1. Most studies only performed follow-up in acute 
Q-fever paƟ ents without comparison with an asymptomaƟ c or seronegaƟ ve control group, 
and the ‘comparison items’ in the NOS cannot be scored in this situaƟ on. For screening stud-
ies, three of the nine possible NOS stars could not be retrieved, as these items were not ap-
plicable for these studies (e.g., outcome of interest at start study, follow-up long enough, and 
adequacy of follow-up). Most studies had a fair quality; however, losses to follow-up were 
someƟ mes large or not reported, endocardiƟ s was not always conﬁ rmed to be C. burneƟ i-
related, and reported numbers of cases within the same report were someƟ mes inconsistent 
(S.Table 1).
Follow-up of known acute Q-fever paƟ ents
Individual serological follow-up
Fourteen arƟ cles described or advised serological follow-up of known acute Q-fever paƟ ents 
[7, 8, 12–16, 25, 27, 29–33] (Table 2/S.Table 1). Four studies showed serological follow-
up results, but gave no recommendaƟ on regarding serological follow-up [25, 27, 29, 33]. 
Serological follow-up of each acute Q-fever paƟ ent was advised by three studies, but no 
recommendaƟ ons regarding Ɵ ming and duraƟ on of follow-up were given [8, 13, 14]. Two 
studies only advised on paƟ ents with risk factors, recommending they should be followed 
“carefully” [32] or should be followed for at least two years [30]. Landais et al. [7] proposed 
to test all acute Q-fever paƟ ents systemaƟ cally at three and six months aŌ er the onset of 
disease. Serological screening should be stopped when there is no serologic evidence for a 
chronic infecƟ on six months aŌ er the acute infecƟ on (IgG phase I <1:800), but further clinical 
assessment is needed when IgG phase I ≥1:800 [7]. Wagner-Wiening et al. [16] advised to 
test acute Q-fever paƟ ents at three, six, and twelve months aŌ er diagnosis. Hartzell et al. [31] 
recommended serological and clinical follow-up at 6, 12, 18, and 24 months, or even longer 
when thought to be necessary (IgG phase I Ɵ tre sƟ ll ≥1:1,024 at 24 months, and equivalent to 
or greater than the IgG phase II Ɵ tre, also tesƟ ng at 36 months and case-by-case assessment). 
Van der Hoek et al. [15] recommended a single follow-up at nine months for paƟ ents without 
risk factors (tesƟ ng at three months is not useful in these paƟ ents), and a stringent follow-
up scheme for paƟ ents with risk factors (i.e., at three-, six-, and twelve-month follow-up). 
Hung et al. [12] noƟ ced that some paƟ ents without risk factors had increased IgG phase I 
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anƟ bodies (≥1:800) whilst symptoms were absent and concluded that conƟ nued serological 
follow-up in these paƟ ents is not needed.
Echocardiography
Six studies invesƟ gated or made recommendaƟ ons for targeted case ﬁ nding of heart valve 
lesions with echocardiography in acute Q-fever paƟ ents [7, 8, 12, 13, 26, 31]. Limonard et al. 
performed a baseline transthoracic echocardiography (TTE) in 66/85 (78%) of his paƟ ents 
(standard care in the Netherlands at that Ɵ me), and concluded that echocardiography of 
every acute Q-fever paƟ ent is not useful, since 39/66 (59%) paƟ ents showed evidence for 
valvulopathy using TTE, while none developed chronic Q-fever [13]. Ayres et al. also found no 
evidence for diﬀ erences in echocardiography abnormaliƟ es aŌ er 10-year follow-up between 
acute Q-fever cases and controls [26]. Hartzell et al. advised to use echocardiography only 
for acute Q-fever paƟ ents with an indicaƟ on (known valvulopathy, cardiac symptoms or a 
signiﬁ cant cardiac murmur on physical examinaƟ on), as they also found trivial valvulopathies 
in at least 60% in military personnel with Q-fever [31]. Two studies recommended TTE in all 
acute Q-fever paƟ ents in order to detect minimal valvular diseases [7, 8], based on results 
from a case report by Fenollar et al. [18]. Landais et al. also recommended to perform a 
transoesophageal echocardiogram (TEE) in paƟ ents with IgG phase I ≥1:800 [7]. Hung et al. 
gave paƟ ents the possibility for a TEE, but all parƟ cipants who accepted medical consultaƟ on 
declined to be screened (n=4), though none developed chronic Q-fever [12].
Risk of chronic infecƟ on and Ɵ me from acute to chronic Q-fever
The risk to evolve from acute to chronic Q-fever, with endocardiƟ s as the main clinical 
presentaƟ on, or to develop high IgG phase I Ɵ tres, was described in fourteen studies [7, 8, 
12, 13, 15, 16, 25–30, 32, 33] (Table 2/S.Table 1). The conversion rate of acute to chronic 
Q-fever ranged from 0.0% to 5.0%, with follow-up ranging from two months to twelve years 
[8, 12, 13, 15, 25–30, 32, 33]. High IgG phase I Ɵ tres ranged from 0% at six years to 50% at 
three months following acute Q-fever [13–16, 25]. The Ɵ me to progress from acute to chronic 
Q-fever was invesƟ gated in four studies [7, 8, 30, 32]. Fenollar et al., reported a median Ɵ me 
of 6 months (range 1−18 months) [30], and Landais et al. found a median Ɵ me of 3 months 
(range 1−48 months) with progression within 6 months in 77% of the acute cases [7]. Raoult 
et al. reported a range of six months to three years [32], and Tissot-Dupont et al. observed all 
chronic cases within one year aŌ er acute Q-fever [8]. Overall, Ɵ me to develop chronic Q-fever 
aŌ er an acute infecƟ on ranged from one month to four years, though the majority of chronic 
cases were observed within six months. Between 32% to 100% of chronic Q-fever cases had 
pre-exisƟ ng valvular disease, and 16% to 96% had pre-exisƟ ng vascular disease according to 
studies from the database of a large reference centre [7, 30, 32]. In the only outbreak study 
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that invesƟ gated pre-exisƟ ng cardiovascular diseases in chronic Q-fever paƟ ents, 36% had 
pre-exisƟ ng valvular disease and 18% had pre-exisƟ ng vascular disease [15].
DetecƟ on of asymptomaƟ c or unknown C. burneƟ i infecƟ ons
Targeted screening in high-risk paƟ ents
Six studies performed targeted screening for high-risk paƟ ents [8, 10, 16, 19–21] (Table 2/S.
Table 1). One study focused on vascular paƟ ents (aneurysm or vascular graŌ ) [10], another 
study only included paƟ ents with heart valve disease [20], two studies performed screening 
for vascular as well as valvular paƟ ents [19, 21]. The ﬁ Ō h study included pregnant women, 
cardiovascular paƟ ents, and persons with immunodeﬁ ciencies [8], while the last study 
screened pregnant women and valvular paƟ ents [16].
The ﬁ ve studies that were conducted because of a Q-fever outbreak detected C. burneƟ i 
anƟ bodies in 7% to 21% of screened paƟ ents [8, 16, 19–21], and all advised screening of 
those at risk for chronic infecƟ on during outbreaks.
Two studies recommended tesƟ ng of all pregnant women in outbreak situaƟ ons, regard-
less of symptoms [8, 16]. In an endemic situaƟ on, however, Tissot-Dupont et al. stated that 
tesƟ ng of pregnant women is only necessary when women are febrile or had an abnormal 
delivery [8].
Valvular damage or vegetaƟ ons conﬁ rmed by echocardiography among chronic Q-fever 
cases as presented in two studies ranged from 0% to 11% [20, 21]. Among the screened 
populaƟ on, the detecƟ on rate of chronic Q-fever infecƟ ons ranged from 0.4% to 3.4% [8, 
10, 16, 20, 21], with a rate of 1.2% in the only study performed in an endemic area [10]. No 
addiƟ onal chronic Q-fever cases were observed at three and six months aŌ er iniƟ al screening 
in Kampschreur et al. [20].
General populaƟ on study
Although two studies screened people without known risk factors or visitors of the source of 
infecƟ on [8, 16], we found no reports on general populaƟ on surveys in outbreak areas. One 
of these studies performed acƟ ve serological surveillance aŌ er an outbreak, though sampling 
was not performed systemaƟ cally but on the people’s own iniƟ aƟ ve [8].
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DISCUSSION
The majority of studies invesƟ gaƟ ng serological follow-up of acute Q-fever paƟ ents conclude 
that follow-up is needed, but recommendaƟ ons about opƟ mal Ɵ ming, frequency, and dura-
Ɵ on were inconsistent. Recent studies promote a more stringent follow-up for paƟ ents with 
risk factors than for paƟ ents without risk factors [7, 12, 15, 31]. Problems encountered in vari-
ous studies are the idenƟ ﬁ caƟ on of proven chronic infecƟ ons, the disƟ ncƟ on between pos-
sible, probable, and proven infecƟ ons [34], the unknown incubaƟ on period, the non-speciﬁ c 
clinical diagnosis and non-sensiƟ ve laboratory diagnosis. All these factors may contribute to 
prolonged follow-up or start of treatment of paƟ ents with Ɵ tres indicaƟ ve for chronic Q-fever 
but without symptoms or risk factors for chronic disease. Hung et al. found that high IgG 
phase I anƟ body Ɵ tres eventually resolved and suggested that conƟ nued serological follow-
up in asymptomaƟ c paƟ ents with high IgG phase I Ɵ tres and no predisposing factors might 
not be necessary [12]. As most chronic Q-fever cases are diagnosed within the ﬁ rst year aŌ er 
acute Q-fever [7, 8, 30, 32], it might well be that late cases are due to delayed diagnosis, as a 
result of not recognising the disease rather than a long incubaƟ on Ɵ me.
Three studies that recommended echocardiography for all acute Q-fever paƟ ents were 
not included in this systemaƟ c review, as one study only presented three cases [18], and two 
did not present original data [2, 17]. Two of the included studies [7, 8] adapted the advice of 
Fenollar et al. to screen all acute Q-fever paƟ ents with echocardiography [18]. Data from the 
Netherlands, Taiwan, UK, and USA do not support the screening of all acute Q-fever cases 
for heart valve damage by echocardiography in addiƟ on to serological follow-up, because 
this would probably cause over diagnosis of valvulopathies that are not predicƟ ve for the 
development of chronic Q-fever [12, 13, 20, 21, 26, 30, 31].
Studies invesƟ gaƟ ng targeted screening strategies for high-risk paƟ ents recommended 
screening in outbreak seƫ  ngs [8, 16, 19–21]. However, the implementaƟ on of a screening 
programme depends on the extent of an outbreak, and standard criteria should be applied 
to assess whether screening is indicated [35]. Screening of pregnant women is a maƩ er of 
debate as well. Some studies recommend screening of all pregnant women in an outbreak 
situaƟ on [8, 16], as it is reported that they have an increased risk for chronic Q-fever and 
adverse pregnancy outcome [36], while other studies did not ﬁ nd a higher risk for adverse 
pregnancy outcome and do therefore not recommend to screen all pregnant women [37, 38].
Most of the studies included in this review had a fair quality, although the inclusion of 
cases was not always well deﬁ ned, losses to follow-up were someƟ mes large, endocardiƟ s 
was not always conﬁ rmed to be C. burneƟ i-related, and inconsistencies in reporƟ ng were 
noƟ ced.
Diﬀ erent case deﬁ niƟ ons for chronic Q-fever and the use of diﬀ erent serological tests and 
cut-oﬀ  values make comparison of studies diﬃ  cult (S.Table 2). The case deﬁ niƟ on of chronic 
84  |  Chapter 4
Q-fever is sƟ ll a maƩ er of debate [34, 39, 40]. A Dutch consensus group classiﬁ ed chronic 
Q-fever cases as proven, probable, or possible [34]. Proven chronic Q-fever cases have a 
posiƟ ve C. burneƟ i PCR (or culture) in blood or Ɵ ssue (in the absence of acute infecƟ on), or 
a high phase I IgG Ɵ tre (≥1:800 for in-house developed IFA and ≥1:1,024 for commercial IFA) 
in combinaƟ on with conﬁ rmed endocardiƟ s according to the revised Duke criteria [41], or 
evident infecƟ on of aneurysm or vascular graŌ  on computed tomography (CT), ﬂ uorodeoxy-
glucose positron emission tomography combined with CT (FDG-PET-CT), duplex ultrasound 
or magneƟ c resonance imaging (MRI). Probable chronic Q-fever paƟ ents have an IgG phase 
I ≥1:1,024 with risk factors for chronic Q-fever and echocardiographic abnormaliƟ es that 
do not meet the revised Duke criteria [41]. Rare manifestaƟ ons of chronic Q-fever (e.g., 
hepaƟ Ɵ s, osteomyeliƟ s) or signs of systemic inﬂ ammaƟ on might be present. Possible chronic 
Q-fever cases have an IgG phase I ≥1:1,024, without any of the manifestaƟ ons menƟ oned in 
the categories proven and probable. For each category, speciﬁ c recommendaƟ ons for follow-
up and treatment of paƟ ents are presented [34]. Another issue is that chronic Q-fever is 
relaƟ vely rare, and small sample sizes hamper the assessment of the best follow-up strategy 
and risk for a chronic infecƟ on.
The rates of developing chronic Q-fever between countries ranged from 0% to 5.0% [8, 12, 
13, 15, 25–30, 32, 33]. The risk to develop chronic Q-fever, however, might be overesƟ mated 
in studies with a high percentage of people with pre-exisƟ ng valvular or vascular disease. 
Such high rates of pre-exisƟ ng cardiovascular diseases are unlikely to be representaƟ ve for 
populaƟ ons from which average acute Q-fever paƟ ents originate.
Further, we made a disƟ ncƟ on between studies that were performed in an outbreak or 
in an endemic situaƟ on. This might be relevant since the acute disease might be easier to 
detect in an outbreak situaƟ on, as the Ɵ ming of infecƟ on can be esƟ mated more precisely, 
compared to an endemic situaƟ on or informaƟ on obtained from a (reference) laboratory 
database.
Remarkable is the fact that in some countries, Taiwan and Slovakia for example, no 
chronic Q-fever cases have been diagnosed so far, despite acute Q-fever outbreaks [12, 27], 
in contrast to France, UK, Germany, and the Netherlands [7, 8, 10, 15, 16, 19–21, 26, 29, 30, 
32, 42].
Three arƟ cles included in the present review are frequently cited and provide informaƟ on 
from the large database of the French NaƟ onal Reference Centre [7, 30, 32]. However, study 
periods of the diﬀ erent reports showed overlap and for the chronic Q-fever cases it was not 
always clear whether they had been included in one or more studies.
In conclusion, selecƟ ve serological follow-up for acute Q-fever paƟ ents with risk factors 
for chronic Q-fever infecƟ on is highly recommended, although there is no consensus on 
the frequency, Ɵ ming, and duraƟ on. For acute Q-fever paƟ ents without known risk factors, 
follow-up is recommended at least once, but should be performed later than three months 
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aŌ er the acute Q-fever infecƟ on, for example at six or nine months. Echocardiography should 
be reserved for acute Q-fever paƟ ents with a clinical indicaƟ on of cardiac abnormaliƟ es. In 
an outbreak seƫ  ng, screening of all paƟ ents with heart valve disease, vascular prosthesis 
or aneurysm might be useful. In general, data on cost-eﬀ ecƟ veness are lacking, although 
screening of pregnant women was not cost-eﬀ ecƟ ve in a study performed in the Netherlands 
[43]. The implementaƟ on of screening strategies is highly dependent on the extent of the 
outbreak. We found no evidence that a general populaƟ on study in an outbreak area would 
be useful. Major issues to be resolved are the deﬁ niƟ on of acute cases, the risk for chronic 
Q-fever in asymptomaƟ c cases, the incubaƟ on period of chronic Q-fever, and ﬁ nally the true 
incidence of chronic Q-fever. These issues can only be addressed with long-term follow-up 
studies that are diﬃ  cult, if not impossible to implement in the absence of a large Q-fever 
epidemic.
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N
R
; a
ls
o 
in
cl
ud
es
 
de
sc
rip
tio
n 
of
 1
3 
C
Q
 c
as
es
 w
ith
 C
B
I 
of
 a
ne
ur
ys
m
 o
r v
as
cu
la
r g
ra
ft





K
am
ps
ch
re
ur
 
[1
9]
th
e 
N
et
he
rla
nd
s;
 
va
sc
ul
ar
 2
00
9,
 v
al
vu
la
r 
20
10
, i
nc
lu
si
on
 w
ith
 
hi
st
or
y 
(b
ot
h)
 a
nd
 1
.5
yr
 
pr
os
pe
ct
iv
el
y 
(v
as
cu
la
r 
on
ly
); 
ou
tb
re
ak
; P
R
C
/
S
H
R
G
A
or
tic
 a
ne
ur
ys
m
, 
ce
nt
ra
l v
as
cu
la
r 
re
co
ns
tru
ct
io
n,
 
ca
rd
ia
c 
va
lv
e 
su
rg
er
y 
hi
st
or
y
n=
78
5;
 IF
A 
C
B
 Ig
G
II 
≥1
:1
28
 (t
ot
al
 s
er
op
os
iti
ve
): 
84
 
(1
0.
7%
, 9
5%
 C
I 8
.5
−1
2.
9)
, v
as
cu
la
r 3
1/
27
6 
(1
1.
2%
, 9
5%
 C
I 7
.5
−1
4.
9)
; v
al
vu
la
r: 
53
/5
09
 
(1
0.
4%
, 9
5%
 C
I 7
.8
−1
3.
1)
, c
ut
-o
ﬀ  
≥1
:6
4 
se
ro
po
si
tiv
e:
 1
17
 (1
4.
9%
)
C
lin
ic
ia
ns
 in
 h
ig
h-
in
ci
de
nc
e 
Q
F 
re
gi
on
s 
sh
ou
ld
 b
e 
al
er
t f
or
 C
Q
 in
 
hi
gh
-r
is
k 
pa
tie
nt
s,
 e
ve
n 
if 
no
 A
Q
 
ep
is
od
e 
is
 re
po
rte
d
Va
lv
ul
ar
 c
as
es
 a
re
 a
ls
o 
in
cl
ud
ed
 in
 
[2
0]
; s
er
op
re
va
le
nc
e 
no
t c
or
re
ct
ed
 
fo
r b
ac
kg
ro
un
d 
se
ro
pr
ev
al
en
ce
; 
de
ve
lo
pm
en
t o
f C
Q
 N
R





K
am
ps
ch
re
ur
 
[2
0]
th
e 
N
et
he
rla
nd
s;
 2
01
0,
 
in
cl
us
io
n 
w
ith
 h
is
to
ry
; 
ou
tb
re
ak
; P
C
/S
H
R
G
C
ar
di
ac
 v
al
ve
 
su
rg
er
y 
hi
st
or
y
n=
56
8;
 IF
A
, 
P
C
R
 if
 Ig
G
I 
≥1
:5
12
C
Q
 o
r P
Q
: n
=1
16
 (2
0.
4%
); 
pr
ov
en
/p
ro
ba
bl
e 
C
Q
: 9
 (7
.8
%
), 
1.
6%
 s
cr
ee
ne
d 
po
pu
la
tio
n,
 
4 
(4
4.
4%
) P
C
R
 p
os
, a
sy
m
pt
om
at
ic
 C
Q
 7
 
(7
7.
8%
)
P
at
ie
nt
s 
w
ith
 h
is
to
ry
 o
f v
al
ve
 
su
rg
er
y:
 s
cr
ee
ni
ng
 fo
r C
B
 
an
tib
od
ie
s 
is
 re
co
m
m
en
de
d 
in
 
ou
tb
re
ak
S
om
e 
va
lv
ul
ar
 p
at
ie
nt
s 
al
so
 
pr
es
en
te
d 
in
 [1
9]
; s
er
op
re
va
le
nc
e 
no
t c
or
re
ct
ed
 fo
r b
ac
kg
ro
un
d 
se
ro
pr
ev
al
en
ce
; m
ed
ic
al
 re
co
rd
s 
of
 
de
ce
as
ed
 p
at
ie
nt
s 
ch
ec
ke
d





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R
ef
.
C
ou
nt
ry
; s
ta
rt
 s
tu
dy
 
pe
ri
od
, d
ur
at
io
n;
 
ep
id
em
io
lo
gi
c 
si
tu
at
io
n;
 s
tu
dy
 ty
pe
H
ig
h-
ri
sk
 
pa
tie
nt
s
To
ta
l n
o.
 
sc
re
en
ed
; 
sa
m
pl
in
g 
pr
oc
ed
ur
e 
N
o.
 o
f p
at
ie
nt
sb
, p
op
ul
at
io
n,
 s
er
op
os
iti
ve
 / 
pr
e-
ex
is
tin
g 
di
se
as
e
C
on
cl
us
io
n 
/
re
co
m
m
en
da
tio
n
C
om
m
en
ts
 / 
in
te
rp
re
ta
tio
n
N
O
S
 s
co
re
c   
 
 
S
 
C
  
O
W
eg
da
m
-
B
la
ns
 [2
1]
th
e 
N
et
he
rla
nd
s;
 2
01
0,
 
in
cl
us
io
n 
fro
m
 2
00
0 
on
 
an
d 
1y
r p
ro
sp
ec
tiv
el
y;
 
ou
tb
re
ak
; P
R
C
/S
H
R
G
K
no
w
n 
ao
rti
c 
an
eu
ry
sm
, 
va
sc
ul
 ar
/ 
en
do
va
sc
ul
ar
/
he
ar
t v
al
ve
 
pr
os
th
es
is
n=
76
3;
 IF
A
, 
P
C
R
 
P
Q
: n
=4
2,
 C
Q
: n
=1
0,
 to
ta
l C
B
 s
er
op
os
iti
ve
: 
n=
52
 (6
.8
%
), 
C
Q
 1
.3
%
 o
f s
cr
ee
ne
d 
po
pu
la
tio
n:
 C
Q
: 2
 (2
0.
0%
) P
C
R
 p
os
, 
as
ym
pt
om
at
ic
 C
Q
 9
 (9
0.
0%
), 
4 
(4
0.
0%
) 
va
sc
ul
ar
 p
ro
st
he
si
s,
 3
 (3
0.
0%
) h
ea
rt 
va
lv
e 
pr
os
th
es
is
, 3
 (3
0.
0%
) c
om
bi
ne
d 
pr
os
th
es
is
, 
no
 A
A
A 
ta
rg
et
ed
 s
cr
ee
ni
ng
 p
ro
gr
am
m
e 
is
 a
dv
is
ab
le
In
cl
ud
es
 h
yp
ot
he
tic
al
 c
os
t o
ve
rv
ie
w
; 
hy
po
th
es
is
 th
at
 C
Q
 is
 c
on
tin
uo
us
 
pr
oc
es
s 
th
at
 fo
llo
w
s 
sy
m
pt
om
at
ic
 
A
Q





95
%
 C
I: 
95
%
 c
on
ﬁ d
en
ce
 in
te
rv
al
; A
Q
: a
cu
te
 Q
 fe
ve
r; 
C
1:
 c
oh
or
t 1
; C
2:
 c
oh
or
t 2
; C
B
: C
ox
ie
lla
 b
ur
ne
tii
; C
B
I: 
C
ox
ie
lla
 b
ur
ne
tii
 in
fe
ct
io
n;
 C
FT
: c
om
pl
em
en
t ﬁ
 x
at
io
n 
te
st
; C
Q
: c
hr
on
ic
 Q
 fe
ve
r; 
D
C
: d
at
a 
co
lle
ct
io
n;
 E
C
: e
nd
oc
ar
di
tis
; F
U
: f
ol
lo
w
-u
p;
 IF
A
: i
nd
ire
ct
 im
m
un
oﬂ
 u
or
es
ce
nc
e 
as
sa
y;
 Ig
G
I: 
an
ti-
ph
as
e 
Ig
G
 I 
tit
re
; I
gG
II:
 a
nt
i-p
ha
se
 Ig
G
 II
 ti
tre
; M
IF
: m
ic
ro
-im
m
un
oﬂ
 u
or
es
ce
nc
e;
 
m
ed
: m
ed
ia
n;
 m
o:
 m
on
th
; N
A
: n
ot
 a
pp
lic
ab
le
; n
eg
: n
eg
at
iv
e;
 n
o.
: n
um
be
r; 
N
R
: n
ot
 r
ep
or
te
d;
 P
C
R
: p
ol
ym
er
as
e 
ch
ai
n 
re
ac
tio
n;
 p
os
: p
os
iti
ve
; P
Q
: p
as
t-r
es
ol
ve
d 
Q
 fe
ve
r; 
Q
F:
 Q
 fe
ve
r; 
Q
FS
: Q
 fe
ve
r f
at
ig
ue
 s
yn
dr
om
e;
 P
: p
ro
sp
ec
tiv
e 
st
ud
y;
 P
C
/F
U
S
: p
ro
sp
ec
tiv
e 
co
ho
rt/
fo
llo
w
-u
p 
st
ud
y;
 P
C
/S
H
R
G
: p
ro
sp
ec
tiv
e 
co
ho
rt/
sc
re
en
in
g 
hi
gh
-r
is
k 
gr
ou
ps
; P
R
C
/S
H
R
G
: p
ro
sp
ec
tiv
e 
an
d 
re
tro
sp
ec
tiv
e 
co
ho
rt/
sc
re
en
in
g 
hi
gh
-r
is
k 
gr
ou
ps
; R
: r
et
ro
sp
ec
tiv
e 
st
ud
y;
 R
C
S
: r
et
ro
sp
ec
tiv
e 
ca
se
 s
er
ie
s;
 R
F:
 r
is
k 
fa
ct
or
s;
 R
R
: r
is
k 
ra
tio
; T
E
E
: t
ra
ns
es
op
ha
ge
al
 e
ch
oc
ar
di
og
ra
m
; 
TT
E
: t
ra
ns
th
or
ac
ic
 e
ch
oc
ar
di
og
ra
m
; v
s:
 v
er
su
s;
 w
k:
 w
ee
k;
 y
r: 
ye
ar
.
a  T
ot
al
 n
um
be
r o
f C
. b
ur
ne
tii
 in
fe
ct
io
ns
 in
 th
e 
or
ig
in
al
 o
ut
br
ea
k 
or
 to
ta
l n
um
be
r o
f C
. b
ur
ne
tii
 in
fe
ct
io
ns
 d
es
cr
ib
ed
 in
 a
n 
en
de
m
ic
 s
itu
at
io
n.
b  F
or
 c
as
e 
de
ﬁ n
iti
on
s,
 s
ee
 T
ab
le
 2
.A
2.
c  N
ew
ca
st
le
-O
tta
w
a 
S
ca
le
 (N
O
S
): 
S
=s
el
ec
tio
n 
(m
ax
im
um
 o
f 4
 s
ta
rs
), 
C
=c
om
pa
ra
bi
lit
y 
(m
ax
im
um
 o
f 2
 s
ta
rs
), 
O
=o
ut
co
m
e 
(m
ax
im
um
 o
f 3
 s
ta
rs
); 
:
 s
ta
r e
ar
ne
d;
 
: i
te
m
 n
ot
 a
pp
lic
ab
le
.
d  D
at
a 
fo
cu
si
ng
 o
n 
Q
 fe
ve
r f
at
ig
ue
 s
yn
dr
om
e 
(Q
FS
) a
re
 n
ot
 in
cl
ud
ed
 in
 th
is
 s
ys
te
m
at
ic
 re
vi
ew
.
e  F
ift
y-
ni
ne
 p
at
ie
nt
s 
w
ith
 re
si
du
al
 a
nt
ib
od
ie
s 
no
t i
nc
lu
de
d.
f  I
nc
lu
de
s 
fo
llo
w
-u
p 
of
 k
no
w
n 
ac
ut
e 
Q
 fe
ve
r c
as
es
 a
nd
 s
cr
ee
ni
ng
 o
f h
ig
h-
ris
k 
gr
ou
ps
 in
 o
rd
er
 to
 d
et
ec
t a
sy
m
pt
om
at
ic
 o
r u
nk
no
w
n 
C
. b
ur
ne
tii
 in
fe
ct
io
ns
.
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Ta
bl
e 
2.
 D
eﬁ
 n
iti
on
 o
f a
cu
te
, p
as
t-r
es
ol
ve
d,
 a
nd
 c
hr
on
ic
 Q
 fe
ve
r 
or
 h
ig
h 
tit
re
. T
he
 s
tu
di
es
 a
re
 c
at
eg
or
is
ed
 in
 c
hr
on
ol
og
ic
al
 o
rd
er
 o
f s
ta
rt 
st
ud
y 
fo
r 
fo
llo
w
-u
p 
of
 
kn
ow
n 
ac
ut
e 
Q
 fe
ve
r p
at
ie
nt
s 
an
d 
de
te
ct
io
n 
of
 a
sy
m
pt
om
at
ic
 o
r u
nk
no
w
n 
C
. b
ur
ne
tii
 in
fe
ct
io
ns
.
(a
) F
ol
lo
w
-u
p 
of
 k
no
w
n 
ac
ut
e 
Q
 fe
ve
r p
at
ie
nt
s
R
ef
.
C
ou
nt
ry
; s
ta
rt
 
st
ud
y 
pe
ri
od
D
eﬁ
 n
iti
on
 a
cu
te
 Q
 fe
ve
r
D
eﬁ
 n
iti
on
 p
as
t-
re
so
lv
ed
 Q
 fe
ve
r
D
eﬁ
 n
iti
on
 c
hr
on
ic
 Q
 fe
ve
r 
/ h
ig
h 
tit
re
S
er
ol
og
y
C
lin
ic
al
S
er
ol
og
y
C
lin
ic
al
S
er
ol
og
y
C
lin
ic
al
R
ei
lly
 [1
4]
U
K
; 1
97
2
≥F
ou
rfo
ld
 ri
se
 in
 p
hI
I t
itr
e 
or
 a
 
st
ab
le
 p
hI
I ≥
1:
80
 (C
FT
)
N
C
S
I, 
if 
st
ab
le
 p
hI
I 
≥1
:8
0 
N
S
N
A
N
A
C
Q
: p
hI
 a
nd
 p
hI
I >
1:
51
2 
at
 p
re
se
nt
at
io
n 
an
d 
pe
rs
is
te
nc
e 
of
 il
ln
es
s 
fo
r s
ev
er
al
 
m
on
th
s;
 H
T 
am
on
g 
pr
ev
io
us
 A
Q
: p
hI
 
≥1
:1
92
 
N
C
S
I
S
or
ia
no
 [3
3]
S
pa
in
; 1
98
3
P
hI
I a
nt
ig
en
 s
er
oc
on
ve
rs
io
n 
(C
FT
, V
iri
on
)
N
S
N
A
N
A
S
er
ol
og
ic
al
 te
st
s,
 ti
tre
 N
S
, a
nd
 w
he
n 
po
ss
ib
le
 is
ol
at
io
n 
of
 th
e 
m
ic
ro
-o
rg
an
is
m
 
fro
m
 ti
ss
ue
s;
 e
nd
oc
ar
di
tis
 s
er
ol
og
ic
al
 
pr
oﬁ
 le
: I
gA
 ≥
1:
64
0
E
nd
oc
ar
di
tis
, d
et
ai
ls
 N
R
Lo
ve
y 
[2
8]
S
w
itz
er
la
nd
; 1
98
3
≥F
ou
rfo
ld
 in
cr
ea
se
 in
 ti
tre
 
be
tw
ee
n 
2 
se
ru
m
 s
am
pl
es
 o
r 
Ig
M
 ≥
1:
20
 (C
FT
 a
nd
 IF
A
)
N
C
S
I
Ig
G
II 
≥1
:2
0 
w
ith
ou
t I
gM
N
C
S
I
N
o 
se
ro
lo
gy
E
nd
oc
ar
di
tis
 (c
au
se
 o
f d
ea
th
, 
as
so
ci
at
ed
 d
is
ea
se
 o
n 
de
at
h 
ce
rti
ﬁ c
at
e,
 
or
 c
ite
d 
as
 a
 m
ed
ic
al
 p
ro
bl
em
 in
 
qu
es
tio
nn
ai
re
)
R
ao
ul
t [
32
]
Fr
an
ce
; 1
98
5
Ig
G
II 
≥1
:2
00
 a
nd
 Ig
M
II 
≥1
:5
0 
(in
-h
ou
se
 IF
A
), 
cl
in
ic
al
 ﬁ 
nd
in
gs
 
co
ns
id
er
ed
 w
he
n 
Ig
G
I ≥
1:
80
0
Is
ol
at
ed
 fe
ve
r, 
he
pa
tit
is
, 
pu
lm
on
ar
y 
or
 n
er
vo
us
 
sy
st
em
 in
vo
lv
em
en
t, 
pe
ric
ar
di
tis
, m
yo
ca
rd
iti
s
N
A
N
A
Ig
G
I ≥
1:
80
0
E
nd
oc
ar
di
tis
, v
as
cu
la
r i
nf
ec
tio
n,
 
os
te
oa
rti
cu
la
r i
nf
ec
tio
n,
 c
hr
on
ic
 
he
pa
tit
is
, p
re
gn
an
cy
, o
th
er
Fe
no
lla
r [
30
]
Fr
an
ce
; 1
98
5
Ig
G
II 
≥1
:2
00
 a
nd
 Ig
M
II 
≥1
:5
0 
(in
-h
ou
se
 IF
A
), 
cl
in
ic
al
 ﬁ 
nd
in
gs
 
co
ns
id
er
ed
 w
he
n 
Ig
G
I ≥
1:
80
0 
N
C
S
I, 
if 
Ig
G
I ≥
1:
80
0 
N
S
N
A
N
A
Ig
G
I ≥
1:
80
0
E
nd
oc
ar
di
tis
 a
cc
or
di
ng
 to
 th
e 
m
od
iﬁ 
ed
 
D
uk
e 
cr
ite
ria
La
nd
ai
s 
[7
]
Fr
an
ce
; 1
98
5
Ig
G
II 
≥1
:2
00
 a
nd
 Ig
M
II 
≥1
:5
0 
(in
-h
ou
se
 IF
A
), 
an
d 
ev
id
en
ce
 
of
 s
er
oc
on
ve
rs
io
n 
fo
r s
pe
ci
ﬁ c
 
an
tib
od
ie
s 
S
ug
ge
st
iv
e 
sy
m
pt
om
s 
of
 A
Q
, i
nc
lu
di
ng
 h
is
to
ry
 
of
 fe
ve
r, 
he
pa
tit
is
, o
r 
at
yp
ic
al
 p
ne
um
on
ia
N
A
N
A
Ig
G
I ≥
1:
80
0 
E
nd
oc
ar
di
tis
 b
as
ed
 o
n 
th
e 
m
od
iﬁ 
ed
 
D
uk
e 
cr
ite
ria
A
yr
es
 [2
6]
a
U
K
; 1
98
9
P
hI
I >
1:
25
6 
or
 >
fo
ur
fo
ld
 ri
se
 
in
 ti
tre
 a
t t
he
 ti
m
e 
of
 o
ut
br
ea
k 
(C
FT
)
R
ec
en
t f
ev
er
 o
r 
pn
eu
m
on
ia
N
A
N
A
N
S
E
nd
oc
ar
di
tis
M
ar
m
io
n 
[2
9]
a
U
K
; 1
98
9
≥F
ou
rfo
ld
 in
cr
ea
se
 in
 ti
tre
 to
 
ph
II 
an
tig
en
 o
r p
hI
I ≥
1:
25
6 
in
 a
 
co
nv
al
es
ce
nt
 s
er
um
 s
am
pl
e 
or
 
at
 th
e 
tim
e 
of
 o
ut
br
ea
k 
(C
FT
)
C
om
pa
tib
le
 c
lin
ic
al
 
ill
ne
ss
N
A
N
A
N
S
E
nd
oc
ar
di
tis
 (p
ro
ba
bl
e)
K
ov
áč
ov
á 
[2
7]
S
lo
va
ki
a;
 1
99
3
S
er
oc
on
ve
rs
io
n 
or
 fo
ur
fo
ld
 
ris
e 
of
 p
hI
I o
r I
gM
 (t
es
ts
 n
ot
 
sp
ec
iﬁ 
ed
; M
IF
 [9
] (
C
O
 1
:3
2)
, 
E
IA
 (p
os
: a
bs
or
be
nc
y 
≥ 
m
ea
n 
of
 3
0 
ne
g 
se
ra
 p
lu
s 
3 
S
D
s)
, 
C
FT
 (C
O
 1
:1
6)
, M
A 
(C
O
 1
:1
6)
)
S
ub
je
ct
iv
e 
co
m
pl
ai
nt
s
N
A
N
A
P
hI
 ≥
1:
20
0 
(C
FT
) a
nd
 a
n 
el
ev
at
ed
 p
hI
I 
re
sp
on
se
, o
r I
gG
 ≥
1:
80
0 
(M
IF
)
N
S
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R
ef
.
C
ou
nt
ry
; s
ta
rt
 
st
ud
y 
pe
ri
od
D
eﬁ
 n
iti
on
 a
cu
te
 Q
 fe
ve
r
D
eﬁ
 n
iti
on
 p
as
t-
re
so
lv
ed
 Q
 fe
ve
r
D
eﬁ
 n
iti
on
 c
hr
on
ic
 Q
 fe
ve
r 
/ h
ig
h 
tit
re
S
er
ol
og
y
C
lin
ic
al
S
er
ol
og
y
C
lin
ic
al
S
er
ol
og
y
C
lin
ic
al
H
us
sa
in
-Y
us
uf
 
[2
5]
U
K
; 2
00
2
C
on
ﬁ r
m
ed
 A
Q
 d
ur
in
g 
th
e 
20
02
 
Q
 fe
ve
r o
ut
br
ea
k 
in
 N
ew
po
rt,
 
U
K
 (I
gM
II 
>1
:3
20
 (I
FA
), 
or
 
fo
ur
fo
ld
 ri
se
 (C
FT
), 
or
 Ig
M
II 
1:
20
−1
:1
60
 a
nd
 Ig
G
II 
>1
:3
20
) 
[4
4]
S
ym
pt
om
s 
co
m
pa
tib
le
 
w
ith
 A
Q
N
A
N
A
Ig
G
I ≥
1:
80
0
E
nd
oc
ar
di
tis
 a
cc
or
di
ng
 to
 th
e 
m
od
iﬁ 
ed
 
D
uk
e 
cr
ite
ria
 [4
5]
Ti
ss
ot
-D
up
on
t 
[8
]b
Fr
an
ce
; 2
00
2
Ig
G
II 
≥1
:1
00
 a
nd
/o
r I
gM
II 
≥1
:2
5 
(in
-h
ou
se
 IF
A
)
N
C
S
I
N
A
N
A
Ig
G
I ≥
1:
80
0
N
C
S
I
W
ag
ne
r-
W
ie
ni
ng
 [1
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ABSTRACT
IntroducƟ on
From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with 
4,107 noƟ ﬁ caƟ ons. The most serious complicaƟ on of Q-fever is chronic Q-fever.
Methods
In 2014, we contacted all 2,161 adult inhabitants of the ﬁ rst village in the Netherlands 
aﬀ ected by the Q-fever epidemic and oﬀ ered to test for anƟ bodies against Coxiella bur-
neƟ i using immunoﬂ uorescence assay (IFA) to screen for chronic infecƟ ons and assess 
whether large-scale populaƟ on screening elsewhere is warranted.
Results
Of the 1,517 parƟ cipants, 33.8% were IFA-posiƟ ve. Six IFA-posiƟ ve parƟ cipants had an 
IgG phase I Ɵ tre ≥1:512. Two of these six parƟ cipants were previously diagnosed with 
chronic Q-fever. Chronic infecƟ on was diagnosed in one of the other four parƟ cipants 
aŌ er clinical examinaƟ on.
Conclusions
Seven years aŌ er the iniƟ al outbreak, seroprevalence remains high, but the yield of 
screening the general populaƟ on for chronic Q-fever is low. A policy of screening known 
high-risk groups for chronic Q-fever in outbreak areas directly following an outbreak 
might be more eﬃ  cient than populaƟ on screening. A cost-eﬀ ecƟ veness analysis should 
also be performed before iniƟ aƟ ng a populaƟ on screening program for chronic Q-fever.
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INTRODUCTION
Q-fever is a zoonoƟ c disease caused by the bacterial pathogen Coxiella burneƟ i (C. burneƟ i) 
[1, 2]. From 2007 through 2010, the Netherlands experienced a large Q-fever epidemic, with 
4,107 noƟ ﬁ caƟ ons [3]. Prior to 2007, the seroprevalence of Q-fever anƟ bodies among the 
Dutch general populaƟ on was 2.4% [3]. In 2007, a sample of the inhabitants of Herpen—the 
ﬁ rst Dutch village aﬀ ected by the Q-fever outbreak—had a seroprevalence rate of 25.1% [4].
The most serious complicaƟ on of Q-fever is chronic Q-fever. Chronic Q-fever develops in 
1.5-2% of Q-fever infecƟ ons and can be detected months—or even years—aŌ er the iniƟ al 
infecƟ on, which was either symptomaƟ c or asymptomaƟ c [5]. The risk factors for chronic 
Q-fever include pre-exisƟ ng cardiac valvulopathy, vascular graŌ , aneurysm, and immunosup-
pression [5]. Chronic C. burneƟ i infecƟ on can lead to endocardiƟ s, an infected aneurysm or 
vascular graŌ , causing high morbidity and mortality even if opƟ mal treatment is received [1, 
6]. Because chronic Q-fever is not classiﬁ ed as a noƟ ﬁ able disease, precise numbers are not 
available; however, up to May 2012, 284 paƟ ents were voluntarily registered into a database 
as part of a research project run by the University Medical Center Utrecht [7]. For early detec-
Ɵ on of chronic Q-fever, paƟ ents should have at least one serological examinaƟ on within one 
year following the acute infecƟ on [8]. The serological follow-up screening of acute Q-fever 
paƟ ents varies widely among regions, ranging from 25% to 95% [9].
General pracƟ Ɵ oners (GPs), inhabitants of regions with a high Q-fever incidence and the 
Dutch naƟ onal Q-fever paƟ ent organizaƟ on, speculated that the number of chronic Q-fever 
cases of the 2007-2010 epidemic was underesƟ mated. Chronic Q-fever was incidentally di-
agnosed years aŌ er asymptomaƟ c infecƟ on but the extent was never quanƟ ﬁ ed. Therefore, 
seven years aŌ er the iniƟ al outbreak in the Netherlands, we measured the serological 
C. burneƟ i status of inhabitants of the high incidence village Herpen in order to idenƟ fy 
chronic Q-fever infecƟ ons and assess whether large-scale populaƟ on screening elsewhere 
is warranted.
METHODS
The Municipal Health Service (MHS) “GGD Hart voor Brabant” performed this study as part 
of the larger Q Herpen II project. The Medical Ethics Review CommiƩ ee of the University 
Medical Center Utrecht approved the study (protocol 13-367/D Q Herpen II).
For this cross-secƟ onal populaƟ on study, all adult inhabitants (≥18 years of age) of 
the village of Herpen (Dutch postal code 5373) were invited to parƟ cipate. The municipal 
administraƟ on provided demographic data for these 2,161 inhabitants. In January 2014, all 
inhabitants were sent an informaƟ on package by post, including informaƟ on regarding the 
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study, a request to parƟ cipate, a quesƟ onnaire, an informed consent form, and a laboratory 
form for venipuncture.
The quesƟ onnaire included quesƟ ons regarding demographics, smoking history, risk fac-
tors associated with chronic Q-fever, history of Q-fever infecƟ on and vaccinaƟ on. Answers 
to quesƟ ons about general health status, iniƟ al symptoms, chronic medical condiƟ ons, and 
medicaƟ on use are currently being analysed in other sub-studies.
During ﬁ ve days in February and one day in March 2014, parƟ cipants provided their writ-
ten informed consent to parƟ cipate in this study with the quesƟ onnaire. Informed consent 
forms and quesƟ onnaires were checked for missing informaƟ on and errors by medical staﬀ  
and the parƟ cipant, followed by a venipuncture.
Diagnosis
AnƟ bodies against C. burneƟ i were measured using immunoﬂ uorescence assay (IFA) see 
Supplementary InformaƟ on (SI) S1 Text., and an IgG phase I or II Ɵ tre ≥1:64 was interpreted 
as IFA-posiƟ ve.
The Dutch Q-fever Consensus Group [10] considers an IgG phase I Ɵ tre ≥1:1024 an indica-
Ɵ on of possible chronic Q-fever; for a deﬁ niƟ ve diagnosis, a comprehensive medical examina-
Ɵ on is required. In our study, given the lack of an iniƟ al clinical examinaƟ on, the serological 
cut-oﬀ  value was set one diluƟ on lower (at IgG phase I 1:512) in order to maximize sensiƟ vity.
ParƟ cipants with an IgG phase I Ɵ tre ≥1:512 were tested further using the Q-fever 
polymerase chain reacƟ on test (PCR) S1 Text., and referred to the Q-fever clinic at Radboud 
university medical center (Radboudumc) for clinical examinaƟ on, including echocardiography 
and positron emission tomography-computed tomography (PET-CT) [10], when deemed 
necessary.
The IFA results were reported to the parƟ cipants and their GP together with a medical 
recommendaƟ on.
Previous infecƟ ons
The IFA test results of this study in 2014 were compared with those obtained in 2007. The 
2007 and 2014 studies were performed in the same village (Herpen) and used the same 
laboratory tests and cut-oﬀ  values [4]. Data regarding previous Q-fever infecƟ ons and noƟ ﬁ -
caƟ ons were obtained from the MHS.
Data analysis
QuesƟ onnaires were digitally scanned and analysed using SPSS 21.0. The age and gender 
of the non-responders were obtained from the municipal administraƟ on data. ProporƟ ons 
were compared using the chi-square test. Diﬀ erences with p<0.05 were considered to be 
signiﬁ cant (two-tailed analysis). The independent sample t-test was used to calculate means.
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RESULTS
The study populaƟ on
Both a blood sample and a completed quesƟ onnaire were provided by 70.2% (n=1,517/2,161) 
of the adult inhabitants of Herpen, the Netherlands. The characterisƟ cs of the parƟ cipants 
are summarised in Table 1.
ParƟ cipants and non-parƟ cipants were similar with respect to age (p=0.31) and gender 
(p=0.35). The mean age of parƟ cipants and non-parƟ cipants was 51.9 years (SD: 16.5 years) 
and 51.2 years (SD: 21.9 years), respecƟ vely. More parƟ cipants with Q-fever (n=51/1,517) 
were noƟ ﬁ ed by the MHS compared to non-parƟ cipants with Q-fever (n=2/644; p<0.01).
Prevalence of anƟ bodies against C. burneƟ i
Of the 1,517 parƟ cipants, 513 (33.8%) tested posiƟ ve for anƟ bodies against C. burneƟ i (i.e., 
were IFA-posiƟ ve; for Ɵ tres see S1 Table.). Three of the 513 IFA-posiƟ ve parƟ cipants became 
seroposiƟ ve aŌ er receiving a Q-fever vaccinaƟ on in 2011; two other vaccinated parƟ cipants 
were seronegaƟ ve in 2014. The IFA-posiƟ ve and IFA-negaƟ ve parƟ cipants were similar with 
respect to age, gender and educaƟ on level. A risk factor for being IFA-posiƟ ve was current 
smoking (OR 1.4; 95% CI: 1.05-1.80; p=0.02) versus former smoker and never smoked.
Of the 513 IFA-posiƟ ve parƟ cipants, six (1.2%) had an IgG I ≥1:512, Table 2 and a negaƟ ve 
Q-fever PCR test. Two of these six parƟ cipants were diagnosed previously with chronic Q-fever. 
The remaining four (two with an IgG phase I 1: 512) were referred for a comprehensive clinical 
examinaƟ on; three of these parƟ cipants had no evidence of a chronic C. burneƟ i infecƟ on and 
one parƟ cipant -a male over the age of 65, with an increased erythrocyte sedimentaƟ on rate 
and a history of renal insuﬃ  ciency, and diabetes mellitus type 2- was diagnosed with chronic 
Q-fever. This parƟ cipant presented with a cardiac murmur, and although transoesophageal 
echocardiography revealed no signs of endocardiƟ s, he was placed on a treatment regimen 
consisƟ ng of doxycycline (200 mg qd) and hydroxychloroquine (200 mg Ɵ d).
Of the 69 individuals with known cardiovascular risk factors, 16 (23.2%) were IFA-posiƟ ve 
Table 1; three of the 16 parƟ cipants previously received the Q-fever vaccine, and the other 13 
were exposed to Q-fever naturally. Of these 13 parƟ cipants two (15.4 %) developed a chronic 
infecƟ on. These were the two parƟ cipants (out of the six with an IgG I ≥1:512) previously 
diagnosed with chronic Q-fever.
Comparison of the 2014 IFA test results with previous Q-fever tests
In 2007, 25.3% (111/443) of sampled adult inhabitants in Herpen were IFA-posiƟ ve. We com-
pared results from 287 individuals who parƟ cipated in both studies and gave their consent 
to compare their data. Of the 204 IFA-seronegaƟ ve parƟ cipants in 2007, 36 (17.6%) were IFA 
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seroposiƟ ve in 2014; these parƟ cipants presumably became infected aŌ er 2007. Of the 83 
seroposiƟ ve parƟ cipants in 2007, 14 (16.9%) tested negaƟ ve in 2014.
Analysis of the data collected from the MHS, microbiological laboratories, and the Herpen 
2007 study revealed that 24.9% of the IFA-posiƟ ve parƟ cipants in 2014 (n=128/513) previ-
ously tested posiƟ ve. Although the laboratories informed the MHS of these 128 infecƟ ons 
(because acute Q-fever is a noƟ ﬁ able disease), 78 (60.9%) of these cases did not meet the 
naƟ onal noƟ ﬁ caƟ on criteria. Of the 513 posiƟ ve parƟ cipants in 2014, 51 (9.9%) had been 
noƟ ﬁ ed previously by the MHS.
Table 1. CharacterisƟ cs of the study parƟ cipants.
 
All  IFA-posiƟ ve IFA-negaƟ ve  
n=1,517 (100%) n=513 (33.8%) n=1,004 (66.2%) p-value
Mean age, years1 51.9 (SD 16.5)  51.6 (SD 15.7)  52.1 (SD 16.9) 0.58
Gender2 0.70
 Male 752 (49.6) 258 (50.3) 494 (50.8)
 Female 765 (50.4) 255 (49.7) 510 (49.2)
Smoking2 0.02
 Current 276 (18.3) 110 (21.4) 166 (16.6)
 Former 570 (37.7) 194 (37.8) 376 (37.6)
 Never 666 (44.0) 209 (40.8) 457 (45.8)
EducaƟ on level2,3 0.25
 Low 825 (55.2) 290 (57.3) 535 (54.1)
 Average 425 (28.4) 149 (29.4) 276 (27.9)
 High 245 (16.4) 67 (13.2) 178 (18.0)
All cardiovascular risk factors4 93 22 71
 One or more cardiovascular risk factors 69 16 53
 Aneurysm 19 (20.4) 8 (36.4) 11 (15.5)
 AorƟ c bifurcaƟ on prosthesis 2 (2.2) 0 (0.0) 2 (2.8)
 Stent graŌ 40 (43.0) 6 (27.3) 34 (47.9)
 Tube graŌ 1 (1.1) 1 (4.5) 0 (0.0)
 Bypass 20 (21.5) 3 (13.6) 17 (23.9)
 Heart valve surgery 11 (11.8) 4 (18.2) 7 (9.9)  
1Independent sample t-test, 2Pearson’s chi-square test. For the purpose of the analysis current smoking 
was compared with past and never smoked and for educaƟ on level low was compared with average 
combined with high. 3EducaƟ on level: low, ranging from no educaƟ on to vocaƟ onal training; average, 
ranging from secondary vocaƟ onal educaƟ on to preparatory academic training and high, higher profes-
sional and/or university educaƟ on. 4The p-value was not calculated for this heterogeneous group
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Table 2. Summary of the six parƟ cipants with an IgG I Ɵ tre ≥1:512 and Q-fever status aŌ er clinical ex-
aminaƟ on.
PaƟ ent
IgG 
phase I
IgG phase 
II Gender Age*
IniƟ al 
symptoms
Year 
diagnosis 
Q-fever Underlying disease
Chronic
Q-fever 
diagnosed
1 1:512 1:4096 female <65 yes 2007 None no
2 1:512 1:4096 male <65 no 2014 None no
3 1:1024 1:1024 female ≥65 no 2014 Diabetes mellitus type II no
4 1:1024 1:2048 male ≥65 yes 2008 Aneurysm + stent yes, 2008
5 1:1024 1:2048 male ≥65 yes 2010 Heart valve surgery yes, 2011
6 1:1024 1:4096 male ≥65 no 2014 Diabetes mellitus type II yes, 2014
Impaired renal funcƟ on
*The age is not shown as the exact age of the parƟ cipant as this could compromise the privacy of the 
individual. ParƟ cipants 1, 2, 3, and 6 were due this study referred for a comprehensive clinical examina-
Ɵ on to exclude chronic Q-fever. ParƟ cipant number 4, 5 and 6 were diagnosed with chronic Q-fever; 
number 4 aŌ er the development of an aneurysm, number 5 during screening before vaccinaƟ on of high 
risk groups and, number 6 as a consequence of screening during the current study.
DISCUSSION
Seven years aŌ er a naƟ onal Q-fever outbreak in the Netherlands, screening of 1,517 adults 
in one Dutch village revealed 33.8% seroposiƟ ve parƟ cipants and six parƟ cipants with an 
IgG I Ɵ tre ≥1:512. Two of these six parƟ cipants were previously idenƟ ﬁ ed as having chronic 
Q-fever. Clinical evaluaƟ on of the remaining four individuals revealed one new chronic infec-
Ɵ on in a paƟ ent who had no prior history of acute Q-fever, no known cardiovascular risk 
factors, and no symptoms associated with an acute episode.
Prevalence of Q-fever
To the best of our knowledge, this is the ﬁ rst large-scale seroprevalence study conducted 
in an enƟ re village in order to idenƟ fy paƟ ents with chronic Q-fever. The seroprevalence of 
anƟ bodies against C. burneƟ i in our study (33.8%) is higher than the 12.2% reported among 
blood donors from high-incidence areas [5]. Lower and higher [11] IFA cut-oﬀ  values are 
used for screening. Lacking an internaƟ onal standard we used the value commonly used in 
the Netherlands. Because the village populaƟ on presumably was exposed to C. burneƟ i from 
2007 through 2010, we expected to ﬁ nd evidence of waning immunity in 2014. Our ﬁ nding 
that 16.9% parƟ cipants seroreverted from IFA-posiƟ ve to IFA-negaƟ ve is consistent with a 
study in Wales that reported a seroreverƟ on rate of 18% aŌ er six years [12]. Thus, our 2014 
test results are likely an underesƟ maƟ on of the actual number of infecƟ ons that occurred 
during the outbreak.
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A recent study conducted among blood donors from high-incidence areas concluded that 
each noƟ ﬁ caƟ on might actually represent ≥12 infecƟ ons [13]. In our study, 9.9 % of IFA–
posiƟ ve parƟ cipants were noƟ ﬁ ed, conﬁ rming that the number of infecƟ ons is approximately 
ten-fold greater than the number of noƟ ﬁ caƟ ons. Because these results were obtained from 
a village in which both the GPs and the general public are highly aware of Q-fever, we expect 
that even more infecƟ ons went undiagnosed in other regions. Such underreporƟ ng is due 
primarily to asymptomaƟ c infecƟ ons, symptomaƟ c but undiagnosed infecƟ ons, and infec-
Ɵ ons that do not meet our naƟ onal noƟ ﬁ caƟ on criteria.
We found that 0.6% of seroposiƟ ve parƟ cipants in our study populaƟ on developed chronic 
Q-fever, which is a lower rate than the 1.5–2% reported in the literature [5, 6]. Serological 
tesƟ ng within one year detects 98% [14] of the paƟ ents at risk for developing chronic Q-fever. 
However, the incubaƟ on Ɵ me for chronic Q-fever is unknown and without further serological 
and clinical invesƟ gaƟ on can present years or even decades later [15].
Strengths and limitaƟ ons of the study
The primary strengths of our study are the large sample size, the high response rate (70.2% of 
the enƟ re adult populaƟ on in Herpen), the relaƟ ve homogeneity of the study populaƟ on, and 
the similarity between parƟ cipants and non-parƟ cipants. A limitaƟ on of our study is the pos-
sibility that individuals developed chronic Q-fever earlier and died without being diagnosed. 
It cannot be excluded that those with severe disease were unable to parƟ cipate, moved or 
also died since the outbreak. We have no informaƟ on on non-parƟ cipants and their Q-fever 
status. We cannot exclude that one or more non-parƟ cipants have chronic Q-fever. We can-
not exclude potenƟ al bias caused by non-parƟ cipaƟ on. SeroposiƟ ve individuals could have 
been over represented if they desired to know their serological status because of certain 
risk factors. On the other hand they could have been under represented as they knew their 
long-term status due to serological follow-up. Those with an unknown Q-fever status or with 
a perceived risk for example occupaƟ onal might have shown increased interest in the study. 
Furthermore we could only contact those who were registered by the municipality but we 
expect the number of unregistered inhabitants to be very low.
Conclusions
The Q-fever seroprevalence rate found in our study was remarkably high (34%), and 15% 
of the infected parƟ cipants with at least one cardiovascular risk factor developed a chronic 
infecƟ on. Although our study revealed one new individual with chronic Q-fever, it is unlikely 
that screening other communiƟ es for chronic infecƟ ons—parƟ cularly communiƟ es that were 
not as heavily exposed to C. burneƟ i during the outbreak—would yield signiﬁ cantly more 
infecƟ ons. A policy of screening known high-risk groups for chronic infecƟ ons in outbreak 
areas following an outbreak [8] might be more eﬃ  cient and should be implemented rather 
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than ad hoc populaƟ on screening. A cost-eﬀ ecƟ veness analysis should also be performed 
before iniƟ aƟ ng a populaƟ on screening program for chronic Q-fever.
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APPENDIX SUPPLEMENTARY INFORMATION
S1 Table. IFA test results of 1517 parƟ cipants.
IgG Phase I IgG Phase II n (%)
NegaƟ ve test results 1004 (66.2)
<1:64 <1:64 1004
PosiƟ ve test results 513 (33.8)
<1:64 1:64 5
<1:64 posiƟ ve* 402
<1:64 1:256 1
1:64 <1:64 1
1:64 1:64 4
1:64 posiƟ ve 13
1:64 1:128 2
1:64 1:256 8
1:64 1:512 9
1:64 1:1024 1
1:64 >1:1024 2
1:128 1:128 4
1:128 1:256 5
1:128 >1:256 1
1:128 1:512 11
1:128 1:1024 10
1:128 >1:1024 10
1:256 >1:256 3
1:256 1:256 2
1:256 1:512 3
1:256 1:1024 3
1:256 >1:1024 4
1:256 1:2048 3
1:512 1:4096 2
1:1024 1:1024 1
1:1024 1:2048 2
1:1024 1:4096 1  
*PosiƟ ve means a Ɵ ter ≥1:64. The sample was however not Ɵ trated as phase I was not higher than 1:64. 
This made Ɵ traƟ on -in order to detect chronic Q-fever- unnecessary. The six potenƟ al chronic cases are 
shown in bold italics.
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S1 Text. Laboratory material and methods
Immunoﬂ uorescence Assay
The IFA assay used for this study is from a commercially available kit of Focus diagnosƟ cs, 
Cypress, CA, USA.
The area is post epidemic. In the Netherlands the cut-oﬀ  of 1/64 is used. Some studies 
even use a cut oﬀ  of 1/32. We compared the ﬁ ndings of 2007 and 2014 – similar cut oﬀ  
values and have no reasons to suspect that our cut oﬀ  was to low. On the contrary one could 
argue that years aŌ er an outbreak the even lower Ɵ tre of 1/32 might be used as anƟ -bodies 
might be weaning and past infecƟ ons could be missed. As this low Ɵ tre is one step away from 
a negaƟ ve ﬁ nding we found that Ɵ tre to low and could lead to false sero posiƟ ves. As the 
aim of the study was not to determine the correct or best cut oﬀ  value for detecƟ ng a past 
infecƟ on it is not discussed in the concluding secƟ on of the manuscript. I do hope that the 
explanaƟ on given above does suﬃ  ce without changing the conclusion especially as we are 
only allowed 2,000 words in this brief report.
Q-fever polymerase chain reacƟ on
We used serum samples for the Q-fever polymerase chain reacƟ on (PCR) test.
The gene targeted for the Q-fever polymerase chain reacƟ on (PCR) test is the inserƟ on 
element IS1111 of the C. burneƟ i genome of the Nine Mile strain. More informaƟ on can be 
found in the arƟ cle:
Schneeberger PM., Hermans MH, van Hannen EJ, Schellekens JJ, Leenders AC, Wever PC. 
Real-Ɵ me PCR with serum samples is indispensable for early diagnosis of acute Q fever. Clinical 
and Vaccine Immunology, 2010 17(2), 286-290. hƩ p://cvi.asm.org/content/17/2/286.short
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ABSTRACT
Background
In the Netherlands, 1,168 Q-fever paƟ ents were noƟ ﬁ ed in 2007 and 2008. PaƟ ents and 
general pracƟ Ɵ oners (GPs) regularly reported persisƟ ng symptoms aŌ er acute Q-fever, 
especially faƟ gue and long periods of sick leave, to the public health authoriƟ es. Inter-
naƟ onal studies on smaller Q-fever outbreaks demonstrate that symptoms may persist 
years aŌ er acute illness. Data for the Dutch outbreaks were unavailable. The aim of this 
study is to quanƟ fy sick leave and long-term symptoms aŌ er acute Q-fever.
Methods
Our study targeted 898 acute Q-fever paƟ ents, noƟ ﬁ ed in 2007 and 2008 residing in the 
Province of Noord-Brabant. PaƟ ents from the 2008 cohort were mailed a quesƟ onnaire 
at 12 months and those of the 2007 cohort at 12-26 months aŌ er onset of illness. 
PaƟ ents reported underlying illness, Q-fever related symptoms and sick leave.
Results
The response rate was 64%. Forty percent of working paƟ ents reported long-term (>1 
month) sick leave. Pre-existent heart disease odds raƟ o (OR) 4.50; conﬁ dence interval 
(CI) 1.27-16.09), hospitalisaƟ on in the acute phase (OR 3.99;95% CI 2.15-7.43) and 
smoking (OR 1.69; 95% CI 1.01-2.84) were signiﬁ cant predictors for long-term absence. 
Of the paƟ ents who resumed work, 9% were, at the Ɵ me of compleƟ ng the quesƟ on-
naire, sƟ ll unable to funcƟ on at pre-infecƟ on levels due to faƟ gue or concentraƟ on 
problems. Of the respondents 40% reported persisƟ ng physical symptoms at the Ɵ me 
of follow-up. FaƟ gue (20%) was most frequently reported. Daily acƟ viƟ es were aﬀ ected 
in 30% of cases.
Conclusions
Q-fever poses a serious persisƟ ng long-term burden on paƟ ents and society.
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INTRODUCTION
Q-fever is a worldwide zoonoƟ c disease caused by Coxiella burneƟ i (C. burneƟ i), an obligate 
intracellular bacterium. In the Netherlands, Q-fever was uncommon before 2007 with 10-20 
noƟ ﬁ ed cases annually [1]. Since 2007 and up to December 2010 more than 4.000 cases 
[2] were noƟ ﬁ ed in four major outbreaks implicaƟ ng dairy goats as the source [1,3-5]. Ap-
proximately 80% of the noƟ ﬁ ed Q-fever paƟ ents reside in Noord-Brabant, the province with 
the highest dairy goat density in the Netherlands.
C. burneƟ i is common in a wide range of wild and domesƟ c animals but only small ru-
minants, in parƟ cular sheep and goats, are associated with large human outbreaks [6,7]. In-
fected animals excrete billions of bacteria in birth products and to a lesser extent in faeces, 
urine and milk. Human infecƟ on occurs mainly aŌ er inhaling dust parƟ cles contaminated 
with C. burneƟ i [7].
In suscepƟ ble individuals infecƟ on develops aŌ er a mean incubaƟ on period of 21 days [6]. 
In general, 60% of the infected Q-fever paƟ ents are asymptomaƟ c, whereas 20% of the pa-
Ɵ ents develop mild symptoms. Another 20%, however, present with more severe symptoms 
ranging from high fever, severe headache, night sweaƟ ng, nausea, diarrhoea, to pneumonia, 
hepaƟ Ɵ s, pericardiƟ s, myocardiƟ s and neurological symptoms [8].
Chronic Q-fever may develop in up to 5% of acute cases [9-11], due to a reacƟ vaƟ on of 
Coxiella. A follow-up of 686 Dutch acute Q-fever paƟ ents from 2007 to 2008 found that 1.6% 
converted to chronic Q-fever [12]. A feared presentaƟ on of chronic Q-fever is endocardiƟ s [11] 
that may take 10-15 years to develop. Pregnant women and people with heart valve disorders, 
vascular prosthesis, or impaired immunity have a higher risk to develop a chronic infecƟ on.
Q-fever paƟ ents may develop Q-fever faƟ gue syndrome (QFS), a debilitaƟ ng faƟ gue out 
of proporƟ on with exerƟ on that may last up to 10 years [13,14]. Post-infecƟ on faƟ gue [15] is 
not unique for Q-fever. It may also occur aŌ er other infecƟ ous diseases such as Lyme disease, 
Epstein–Barr virus infecƟ on [16], legionnaires disease [17], and other pneumonias [18].
Anecdotal informaƟ on suggests that paƟ ents from the 2007 cohort had a more severe 
course of illness compared with those from the 2008 outbreak and were longer absent from 
work. However, evidence on the recovery of paƟ ents from the Dutch 2007 and 2008 cohorts 
is lacking. This study aims to ﬁ ll that gap. The ﬁ rst objecƟ ve is to assess the duraƟ on of sick 
leave aŌ er an episode of acute Q-fever-in 2007 or 2008-and the long-term self-reported 
symptoms and associated risk factors. The second objecƟ ve is to asses diﬀ erences between 
the two cohorts for the duraƟ on of self reported sick leave and the occurrence and frequency 
of long-term health symptoms.
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METHODS
Study design and populaƟ on
The populaƟ on for this cohort study consisted of 898 paƟ ents noƟ ﬁ ed in 2007 and 2008 to 
the Municipal Health Services ‘Hart voor Brabant’ and ‘Brabant Zuid-Oost’. Due to incomplete 
data or an unknown month of onset of illness, 28 paƟ ents were excluded (Figure 1). The re-
maining 870 Q-fever paƟ ents ﬁ Ʃ ed the Dutch noƟ ﬁ caƟ on criteria; a laboratory conﬁ rmaƟ on 
of Q-fever and clinical presentaƟ on with fever, pneumonia or hepaƟ Ɵ s
Data collecƟ on
In February 2009, all paƟ ents received a study informaƟ on folder including a parƟ cipaƟ on 
request and consent form by post (Figure 1). PaƟ ents could state their willingness to take part 
in any of a number of studies under the so-called Q Quest-1 project, by signing and returning 
the consent form. ParƟ cipaƟ ng paƟ ents received a quesƟ onnaire -by postal mail -focussing on 
demographic characterisƟ cs, medical history, smoking behaviour, current Q-fever related physi-
cal symptoms and employment related items, such as duraƟ on of sick leave following acute 
Q-fever, resumpƟ on and current ability to work (employed, self-employed, volunteer work, 
household work). During a pre-test, the compleƟ on of the quesƟ onnaire took 20 - 30 minutes.
All paƟ ents from the 2007 cohort received the quesƟ onnaire in February 2009 (13-26 
months aŌ er onset of illness). PaƟ ents noƟ ﬁ ed in 2008 were mailed a quesƟ onnaire one 
year aŌ er the month of onset of illness. PaƟ ents from both cohorts, received two reminders 
aŌ er three and six weeks. We obtained data on non-responders regarding gender, age, year 
of onset of disease and hospitalizaƟ on from the noƟ ﬁ caƟ on data of the Municipal Health 
Services.
Data analysis
QuesƟ onnaires were double scanned and data were cleaned. StaƟ sƟ cal analysis was done 
using SPSS 16 for windows. We used the Mantel–Haenzel Chi square and Fishers exact test 
to compare proporƟ ons. P-values are based on two tailed tests with a p-value<0.05 deﬁ ned 
as signiﬁ cant. The noƟ ﬁ caƟ on data of the Municipal Health Services were used to compare 
responders and non-responders for age, gender, year of onset of illness and hospitalisaƟ on.
MulƟ variate logisƟ c regression was used to model the relaƟ onship between outcome 
(sick leave >1 month or presence of symptoms) and the independent variables age, gender, 
hospitalisaƟ on, underlying diseases and year of onset of illness. MulƟ variate logisƟ c regres-
sion was used to model the relaƟ onship between the determinants year of onset of illness 
and hospitalisaƟ on with the outcomes presence of symptoms (faƟ gue)and long-term sick 
leave. For the potenƟ al confounders, age, gender, smoking and co-morbidity , we used the 
same model.
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RESULTS
PaƟ ent parƟ cipaƟ on
The overall response rate was 63.9% (Figure 1). The mean Ɵ me between the day of onset 
of illness and receiving the quesƟ onnaire was 19.5 months (SD 2.3) for paƟ ents of the 2007 
cohort and 12.1 months (SD 0.5) for paƟ ents of the 2008 cohort. We were informed that ﬁ ve 
paƟ ents died, but had no informaƟ on on the cause of death.
The response rate of men was lower than that of women as was that of younger (≤30 
years of age) compared with older paƟ ents (> 30 years of age). There were no diﬀ erences 
between responders and non-responders for year of onset of illness and hospitalizaƟ on (see 
Supplementary Table S1 for details).
Figure 1.Response rate of paƟ ents from cohorts 2007 to 2008. Division in cohorts is on the basis of 
month of onset of illness.
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CharacterisƟ cs of the study populaƟ on
The study populaƟ on (Table 1) of the 2007 and 2008 cohorts was similar with respect to 
gender, age group, smoking behaviour and underlying diseases. The hospitalisaƟ on rate of 
paƟ ents of the 2007 cohort, however, was signiﬁ cantly higher [relaƟ ve risk (RR) 2.50, 95% CI 
1.68-3.01;p< 0.000] than that of the 2008 cohort. PaƟ ents from the 2007 cohort were more 
oŌ en depressed (OR 1.88, 95% CI 1.10-3.34; p= 0.044) than paƟ ents from the 2008 cohort.
Sick leave
Prior to the Q-fever infecƟ on 62% of the study populaƟ on was gainfully employed. During the 
episode of acute fever 91.3% of these paƟ ents reported sick for work (Figure 2). Overall 132 
(39.6%) of study subjects that worked prior to the infecƟ on, were longer than one month (long-
term sick leave) absent from work following an acute Q-fever infecƟ on. See Supplementary 
Table S2 for sick leave of the gainfully employed, volunteers and those who do household work.
Table 1. CharacterisƟ cs of the study populaƟ on (n= 556) of two cohorts (2007 and 2008) of acute 
Q-fever paƟ ents noƟ ﬁ ed in The Netherlands.
CharacterisƟ cs Cohort 2007, n = 96 (%) 2008, n = 460 Total, n = 556 p-value
Gender
Male 55 (57.3) 278 (60.4) 333 (60.0)
Female 41 (42.7) 182 (39.6) 223 (40.0) 0.568
Mean age in years (SD) 50.4 (14.9) 51.8 (13.3)
Smoker
Yes 36 (39.2) 150 (33.6) 186 (34.6)
No 56 (60.8) 296 (66.4) 352 (65.4) 0.317
Hospitalised
Yes 42 (43.8) 89 (19.5) 131 (23.7)
No 54 (56.2) 368 (80.5) 422 (76.3) <0.000
Underlying diseasea
Yes 57 (59.4) 261 (56.7) 318 (57.2)
No 39 (40.6) 199 (43.3) 238 (42.8) 0.639
Underlying diseases
Diabetes 7 (7.3) 29 (6.3) 36 (6.5) 0.721
Heart disease 8 (8.3) 38 (8.3) 46 (8.3) 0.981
Lung disease 10 (10.4) 34 (7.4) 44 (7.9) 0.318
ArthriƟ s 2 (2.1) 20 (4.3) 22 (3.9) 0.301
Depression 9 (9.4) 20 (4.3) 29 (5.2) 0.044
Other speciﬁ ed 4 (4.2) 40 (8.7) 44 (7.9) 0.158
Other unspeciﬁ ed 21 (21.9) 73 (15.9) 94 (16.9) 0.135
aPaƟ ents can state more than one underlying disease.
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HospitalisaƟ on, smoking and underlying heart disease were independent predictors for 
long-term sick leave (Table 2). Gender, age, year of onset of illness, underlying lung disease, 
depression or level of educaƟ on were not signiﬁ cantly related to long-term sick leave (Table 2).
Self-reported symptoms
Almost 40% of paƟ ents reported at least one current health complaint at the Ɵ me of follow-
up that they perceived to be Q-fever related (Supplementary Table S3). The most frequently 
reported symptoms were: faƟ gue, 19.8%; diﬃ  culty concentraƟ ng, 9.5%; muscle pain, 9.0%; 
and night-Ɵ me sweaƟ ng, 7.9%. Women (OR 1.84, 95% CI 1.27-2.67; p= 0.001) were more 
likely to report symptoms than men. For faƟ gue this was 25.1% of women versus 16.2% 
among men.
The 2007 and 2008 cohorts were similar in number, type and frequency of reported 
symptoms (Supplementary Table S3). MulƟ variate logisƟ c regression showed that year of 
onset of illness was not signiﬁ cantly related to the reporƟ ng of a health complaint, when 
controlling for diﬀ erences in age, smoking, underlying heart/lung disease and depression. 
Women and paƟ ents that had been hospitalised or suﬀ ered depression were more likely to 
report faƟ gue at the Ɵ me of follow-up (Table 2).
Figure 2. The week of self-reported work resumpƟ on following an epidode of acute Q-fever in 344 
workers.
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Long term sick leave, resumpƟ on of work or daily acƟ viƟ es in relaƟ on to perceived 
Q-fever related health symptoms
Study subjects (n= 132) 39.6% that were longer than one month (long-term sick leave) absent 
from work following an acute Q-fever infecƟ on showed more faƟ gue at 12-26 months aŌ er 
the iniƟ al illness than paƟ ents with a shorter sick leave period.
Of the paƟ ents that resumed work, 9.3% reported that they were unable to funcƟ on at 
pre Q-fever levels at the Ɵ me they completed the quesƟ onnaire, due to perceived Q-fever 
related health symptoms, mainly faƟ gue and concentraƟ on problems. Almost one third of 
paƟ ents (29.0% of the 2007 cohort and 33.1% of the 2008 cohort), reported that they had 
not fully resumed their daily acƟ viƟ es at 12-26 months aŌ er onset of illness. Stated reasons 
were faƟ gue (80.8%) and respiratory problems (4.9%).
Table 2. MulƟ variate logisƟ c regression analysis of risk factors for self-reported long-term faƟ gue mea-
sured at 12 to 26 months follow-up in 556 Q-fever paƟ ents and for sick leave (exceeding one month) in 
334 paid workers aŌ er acute Q-fever.
Risk factor for
Long-term faƟ gue n= 110 Long-term sick leave n= 132
OR (95% CI) p-value OR (95% CI) p-value
Gender  
 Female 1.77 (1.14 - 2.75) 0.012 1.39 (0.83 - 2.35) 0.213
 Male (ref)
Age a 1.01 (0.99 - 1.03) 0.213 1.01 (0.97–1.03) 0.890
HospitalizaƟ on b
 Yes 1.95 (1.19 - 3.19) 0.008 3.99 (2.15 – 7.43) 0.000
 No (ref)
Cohort
 2007 1.23 (0.71 - 2.15) 0.461 1.18 (0.60 – 2.33) 0.626
 2008 (ref)
Smoking
 Yes 1.29 (0.79 - 2.10) 0.299 1.69 (1.01 - 2.84) 0.046
 No (ref)
Underlying Heart disease
 Yes 1.66 (0.79 - 3.49) 0.182 4.51 (1.27-16.09) 0.020
 No (ref)
Underlying Lung disease
 Yes 1.61 (0.77 - 3.33) 0.204 2.78 (0.93 - 8.34) 0.068
 No (ref)
Depression
 Yes 2.53 (1.11 - 5.76) 0.027 0.98 (0.23 - 4.26) 0.976
 No (ref)       
aAge has been modelled as a conƟ nues variable. bHospitalizaƟ on during the acute phase of illness.
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DISCUSSION
We analysed data from noƟ ﬁ caƟ ons and quesƟ onnaires of 556 Q-fever paƟ ents noƟ ﬁ ed in 
2007 and 2008 in the Netherlands. Our most important ﬁ ndings were that aŌ er an episode of 
acute Q-fever, two out of ﬁ ve paƟ ents were over a month absent from work. We found that 
hospitalisaƟ on in the acute phase, underlying heart disease and smoking behaviour were 
independent predictors for sick leave exceeding a month. Almost, one in ten paƟ ents were 
unable to funcƟ on at pre Q-fever infecƟ on level at the Ɵ me of the quesƟ onnaire mainly due 
to faƟ gue and concentraƟ on problems. Two out of ﬁ ve paƟ ents reported Q-fever related 
symptoms and one third indicated that they had not resumed their daily acƟ viƟ es to the pre 
Q-fever infecƟ on level.
Work and sick leave
To our knowledge, this is the ﬁ rst Ɵ me that data on Q-fever and sick leave following a Q-fever 
outbreak are presented. We are therefore unable to compare the results with other studies 
on Q-fever. We do, however, know that in the Netherlands the average duraƟ on of sick leave 
per employee was 6.3 days [19] in 2008. One in three Dutch paƟ ents with sick leave have 
a cold or ﬂ u like symptoms, but are rarely longer than one week absent from work [19]. In 
a large cross secƟ onal study [20], 16% of Dutch employees reported more than 9 days sick 
leave per year. In our study 57% of Q-fever paƟ ents reported more than 9 days sick leave per 
year.
PaƟ ents that reported persisƟ ng faƟ gue at 12-26 months, were also signiﬁ cantly more 
oŌ en long-term absent from work due to sick leave following the acute infecƟ on. Our ﬁ nd-
ings are in line with a study from Huibers, et al [21], that showed that persisƟ ng faƟ gue has a 
strong correlaƟ on with sick leave exceeding 42 days.
Symptoms
One to two years aŌ er acute Q-fever, two thirds of the paƟ ents sƟ ll reported symptoms 
that they aƩ ributed to Q-fever. Cohorts did not diﬀ er in the overall reported symptoms and 
speciﬁ c symptoms. We had expected to ﬁ nd a diﬀ erence in symptoms between the cohorts 
as clinicians oŌ en reported that paƟ ents of the 2007 cohort had more serious illness. Due to 
methodological reasons (see under Methodological consideraƟ ons and study limitaƟ ons) we 
are unable to asses if the 2007 cohort iniƟ ally had more symptoms during the convalescence 
period and parƟ ally recovered or that the level of persistent symptoms was similar for both 
cohorts.
HatcheƩ e and Hayes [22] reported 51% of the Q-fever paƟ ents with persistent symptoms 
26 months aŌ er the acute Q-fever episode. Ayres, et al. [14] studied a cohort of 71 Q-fever 
paƟ ents and found that ﬁ ve years aŌ er the iniƟ al infecƟ on up to 68% of study subjects pre-
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sented with symptoms. Our ﬁ ndings are in line with these two studies. It may be quesƟ oned 
whether long-term persistence of symptoms is unique for Q-fever. In a study of paƟ ents with 
community acquired pneumonia (of varying degrees of severity) a full recovery was reported 
aŌ er 6-18 months. Persistence of symptoms was mostly aƩ ributed to morbidity that existed 
before the pneumonia episode [18]. In our study, paƟ ents with pre-existent heart or lung dis-
ease had similar outcomes for persisƟ ng symptoms than those without pre-existent disease.
FaƟ gue
In the present study, 19.8 % of the Q-fever paƟ ents report faƟ gue 12-26 months aŌ er the 
onset of illness, without a signiﬁ cant diﬀ erence between both cohorts. Although paƟ ents 
from the 2007 cohort were more oŌ en hospitalised and our study shows that hospitalisaƟ on 
in the past-due to Q-fever is signiﬁ cantly related to faƟ gue 12-26 months later, it appeared 
that the year of onset of illness did not inﬂ uence long-term faƟ gue.
In another study [23] on these same paƟ ents, we found that when using a validated in-
strument the Nijmegen Clinical Screening Instrument (NCSI ) [24,25] up to 43.5% of paƟ ents 
stated faƟ gue. Other studies also report much higher rates of 52% [26] undue Ɵ redness aŌ er 
one year, 51% up to ﬁ ve years later [14] or even 64% 10 years aŌ er a Q-fever infecƟ ons [13]. 
We therefore suspect that the outcome is related to the way the informaƟ on on faƟ gue is 
gathered.
Our ﬁ nding that paƟ ents who reported faƟ gue had been more oŌ en hospitalised is in line 
with Hickie et al. [27] who report that the key risk factor for post-infecƟ ve faƟ gue syndromes 
is the severity of the acute illness. In their study, they found no age, sex-related or psychologi-
cal risk factors. We found, however, that women and paƟ ents with depression reported more 
faƟ gue. Depression has two components [28] a somaƟ c factor oŌ en expressed as faƟ gue and 
a depression factor. The dominaƟ ng factor may determine the diagnosis. In our study, we 
could not make a disƟ ncƟ on between the two as we did not ask addiƟ onal quesƟ ons. Diﬀ er-
ent co morbidiƟ es –including chronic faƟ gue-associated with depression can be explained 
by (neuro) inﬂ ammatory and oxidaƟ ve and nitrosaƟ ve stress path ways [29]. Unexplained 
faƟ gue and depression might act as independent risk factors of each other [30]. The quesƟ on 
is whether the explainable faƟ gue caused by Q-fever might be a pre-curser to depression. 
The quesƟ on is whether the explainable faƟ gue caused by Q-fever might be a pre-cursor to 
depression.
Women reported other symptoms signiﬁ cantly more oŌ en than men. This does not nec-
essarily mean that women have more symptoms, as woman are known to present symptoms 
more oŌ en [31].
We did not medically examine paƟ ents and could not establish whether the faƟ gue ful-
ﬁ lled the diagnosƟ c criteria of the chronic faƟ gue syndrome (CFS) [32, 33]. Nor did we have 
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informaƟ on on the duraƟ on, the severity of the faƟ gue, the presence of tender lymph nodes 
or possible other causes.
Cohort comparison
PaƟ ents from the 2007 cohort received the quesƟ onnaire later (13 to 26 months aŌ er the 
acute episode) than those of the 2008 cohort (at 12 months). Therefore, data from the two 
cohorts are not enƟ rely comparable as we are unable to assess the iniƟ al level of symptoms 
of the 2007 cohort.
The hospitalisaƟ on rate was much higher for the 2007 cohort (43.8%) than for the 2008 
cohort (19.5%). This shows that our study populaƟ on is in this respect a good representaƟ on 
of the noƟ ﬁ ed Q-fever paƟ ents as mandatory noƟ ﬁ caƟ on data show that the hospitalisaƟ on 
rate for our area was 43.7% in 2007 and 16.3% in 2008. This is much higher than the rate of 
2-3% reported in literature [34]. The high percentage of hospitalized paƟ ents in 2007 was 
largely inﬂ uenced by acƟ ve case ﬁ nding in a retrospecƟ ve survey among hospitalized cases 
[35]. Both paƟ ents and clinicians recognised and diagnosed Q-fever more readily in 2008 
when it had become apparent that this previously uncommon disease presented more oŌ en 
in the area. Only the very ill paƟ ents might have been recognised and diagnosed by clinicians 
in 2007.
Although hospitalized paƟ ents reported more long-term faƟ gue and sick leave, we did 
not ﬁ nd an independent signiﬁ cant relaƟ on between cohort and reported faƟ gue or absence 
from work.
Methodological consideraƟ ons and study limitaƟ ons
A limitaƟ on of this study is that we lacked a control group. The reason was that this study was 
designed as a cost of illness study rather than an eƟ ological study.
One of the complexiƟ es of this study is that we were dealing with many confounders 
such as age, gender and co-morbidity; for example heart disease, depression and health 
symptoms such as faƟ gue. Our determinants of interest were, however, hospitalisaƟ on and 
the year of onset of illness. In the absence of other data our data give a valuable insight into 
sick leave and symptoms related to Q-fever.
The response rate was signiﬁ cantly higher for woman and paƟ ents older than 30 years. 
This is in line with survey response rates in the Netherlands [36]. Due to this selecƟ on bias, 
the percentage of faƟ gue found in this study might be slightly higher than that in the total 
Q-fever populaƟ on.
Access to pre-Q fever heath status and sick leave data would have been ideal but these 
data were unavailable. Therefore, we cannot proof if all reported sick leave and health symp-
toms are completely related to Q-fever.
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In the absence of other data, our data give a valuable insight into sick leave and symptoms 
related to Q-fever. One could quesƟ on whether these symptoms were caused by Q-fever 
because symptoms of Q-fever may not be very speciﬁ c. By asking per symptom whether the 
symptom was present we might have prompted paƟ ents wich could have led to overreport-
ing. The same could have applied for co-morbidity.
Although we asked quesƟ ons on past or iniƟ al symptoms, we only analysed current 
symptoms thereby omiƫ  ng problems with recall bias. For sick leave, we cannot exclude 
recall bias as we asked paƟ ents to recall their sick leave up to 26 months aŌ er an episode 
of acute Q-fever. Many paƟ ents were, however, very precise and even stated dates of sick 
leave. Although we asked paƟ ents about producƟ vity loss at work we did not use a validated 
instrument and can therefore not directly compare our ﬁ ndings with other studies.
Data on sick leave were only available for responders. This might have biased the results 
on sick leave. Although we are not sure about that, we do have some indicaƟ ons about the 
validity of our ﬁ ndings. The strongest indicaƟ on is that the hospitalisaƟ on rate, one of the 
most important determinants of the duraƟ on of sick leave, was similar for responders and 
non-responders.
Conclusions
The negaƟ ve impact of Q-fever on producƟ vity and perceived health status is considerable, 
especially when taking the high incidence in certain communiƟ es into account. Hospitalisa-
Ɵ on, as an indicator of severity of the acute illness, turned out to be a strong predictor for 
long-term sick leave and persistent faƟ gue in Q-fever paƟ ents.
This study demonstrates the considerable burden of disease from Q-fever for individual 
paƟ ents, families, and society.
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Key-points:
• AŌ er an episode of acute Q-fever, 40% of the working paƟ ents were longer than one 
month absent from work. HospitalisaƟ on in the acute phase, underlying heart disease 
and smoking behaviour were independent predictors for sick leave exceeding a month.
• More than one year aŌ er an episode of acute Q-fever 9% of paƟ ents had not completely 
resumed work. FaƟ gue and concentraƟ on problems were the main reasons.
• One year aŌ er an episode of acute Q-fever, 40% of paƟ ents sƟ ll report Q-fever related 
symptoms.
• More than 30% of our study populaƟ on report that they have not resumed their daily 
acƟ viƟ es to the pre Q-fever infecƟ on levels.
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APPENDIX SUPPLEMENTARY TABLES
Table S1: Weeks of sick leave following acute Q-fever per type of work and year of onset of illness.
Type of work* Cohort 2007 2008 Totaal
Paid work n=53 n= 281 n= 334
Weeks sick leave
 Mean duraƟ on (SD) 11.4 (15.1) 7.3 (9.9) 7.9 (11.0)
Volunteer n= 12 n= 48 n= 60
 Mean duraƟ on (SD) 10.1 (18.8) 7.5 (11.3) 8.0 (12.9)
Housekeeping n= 43 n=190 N=233
 Mean duraƟ on (SD) 10.4 (14.7) 5.6 (8.8) 6.5 (10.6)
*PaƟ ents can state more than one work situaƟ on.
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Table S2. Self-reported symptoms 12 to 26 months aŌ er an episode of acute Q-fever perceived to be at-
tributed to Q-fever of two cohorts (2007 & 2008)* of acute Q-fever paƟ ents noƟ ﬁ ed in the Netherlands.
Symptom /problem**
Cohort 2007 2008 Total
n=93 (%) n=444 (%) n=537 (%)
No 56 (60.2) 269 (60.5) 325 (60.4)
Yes 37 (39.8) 175 (39.5) 212 (39.6)
 FaƟ gue 25 (26.0) 85 (18.5) 110 (19.8)
 Poor concentraƟ on/memory 12 (12.5) 41 (8.9) 53 (9.5)
 Muscle aches 9 (9.4) 41 (8.9) 50 (9.0)
 Joint pain 7 (7.3) 39 (8.5) 46 (8.3)
 Night Ɵ me sweaƟ ng 5 (5.2) 39 (8.5) 44 (7.9)
 Breathing diﬃ  culty 6 (6.2) 36 (7.8) 42 (7.6)
 Malaise 10 (10.4) 27 (5.9) 37 (6.7)
 Chest pain or pressure 7 (7.3) 29 (6.3) 36 (6.5)
 Headache 5 (5.2) 29 (6.3) 34 (6.1)
 SƟ ﬀ  neck 10 (10.4) 24 (5.2) 34 (6.1)
 Coughing 6 (6.2) 28 (6.1) 34 (6.1)
 Skin rash 6 (6.2) 18 (3.9) 24 (4.3)
 Eye problems 4 (4.2) 17 (3.7) 21 (3.8)
 Stomach ache 4 (4.2) 13 (2.8) 17 (3.1)
 Ear problems 3 (3.1) 13 (2.8) 16 (2.9)
 Confusion 3 (3.1) 12 (2.6) 15 (2.7)
 Nausea 4 (4.2) 9 (2.0) 13 (2.3)
 Pain upper belly 1 (1.0) 11 (2.4) 12 (2.2)
 Weight loss 3 (3.1) 8 (1.7) 11 (2.0)
 Diarrhoea 3 (3.1) 6 (1.3) 9 (1.6)
 Sore throat 0 (0.0) 7 (1.5) 7 (1.3)
 Jaundice 1 (1.0) 2 (0.4) 3 (0.5)
 Fever 0 (0.0) 2 (0.4) 2 (0.4)
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ABSTRACT
Background
In the Netherlands, from 2007 to 2009, 3,522 Q-fever cases were noƟ ﬁ ed from three 
outbreaks. These are the largest documented outbreaks in the world. Previous studies 
suggest that symptoms can persist for a long period of Ɵ me, resulƟ ng in a reduced 
quality of life (QoL). The aim of this study was to qualify and quanƟ fy the health status 
of Q-fever paƟ ents aŌ er long-term follow-up.
Methods
870 Q-fever paƟ ents of the 2007 and 2008 outbreaks were mailed a quesƟ onnaire 12 
to 26 months aŌ er the onset of illness. We assessed demographic data and measured 
health status with the Nijmegen Clinical Screening Instrument (NCSI). The NCSI consists 
of three main domains of funcƟ onal impairment, symptoms and QoL that are divided 
into eight sub-domains. The NCSI scores of Q-fever paƟ ents older than 50 years (n = 
277) were compared with paƟ ents younger than 50 years (n = 238) and with norm 
data from healthy individuals (n = 65) and paƟ ents with chronic obstrucƟ ve pulmonary 
disease (n = 128).
Results
The response rate was 65.7%. AŌ er applying exclusion criteria 515 Q-fever paƟ ents 
were included in this study. The long-term health status of two thirds of Q-fever pa-
Ɵ ents (both younger and older than 50 years) was severely aﬀ ected for at least one 
sub-domain. PaƟ ents scores were most severely aﬀ ected on the sub-domains general 
QoL (44.9%) and faƟ gue (43.5%). HospitalisaƟ on in the acute phase was signiﬁ cantly 
related to long-term behavioural impairment (OR 2.8, CI 1.5-5.1), poor health related 
QoL (OR 2.3, CI 1.5-4.0) and subjecƟ ve symptoms (OR 1.9, CI 1.1-3.6). Lung or heart 
disease, depression and arthriƟ s signiﬁ cantly aﬀ ected the long-term health status of 
Q-fever paƟ ents.
Conclusions
Q-fever paƟ ents presented 12 to 26 months aŌ er the onset of illness severe -clinically 
relevant- subjecƟ ve symptoms, funcƟ onal impairment and impaired QoL. All measured 
sub-domains of the health status were impaired. HospitalisaƟ on and co-morbidity were 
predictors for worse scores. Our data emphasise that more aƩ enƟ on is needed not 
only to prevent exposure to Q-fever but also for the prevenƟ on and treatment of the 
long-term consequences of this zoonosis.
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BACKGROUND
Q-fever is a worldwide zoonoƟ c disease caused by Coxiella burneƟ i (C. burneƟ i), an obligate 
intracellular bacterium. UnƟ l 2007 Q-fever was uncommon in the Netherlands, with 5-20 no-
Ɵ ﬁ ed cases annually [1]. From 2007-2009, 3,522 cases were noƟ ﬁ ed in three large outbreaks 
[2], with dairy goats implicated as the source [1, 2]. The majority of Q-fever paƟ ents (80%) 
reside in the southern province of Noord-Brabant [1-3]. Between 2007 and early 2010 some 
hard-hit communiƟ es suﬀ ered a cumulaƟ ve incidence of 2,650 noƟ ﬁ ed Q-fever cases per 
100,000 inhabitants (one in 38 people).
In general 60% of infected Q-fever paƟ ents are asymptomaƟ c, while 20% develop mild 
symptoms [4]. The remaining 20% of Q-fever paƟ ents present with more severe symptoms 
ranging from high fever, severe headache, night sweaƟ ng, nausea and diarrhoea, to pneu-
monia, hepaƟ Ɵ s, pericardiƟ s, myocardiƟ s and neurological symptoms [5]. Chronic Q-fever 
may develop in 1.5-5% of acute cases, due to reacƟ vaƟ on of C. burneƟ i [4, 6, 7]. A feared 
complicaƟ on is endocardiƟ s, which may take 10-15 years to develop. In parƟ cular pregnant 
women and paƟ ents with heart valve disorders, vascular prosthesis and impaired immunity 
have a higher risk to develop chronic infecƟ on [4, 6, 7]. Protracted faƟ gue up to 10 years aŌ er 
infecƟ on [8, 9] is another late sequel. A Post-InfecƟ on FaƟ gue Syndrome (PIFS) [9] may also 
occur aŌ er other infecƟ ons such as Lyme disease [10]. In 10-15% of Q-fever paƟ ents faƟ gue 
can last up to 5-10 years [11] and is referred to as Post Q-fever faƟ gue Syndrome (PQFS). Other 
authors [8, 9] state higher percentages of faƟ gue. PQFS presents with symptoms resembling 
those of Chronic FaƟ gue Syndrome (CFS).
During the Dutch Q-fever outbreaks paƟ ents and general pracƟ Ɵ oners (GPs) repeatedly 
reported persisƟ ng symptoms to the public health authoriƟ es and in parƟ cular about faƟ gue. 
These signals could not be substanƟ ated, as we lacked speciﬁ c informaƟ on on the health 
status at individual and at Q-fever paƟ ent populaƟ on level. Furthermore, we were uncertain 
whether data from other small naƟ onal [12] and internaƟ onal studies, would also apply to 
our large Dutch Q-fever cohorts. In order to assess the long-term health status of Dutch 
Q-fever paƟ ents we started this study.
Long-term health status impairment may have a large impact on paƟ ents, their families 
and the socieƟ es that they are part of. In this study, the primary aim was to provide a detailed 
assessment of the health status of Q-fever paƟ ents 12 to 26 months aŌ er the onset of illness. 
This informaƟ on will assist clinicians and paƟ ents to beƩ er understand the natural course, 
consequences of the disease and predictors for an aﬀ ected health status.
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METHODS
Q-Quest I study
This cohort study is part of the collaboraƟ ve Q-Quest I study, which aims to measure the 
impact of the Q-fever outbreaks in terms of populaƟ on health and societal implicaƟ ons. The 
study started in May 2008 and includes studies on diagnosƟ cs, treatment, clinical symptoms, 
costs and the long-term health status.
Study design and populaƟ on
Eligible for inclusion in this study were Q-fever paƟ ents noƟ ﬁ ed in 2007 and 2008 to the 
Municipal Health Service “Hart voor Brabant” and “Brabant Zuid-Oost” with a ﬁ rst day of 
illness in 2007 or 2008. All paƟ ents ﬁ Ʃ ed the Dutch noƟ ﬁ caƟ on criteria; a laboratory conﬁ r-
maƟ on of Q-fever and clinical presentaƟ on of fever, pneumonia or hepaƟ Ɵ s. PaƟ ents were 
diagnosed by 4 diﬀ erent laboratories. At the beginning of the outbreak in 2007 the laboratory 
test most frequently used was the CFT (complement ﬁ xaƟ on test). A sero-conversion or a 
fourfold increase in Ɵ tre, between two subsequent tests with a minimum Ɵ me interval of two 
to four weeks, was considered posiƟ ve. Later during the outbreak one laboratory used the 
IFA (Immuno Fluorescence Assay). This laƩ er test disƟ nguished between phases I en II IgM 
and IgG [13].
Exclusion criteria were: an unknown onset of Q-fever infecƟ on, a quesƟ onnaire completed 
by another person or an incomplete quesƟ onnaire. ParƟ cipants younger than 18 years of 
age, were excluded because the quesƟ onnaire instruments were developed for adults.
QuesƟ onnaires
All paƟ ents that agreed to parƟ cipate in the Q-Quest I study, received a quesƟ onnaire that 
comprised two parts: the cost and symptoms quesƟ onnaire which collected data on demo-
graphics, self-reported symptoms, co morbidity, hospitalisaƟ on, healthcare consumpƟ on, 
educaƟ on and employment and the Nijmegen Clinical Screening Instrument (NCSI) [14] to 
measure health status.
The NCSI is based on an empirical deﬁ niƟ on of health status [15], covering physiological 
funcƟ oning, symptoms, funcƟ onal impairment, and quality of life (Qol) as main domains. In 
this study we only measured the main domains symptoms, funcƟ onal impairment and QoL. 
These main domains are subdivided into 8 sub-domains: subjecƟ ve symptoms; dyspnoea 
emoƟ ons; faƟ gue; behavioural impairment; subjecƟ ve impairment; general Quality of Life 
(General QoL); Health Related Quality of Life (HRQoL); and saƟ sfacƟ on with relaƟ ons [14]. 
Consult table 1. for deﬁ niƟ ons and instruments [15-20] of the sub-domains of health status 
measured by the NCSI.
The health status of Q-fever paƟ ents aŌ er long-term follow-up  |  135
7
The NCSI provides normaƟ ve data indicaƟ ng normal funcƟ oning, mild - or severe prob-
lems for each sub-domain. The NCSI contains 8 sub-domains, each expressed as a single 
score on its own scale. Thus eight diﬀ erent scales were used. The score range indicaƟ ng 
severe problems was based on paƟ ents with COPD aƩ ending a mulƟ disciplinary inpaƟ ent 
pulmonary rehabilitaƟ on program (n = 128). The key requirement for inclusion was severe 
problems in mulƟ ple areas of the health status. This decision was based on a three-day intake 
procedure, in which elaborate assessment, physiological tests and clinical interviews with 
seven medical disciplines were undertaken. The score range indicaƟ ng normal funcƟ oning 
was based on a group of healthy subjects (n = 65). Scores below the 80th percenƟ le of healthy 
controls indicate the score range of normal funcƟ oning. Scores above the 20th percenƟ le of 
the pulmonary rehabilitaƟ on group indicate the score range of severe problems. Higher NCSI 
scores indicate more problems. For more details see Peters et al [14].
Table 1. Deﬁ niƟ ons and instruments of the health status sub-domains measured by the Nijmegen Clini-
cal Screening Instrument
Domain Sub-domain Deﬁ niƟ on Instruments
Symptoms SubjecƟ ve 
symptoms
The paƟ ent’s overall burden of 
pulmonary symptoms
PARS-D Global Dyspnoea 
AcƟ vity, Global Dyspnoea 
Burden (15)
Dyspnoea 
emoƟ ons
The level of frustraƟ on and anxiety a 
person experiences when dyspnoeic
DEQ FrustraƟ on, Anxiety 
(15)
FaƟ gue The level of experienced faƟ gue CIS SubjecƟ ve faƟ gue (16)
FuncƟ onal 
impairment
Behavioural 
impairment
The extent to which a person cannot 
perform speciﬁ c and concrete acƟ viƟ es 
as a result of having the disease
SIP Home Management, 
AmbulaƟ on (17)
SubjecƟ ve 
impairment
The experienced degree of impairment 
in general and in social funcƟ oning
QoLRiQ General 
AcƟ viƟ es(18)
Quality of 
Life
General Quality 
of Life
Mood and the saƟ sfacƟ on of a person 
with his/her life as a whole
BDI Primary Care (19) 
SaƟ sfacƟ on with Life Scale 
(20)
Health-related 
Quality of Life
SaƟ sfacƟ on related to physiological 
funcƟ oning and the future
SaƟ sfacƟ on Physiological 
FuncƟ oning, SaƟ sfacƟ on 
Future (15)
SaƟ sfacƟ on 
relaƟ ons
SaƟ sfacƟ on with the (absent) 
relaƟ onships with spouse and others
SaƟ sfacƟ on spouse, 
SaƟ sfacƟ on social (15)
PARS-D: Physical AcƟ vity RaƟ ng Scale-Dyspnoea; DEQ: Dyspnoea EmoƟ ons QuesƟ onnaire; CIS: Checklist 
Individual Strength; SIP: Sickness Impact Proﬁ le; QoLRiQ: Quality of Life for Respiratory Illness QuesƟ on-
naire; BDI: Beck Depression Inventory.
136  |  Chapter 7
Data collecƟ on
In February 2009, 870 paƟ ents received a Q-Quest study informaƟ on folder and a parƟ cipa-
Ɵ on request form by post. PaƟ ents could state their willingness to take part in any of the 
Q-Quest I studies by signing the consent-form. All paƟ ents from the 2007 cohort received 
a Q-Quest I quesƟ onnaire (12-26 months aŌ er onset of Q-fever illness) together with the 
consent form in February 2009. PaƟ ents from the 2008 cohort, who had stated their willing-
ness to parƟ cipate, were mailed the quesƟ onnaire exactly one year aŌ er the month of onset 
of illness. If quesƟ onnaires were not returned within three weeks, paƟ ents from both cohorts 
received two reminders three weeks apart. See ﬁ gure 1 for detailed informaƟ on.
The study design and protocol were approved by the local Medical Ethics Review Commit-
tee of the Jeroen Bosch Hospital.
Data analysis
In this study we compared the Q-fever paƟ ents NCSI scores with those of the norm groups: 
healthy individuals (n = 65) and the special group of severe COPD paƟ ents (n = 128).
QuesƟ onnaires were double scanned in November 2009. SPSS 15.0 for windows was used 
for staƟ sƟ cal analysis. P-values were based on two tailed tests with p < 0.05 deﬁ ned as signiﬁ -
cant. Chi-square test was used to compare proporƟ ons. LogisƟ c regression and the general 
linear model were used to model outcomes (8 sub-domains of NCSI) for the three groups 
(healthy COPD-norm group and Q-fever paƟ ents), while controlling for the potenƟ al con-
founders: age, gender, smoking and educaƟ on-level. During logisƟ c regression we regrouped 
the outcomes normal, mild and severe for the 8 sub-domains into normal and abnormal 
(combining mild and severe). NoƟ ﬁ caƟ on data of the Municipal Health Service enabled us to 
compare Q-fever respondents and non-responders for year of onset of illness, age, gender 
and hospitalisaƟ on at the acute stage of the infecƟ on. As the control groups providing the 
normaƟ ve data for the NCSI were older than 50 years, Q-fever paƟ ents younger than 50 years 
of age were analysed separately from paƟ ents older than 50 years.
For comparison of parƟ cipaƟ ng Q-fever paƟ ents younger or older than 50 years of age, 
we also looked at co-morbidity and hospitalisaƟ on. These data were unavailable for healthy 
individuals and COPD paƟ ents.
RESULTS
PaƟ ent parƟ cipaƟ on
Of the 898 paƟ ents noƟ ﬁ ed in 2007-2008, 28 were excluded due to incomplete data or un-
known month of onset of illness (Figure 1). Of the 5 paƟ ents that died, we lacked informaƟ on 
on the cause of death. In total 572 quesƟ onnaires were received (65.7%). Fewer men than 
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women returned the quesƟ onnaire (responders vs. non-responders women 223/106, men 
323/218 p = 0.017). The response rate was higher for paƟ ents aged over 35 (P = 0.011). AŌ er 
excluding parƟ cipants younger than 18 years (n = 9), parƟ cipants who did not complete the 
quesƟ onnaire themselves (n = 22) and incomplete quesƟ onnaires (n = 26), 515 quesƟ on-
naires were leŌ  (see Figure 1). The mean interval between the ﬁ rst day of illness for Q-fever 
paƟ ents of cohort 2007 and cohort 2008 and ﬁ lling out the quesƟ onnaire was 19.6 months 
(SD 2.3) and 11.6 months (SD 1.0), respecƟ vely.
Figure 1. Flowchart. Response rate of 898 Q-fever paƟ ents with onset of disease in 2007 and 2008
CharacterisƟ cs of the study populaƟ on
Q-fever paƟ ents, the healthy and COPD norm group were similar with respect to gender and 
level of educaƟ on. The characterisƟ cs of the study populaƟ on are presented in table 2.
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Table 2. CharacterisƟ cs of the study populaƟ on
CharacterisƟ cs
Q-fever COPD Healthy Total
Age <50 >50 yrs      
n = 238 (%) n = 277 (%) n = 128 (%) n = 65 (%) n = 708
Gender          
 Male 140 (58.8) 166 (59.9) 86 (67.2) 47 (72.3) 439
 Female 98 (41.2) 111 (40.1) 42 (32.8) 18 (27.7) 269
Age          
 Mean 40.4  60.3  62.5  63.5  56.7
 SD  7.4   7.6   6.9   6.6   
Current smoking          
 Yes 96 (40.3) 71 (26.6) 11 (8.9) 11 (16.9) 189
 No 137 (57.6) 196 (73.4) 113 (91.1) 54 (83.1) 500
EducaƟ on-level          
 Low 56 (23.5) 97 (35.5) 62 (50.4) 20 (30.8) 235
 Average 120 (50.4) 126 (46.2) 38 (30.9) 26 (40.0) 310
 High 60 (25.2) 50 (18.3) 23 (18.7) 19 (29.2) 152
Q-fever paƟ ents younger and older than 50 years, Norm groups Chronic ObstrucƟ ve Pulmonary Dis-
ease- and healthy individuals. Q-fever paƟ ents >50 currently smoke signiﬁ cantly more than COPD-con-
trols. None of the other characterisƟ cs diﬀ er signiﬁ cantly (logisƟ c regression).
Health status
The long-term health status of Q-fever paƟ ents was severely aﬀ ected especially for the sub-
domains General QoL (44.9%) and faƟ gue (43.5%) (see ﬁ gure 2). Almost two ﬁ Ō hs of the 
Q-fever paƟ ents (38.2%) older than 50 years, had severe problems on more than one sub-
domain (see ﬁ gure 3). Of the Q-fever paƟ ents with abnormal faƟ gue, 79.5% also reported 
abnormal scores on subjecƟ ve symptoms, 77.9% on behavioural impairment, 65.0% on 
HRQoL, 60.7% on dyspnoea emoƟ ons and 57.7% on General QoL.
Female Q-fever paƟ ents consistently reported abnormal funcƟ oning (mild and severe on 
the sub-domains of the NCSI) more frequently than males. This diﬀ erence was only signiﬁ cant 
for saƟ sfacƟ on with relaƟ ons (34.0% of the women vs. 28.1% of the men, p = 0.012).
No signiﬁ cant diﬀ erences were found for 7 sub-domain scores between Q-fever paƟ ents 
older and younger than 50 years. Although the frequency with which dyspnoea was reported 
was similar for the age groups (45.8% >50 years n = 277 and 42.9% < 50 years n = 238) 
paƟ ents younger than 50 years suﬀ ered more oŌ en from dyspnoea emoƟ ons (OR 2.0, CI 
1.3-3.1 p = 0.001).
In comparison to the healthy norm score, Q-fever paƟ ents showed signiﬁ cantly more 
abnormal health status (mild and severe) in 7 of the 8 sub-domains (see table 3). The worst 
scores were found for the sub-domains faƟ gue, subjecƟ ve symptoms and subjecƟ ve impair-
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ment. Q-fever paƟ ents had signiﬁ cantly lower (healthier) scores in all 8 NCSI-sub-domains, 
compared to the COPD-norm score.
The year of onset of illness, level of educaƟ on and smoking behaviour had no signiﬁ cant 
inﬂ uence on sub-domain mean scores. However, paƟ ents that were hospitalised (23.6% of 
paƟ ents older than 50 years) during the onset of illness or with underlying heart or lung 
disease, arthriƟ s and depression scored signiﬁ cantly worse for several sub-domains (see 
Table 4). The outcomes for paƟ ents younger than 50 years were similar.
Heart disease increased the risk for an abnormal outcome for the sub-domains subjecƟ ve 
symptoms, behavioural and subjecƟ ve impairment, HRQoL and dyspnoea emoƟ ons. Lung 
disease had a negaƟ ve inﬂ uence on the outcome of the ﬁ rst three aforemenƟ oned domains.
Figure 2. The 8 sub-domain scores of Q-fever paƟ ents older (n = 277) and younger than 50 years of age 
(n = 238).
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Figure 3. Percentage of Q-fever paƟ ents with the number of severely aﬀ ected domains of the health 
status.
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Table 3. Comparison 8 NCSI sub-domains scores between Q-fever paƟ ents > 50 years and the healthy 
norm group
Domain and subdomain
Q-fever Healthy control Q-fever vs. Healthy (ref)
n = 277 (%) n = 65 (%) OR (CI) p-value
Symptoms     
 SubjecƟ ve symptoms    
 n 255 65   
 Normal 123 (48.2) 59 (90.8)   
 Abnormal 132 (51.8)  6 (9.2) 9.9 (4.0-24.5) 0.000
 Dyspnoea emoƟ ons    
 n 172 65   
 Normal 103 (59.9) 55 (84.6)   
 Abnormal  69 (40.1) 10 (15.4) 3.1 (1.4-6.8) 0.006
 FaƟ gue     
 n 207 65   
 Normal  85 (41.1) 57 (87.7)   
 Abnormal 122 (58.9)  8 (12.3) 9.2 (4.0-20.8) 0.000
FuncƟ onal impairment    
 Behavioural impairment    
 n 277 65   
 Normal 126 (45.5) 49 (75.4)   
 Abnormal 151 (54.5) 16 (24.6) 3.8 (1.9-7.3) 0.000
 SubjecƟ ve impairment    
 n 249 65   
 Normal 173 (69.5) 60 (92.3)   
 Abnormal  76 (30.5)  5 (7.7) 5.0 (1.9-13.4) 0.001
Quality of life     
 General Quality of Life    
 n 234 65   
 Normal 129 (55.1) 51 (78.5)   
 Abnormal 105 (44.9) 14 (21.5) 2.4 (1.2-4.7) 0.011
 Health related Quality of Life    
 n 271 65   
 Normal 151 (55.7) 55 (84.6)   
 Abnormal 120 (44.3) 10 (15.4) 3.7 (1.8-7.7) 0.001
 SaƟ sfacƟ on relaƟ ons    
 n 252 65   
 Normal 166 (65.9) 37 (56.9)   
 Abnormal  86 (34.1) 28 (43.1) 0.5 (0.3-0.9) 0.040
Abnormal is a combinaƟ on of mild and severe scores. Used method chi square.
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DISCUSSION
The present study is the largest and longest follow-up study of Dutch Q-fever paƟ ents of the 
2007 and 2008 outbreaks. Using a validated quesƟ onnaire, the Nijmegen Clinical Screening 
Instrument (NCSI), we provided a detailed assessment of the long-term eﬀ ects of Q-fever on 
health status 12-26 months aŌ er onset of illness. The most important ﬁ nding of this study 
was that, in two thirds of Q-fever paƟ ents of all ages, at least one sub-domain was severely 
(clinically) aﬀ ected up to 26 months aŌ er the iniƟ al illness. The sub-domains General QoL 
(44.9%) and faƟ gue (43.5%) were most frequently severely aﬀ ected.
Published data on health status, and its sub-domains, in Q-fever paƟ ents are scarce. 
HatcheƩ e reported [21] that 52% of Q-fever paƟ ents were symptomaƟ c and had an impaired 
QoL 27 months aŌ er infecƟ on, with signiﬁ cant lower scores on ﬁ ve of eight domains of the 
Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), as compared to non-
infected controls. Impaired domains were: physical pain, physical funcƟ on, emoƟ onal role, 
physical role and social funcƟ on.
In our study we found 58.9% of paƟ ents with abnormal (mild and severe) faƟ gue. This 
is similar to other publicaƟ ons that state 68.7% [9] ﬁ ve and 64.9% [8] protracted faƟ gue up 
to ten to years aŌ er infecƟ on. Unfortunately we were unable to establish if Q fever paƟ ents 
mainly suﬀ ered faƟ gue the ﬁ rst year and later recovered as we only had contact with paƟ ents 
once. The fact that we found no diﬀ erences between paƟ ents of the 2007 and 2008 cohorts 
is suggesƟ ve of persisƟ ng complaints.
Some studies state that cytokine deregulaƟ on and immuno-modulaƟ on from persistence 
of C. burneƟ i, might be responsible [22] for prolonged faƟ gue, but others contradict this [23].
Other studies ﬁ nd prolonged impairment of the health status months aŌ er legionellosis 
and pneumonia. Dutch pneumonia paƟ ents had signiﬁ cantly aﬀ ected SF-36 scores 18 months 
aŌ er pneumonia on the subscales physical funcƟ on and general health status [24]. Survivors 
of a Legionnaires Disease-outbreak in the Netherlands reported 17 months aŌ er infecƟ on 
severely impaired SF-36-domains: physical role funcƟ on, general health and vitality [25]. Up 
to 75.0% of paƟ ents reported faƟ gue [25]. Although all three infecƟ ous diseases seem to 
cause long-term impairment; the impaired sub-domains diﬀ er.
The severity of iniƟ al illness in general negaƟ vely inﬂ uences the long-term QoL [26, 
27]. Similarly, the severity of the acute Q-fever symptoms predicts long-term symptoms 
[28]. Our study shows that hospitalised paƟ ents more oŌ en scored abnormal on the sub-
domains HRQoL, behavioural impairment and subjecƟ ve symptoms than those that were not 
hospitalised during the acute phase of illness. We consider hospitalisaƟ on to be an indicator 
of the severity of the iniƟ al infecƟ on. Our assumpƟ on that Q-fever paƟ ents with severe acute 
illness are more likely to experience long-term impaired QoL was therefore proven correct. 
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Another study shows that paƟ ents that had been admiƩ ed to the Intensive Care Unit - regard-
less of the cause - have an impaired QoL (SF-36) up to 18 months [29].
General QoL (44.9%) and faƟ gue (43.5%) were severely aﬀ ected in our study subjects. A 
small study on Dutch Q-fever paƟ ents that measured the one year follow-up and also used the 
NCSI reported a higher rate of 53% of paƟ ents with severe faƟ gue [12]. We suspect that the 
paƟ ents in that study had a higher hospitalisaƟ on rate and presented with more pneumonia 
than our paƟ ents. ConsultaƟ on of our noƟ ﬁ caƟ on data conﬁ rmed this presumpƟ on, but the 
diﬀ erence was marginal. Furthermore, proporƟ onally more paƟ ents in that study might have 
been recruited from the local hospital’s chest clinic. In the present study, we approached all 
paƟ ents in the region, regardless of the severity of the iniƟ al disease.
We found that heart disease increased the risk of subjecƟ ve symptoms, behavioural and 
subjecƟ ve impairment, HR QoL and dyspnoea emoƟ ons. Whereas lung disease negaƟ vely 
inﬂ uenced the outcomes of the ﬁ rst three of these sub-domains.
Other authors stated that underlying heart [30,31] or lung disease [32], arthriƟ s [33], 
depression [34] and diabetes [35], all had a negaƟ ve eﬀ ect on the health status in diﬀ erent 
sub-domains. We also found this eﬀ ect, except for diabetes, but could not compare data 
with exisƟ ng studies, as most of these studies focus on speciﬁ c diseases (such as COPD) and 
grades of severity. We however, combined all diseases of a certain tract.
Methodological consideraƟ ons and study limitaƟ ons
The NCSI is not widely used in Q-fever research. This makes comparison to other QoL-research 
in Q-fever diﬃ  cult. The advantage of the NCSI is that it provides a detailed assessment includ-
ing many domains of health status covering symptoms, funcƟ onal impairment and quality of 
life. The NCSI provides more and speciﬁ c informaƟ on on sub-domains than some of the other 
instruments such as the SF-36. Furthermore, the availability of datasets of both a COPD and a 
healthy norm group for the NCSI, enabled us to compare the health status of Q-fever paƟ ents 
with these two groups. Such a comparison provides useful informaƟ on for GPs and medical 
specialists in their understanding of Q-fever paƟ ents. Another advantage is that the NCSI 
quesƟ onnaire for the domain faƟ gue is based on the CIS (Checklist Individual Strength). This 
instrument corrects for normal faƟ gue [36]. As many Q-fever paƟ ents suﬀ er from faƟ gue, the 
NCSI seemed the right choice.
The municipal health service regularly received Q-fever paƟ ent reports of conƟ nuing 
respiratory complaints. We therefore looked for a norm group with a known respiratory 
component that we could compare these Q-fever paƟ ents with. When we compared data 
from Q-fever paƟ ents with the NCSI norm group of COPD paƟ ents it should be realized that 
this is a speciﬁ c subgroup of COPD paƟ ents with a severely impaired health status in mulƟ ple 
sub-domains. We made the choice to use this COPD norm group as we wished to compare 
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the long-term health status of Q-fever paƟ ents (who oŌ en suﬀ ered a pneumonia iniƟ ally) 
with another group of paƟ ents with a known impaired health status.
The healthy control group was rather small with 65 individuals all over 50 years of age. 
However, the number of controls provided suﬃ  cient power for us to show a large and clear 
diﬀ erence between the groups.
NormaƟ ve data of healthy subjects and those with COPD were only available for paƟ ents 
older than 50 years of age. This was unfortunate as 46.2% of Q-fever paƟ ents were younger 
than 50. As we chose our method to be as strict and transparent as possible, we presented 
data for paƟ ents younger and older than 50 years of age separately.
In at least 1.6% of the Q-fever paƟ ents in the Dutch 2007-2008 cohorts, the condiƟ on 
became chronic (van der Hoek et al, submiƩ ed for publicaƟ on). For our study populaƟ on 
this could potenƟ ally mean eight or nine paƟ ents with chronic Q-fever. As not all paƟ ents in 
our study were followed up serologically we were unable to establish if and who developed 
chronic Q-fever or any of its presentaƟ ons such as endocardiƟ s.
Data were collected during the early stages of the Q-fever outbreaks in the Netherlands. 
At that stage there was liƩ le to no media aƩ enƟ on for these outbreaks. The general public 
was mostly unaware of Q-fever and the possible negaƟ ve long-term outcome. PaƟ ents were 
not medicalised and mostly unaware. We therefore believe that our data were not negaƟ vely 
inﬂ uenced by the media or the general knowledge of the paƟ ent of the negaƟ ve long-term 
outcomes.
ImplicaƟ ons
By assessing the long-term health status of Q-fever paƟ ents of the largest outbreak in the 
world, we are able to describe and quanƟ fy the impact of Q-fever on paƟ ent’s lives. Hospitali-
saƟ on is an important predictor of severe illness, poor long-term health status outcome and 
long-term absence from work (unpublished data G.Morroy).
The outbreaks are conƟ nuing and Q-fever has become endemic in the area. Since symp-
toms could last for ten years or more [8], the burden of disease for the aﬀ ected communiƟ es 
is likely to be considerable.
A beƩ er understanding of long-term outcomes is essenƟ al for policy makers dealing with 
these outbreaks. GPs and other Medical Doctors should be aware that Q-fever paƟ ents may 
present with long-term symptoms especially in those that were hospitalised and or with co-
morbidity (heart-, lung-disease, and depression). Knowledge of these detrimental long-term 
outcomes should help MDs to be more supporƟ ve to these paƟ ents and refer promptly and 
adequately to specialist care.
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Conclusions
Our study of the largest described Q-fever cohort in the world shows a large long-term im-
pact of Q-fever on the health status of Q-fever paƟ ents of all ages. This is but an indicaƟ on of 
the burden of disease in the years to come considering the more than 4,000 reported Dutch 
Q-fever cases since 2007. Policy makers ought to take the long-term burden of disease into 
account, when considering measures to be taken to curb these extensive Dutch outbreaks. 
We recommend further research to develop adequate prevenƟ on, treatment and revalida-
Ɵ on guidelines that might beneﬁ t these aﬀ ected paƟ ents.
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SUMMARY
From 2007 through 2010, the Netherlands experienced a major Q-fever outbreak with 
more than 4000 noƟ ﬁ caƟ ons. Previous studies suggested that Q-fever paƟ ents could 
suﬀ er long-term post infecƟ on health impairments, especially faƟ gue. Our objecƟ ve 
was to assess the Coxiella burneƟ i anƟ body prevalence and health status including 
faƟ gue, and assess their interrelaƟ onship, in Herpen a high incidence village, seven 
years aŌ er the outbreak began.
In 2014, we invited all 2161 adult inhabitants for a quesƟ onnaire and a C. burneƟ i 
Indirect Fluorescence AnƟ body Assay (IFA). The health status was measured with the 
Nijmegen Clinical Screening Instrument (NCSI), consisƟ ng of eight sub-domains includ-
ing faƟ gue.
Of the 70.1% (1517/2161) parƟ cipants, 33.8% (513/1517) were IFA posiƟ ve. Of 147 
parƟ cipants who were IFA posiƟ ve in 2007, 25 (17%) seroreverted and were now IFA 
negaƟ ve. Not a posiƟ ve IFA status, but an age <50 years, smoking and co-morbidity, 
were independent risk factors for faƟ gue. NoƟ ﬁ ed parƟ cipants reported signiﬁ cantly 
more oŌ en faƟ gue (31/49, 63%) than not noƟ ﬁ ed IFA posiƟ ve parƟ cipants (150/451, 
33%). Although faƟ gue is a common sequel aŌ er acute Q-fever, we found -in this 
community-based survey- no diﬀ erence in faƟ gue levels between parƟ cipants with and 
without C. burneƟ i anƟ bodies.
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INTRODUCTION
Q-fever is a zoonosis caused by the bacterium Coxiella burneƟ i (C. burneƟ i). In 2007, Herpen, 
a small village in the south of the Netherlands was heavily aﬀ ected by a Q-fever outbreak [1]. 
This outbreak was followed by larger outbreaks in 2008 and 2009, in a larger geographical 
area and culminated in 4107 noƟ ﬁ caƟ ons naƟ onwide by 2010 [2].
A common sequel of acute Q-fever is protracted incapacitaƟ ng faƟ gue [3-5], oŌ en de-
noted as the Q-fever FaƟ gue Syndrome (QFS) that may conƟ nue ten years or longer[6,7]. 
PaƟ ents with QFS may experience severe sweaƟ ng, breathlessness, blurred vision, reduced 
exerƟ on, myalgia, arthralgia, sleeping disorders and mood swings [7, 8], symptoms that re-
semble the Chronic FaƟ gue Syndrome (CFS). The aeƟ ology of QFS is not enƟ rely understood. 
DysregulaƟ on of cytokines due to persisƟ ng anƟ gens of C. burneƟ i are described to cause 
chronic sƟ mulaƟ on of the immune system [9, 10]. A Post InfecƟ on FaƟ gue Syndrome (PIFS) 
[11] may also occur aŌ er other infecƟ ons [12], such as Borrelia burgdorferi [13], Legionella 
pneumophila [14], Epstein Barr and Ross River virus infecƟ on [12]. According to several studies, 
Q-fever paƟ ents have an impaired health status, pulmonary disorders and an increased risk of 
problems in general and social funcƟ oning [3-8, 12, 14].
General pracƟ Ɵ oners (GPs) and the populaƟ on in the Q-fever aﬀ ected area, and the na-
Ɵ onal Q-fever paƟ ent organisaƟ on, speculated that the number of infecƟ ons and long-term 
consequences such as faƟ gue were underesƟ mated. The local municipal health service (MHS) 
therefore iniƟ ated the ‘Q-Herpen-II’ study in - this small rural village with a stable Caucasian 
populaƟ on – in order to invesƟ gate the presence of anƟ bodies against C. burneƟ i in relaƟ on 
to the health status with an emphasis on faƟ gue.
METHODS
Study design and study populaƟ on
The Municipal Health Service (MHS) “GGD Hart voor Brabant” executed this study as part of 
the larger ‘Q-Herpen-II’ study. The Medical Ethics Review CommiƩ ee of the Utrecht University 
Medical Centre, approved the study (protocol 13-367/D Q-Herpen II). For this cross-secƟ onal 
populaƟ on study all adult inhabitants (≥18 years of age) of the village Herpen (postal code 
5373) were invited to parƟ cipate. The municipal administraƟ on provided demographic data 
for the 2161 inhabitants. In January 2014, all were sent a leƩ er by mail containing informaƟ on 
on the study with a parƟ cipaƟ on request, a quesƟ onnaire and an informed consent form. The 
quesƟ onnaire included quesƟ ons on demographics, smoking, the parƟ cipant’s knowledge 
or percepƟ on of their Q-fever status, risk factors associated with chronic Q-fever, Q-fever 
vaccinaƟ on status, chronic medical condiƟ ons and medicaƟ on use.
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The current health status was assessed with the Nijmegen Clinical Screening Instrument 
(NCSI), which is a validated method originally developed to measure the health status of 
COPD paƟ ents in a clinical seƫ  ng [15]. The instrument consists of the main domains: Symp-
toms, FuncƟ onal Impairment, and Quality of Life. These are divided into eight sub-domains 
(table 1). PaƟ ents’ scores are subdivided in “normal”, “mild problems” and “clinically relevant 
problems”. The only excepƟ on is the sub-domain General Quality of Life that is divided in 
“normal” and “clinically relevant problems”/“severe problems”. In the univariate and mul-
Ɵ variate analysis, the NCSI categories mild problems and clinically relevant problems were 
Table 1. Domains and sub-domains of the Nijmegen Clinical Screening Instrument (NCSI) with their 
deﬁ niƟ on, the instruments on which they are based and number of quesƟ on used.
Domains Sub-domain Deﬁ niƟ on Instruments
Number of 
quesƟ ons
Symptoms SubjecƟ ve 
Pulmonary 
Symptoms
Overall burden of 
pulmonary symptoms
PARS-D1 Global 
Dyspnoea AcƟ vity, 
Global Dyspnoea Burden
2
Dyspnoea 
EmoƟ ons
Level of frustraƟ on and 
anxiety experienced when 
dyspnoeic
DEQ2 FrustraƟ on, 
Anxiety
6
FaƟ gue Level of experienced 
faƟ gue
CIS3 SubjecƟ ve FaƟ gue 8
FuncƟ onal 
Impairment
Behavioural 
Impairment
The extent of inability 
to perform speciﬁ c and 
concrete acƟ viƟ es as a 
result of the disease
SIP4 Home Management, 
AmbulaƟ on
22
SubjecƟ ve 
Impairment
Experienced degree of 
impairment in general and 
in social funcƟ oning
QoLRiQ5 General 
AcƟ viƟ es
4
Quality of 
Life
General (GQOL) Mood and the saƟ sfacƟ on 
with life as a whole
BDI6 Primary Care 
SaƟ sfacƟ on With Life 
Scale
12
Health Related 
(HRQOL)
SaƟ sfacƟ on related to 
physiological funcƟ oning 
and the future
SaƟ sfacƟ on Physiological 
FuncƟ oning, SaƟ sfacƟ on 
Future
2
SaƟ sfacƟ on 
RelaƟ ons
SaƟ sfacƟ on with the 
(absent) relaƟ onships with 
spouse and others
SaƟ sfacƟ on Spouse, 
SaƟ sfacƟ on Social
2
PARS-D1 physical acƟ vity raƟ ng scale-dyspnoea, DEQ2 dyspnoea emoƟ ons quesƟ onnaire, CIS3 checklist 
individual strength, SIP4 sickness impact proﬁ le, QoL-RiQ5 quality of life for respiratory illness quesƟ on-
naire, BDI 6 beck depression inventory.
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combined into one category problems. Age, smoking behaviour, and educaƟ onal level were 
dichotomized.
During ﬁ ve days in February and one in March 2014, quesƟ onnaires were handed in by 
parƟ cipants and checked for missing informaƟ on and errors by medical staﬀ  together with 
the parƟ cipant. This was followed by a venipuncture.
AnƟ bodies against C. burneƟ i were determined with the Indirect Fluorescence AnƟ body 
Assay (IFA). An IFA IgG phase I or II Ɵ tre ≥1:64 was considered posiƟ ve. The IFA results were 
reported to parƟ cipants and their GPs with a medical recommendaƟ on. Data on the occur-
rence of chronic Q-fever are described in a separate publicaƟ on [16].
We veriﬁ ed if parƟ cipants had been noƟ ﬁ ed previously, by using the local MHS data. In 
the Netherlands acute Q-fever is noƟ ﬁ able. Any acute Q-fever diagnosis must be reported to 
the MHS both by the clinician and the laboratory of medical microbiology. Reported cases 
that according to the MHS meet the predeﬁ ned naƟ onal case deﬁ niƟ ons are noƟ ﬁ ed and 
registered in a naƟ onal surveillance system. NoƟ ﬁ caƟ on criteria used at the beginning of the 
outbreak in 2007 were: a laboratory conﬁ rmaƟ on and matching clinical symptoms. In July 
2008 the Dutch Q-fever noƟ ﬁ caƟ on criteria were changed to; the presence of fever, pneumo-
nia or hepaƟ Ɵ s and a laboratory diagnosis plus reported to the MHS within 90 days following 
the onset of illness. For noƟ ﬁ caƟ on at least one of the following laboratory criteria should be 
met: seroconversion or a fourfold or larger C. burneƟ i IgG-anƟ body Ɵ tre increase in paired 
sera (minimally two weeks apart) of an IFA or a complement ﬁ xaƟ on test (CFT), or presence of 
IgM-Phase II anƟ bodies or a posiƟ ve C. burneƟ i PCR (unless the sample is from a paƟ ent with 
chronic Q-fever). If any of the clinical, laboratory or Ɵ me criteria were not met a Q-fever case 
would -although reported- not be registered (noƟ ﬁ ed) in the naƟ onal surveillance system.
We assumed that IFA posiƟ ve (IgG phase I or II ≥ 1:64) parƟ cipants who reported that they 
did not to recall an acute Q-fever episode, had either previously experienced an asymptomaƟ c 
or mild acute infecƟ on, which had not been medically evaluated. These individuals were clas-
siﬁ ed as “no recollecƟ on of a previous infecƟ on”. ParƟ cipants that were adamant that they 
had been infected and reported their belief in a past infecƟ on even if this was regardless of 
any medical proof were classiﬁ ed as “belief in a previous infecƟ on”. We conducted a straƟ ﬁ ed 
analysis - the Mantel Haenzel Summary Chi Square test -to control for the confounding eﬀ ect 
of knowledge of/belief in a past episode of acute Q-fever. It is therefore not a mulƟ variate 
staƟ sƟ cal model.
StaƟ sƟ cal analysis
QuesƟ onnaires were digitally scanned into a SPSS database and analysed with SPSS 21.0 
and Open Epi. InformaƟ on on age and gender of non-parƟ cipants was obtained from the 
municipal administraƟ on.
ParƟ cipants that had been vaccinated against Q-fever were excluded from the analysis.
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ProporƟ ons were compared with the chi-square test. MulƟ variate logisƟ c regression 
analyses was used to compare the NCSI sub-domain scores incorporaƟ ng the 2014 IFA status, 
age, gender, smoking, educaƟ onal-level, rheumatoid arthriƟ s, psychiatric disorders and 
or use of psychiatric medicaƟ on, and other co-morbidity. A p-value <0.05 was considered 
signiﬁ cant.
RESULTS
ParƟ cipants and non-parƟ cipants
Of the 2161 inhabitants, 70.9% (1534/2161) parƟ cipated. Both a blood sample and a ques-
Ɵ onnaire were received from 70.2% (1517/2161) parƟ cipants.
ParƟ cipants and non-parƟ cipants were comparable with respect to gender and age (data 
not shown).
CharacterisƟ cs and IFA status of parƟ cipants
Of the parƟ cipants 33.8% (n=513) were IFA posiƟ ve. As the ﬁ ve parƟ cipants vaccinated 
against Q-fever were removed from our database, data were analysed for the remaining 1512 
parƟ cipants, including 510 IFA posiƟ ves.
There were no diﬀ erences in gender, age, educaƟ onal level and presence of co- morbidity 
between IFA posiƟ ve and IFA negaƟ ve parƟ cipants (Table 2). IFA posiƟ ve parƟ cipants were 
more oŌ en current smokers than IFA negaƟ ve parƟ cipants (Table 2). Of note; of the 147 
parƟ cipants who were IFA posiƟ ve in 2007, 25 (17%) seroreverted and were IFA negaƟ ve in 
2014 [16].
NCSI sub-domains in relaƟ on to IFA status
IFA posiƟ ve parƟ cipants did not score signiﬁ cantly higher (worse) on NSCI sub-domains 
compared to IFA negaƟ ve parƟ cipants (Figure 1, for data see supplementary Table S1). On 
the contrary, amongst IFA posiƟ ve parƟ cipants, the ORs for the three sub-domains; subjec-
Ɵ ve pulmonary complaints (OR 0.69 (CI 0.55-0.88), p<0.01), dyspnoea emoƟ ons (OR 0.65 
(CI 0.49-0.85), p<0.01) and subjecƟ ve impairment (OR 0.77, (CI 0.59-0.98), p=0.04) were <1.
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Table 2. CharacterisƟ cs of study parƟ cipants and the presence of Coxiella burneƟ i anƟ bodies measured 
with the immunoﬂ uorescence assay (IFA).
All IFA-posiƟ ve IFA-negaƟ ve
n=1512 100% n=510 (33.8%) n=1002 (66.2%) p-value
Mean age, years 51.9 (SD 16.5) 51.5 (SD 15.7) 52.1 (SD 16.9) 0.541
Gender 0.702
Male 748 (49.6) 256 (50.2) 492 (49.1)
Female 764 (50.4) 254 (49.8) 510 (50.9)
Smoking 0.042
Current 276 (18.3) 110 (21.6) 166 (16.6)
Former 565 (37.5) 191 (37.5) 374 (37.5)
Never 666 (44.2) 209 (41.0) 457 (45.8)
EducaƟ onal level2 0.052*
Low 822 (55.2) 289 (57.5) 533 (54.0)
Average 425 (28.5) 149 (29.6) 276 (28.0)
High 243 (16.3) 65 (12.9) 178 (18.0)
Known or perceived previous Q-fever 2
Yes, medically conﬁ rmed 147 (9.8) 122 (24.1) 25 (2.5) <0.012
Yes, own belief 46 (3.1) 23 (4.5) 23 (2.3)
No 775 (51.8) 219 (42.3) 556 (56.2)
Don’t know 527 (35.3) 142 (28.1) 385 (38.9)
Rheumatoid arthriƟ s
Yes 127 (8.4) 37 (7.3) 90 (9.0) 0.282
No 1378 (91.6) 471 (92.7) 907 (91.0)
Psychological disease or medicaƟ on2
Yes 80 (5.3) 31 (6.1) 49 (4.9) 0.332
No 1430 (94.7) 479 (93.9) 951 (95.1)
Other co-morbidity
Yes 442 (29.3) 144 (28.2) 298 (29.8) 0.552
No 1069 (70.7) 366 (71.8) 703 (70.2)
1Analysed with the independent sample t-test or 2the Pearson’s chi-squared test. * The actual p-value 
is 0.054.
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Figure 1.NCSI sub-domains in paired columns as IFA posiƟ ve (IFA+) (n= 509) and negaƟ ve (IFA-) (n= 998) 
divided in: clinically relevant problems boƩ om, mild problems –middle and normal top.
GQOL is General Quality of Life and HRQOL is the Health Related Quality of Life.
A posiƟ ve IFA status was not an independent risk factors for faƟ gue in the mulƟ variate 
model but being younger than 50 years of age, a current smoker, and having an underlying 
medical condiƟ on (co-morbidity) were Table 3. See Table 4. for the independent risk factors 
for the general quality of life (GQOL).
Regardless of the IFA status 37.7% of parƟ cipants reported faƟ gue including 22.6% with 
clinically relevant faƟ gue. ParƟ cipants with chronic medical condiƟ ons such as psychiatric 
disorders had both a severely impaired GQOL and faƟ gue in resp. 64.0% and 48.0% of cases. 
While 35.4% of parƟ cipants with rheumatoid arthriƟ s had a severely impaired GQOL, for 
faƟ gue this was 36.9%.
When using the IFA Ɵ tre as a semi-quanƟ taƟ ve measure, parƟ cipants with a higher IFA 
Ɵ tre did not report more faƟ gue than those with a lower IFA Ɵ tre (data not shown).
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Table 3. Univariate and mulƟ variate logisƟ c regression of factors for the outcome faƟ gue1.
CharacterisƟ c
FaƟ gued1
Univariate analysis MulƟ variate analysis
Total n OR CI p-value Total n OR CI p-value
IFA
 PosiƟ ve 482 0.8 (0.7-1.1) 0.2 472 0.8 (0.6-1.03) 0.08
 NegaƟ ve 942 1.02 921 1.02
Age dichotomous
 ≤50 654 1.4 (1.1-1.7) <0.01 641 2.0 (1.5-2.5) <0.01
 >50 780 1.02 752 1.02
Gender
 Female 730 1.3 (1.1-1.6) 0.01 705 1.2 (0.9-1.5) 0.12
 Male 704 1.02 688 1.02
Smoking
 Current 260 1.9 (1.5-2.6) <0.01 256 1.8 (1.3-2.4) <0.01
 Former or never 1172 1.02 1137 1.02
EducaƟ on level
 Median and high 756 1.2 (0.9-1.5) 0.05* 751 1.3 (1.0-1.6) 0.05**
 Low 642 1.02 642 1.02
Rheumatoid arthriƟ s
 Yes 122 2.1 (1.4-3.0) <0.01 122 2.1 (1.4-3.2) <0.01
 No 1309 1.02 1309 1.02
Psychiatric condiƟ on/medicaƟ on
 Yes 75 4.6 (2.7-7.7) <0.01 74 4.1 (2.4-6.9) <0.01
 No 1359 1.02 1319 1.02
Other chronic diseases
 Yes 418 1.9 (1.5-2.4) <0.01 407 2.0 (1.6-2.6) <0.01
 No 1016 1.02 689 1.02
1FaƟ gue is divided in normal versus the combinaƟ on of mild and clinically relevant faƟ gue scores here 
called faƟ gued or abnormal faƟ gue score. 2 Is the reference group. *The actual p-value is 0.053 and 
**0.054 respecƟ vely.
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Table 4. Univariate and mulƟ variate logisƟ c regression of factors for the outcome General Quality of 
Life (GQOL)1
Clinically relevant abnormal General Quality of life1
p-value
Univariate analysis  MulƟ variate analysis
CharacterisƟ c Total n OR CI p-value Total n OR CI
IFA
 PosiƟ ve 497 1.1 (0.9-1.4) 0.46 487 1.0 (0.8-1.3) 0.94
 NegaƟ ve 978 1.02 954 1.02
Age dichotomous
 ≤50 665 0.9 (0.7-1.1) 0.35 651 1.4 (1.1-1.8) 0.01
 >50 825 1.02 790 1.02
Gender
 Female 752 0.9 (0.7-1.1) 0.27 718 1.0 (0.8-1.3) 0.88
 Male 738 1.02 723 1.02
Smoking
 Current 266 1.5 (1.1-2.0) <0.01 260 1.3 (0.9-1.8) 0.09
 Former or never 1222 1.02 1368 1.02
EducaƟ on level
 Median and high 790 1.2 (0.9-1.6) 0.08 785 1.2 (0.9-1.6) 0.14
 Low 656 1.02 656 1.02
Rheumatoid arthriƟ s
 Yes 127 1.5 (>1.0-2.2) 0.38 121 1.5 1.0-2.3) 0.06
 No 1359 1.02 1,32 1.02
Psychiatric condiƟ on/medicaƟ on
 Yes 75 5.2 (3.2-8.4) <0.01 73 4.7 (2.9-7.8) <0.01
 No 1415 1.02 1368 1.02
Other chronic diseases
 Yes 441 1.5 (1.2-1.9) <0.01 424 1.4 (1.1-1.9) 0.04
 No 1049 1.02 1017 1.02
1GQOL is divided in normal versus clinically relevant abnormal GQOL. 2Is the reference group.
The health status of a village populaƟ on  |  161
8
NoƟ ﬁ caƟ on in relaƟ on to the subdomains faƟ gue and General Quality of Life
Of the 510 IFA posiƟ ve parƟ cipants, 51 had previously been noƟ ﬁ ed for acute Q-fever, 49 of 
whom completed the sub-domain faƟ gue part of the quesƟ onnaire. These noƟ ﬁ ed parƟ ci-
pants presented signiﬁ cantly more oŌ en mild and clinically relevant faƟ gue 63.3% (n=31/49), 
Table 5, than IFA posiƟ ve parƟ cipants with a known posiƟ ve Q-fever status, who had not 
ﬁ Ʃ ed the noƟ ﬁ caƟ on criteria combined with those who were ﬁ rst idenƟ ﬁ ed during this study 
33.3% (n=150/451), OR 3.4 (1.9-6.5) p<0.01. These noƟ ﬁ ed and not noƟ ﬁ ed IFA posiƟ ve 
parƟ cipants did not diﬀ er signiﬁ cantly for the subdomain General Quality of Life (GQOL).
Table 5. NoƟ ﬁ caƟ on status and characterisƟ cs of 500 IFA posiƟ ve parƟ cipants in relaƟ on to the faƟ gue 
status.
Total Male
Age ≤50 
years FaƟ gue status
Normal Mild 
problem
Clinical 
relevant 
problem
n n %
Mean 
age
(SD) n % n (%) n (%) n (%)
NoƟ ﬁ ed 49 29 58.2 52.9 (14.3) 22 44.9 18 36,7 8 16,3 23 46,9
PosiƟ ve not noƟ ﬁ ed 72 47 65.3 56.3 (11.7) 19 26.4 49 68,1 6 8,3 17 23,6
IdenƟ ﬁ ed in 2014 379 176 46.4 50.2 (16.3) 187 49.3 252 66,5 54 14,2 73 19,3
Total 500 319 68 113
Belief in a previous Q-fever infecƟ on in relaƟ on to faƟ gue
The quesƟ onnaire contained several quesƟ ons about perceived or medically conﬁ rmed 
acute Q-fever. Among the 181 parƟ cipants that reported a medically conﬁ rmed diagnosis 
or believed that they had suﬀ ered from acute Q-fever, 137 (76%) were IFA posiƟ ve in 2014 
(Supplementary Table S2). We assumed that IFA posiƟ ve parƟ cipants who did not recall an 
acute Q-fever episode had previously experienced an asymptomaƟ c acute infecƟ on, or mild 
illness that had not been medically evaluated. A straƟ ﬁ ed analysis showed no evidence of 
confounding by belief in a past Q-fever episode in the relaƟ onship between IFA status and 
faƟ gue (Supplementary Table S2).
DISCUSSION
In this unique and large cross-secƟ onal populaƟ on study in a Q-fever high incidence village, 
seven years aŌ er a large Q-fever outbreak, we found a high seroprevalence C. burneƟ i of 
anƟ bodies of 34%. An impaired general quality of life or abnormal faƟ gue status was not 
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associated with C. burneƟ i IFA posiƟ ve serological test results. Overall 37.7% parƟ cipants re-
ported faƟ gue including 22.6% with clinically relevant faƟ gue. In the nearby city of Nijmegen, 
the Netherlands, a study in 2009 found that more than 30% of a random populaƟ on sample 
suﬀ ered from faƟ gue for longer than six months [17]. A German study, also reported that 
30% of parƟ cipants from a general populaƟ on sample reported moderate faƟ gue during the 
last six months whilst 10% of parƟ cipants had substanƟ al faƟ gue for the last six months or 
longer [18]. These two studies clearly indicate that faƟ gue levels in the general populaƟ on 
are high. The reported 37.7% prevalence ﬁ gure for faƟ gue in our study seems large, but when 
compared to the above menƟ oned ﬁ gure of 30% is not. As these two studies used diﬀ erent 
instruments to assess faƟ gue, only a rough comparison of prevalence of faƟ gue is possible.
The GQOL and faƟ gue were in this study severely impaired in parƟ cipants with chronic 
medical condiƟ ons such as psychiatric disorders and rheumatoid arthriƟ s. The inﬂ uence of 
chronic medical condiƟ ons on faƟ gue has been reported previously for psychiatric disorders 
[19, 20, 21], rheumatoid arthriƟ s [22] diabetes [23], and heart failure [24, 25].
Studies in the Netherlands and elsewhere clearly documented persisƟ ng faƟ gue and an 
impaired quality of life aŌ er Q-fever. These studies focused on proven acute Q-fever episodes, 
i.e. paƟ ents with clinical disease and with a conﬁ rmed laboratory diagnosis that oŌ en ﬁ Ʃ ed 
the naƟ onal noƟ ﬁ caƟ on criteria (symptomaƟ c cases) [3, 4, 11, 14, 26]. Our ﬁ ndings are in line 
with the internaƟ onal literature, as we also documented persisƟ ng faƟ gue in the small group 
of 49 previously noƟ ﬁ ed parƟ cipants. However, in this community-based study we found no 
increased risk for an impaired health status or faƟ gue in parƟ cipants with C. burneƟ i anƟ bod-
ies. Nor could we ﬁ nd a relaƟ onship between the faƟ gue level and IFA Ɵ tre. This ﬁ nding 
was similar to data from Hussain-Yusuf et al. [27] who also found no detectable relaƟ onship 
between faƟ gue levels and serology six years aŌ er exposure.
The present study and other studies support the noƟ on that the severity of symptoms 
during the acute episode predicts long-term symptoms such as faƟ gue [4, 12] and that QFS 
follows clinically overt infecƟ ons, but rarely that of a subclinical infecƟ on [28]. While the se-
verity of the infecƟ on during the acute phase (here noƟ ﬁ caƟ on) was related to the intensity 
of the later PIFS, psychological and microbiological factors were not.
The majority of parƟ cipants with a posiƟ ve IFA result had never been noƟ ﬁ ed for acute 
Q-fever, presumably because the acute infecƟ on episode had passed with only mild clinical 
symptoms or was enƟ rely asymptomaƟ c.
A previous study from the Netherlands reported no signiﬁcant diﬀ erence in the NCSI 
sub-domain scores between asymptomaƟ c cases infected with C. burneƟ i (n=11) and healthy 
controls (n=23) [5]. Although the sample size was small results are in accordance with our 
ﬁndings.
A comparison between paƟ ents with a lower respiratory tract infecƟ on (LRTI) of several 
causes (n=32) and those with Q-fever (n=50) showed no signiﬁ cant diﬀ erences for most NCSI 
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sub-domains (including faƟ gue and (GQOL) approximately 15 months aŌ er the iniƟ al infec-
Ɵ on [29]. Twelve months aŌ er the onset of symptoms 50% vs. 42.6% of paƟ ents with a Legio-
nella infecƟ on had respecƟ vely severe faƟ gue and GQOL (measured with the NCSI) [14]. But 
noƟ ﬁ ed (and therefore symptomaƟ c) Q-fever paƟ ents scored worse for respecƟ vely severe 
faƟ gue and GQOL with 60.2% and 50.0% compared to those with a Legionella infecƟ on [14].
We were unable to verify the severity of any acute illness episode with certainty because 
the acute episode could have taken place years ago. We speculated that parƟ cipants who 
believed that they had suﬀ ered from an acute Q-fever episode in the past would report cur-
rent faƟ gue more oŌ en. We also expected to ﬁ nd that people with faƟ gue in communiƟ es 
aﬀ ected by Q-fever would aƩ ribute their faƟ gue to a previous Q-fever episode, even when 
acute Q-fever was not medically diagnosed. However, our analysis showed that this factor 
was not signiﬁ cant and could be disregarded.
From historical data we know that 17% of parƟ cipants from this populaƟ on that were IFA 
seroposiƟ ve in 2007, had become seronegaƟ ve by 2014 [16].This shows that negaƟ ve Q-fever 
serology does not rule out a previous C. burneƟ i infecƟ on which should be taken into account 
if high risk populaƟ ons are vaccinated against Q-fever. This also shows that Q-fever serology 
is insuﬃ  cient to diagnose whether long-term faƟ gue might been caused by Q-fever.
The major strengths of this study are the high response rate of 70.9%, a quesƟ onnaire 
check on the spot and the inclusion of parƟ cipants from the same homogenous village 
with a high-Q-fever prevalence. This is the ﬁ rst large study to compare IFA posiƟ ve and 
negaƟ ve cases from the same homogenous populaƟ on. The whole spectrum from iniƟ ally 
asymptomaƟ c, mildly symptomaƟ c and severe symptoms during an acute Q-fever infecƟ on is 
included. Furthermore the control groups used in many other studies, were oŌ en healthier 
than the general populaƟ on as only individuals without known comorbidiƟ es were selected 
[3, 4, 14]. Our control group included parƟ cipants with comorbidiƟ es and is therefore a realis-
Ɵ c representaƟ on of the general populaƟ on. Together this results in unique and robust data.
Another strength is that by using the validated instrument NCSI we can compare our data 
with other studies that used this instrument.
Lower and higher [30] IFA cut-oﬀ  values are internaƟ onally used for screening. Lacking an 
internaƟ onal standard we used the IFA value 1:64 that is commonly used in the Netherlands.
Another limitaƟ on of the study is that the faƟ gue status of parƟ cipants before the 
outbreak is unknown, thus parƟ cipants might already have been faƟ gued for other reasons 
before the outbreak took place. The use of a self-reporƟ ng quesƟ onnaire is also a limitaƟ on. 
Even though quesƟ onnaires were checked for missing informaƟ on or errors by medical and 
paramedical staﬀ , it was not possible to enƟ rely prevent missing informaƟ on. A not quan-
Ɵ ﬁ able recall bias is likely to have occurred for the following two reasons: perceived acute 
Q-fever episodes were reported with a Ɵ me lag of four to seven years [31]. Furthermore, 
cross-secƟ onal study designs with retrospecƟ ve components have in general a higher risk of 
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recall bias [32]. An acute illness in the past could also have been erroneously reported by a 
parƟ cipant as Q-fever regardless of the cause.
CONCLUSIONS
Seven years aŌ er the start of the Q-fever epidemic in the Netherlands, the prevalence of 
anƟ bodies against C. burneƟ i among the adult populaƟ on of an aﬀ ected village was sƟ ll 34%. 
A large proporƟ on of the populaƟ on reported an impaired health status with faƟ gue. How-
ever, there were no diﬀ erences between those with and those without anƟ bodies against 
C. burneƟ i for faƟ gue and other health status parameters.
ParƟ cipants who had been noƟ ﬁ ed for clinically apparent acute Q-fever, reported twice 
as much faƟ gue compared to those who had serological evidence of a past infecƟ on but 
who had previously not been noƟ ﬁ ed because they did not fulﬁ l the noƟ ﬁ caƟ on criteria or 
because they had experienced a mild or asymptomaƟ c infecƟ on.
There are many reasons for faƟ gue and in some cases a Q-fever episode can be an aƩ rib-
uƟ ng or causaƟ ve factor. Even though some individuals developed faƟ gue aŌ er a C. burneƟ i 
infecƟ on the majority of individuals became faƟ gued due to other and oŌ en unknown 
reasons.
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APPENDIX SUPPLEMENTARY TABLES
Supplementary Table S1. NCSI sub-domains divided in normal, mild and clinically relevant problems in 
relaƟ on to the IFA status1.
Sub-domains
 
IFA posiƟ ve IFA negaƟ ve p-value
n (%) n (%)  
SubjecƟ ve pulmonary symptoms 509  997  0.04
 Normal 358 (70.3) 639 (64.1)
 Mild problem 104 (20.4) 232 (23.3)
 Clinically relevant problem 47 (9.2) 126 (12.6)
Dyspnoea EmoƟ ons 507 994 0.05*
 Normal 410 (80.9) 749 (75.4)
 Mild problem 52 (10.3) 134 (13.5)
 Clinically relevant problem 45 (8.9) 111 (11.2)
FaƟ gue 482 942 0.45
 Normal 311 (64.5) 576 (61.1)
 Mild problem 67 (13.9) 148 (15.7)
 Clinically relevant problem 104 (21.6) 218 (23.1)
Behavioural Impairment 507 997 0.28
 Normal 365 (72.0) 724 (72.6)
 Mild problem 113 (22.3) 198 (19.9)
 Clinically relevant problem 29 (5.7) 75 (7.5)
SubjecƟ ve Impairment 507 995 0.17
 Normal 366 (72.2) 683 (68.6)
 Mild problem 113 (22.3) 233 (23.4)
 Clinically relevant problem 28 (5.5) 79 (7.9)
GQOL 497 978 0.46
 Normal 356 (71.6) 719 (73.5)
 Clinically relevant problems 141 (28.4) 259 (26.5)
HRQOL 507 992 0.59
 Normal 358 (70.6) 677 (68.2)
 Mild problem 90 (17.8) 184 (18.5)
 Clinically relevant problem 59 (11.6) 131 (13.2)
SaƟ sfacƟ on relaƟ on 501 986 0.27
 Normal 337 (67.3) 671 (68.1)
 Mild problem 107 (21.4) 182 (18.5)
 Clinically relevant problem 57 (11.4) 133 (13.5)  
1Analysed with the Pearson’s chi-squared test. *The actual p-value is 0.054.
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Supplementary Table S2.The IFA status and faƟ gue, straƟ ﬁ ed by perceived or known episode of acute 
Q-fever
History acute Q-fever
Total
n=1413 FaƟ gue (%) No faƟ gue (%) OR CI p-value
Medically conﬁ rmed or 
perceived
IFA posiƟ ve 137 67 (48.9) 70 (51.1) 0.60 (0.30-1.2) 0.17
IFA negaƟ ve 44 27 (61.4) 17 (38.6)
Total 181 94 (51.9) 87 (48.1)
No or don’t know IFA posiƟ ve 343 103 (30.0) 240 (70.0)  0.71 (0.54-0.93) 0.01
IFA negaƟ ve 889 335 (37.7) 554 (62.3)
Total 1,232 438 (35.6) 794 (64.4)
Adjusted Mantel Haenzel Summary Chi Square test 0.69 (0.54-0.89) 0.67
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ABSTRACT
Background
Long-term faƟ gue with detrimental eﬀ ects on daily funcƟ oning oŌ en occurs following 
acute Q-fever. Following the 2007-2010 Q-fever outbreak in the Netherlands with over 
4000 noƟ ﬁ ed cases, the emphasis on long-term consequences of Q-fever increased. 
The aim of this study was to provide an overview of all relevant available literature, and 
to idenƟ fy knowledge gaps regarding the deﬁ niƟ on, diagnosis, background, descrip-
Ɵ on, aeƟ ology, prevenƟ on, therapy, and prognosis, of faƟ gue following acute Q-fever.
Design
A systemaƟ c review was conducted through searching Pubmed, Embase, and PsycInfo 
for relevant literature up to 26th May 2015. References of included arƟ cles were hand 
searched for addiƟ onal documents, and included arƟ cles were quality assessed.
Results
FiŌ y-seven arƟ cles were included and four documents classiﬁ ed as grey literature. The 
quality of most studies was low. The studies suggest that although most paƟ ents re-
cover from faƟ gue within 6-12 months aŌ er acute Q-fever, approximately 20% remain 
chronically faƟ gued. Several names are used indicaƟ ng faƟ gue following acute Q-fever, 
of which Q-fever faƟ gue syndrome (QFS) is most customary. Although QFS is described 
to occur frequently in many countries, a uniform deﬁ niƟ on is lacking. The studies 
report major health and work-related consequences, and is frequently accompanied 
by nonspeciﬁ c complaints. There is no consensus with regard to aeƟ ology, prevenƟ on, 
treatment, and prognosis.
Conclusions
Long-term faƟ gue following acute Q-fever, generally referred to as QFS, has major 
health-related consequences. However, informaƟ on on aeƟ ology, prevenƟ on, treat-
ment, and prognosis of QFS is underrepresented in the internaƟ onal literature. In order 
to facilitate comparison of ﬁ ndings, and as plaƞ orm for future studies, a uniform deﬁ ni-
Ɵ on and diagnosƟ c work-up and uniform measurement tools for QFS are proposed.
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INTRODUCTION
Q-fever, caused by the Gram-negaƟ ve intracellular coccobacillus Coxiella burneƟ i, is a zoo-
nosis that occurs worldwide [1]. Between 2007 and 2010 the largest Q-fever outbreak ever 
described in the literature occurred in the Netherlands, resulƟ ng in 4107 noƟ ﬁ caƟ ons [2].
FaƟ gue following acute Q-fever, also referred to as Q-fever faƟ gue syndrome (QFS), has 
been described worldwide in up to 20%-30% of paƟ ents [3-8] and may last up to ten years 
or longer [7, 9]. Although some debated the term QFS [10], it has been frequently used 
throughout literature. QFS paƟ ents experience an impaired health status, pulmonary disor-
ders, and impairment of general and social funcƟ oning [3, 7-9, 11, 12], and QFS accounted 
for major Q-fever-related economic cost during the Dutch outbreak [13]. Therefore, although 
not always recognised as a (diagnosƟ c) problem, this sequel has major implicaƟ ons. The 
word “syndrome” refers to other frequently accompanying nonspeciﬁ c symptoms [3, 8, 9, 14] 
resembling chronic faƟ gue syndrome (CFS) [15, 16]. However, in CFS the cause is usually un-
known, while in QFS a C. burneƟ i infecƟ on can be idenƟ ﬁ ed as the trigger. Furthermore, QFS 
has a sudden onset of faƟ gue, while in CFS this is oŌ en not the case. Several queries regard-
ing QFS without clear answers exist. A uniform internaƟ onal deﬁ niƟ on is not available, and 
tools to assess this syndrome and its consequences vary [5, 6, 17]. Hypotheses on aeƟ ology 
appear contradictory [18], and vary from altered cytokine producƟ on [6, 19], development of 
symptoms determined by host and geneƟ c factors [19-21], to the perpetuaƟ on of symptoms 
due to psychogenic factors and behaviour [8]. Furthermore, opinions on possible treatment 
of QFS diﬀ er [5, 6, 17], and quesƟ ons exist regarding prevenƟ on and prognosis.
The aim of this ﬁ rst systemaƟ c review regarding faƟ gue aŌ er acute Q-fever in humans 
is to provide an overview of all relevant available literature, and to idenƟ fy knowledge gaps 
regarding the deﬁ niƟ on, diagnosis, background, descripƟ on, aeƟ ology, prevenƟ on, therapy, 
and prognosis. This provides an evidence map both for physicians and paƟ ents.
METHOD
Search strategy and selecƟ on criteria
Relevant arƟ cles were idenƟ ﬁ ed through a systemaƟ c literature search in the scienƟ ﬁ c 
databases Medline, Embase and PsycInfo up to the 26th of May 2015 (Table 1). As Pubmed 
was used to search in Medline, only Pubmed is menƟ oned in this arƟ cle. There were no 
restricƟ ons on year of publicaƟ on, language, and arƟ cle or study type. Abstracts without 
full-text were excluded, as well as non-human studies. During the ﬁ rst selecƟ on step, poten-
Ɵ ally relevant references were selected based on screening of Ɵ tles and or abstracts by two 
invesƟ gators independently (GM and SPK, both content area experts). PotenƟ ally relevant 
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arƟ cles were included for full-text assessment. ArƟ cles on faƟ gue following acute Q-fever 
that could provide informaƟ on on the following domains: diagnosis (i.e. deﬁ niƟ on and/or 
diagnosis), background/descripƟ ve (i.e. incidence, prevalence, the course of faƟ gue and the 
role of co-morbidity, and other complaints besides faƟ gue), aeƟ ology (i.e. pathophysiology, 
predictors), prevenƟ on/therapy, and prognosis, were selected.
Table 1. Search strategy used in Pubmed, Embase, and PsycInfo
Pubmed Search terms† Hits
6-5-2014 (“coxiella burneƟ i” OR “Q fever” OR “coxiella” OR “Q-fever” OR 
“rickeƩ sia burneƟ i” OR “rickeƩ sia burneƫ  ” OR “rickeƩ siosis infecƟ on” 
OR “rickeƩ siosis rickeƩ sia” OR “australian Q fever”)
AND
(“faƟ gue” OR “syndrome” OR “Q fever FaƟ gue Syndrome” OR “Q-fever 
FaƟ gue Syndrome” OR QFFS OR QFS OR persisten* OR progress* OR 
“long term” OR “long-term” OR consequence* OR “chronic faƟ gue” OR 
Ɵ red*)
494
26-5-2015 537
Embase Search terms† Hits
6-5-2014 (exp Q fever/ OR Q fever.tw. OR exp Coxiella/ OR coxiella.tw. OR rickeƩ sia 
burneƟ i.tw. OR rickeƩ siosis.tw.)
AND
(exp faƟ gue/ OR exp FaƟ gue Impact Scale/ OR exp chronic faƟ gue 
syndrome/ OR exp FaƟ gue Severity Scale/) OR faƟ gue.tw. OR QFFS.tw. 
OR QFS.tw. OR exp persistent infecƟ on/ OR (persistence or persistent).
tw. OR (progression or progressive or consequence or consequenƟ al).
tw. OR exp chronic faƟ gue syndrome/ OR (Ɵ red or Ɵ red’ or Ɵ redeness or 
Ɵ reding or Ɵ redness or Ɵ redness).tw.
440
26-5-2015 489
PsycInfo Search terms Hits
6-5-2014 (Q fever OR coxiella OR rickeƩ sia burneƟ i OR rickeƩ sia burneƫ   OR 
rickeƩ siosis OR rickeƩ siosis rickeƩ sia)
15
26-5-2015 18
Literature search performed on 6th May 2014, updated on 26th May 2015, using the same search 
terms as in the ﬁ rst search. † Excluded from the search: Mesh term for rickeƩ siosis, as this labels for 
several typhus infecƟ ons with a total hits of 15600 records; and the word ‘chronic’, to avoid inclusion 
of chronic Q-fever arƟ cles
During the full-text assessment, arƟ cles without original or relevant data were excluded, 
upon an independent decision of each invesƟ gator, followed by consensus if needed. In case 
of any disagreement, the verdict of a third independent invesƟ gator was conclusive. If GM 
or SPK was a (co)author of a potenƟ ally relevant arƟ cle, a third independent invesƟ gator 
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assessed and decided (both selecƟ on steps) on inclusion. GM and SPK translated non-English 
arƟ cles, if needed, naƟ ve speakers where sought. If naƟ ve speakers were unavailable, the 
corresponding author was contacted. If this yielded no response, the arƟ cle was excluded.
Reference lists of included full-text arƟ cles were hand searched for addiƟ onal relevant 
publicaƟ ons. If the Ɵ tle (or keyword in the Ɵ tle) suggested potenƟ al informaƟ on on the topic, 
retrieval and full-text assessment followed. Finally, the World Health OrganizaƟ on, Centres 
for Disease Control and PrevenƟ on (CDC), Queensland Health, and gov.uk websites were 
searched for guidelines. Documents with relevant informaƟ on that were idenƟ ﬁ ed during 
the search, but not classiﬁ ed as peer-reviewed arƟ cles, were included as grey literature.
Quality assessment
The methodological quality of case-control and cohort studies was assessed with the 
Newcastle-OƩ awa Scale (NOS) [22], that evaluates selecƟ on (maximum of 4 stars), compa-
rability (maximum of 2 stars), and outcome (maximum of 3 stars). For economic evaluaƟ ons, 
the ‘Evers checklist’ was used [23]. Case-series were assessed with a quality appraisal tool 
with 18 criteria. A score of ≥14 criteria (≥70%) was considered acceptable [24]. No speciﬁ c 
instruments exist to assess the quality of case-reports, which in general is considered to have 
a low level of evidence. Therefore, the quality was assessed with a method based on the 
CoordinaƟ on of Cancer Clinical PracƟ ce Guidelines in Europe (CoCanCPG), addressing eight 
criteria: an appropriate and clearly focused quesƟ on, representaƟ ve populaƟ on, descripƟ on 
of the survey method or data collecƟ on, outcome measures deﬁ ned and described, response 
rate reported, and results valid and applicable to the targeted paƟ ent group. ArƟ cles could 
score: -/-, -, +/-, +, or ++ on these items. Although personal opinions were included to obtain a 
complete overview of all literature, these were not quality assessed as in general the quality 
is considered low.
Data extracƟ on and presentaƟ on
Study populaƟ ons and deﬁ niƟ ons per included arƟ cle were summarised in a separate table 
(S1 Table). Included arƟ cles were summarised in main domain tables: diagnosis, background/
descripƟ ve, aeƟ ology, prevenƟ on/therapy, and prognosis (S2-S5 Tables). If arƟ cles contained 
addiƟ onal informaƟ on on other domains, this was noted in the main table. The following 
informaƟ on was provided per arƟ cle, if applicable: year of publicaƟ on in chronological order 
starƟ ng with the oldest arƟ cles; ﬁ rst author; country; year of the study; study period and 
duraƟ on; study type; number of paƟ ents and controls; paƟ ent characterisƟ cs; co-morbidity; 
outcome measurement tools; intervenƟ on(s); outcome; conclusion(s)/recommendaƟ on(s); 
and the quality of the arƟ cle. In case an arƟ cle could not be assessed with any of the men-
Ɵ oned tools, this was stated in the table in column quality assessment (QA) as not applicable 
(NA). Grey literature was similarly ordered in a separate table (S6 Table).
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RESULTS
Inclusion of arƟ cles
The search yielded 1044 references (Fig 1); Pubmed n=537, Embase n=489, PsycInfo n=18, of 
which 223 were duplicates. During the ﬁ rst selecƟ on phase, 680 references were excluded as 
not relevant, 141 idenƟ ﬁ ed as potenƟ ally relevant, and the full-text arƟ cles were searched. 
One full-text arƟ cle (Spanish) could not be obtained from three diﬀ erent libraries and as 
the author could not be reached, the arƟ cle was excluded. Three conference abstracts with-
out full-text arƟ cle were excluded. Of the remaining 137 full-text arƟ cles, 51 arƟ cles were 
deemed not relevant, 29 had no original data, and for three no translaƟ on was available 
(two Russian, one Japanese). The remaining 54 arƟ cles were included and hand searching 
their reference lists yielded 22 potenƟ ally relevant arƟ cles, of which three were included 
aŌ er full-text assessment. From the reference lists of included arƟ cles, we idenƟ ﬁ ed one 
guideline, one dissertaƟ on, two book chapters, and one economic report. AŌ er conﬁ rmaƟ on 
of relevance, these were included as grey literature except for one book chapter as retrieval 
was not possible. In total, we included 57 arƟ cles and four grey literature documents.
Classiﬁ caƟ on in domains
The 57 included arƟ cles were classiﬁ ed into one of the main domains: diagnosis (n=4, S2 
Table), background/descripƟ ve (n=29, S3 Table), aeƟ ology (n=18, S4 Table), and prevenƟ on/
therapy (n=6, S5 Table). As none of the included arƟ cles described the course of faƟ gue in 
QFS, no arƟ cles were classiﬁ ed into the domain prognosis. Grey literature (n=4) is presented 
in S6 Table.
Quality of included literature
From the four arƟ cles in the table diagnosis, one arƟ cle was assessed with the NOS and 
scored 4/9 possible stars [25]. The remaining items (ﬁ ve stars) could not be assessed, as these 
items were not applicable for this study. The other three arƟ cles were personal opinions [10, 
26, 27].
The quality of 21/29 arƟ cles in the domain background/descripƟ ve was assessed with the 
NOS. Most arƟ cles had a moderate quality; however, none scored on all speciﬁ c applicable 
criteria, mostly because of inadequate controls in the design or analysis. For four arƟ cles, 
not all items could be assessed, as these were not applicable for these studies. The quality 
of three case-reports (n=1) was low [28-30]. The quality of one study regarding burden of 
disease was not assessed [31], as no standard quality assessment checklist was available for 
this study category. One economic evaluaƟ on scored well (16/19) [32]. Two arƟ cles were 
personal opinions [33, 34], and one was a personal observaƟ on [35].
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The quality of 15/18 arƟ cles on aeƟ ology was assessed with the NOS. Although none 
scored on all speciﬁ c applicable criteria, the quality of the arƟ cles was considered moderate. 
Seven arƟ cles did not score on comparability although applicable, as they lacked a correcƟ on 
for other factors that might explain the outcome. For four arƟ cles, not all possible stars could 
be retrieved, as these items were not applicable for these studies. Two laboratory case stud-
ies were not quality assessed [36, 37], and one arƟ cle was a personal opinion [38].
Fig 1. Flowdiagram of identified literature.  
 
Literature included (n=61) 
x Pubmed (n=47 articles) 
x Embase (n=3 articles) 
x PsycInfo (n=4 articles) 
x Reference lists (n=3 articles) 
x Grey literature (n=4)
Potentially relevant references (n=141) 
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The quality of 2/6 prevenƟ on/therapy arƟ cles was assessed with the NOS. One study scored 
4/9 stars, but none on comparability [39], while the other scored on 4/5 applicable items 
[6]. The quality of two case-reports (n=1) [40, 41] was below average, as was that of the 
case-series (n=3) [5], that scored on only 9/18 criteria. One arƟ cle, a study protocol, was not 
quality assessed [42].
The Dutch QFS guideline was developed based on the AGREE criteria [43], and therefore 
considered to be of good quality [17]. The quality of the other grey literature was not as-
sessed.
Deﬁ niƟ on and diagnosis
Nineteen arƟ cles contained informaƟ on on diagnosis of which four were classiﬁ ed in the 
main table diagnosis (S2 Table) [10, 25-27].
Terminology. The name QFS was introduced in 1992 [44]. Ever since, it has been debated 
whether faƟ gue following acute Q-fever is a separate enƟ ty compared to other forms of post-
infecƟ ve faƟ gue or CFS [27]. Some argue that chronic faƟ gue is a non-speciﬁ c subjecƟ ve state 
or symptom aŌ er Q-fever rather than a diagnosis [27]. Other consider QFS as a descripƟ on of 
CFS implicaƟ ng a speciﬁ c micro-organism, and that this terminology might result in increased 
health-care costs [10]. Others stated that due to convincing evidence of a causal factor, QFS is 
a causally-deﬁ ned subset of CFS, and that this factor should take precedence in the diagnosƟ c 
statement [26]. Names used to indicate faƟ gue following acute Q-fever, include: residual as-
thenia following Q fever [38], posƟ nfecƟ ve faƟ gue or posƟ nfecƟ ve faƟ gue syndrome [10, 12, 
18, 31, 45-47], posƟ nfecƟ ous chronic faƟ gue [11], post-Q-fever debility syndrome [35], post-
Q-fever chronic faƟ gue syndrome [35], qCFS [36], Q fever induced chronic faƟ gue syndrome 
[48], post-Q-fever faƟ gue or post-Q-fever faƟ gue syndrome [36, 49], post-(acute) Q-fever 
(faƟ gue) syndrome [5, 14, 26, 28, 33, 50], and most frequently Q-fever faƟ gue syndrome 
(QFS or QFFS) [6, 8, 10, 19-21, 26, 30, 33, 36, 39, 42, 50-52].
In conclusion, the term QFS has been used for years and seems generally accepted.
Deﬁ niƟ on of QFS. An overview of the study populaƟ ons and deﬁ niƟ ons used is provided 
for arƟ cles (S1 Table) and grey literature (S6 Table). Seven arƟ cles lacked a deﬁ niƟ on of the 
study populaƟ on or of QFS [10, 26, 27, 33-35, 38]. In 32 arƟ cles the study populaƟ on was 
deﬁ ned but QFS was not [3, 7, 9, 11, 12, 14, 18, 25, 31, 32, 36, 37, 45-47, 49, 52-67]. In ﬁ ve 
arƟ cles individual paƟ ents were considered to have QFS, without providing a deﬁ niƟ on [5, 
28-30, 40]. Six arƟ cles provided a deﬁ niƟ on of QFS [6, 8, 19, 39, 42, 48], which has been used 
in arƟ cles in subsequent years [20, 21, 50, 51]. A detailed descripƟ on of QFS is published in 
a thesis [44], but is based on a retrospecƟ ve comparaƟ ve-cohort study and is not available 
online. In the Dutch QFS guideline [17], QFS is deﬁ ned as: a severe faƟ gue causing signiﬁ cant 
disabiliƟ es in daily life present for at least 6 months, with a temporal relaƟ onship with acute 
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Q-fever, and not caused by co-morbidity. FaƟ gue should be absent before acute Q-fever or 
should have signiﬁ cantly increased since the infecƟ on.
In conclusion, there is no internaƟ onal uniform deﬁ niƟ on for QFS.
Diagnosis. No arƟ cles provided complete informaƟ on on the diagnosƟ c work-up. The 
Dutch guideline on QFS bases diagnosis on a combinaƟ on of history, physical examinaƟ on 
and laboratory examinaƟ on excluding other causes of faƟ gue, and should at least include 
erythrocyte sedimentaƟ on rate, C-reacƟ ve protein (CRP), creaƟ ne kinase, thyroid sƟ mulaƟ ng 
hormone, leukocytes with diﬀ erenƟ aƟ on, creaƟ nine, alkaline phosphatase, alanin amino-
transferase, calcium, glucose, ferriƟ n, and a urinary sediment. Through the use of validated 
quesƟ onnaires faƟ gue severity should be objecƟ ﬁ ed. Morbid obesity (BMI>40) and substance 
abuse should lead to refraining from diagnosing QFS. It is not possible to diagnose QFS in case 
of: depression (if this preceded current symptoms), schizophrenia, psychosis, demenƟ a or 
eaƟ ng disorders (unless already resolved for a minimum of 5 years) [17].
In conclusion, the Dutch guideline on QFS provides a clear diagnosƟ c work-up.
Background/descripƟ ve
Of the 40 arƟ cles containing background/descripƟ ve informaƟ on, 29 were classiﬁ ed in the 
main table background/descripƟ ve (S3 Table) [3, 7-9, 11, 12, 14, 28-35, 52, 53, 56-59, 61, 62, 
64-69].
Incidence and prevalence of faƟ gue following C. burneƟ i infecƟ on. FaƟ gue following 
acute Q-fever was ﬁ rst described in 1960 [68]. Without indicaƟ ng a Ɵ me-relaƟ on with acute 
Q-fever, it was noted in 1990 that 4% of acute Q-fever cases had prolonged faƟ gue [53]. 
In 1992, it was stated that approximately 23% of study subjects developed QFS within 12 
months following acute Q-fever [44]. Ever since, several studies on faƟ gue following acute 
Q-fever reported diﬀ erent prevalences. It was stated that 5-10% of paƟ ents experience re-
sidual asthenia six months aŌ er acute Q-fever and only few aŌ er one year [38]. In a reacƟ on, 
it was underlined that a substanƟ al proporƟ on of acute Q-fever paƟ ents have symptoms 
similar to QFS for 6-9 months aŌ er the acute infecƟ on and then recover, but 8-10% of 
paƟ ents exhibit symptoms for at least a year [33]. This is similar to other reports, showing 
persistent symptoms for longer than two years [3], up to six years aŌ er the infecƟ on with 
66% of paƟ ents reporƟ ng faƟ gue [14]. In Australia, QFS is the most common sequel of acute 
Q-fever reported to aﬀ ect 10-15% of paƟ ents [70]. Higher percentages were described, with 
up to 28% of paƟ ents meeƟ ng the Centres for Disease Control and PrevenƟ on criteria for CFS 
5 to 14 years aŌ er acute Q-fever, compared to none in the control group [8, 15]. The highest 
percentage of reported faƟ gue was 69% ﬁ ve years aŌ er acute Q-fever [9]. CFS criteria were 
met by 42% of C. burneƟ i-infected paƟ ents and 26% of controls [9, 15]. Ten years aŌ er acute 
Q-fever, 68% of paƟ ents reported faƟ gue of any duraƟ on [54], of whom 20% met the CFS 
criteria [15]. Excluding co-morbidity, 8% of paƟ ents met the CFS criteria compared to none of 
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the controls [54]. C. burneƟ i-exposed compared to non-exposed subjects reported ten years 
later a faƟ gue prevalence of 65% vs. 35%, respecƟ vely, and 19% vs. 4% met the CFS criteria 
[7, 15]. In accordance, later results demonstrated faƟ gue to be more common aŌ er Q-fever 
compared to controls [58], up to two [61] and six years later [49, 69].
Post-infecƟ ve faƟ gue following Epstein-Barr virus, Ross River virus or C. burneƟ i infecƟ on, 
was reported in 35% of cases aŌ er six weeks, 27% aŌ er three months, 12% aŌ er six months, 
and 9% aŌ er 12 months, regardless of the infecƟ ve agent [12]. And, although not signiﬁ cantly 
diﬀ erent, 12 months aŌ er acute Q-fever, paƟ ents were more faƟ gued than aŌ er Legionnaires’ 
disease, while being younger and having less pre-exisƟ ng health problems [11]. In paƟ ents 
with a lower respiratory tract infecƟ on who were C. burneƟ i seroposiƟ ve 10-19 months aŌ er 
the acute illness, 40% reported clinically relevant faƟ gue, compared to 64% of seronegaƟ ves, 
concluding that paƟ ents have long-term health problems aŌ er a lower respiratory tract infec-
Ɵ on in general [64].
In conclusion, faƟ gue following acute Q-fever might not be speciﬁ c but occurs frequently 
and may persist for years. A large variance in prevalence of faƟ gue aŌ er Q-fever is reported 
between countries, due to diﬀ erences in deﬁ niƟ ons, study designs and populaƟ ons, and 
measurement tools, which impairs direct comparisons.
Health status, burden of disease and economic impact. A sustained decrease in health 
status or health-related quality of life was reported [3, 58, 61]. Twelve months aŌ er acute 
Q-fever, 50% of paƟ ents had a reduced general quality of life [11]. Other studies show a 
signiﬁ cant linear improvement in health status aŌ er acute Q-fever, but it was sƟ ll reduced 
aŌ er 24 months in more than one third of all paƟ ents [67]. Twenty-seven months aŌ er acute 
Q-fever, 52% of paƟ ents reported persistent symptoms and lower scores on 5/8 Short Form 
36 (SF-36) scales [71] compared to uninfected controls [3]. Four years aŌ er acute Q-fever, 
paƟ ents also had a signiﬁ cantly reduced health status compared to healthy controls [65]. To 
obtain a detailed overview of the paƟ ents’ health, a combinaƟ on of the complete Nijmegen 
Clinical Screening Instrument (NCSI) [72] with subdomains (Role Physical, Bodily Pain, Social 
FuncƟ oning, and Role EmoƟ onal) of the SF-36 was advised [25]. Two studies focus on the 
burden of disease of faƟ gue following acute Q-fever [31, 32], one also assessed the economic 
impact of the outbreak in the Netherlands [13]. In 1992, for Australian C. burneƟ i-infected 
abaƩ oir workers the costs per year for medical care and loss of wages for endocardiƟ s and 
for QFS were calculated [44]. QFS represented the largest burden of disease [32, 44]. Further-
more, others found that, although the number of disability adjusted life years was higher for 
inﬂ uenza, on a per case basis, Q-fever was more severe, and overall the burden of disease 
was more than eight Ɵ mes higher than for inﬂ uenza, due to long-term sequelae [31]. The 
esƟ mated income loss was largest due to the accumulaƟ on over Ɵ me as a consequence of 
the projected duraƟ on of sick leave, and QFS was esƟ mated to be one of the major Q-fever-
related economic cost during the Dutch outbreak [13].
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In conclusion, there are clear indicaƟ ons that faƟ gue following acute Q-fever results in 
a high burden of disease, a major negaƟ ve impact on the health status of paƟ ents, and has 
signiﬁ cant economic implicaƟ ons.
Work-related consequences. In 1960, it was noƟ ced that the majority of acute Q-fever 
paƟ ents recovered within weeks and returned to work [68]. However, this convalescence 
period was prolonged in 25% of cases who were absent from work for more than 6 weeks, 
20% longer than 8 weeks, up to 23 weeks [68]. The mean period of sick-leave increased with 
age [68]. Later studies revealed that following acute Q-fever, 40% of paƟ ents were absent 
from work for more than one month [62]. AŌ er 12-26 months 9% was unable to funcƟ on at 
premorbid levels due to faƟ gue and diminished concentraƟ on while more than 30% had not 
fully resumed daily acƟ viƟ es, in 81% due to faƟ gue [62]. Besides work-related consequences, 
paƟ ents were more likely to report funcƟ onal impairment in performing daily acƟ viƟ es than 
healthy controls [46]. Q-fever paƟ ents showed a reduced work parƟ cipaƟ on, from 45% aŌ er 
three months to 19% aŌ er 12 months, versus 15% of paƟ ents with Legionnaires’ disease aŌ er 
12 months [66]. Factors associated with reduced work parƟ cipaƟ on were: having symptoms; 
a higher level of sorrow; being a former smoker (compared to never smoking); not consuming 
alcohol; and receiving treatment for health-related eﬀ ects of Q-fever [66].
In conclusion, the majority of paƟ ents return to work within the ﬁ rst 12 months aŌ er 
acute Q-fever, although up to 20% reported reduced work parƟ cipaƟ on.
Course of faƟ gue following acute Q-fever and the role of co-morbidity. Following acute 
Q-fever, 69% of paƟ ents self-reported faƟ gue, which dropped to 52% at six months to 26% 
at 12 months [57]. Studies using the NCSI found that severe faƟ gue following acute Q-fever 
improved from 73% at three months, to 60% at 12 months [11, 67]. Twelve to 26 months 
aŌ er acute Q-fever up to 59% of paƟ ents reported faƟ gue of which 44% had severe faƟ gue 
[59], whilst aŌ er 24 months 37% of paƟ ents compared to 3% of healthy controls, reported 
severe faƟ gue [67]. Higher rates of 51% were described four years aŌ er infecƟ on [65]. Most 
arƟ cles describe a conƟ nuous faƟ gue syndrome, up to 74 months aŌ er the iniƟ al infecƟ on 
[19], while relapsing or remiƩ ent faƟ gue paƩ erns also seemed to occur [3], up to 57 months 
[19] aŌ er acute Q-fever. One arƟ cle reported a faƟ gue free period of 2-4 months aŌ er acute 
Q-fever, eventually followed by QFS [5]. A disease period up to 20 years has also been re-
ported [44]. Pre-exisƟ ng health problems were associated with a long-term reduced health 
status including faƟ gue [59, 62, 67].
In conclusion, the percentage of paƟ ents who experience severe faƟ gue following acute 
Q-fever slowly decreases over Ɵ me, mainly in the ﬁ rst 6-12 months. FaƟ gue remains a per-
sistent complaint in approximately 20% of paƟ ents, with varying percentages and variability 
in the reported course of faƟ gue following acute Q-fever, and may persist for up to 20 years.
Complaints besides faƟ gue. QFS is frequently compared to CFS, and paƟ ents who fulﬁ l 
the internaƟ onal CFS criteria by deﬁ niƟ on have mulƟ ple symptoms [15, 16]. The mean num-
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ber of symptoms was higher in Q-fever exposed subjects 10 years aŌ er exposure compared 
to controls [7]. PaƟ ents with post-infecƟ ve faƟ gue, including Q-fever-related post-infecƟ ve 
faƟ gue, reported more symptoms in general and faƟ gue-related symptoms in parƟ cular [46]. 
Twelve to 26 months aŌ er acute Q-fever 40% of paƟ ents reported addiƟ onal complaints [62]. 
An overview of frequently reported complaints besides faƟ gue aŌ er acute Q-fever is given 
below.
Musculoskeletal complaints. Myalgia and arthralgia were frequent complaints of paƟ ents 
considered to have QFS [5, 6, 17, 28, 39, 40, 44, 70]. Musculoskeletal pain accompanied 
faƟ gue 12 months aŌ er several infecƟ ons [12], and was associated with a higher age [18]. 
Myalgia was signiﬁ cantly more oŌ en present 5-14 years aŌ er acute Q-fever compared to 
controls [8]. Twelve to 26 months aŌ er acute Q-fever, 4% of paƟ ents reported myalgia [62]. 
Myalgia was a major complaint in 23% of working paƟ ents 12 months aŌ er acute Q-fever 
[66]. Arthralgia was reported by 69% of paƟ ents up to six years aŌ er acute Q-fever [14], and 
was more severe compared to controls [9]. Both myalgia and arthralgia were also described 
in up to 70% of paƟ ents aŌ er a laboratory documented C. burneƟ i infecƟ on [52]. Compared 
to controls, presumed QFS paƟ ents had a higher pain score [48].
NeurocogniƟ ve problems. Although some authors found no associaƟ on between 
C. burneƟ i seroposiƟ vity and concentraƟ on diﬃ  culƟ es [56], neurocogniƟ ve diﬃ  culƟ es were 
described in paƟ ents with post-infecƟ ve faƟ gue, including QFS paƟ ents, 12 months aŌ er 
primary infecƟ on [12]. In addiƟ on, older subjects reported more neurocogniƟ ve symptoms 
[18]. Twelve to 26 months aŌ er acute Q-fever, 4% of paƟ ents had diﬃ  culƟ es concentraƟ ng 
[62]. ConcentraƟ on and memory problems were also shown to be a major complaint in 24% 
of working Q-fever paƟ ents 12 months aŌ er the infecƟ on [66]. Although no diﬀ erence was 
found in the frequency of memory problems between cases and controls, the severity was 
signiﬁ cantly higher aŌ er Q-fever [9]. A lack of concentraƟ on and short memory impairment 
within a year following acute Q-fever was also reported [17, 44], while another study found 
decreased concentraƟ on and mental acuity that could last up to 5-10 years [70].
Sleeping problems. Six years aŌ er acute Q-fever, 65% of paƟ ents reported a disturbed 
sleep paƩ ern, which was signiﬁ cantly more frequent than in controls [14]. This was also 
reported by others [17, 29, 44, 70], including unrefreshing sleep [5].
Headache. Headache was frequently reported [5, 6, 17, 28, 30, 39, 52, 68, 70]. Twelve 
months aŌ er acute Q-fever, 24% of working paƟ ents reported frequent headaches [66]. An-
other study reported headache in 47% of paƟ ents six years aŌ er acute Q-fever [14]. Although 
the frequency of headache was similar to controls, the same authors found that the severity 
of headache was more profound in those aŌ er Q-fever [9].
Blurred vision. Blurred vision six years aŌ er acute Q-fever was similar to controls [14], but 
was more prevalent and more severe ﬁ ve years aŌ er acute Q-fever compared to controls in 
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another study (34% vs. 18%) [9]. Blurred vision was also reported by others [17, 44]. Visual 
complaints were noted by 2% of paƟ ents 12 to 26 months aŌ er acute Q-fever [62].
Increased (night) sweaƟ ng. Night sweats starƟ ng 6-12 months aŌ er acute Q-fever were 
described [70]. Twelve to 26 months aŌ er acute Q-fever, 3% of paƟ ents reported night sweats 
[62]. In comparison to controls, night sweats were more common aŌ er acute Q-fever [17, 44, 
70]. Most QFS paƟ ents had this symptom for 5-10 years [70], up to 14 years [8, 28]. A combi-
naƟ on of night sweaƟ ng and increased sweaƟ ng was also reported [30]. Increased sweaƟ ng 
occurred with 53% more frequent aŌ er acute Q-fever compared to controls [14]. Others 
reported 53% of cases with increased sweaƟ ng [5, 9]. Some authors considered abnormal 
sweaƟ ng at least ten Ɵ mes a year as major QFS symptom [44].
Respiratory tract problems. Following acute Q-fever, 9% of paƟ ents complained of persis-
tent chest symptoms [53]. Others reported that 47% of presumed QFS paƟ ents complained 
of cough and a sore throat with a mean symptom duraƟ on of four years [52]. Others reported 
these complaints also [17, 28-30, 39]. Five years aŌ er acute Q-fever, 51% of cases complained 
of breathlessness on exerƟ on [9], compared to 32% of controls. Six years aŌ er acute Q-fever, 
59% of paƟ ents complained of cough, 49% of breathlessness, and 51% of chest pain, all 
signiﬁ cantly more frequently than controls [14]. Furthermore, an associaƟ on between QFS 
and bronchial asthma has been suggested [30].
Mood disorders. PaƟ ents with faƟ gue aŌ er acute Q-fever have been reported to experi-
ence increased irritability [14], mood disturbances [12, 17], and anger [70]. Mental problems, 
e.g. depression and unstable moods, can occur within a year following acute Q-fever [44], 
whereas, with regard to depression, most subjects were healthy before the infecƟ on [44]. 
Two years aŌ er acute Q-fever more psychosocial complaints were observed compared to 
controls [61]. Common symptoms of psychological distress were reported signiﬁ cantly more 
in paƟ ents with post-infecƟ ve faƟ gue, including QFS paƟ ents, compared to healthy controls 
[46]. Others hypothesise that Q-fever-related faƟ gue might be explained by psychological dis-
tress, caused by uncertainty about their illness and repeated medical contacts that reinforce 
percepƟ ons of ill health [7]. Some contradict this hypothesis [67]. InfecƟ on with C. burneƟ i 
was followed by depression in 10% of cases [53]. Three case-reports (all n=1) [28-30] re-
ported a C. burneƟ i-triggered depression, leading to thoughts of death [28], a near suicide 
aƩ empt [30], and suicide [29]. The suggesƟ on was that cytokine network abnormaliƟ es aŌ er 
a C. burneƟ i infecƟ on might underlie the onset of depression [28, 29, 73]. Although a possible 
relaƟ onship between high IgG phase II C. burneƟ i-anƟ bodies and depression was suggested 
[69], others found no associaƟ on between seroposiƟ vity, and depression, depressive ideas or 
overall psychiatric morbidity [56].
Other complaints. Other reported symptoms accompanying prolonged faƟ gue aŌ er 
Q-fever are severe malaise [40, 41], setback upon exerƟ on and the need for prolonged rest 
aŌ er simple tasks [5, 8, 68], poor appeƟ te [30, 68], gastrointesƟ nal symptoms [6, 17, 29, 
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30, 44, 70], muscle fasciculaƟ on or spasms [8, 17, 41, 44, 70], dizziness [14, 17, 30], light 
intolerance [8, 19], Ɵ nnitus [28], taste disturbance [28, 29], loss of libido [17, 19], nasal and 
bronchial congesƟ on [8, 17], and enlarged or painful lymph nodes [17, 70]. Bradycardia was 
postulated as a sign of QFS [35], and palpitaƟ ons were described [30]. Even though reported 
in several studies [8, 17, 19, 44], alcohol intolerance was not staƟ sƟ cally more frequent in 
the Q-fever group six years aŌ er acute Q-fever when compared to controls [14]. A slightly 
elevated body temperature (below 38 degrees Celsius) was described in QFS paƟ ents [5, 6, 
28, 30, 39-41, 44, 70]. Up to 53% of assumed QFS paƟ ents felt feverish for four years [52].
In conclusion, besides faƟ gue as the main complaint, several nonspeciﬁ c symptoms 
accompanying faƟ gue following C. burneƟ i infecƟ on were described. Commonly reported 
symptoms include musculoskeletal complaints, neurocogniƟ ve symptoms, sleeping prob-
lems, headaches, blurred vision, increased (night) sweaƟ ng, respiratory complaints, and 
mood disorders.
AeƟ ology
Of the 28 arƟ cles that contained informaƟ on on aeƟ ology, 18 were classiﬁ ed in the main 
table aeƟ ology (S4 Table) [18-21, 36-38, 45-51, 54, 55, 60, 63].
Pathophysiology. GeneƟ c variance and relaƟ onship with faƟ gue. No relaƟ on [3] or cor-
relaƟ on [47] between geneƟ c factors and QFS was found. A lack of a coherent set of gene 
expression correlaƟ ng across cohorts argued against the geneƟ c signature for post-infecƟ ve 
faƟ gue or CFS [47]. In contrast, another study found similar gene expression paƩ erns for QFS 
and CFS paƟ ents [48]. The frequency of human leukocyte anƟ gen – group DR (HLA-DR)-11 
was signiﬁ cantly increased in QFS paƟ ents compared to controls. Also, more polymorphic 
variants within the NRAMP1 gene diﬀ ering from the wild type were found, as well as sig-
niﬁ cant diﬀ erences in allelic variant frequencies within interferon-y (IFNy) genes, but eﬀ ects 
were thought to be mulƟ genic and cumulaƟ ve. It was hypothesised that QFS might result 
from individual variaƟ ons in immune response to C. burneƟ i [50]. QFS paƟ ents diﬀ ered in 
the frequency of HLA-DRB1*11 carriage and the 2/2 genotype of the IFNy intron 1 micro-
satellite compared to control groups [51]. Carriage was associated with reduced IFNy and 
interleukin(IL)-2 responses from sƟ mulated peripheral blood mononuclear cells (PBMC) [51].
In conclusion, results regarding geneƟ c variaƟ ons in host immune responses in QFS were 
contradictory.
Immunological aspects. An immunological basis for QFS or other post-infecƟ ve faƟ gue 
syndromes was debated in several arƟ cles. A reducƟ on in reported faƟ gue correlated with 
improvement in the delayed-type hypersensiƟ vity skin response and general health scores 
[45]. Resolving faƟ gue aŌ er acute infecƟ on seemed associated with improved cell-mediated 
immunity, supporƟ ng an immunological basis for post-infecƟ ve faƟ gue [45]. UpregulaƟ on of 
2’,5’-oligoadenylate synthetase (2-5AS) acƟ vity in PBMC of CFS paƟ ents was present, but a 
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relaƟ on between C. burneƟ i anƟ body Ɵ tres and 2-5AS acƟ viƟ es lacked [55]. It was however 
suggested that C. burneƟ i infecƟ on is associated with 2-5AS acƟ viƟ es in some CFS paƟ ents, 
as 2-5AS acƟ viƟ es changed from posiƟ ve to negaƟ ve in one CFS paƟ ent when C. burneƟ i 
anƟ bodies disappeared [55]. In acute Q-fever IL-6 and CRP seemed predicƟ ve of more severe 
disease, but no support was found that these were associated with prolonged faƟ gue [63]. 
Markers of inﬂ ammaƟ on and pro-inﬂ ammatory cytokine concentraƟ ons did not remain 
altered in paƟ ents with post-infecƟ ve faƟ gue [12, 18].
In conclusion, no clear evidence exists with regard to an immunological basis involving 
2-5AS, IL-6, and CRP for the development of QFS.
Immunomodulatory complex and cell-mediated immunity. Persistence of C. burneƟ i or 
its anƟ gens resulƟ ng in chronic immune sƟ mulaƟ on with subsequent faƟ gue [8, 19-21, 36, 
37, 49], or causing dysregulaƟ on of the macrophage/T-lymphocyte axis with subsequently 
aberrant monokine and lymphokine producƟ on mediaƟ ng symptoms [8], was hypothesised. 
Cytokine release paƩ erns of PBMC of QFS paƟ ents were aberrant with an accentuated IL-6 
release, a decreased number of IL-2 responders, and an increased number of IFNy respond-
ers [19]. In vitro, using human samples, an increased cellular immune response and cytokine 
dysregulaƟ on was found with increased levels of IL-6 and IL-10, and decreased level of IL-2 
[70]. A signiﬁ cant correlaƟ on between IL-6 and scores for key and total symptoms was found 
[19]. The detecƟ on of low levels of C. burneƟ i DNA in bone marrow aspirates, thin needle 
liver biopsies, and blood mononuclear cells, supports cytokine dysregulaƟ on and immuno-
modulaƟ on caused by C. burneƟ i persistence [20]. Others showed a more complex interacƟ on 
between host-regulated disease and persistent C. burneƟ i DNA carriage - either live, dormant, 
or dead but with undegraded DNA - in bone marrow, irrespecƟ ve of clinical state [21]. An 
addiƟ onal but variable factor of host regulaƟ on of cell-mediated immunity was postulated, 
determining the level of persistence and symptomaƟ c outcomes. It was hypothesised that in 
Q-fever without sequelae, the process of mulƟ plicaƟ on of live Coxiella was largely conﬁ ned to 
bone marrow, in contrast to QFS, in which a modulated immune response caused increased 
levels of C. burneƟ i genome in bone marrow with increased shedding into peripheral blood 
[21]. Subsequently, one of the core hypotheses postulated included the presence of an 
immunomodulatory complex, consisƟ ng of non-viable undegraded C. burneƟ i DNA or its 
anƟ gens, causing an abnormal cell-mediated immune response via damaged macrophages 
[37]. This stops the paƟ ent from clearing the microbe completely, leading to ongoing produc-
Ɵ on of pro-inﬂ ammatory cytokines and subsequently faƟ gue. In contrast to QFS paƟ ents, 
those who fully recovered from acute Q-fever had no immunomodulatory complex [37]. The 
bacteraemia is restricted by humoral and cell-mediated immunity, by clearing of C. burneƟ i 
DNA containing components with an immunomodulatory eﬀ ect of cell-mediated immunity 
and dendriƟ c cells causing dysregulaƟ on, cytokines and other immune mediators, giving rise 
to symptoms [70]. The complexes appeared more likely to be a residue of the original heavy 
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seeding during the bacteraemia of the acute infecƟ on, rather than the product of an ongoing 
mulƟ plicaƟ on, destrucƟ on and renewal of infecƟ on [21]. QFS follows clinical overt infecƟ on, 
rarely subclinical infecƟ on, and the systemic symptoms of QFS may reﬂ ect a wide distribu-
Ɵ on of parasiƟ zed mononuclear phagocytes [36, 37]. In other paƟ ent cohorts, neither viable 
C. burneƟ i nor DNA in PBMC was detected [49].
In conclusion, several studies point towards cytokine dysregulaƟ on mediaƟ ng symptoms 
in QFS. This may originate from an immunomodulatory complex consisƟ ng of non-viable 
undegraded C. burneƟ i DNA or its anƟ gens. However, results regarding remnant C. burneƟ i 
DNA were contradictory.
Cardiac involvement in QFS. No ECG abnormaliƟ es excess in the Coxiella-exposed cohort 
with faƟ gue was found in comparison to controls [54]. Post-infecƟ ve faƟ gue was associated 
with higher heartbeat discriminaƟ on accuracy, increased resƟ ng heart rate with decreased 
heart rate variability, and a lower pressure pain threshold [46]. The altered cardiac response 
was believed to be a stress response portraying an over-responsive system lacking dynamic 
ﬂ exibility [46]. Heightened interocepƟ ve sensiƟ vity with strong symptom correlaƟ on was also 
found. This suggests physiological hyper-vigilance and response inﬂ exibility in post-infecƟ ve 
faƟ gue [46].
In conclusion, there is no evidence for direct cardiac involvements in QFS, but there is 
some evidence for physiological hyper-vigilance and response inﬂ exibility in paƟ ents with 
post-infecƟ ve faƟ gue.
(Bio)psychological origin of QFS. It is unknown whether chronic faƟ gue following Q-fever 
is directly caused by the bacterium or if it is (bio)psychological in origin [38]. As subjecƟ ve 
symptoms are diﬃ  cult to quanƟ fy, it was stated that they might reﬂ ect an observaƟ onal 
bias, C. burneƟ i strain or cultural diﬀ erences, or geneƟ c suscepƟ bility [38]. In addiƟ on to the 
immune sƟ mulaƟ on hypothesis, interpretaƟ ons range from compensaƟ on-driven through 
psychogenic perpetuaƟ on of original symptoms or depression [8]. Q-fever paƟ ents with 
faƟ gue symptoms had higher somaƟ saƟ on scores, a higher tendency for hypochondriac wor-
ries and beliefs, a higher level of psychosocial complaints, and reduced quality of life [61]. The 
non-proven presumpƟ on was that Q-fever triggered faƟ gue development and that the risk 
of developing symptoms might be increased by hypochondriac features and a tendency to 
somaƟ saƟ on, supporƟ ng a biopsychological aeƟ ology [61].
In conclusion, some studies supported the view of a biopsychological aeƟ ology of QFS.
Predictors of post-infecƟ ve faƟ gue syndrome, including QFS. Psychological factors and 
demographics. Post-infecƟ ve faƟ gue appeared to be stereotyped across diﬀ erent infecƟ ve 
triggers, and it was suggested that the host response rather than psychological or microbial 
factors determined ongoing symptoms [18]. No source of exposure was associated with de-
veloping persistent symptoms [3]. Premorbid and intercurrent psychiatric disorders were not 
predicƟ ve for post-infecƟ ve faƟ gue [12]. In contrast to the biopsychological aeƟ ology [61], it 
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was recently suggested that psychological distress was not an important factor in explaining 
increased faƟ gue levels aŌ er acute Q-fever [67]. Although some found that gender was not 
a predictor [12], others found an overrepresentaƟ on of women in high severity groups for 
faƟ gue, mood disturbance and neurocogniƟ ve diﬃ  culƟ es [60]. Being female or a young adult, 
and smoking were characterisƟ cs signiﬁ cantly associated with long-term reduced health 
status including faƟ gue [62, 67]. In contrast, another study found no associaƟ on between 
faƟ gue and age [59].
In conclusion, neither psychological nor microbial factors seem to predict post-infecƟ ve 
faƟ gue, including QFS.
Severity of the acute illness. It was stated that one of the key risk factors for the develop-
ment of post-infecƟ ve faƟ gue, including QFS paƟ ents, is the severity of the acute illness [12]. 
PaƟ ents with post-infecƟ ve faƟ gue had a longer mean duraƟ on of the acute illness, and more 
days in bed and days out of role during the acute phase compared to controls [18].The clinical 
expression of acute Q-fever seemed an essenƟ al factor in the subsequent sustained decrease 
in health status [58], which is supported by the ﬁ nding that QFS usually follows acute Q-fever 
and rarely if ever asymptomaƟ c infecƟ on [70]. Pre-exisƟ ng health problems [62, 67], and 
hospitalisaƟ on, as an indicator of the severity of the iniƟ al infecƟ on, were also faƟ gue predic-
tors [59, 62]. No symptoms during the acute Q-fever infecƟ on were predictors for persisƟ ng 
symptoms [3], nor did these determine the long-term health status [65]. Neither IL-6 and CRP 
levels nor anƟ bioƟ c treatment during the acute infecƟ on were predictors for the develop-
ment of prolonged faƟ gue [3, 63]. No relaƟ onship was found between faƟ gue and anƟ body 
Ɵ tres six years aŌ er the Q-fever infecƟ on [49].
In conclusion, the severity of the acute Q-fever infecƟ on seems a key factor for worse 
long-term health status, including faƟ gue and QFS.
GeneƟ c factors in predicƟ ng faƟ gue. A single nucleoƟ de polymorphism (SNP) of the T 
allele IFNy+874T/A appeared to be the best predictor of increased faƟ gue aŌ er the acute 
phase of several infecƟ ons, including C. burneƟ i [60]. While the C allele of IL-10-592C/A SNP 
exerted a protecƟ ve eﬀ ect on neurocogniƟ ve diﬃ  culƟ es, the A allele IL-10-592 SNP and G 
allele IL-6-174G/C SNP were associated with increased mood disturbance [60].
In conclusion, as evidence is scarce, more research is needed regarding geneƟ c factors 
predicƟ ng faƟ gue in QFS.
PrevenƟ on/therapy
Eleven arƟ cles contained informaƟ on on prevenƟ on/therapy of which six are classiﬁ ed in the 
main table prevenƟ on/therapy (S5 Table) [5, 6, 39-42].
PrevenƟ on. No arƟ cles on the prevenƟ on of QFS were found. The Dutch guideline on 
QFS proposes to advice paƟ ents within the ﬁ rst six months aŌ er acute Q-fever or aŌ er estab-
lished QFS to: i) stay mentally and physically as acƟ ve as possible, adjust pace if necessary; 
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ii) alternate acƟ viƟ es, also within acƟ viƟ es; iii) keep fulﬁ lling the role in daily life; iv) maintain 
a regular sleep-wake paƩ ern; v) avoid focusing on faƟ gue; and vi) focus on feasible acƟ vi-
Ɵ es and appreciate accomplishments [17]. It is also proposed to explain that most paƟ ents 
recover within the ﬁ rst 6-12 months following acute Q-fever.
AnƟ bioƟ c treatment. Four arƟ cles reported on the eﬀ ect of long-term anƟ bioƟ c treat-
ment in assumed QFS paƟ ents [5, 6, 39, 40]. No randomised controlled trial (RCT) was found. 
Treatment with either 3 months of minocycline 200mg/day (n=18), levoﬂ oxacine 200mg/day 
(n=1), or erythromycin 400mg/day (n=1), improved performance status and reduced faƟ gue 
[6], concluding that minocycline was useful in treaƟ ng QFS [6]. In a pilot-study, treatment 
with three months of minocycline 100mg/day (n=29), doxycycline 100mg/day (n=26), or 
levoﬂ oxacin 200mg/day (n=3), showed improvement in performance status, headache, and 
mean weekly temperature [39]. A case-series (n=3) [5] and case-report (n=1) [40] showed 
inconsistent results of treatment with long-term anƟ bioƟ cs. According to others, the posiƟ ve 
eﬀ ect of anƟ bioƟ c treatment for QFS is not conﬁ rmed nor advised [17]. The eﬃ  cacy of long-
term anƟ bioƟ c treatment is now tested in a RCT but results are not yet available [42].
In conclusion, available data on long-term anƟ bioƟ c treatment for QFS are scarce and 
inconsistent.
CogniƟ ve behavioural therapy (CBT) and graded exercise therapy (GET). CBT proved 
eﬀ ecƟ ve in reducing symptoms and improving funcƟ oning in CFS paƟ ents [74, 75], and in 
chronic faƟ gue in chronic illnesses [76-78]. It was suggested as treatment opƟ on for QFS 
paƟ ents who experience psychological distress [61]. Based on CFS literature and similariƟ es 
between CFS and QFS, CBT is advised in the Dutch QFS guideline, although suspected not 
to be beneﬁ cial for all paƟ ents [17]. The eﬀ ecƟ veness of CBT treatment for QFS is currently 
under invesƟ gaƟ on [42]. Also GET is recommended for QFS paƟ ents, as proven eﬀ ecƟ ve in 
reducing faƟ gue in CFS [17].
In conclusion, although evidence is lacking, CBT and GET might be eﬀ ecƟ ve in reducing 
faƟ gue in QFS paƟ ents.
Treatment of QFS-related symptoms. Three arƟ cles (all n=1) reported treatment of 
QFS-related symptoms [28-30]. The authors concluded that educaƟ on and counselling 
about QFS and QFS-related symptoms should be provided to QFS paƟ ents [28]. AƩ enƟ on to 
the paƟ ent’s mental state is necessary in order to recognise accompanying symptoms, e.g. 
depressive thoughts, that should be treated [30], and involving a psychiatrist early ought to 
be considered [29]. This has been recognised before, where tricyclic anƟ depressants were 
beneﬁ cial treatment of mental problems aŌ er acute Q-fever [44].
In conclusion, educaƟ on and counselling of paƟ ents about QFS and QFS-related symp-
toms seems important, as well as considering a paƟ ent’s mental state.
AlternaƟ ve treatment. AlternaƟ ve therapies for QFS paƟ ents were described (both n=1), 
including Kampo formula Tsumura Hochu-ekki-To granules, which appeared not to be eﬀ ec-
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Ɵ ve [40], and Kampo formula Shakuyaku-Kanzo-To granules, which resulted in alleviaƟ on of 
sƟ ﬀ ness in hand and arm [41].
At present, evidence for the use of alternaƟ ve treatment lacks.
DISCUSSION
This ﬁ rst systemaƟ c review on faƟ gue following acute Q-fever, includes 57 arƟ cles and four 
grey documents up to the 26th of May 2015. The main limitaƟ on is the lack of a uniform deﬁ -
niƟ on of faƟ gue aŌ er Q-fever and the absence of a standardized diagnosƟ c tool. In addiƟ on, 
the terminology both for faƟ gue and C. burneƟ i-related faƟ gue diﬀ ered between publicaƟ ons 
and in Ɵ me. Consequently, comparison of outcomes is diﬃ  cult or impossible. Although not 
all arƟ cles could be quality assessed, these were nevertheless included as their informaƟ on 
was considered valuable.
An internaƟ onal uniform deﬁ niƟ on of QFS, discriminaƟ ng faƟ gue caused by C. burneƟ i 
from other post-infecƟ ve faƟ gue syndromes and CFS is unavailable [19, 26, 36]. As the Dutch 
QFS guideline provides the most detailed descripƟ on of QFS [17], we propose to use its deﬁ ni-
Ɵ on and diagnosƟ c work-up internaƟ onally. An internaƟ onal uniform deﬁ niƟ on provides the 
opportunity to achieve uniformity in diagnosis, treatment, and comparison of research re-
sults. It also provides recogniƟ on for physicians and acknowledgement for paƟ ents, reducing 
fear concerning uncertainty about their disease, providing an opportunity to conƟ nue their 
path to recovery [79, 80].
Whether faƟ gue following acute Q-fever is a separate enƟ ty compared to other forms of 
post-infecƟ ve faƟ gue is debatable [10, 12, 18, 27, 44, 47, 81], but should not hamper the use 
of the term QFS.
Although diﬀ erences in incidence and prevalence were reported, approximately 20% of 
paƟ ents remain chronically faƟ gued following an acute Q-fever infecƟ on. These diﬀ erences 
can be explained by lack of recogniƟ on, uniform deﬁ niƟ on and diagnosƟ c work-up, follow-up, 
and assessment tools. Using similar validated screening instruments is essenƟ al to compare 
studies [34]. Therefore, we advocate using validated screening instruments for measuring 
faƟ gue severity and disabiliƟ es, preferably with internaƟ onal available instruments [82], such 
as the Checklist Individual Strength or Chalder FaƟ gue Scale for faƟ gue [83, 84], and the 
NCSI, SF-36, or Sickness Impact Proﬁ le for disabiliƟ es [71, 72, 85]. This also helps to map the 
impact of QFS. The cut-oﬀ  period of 6 months to diagnose QFS has been proposed as most 
paƟ ents recover spontaneously within this period, which corresponds with the internaƟ on-
ally accepted deﬁ niƟ on for CFS [15, 16]. In QFS, faƟ gue frequently lasts beyond a year and 
mostly more than 5 to 10 years [8, 14]. Many nonspeciﬁ c symptoms described accompanying 
faƟ gue in QFS were not systemaƟ cally monitored as prospecƟ ve data were unavailable. Most 
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studies did not report the Ɵ me-relaƟ on between these symptoms, faƟ gue, and the Q-fever 
infecƟ on, nor the frequency of occurrence. Therefore, it was not possible to list all symptoms 
possibly related to faƟ gue following C. burneƟ i infecƟ on nor provide a temporal or causal 
relaƟ onship. However, guidelines with regard to the examinaƟ on of chronic faƟ gue should be 
followed to rule out other diseases which can cause chronic faƟ gue.
Several hypotheses regarding the underlying pathophysiological mechanism of QFS were 
proposed, but no conclusive answers have been idenƟ ﬁ ed yet. Research on the relaƟ onship 
between geneƟ c factors and QFS is contradictory and scarce. Several studies point towards 
cytokine dysregulaƟ on mediaƟ ng symptoms in QFS, including an immunomodulatory com-
plex consisƟ ng of non-viable undegraded C. burneƟ i DNA and or its anƟ gens. However, these 
results need further conﬁ rmaƟ on, as most studies regarding this topic have been done by the 
same study group and contradictory results exist with regard to the presence of C. burneƟ i 
DNA in QFS. Several queries exist regarding predictors of QFS. Neither psychological nor mi-
crobiological factors seemed to predict post-infecƟ ve faƟ gue. Only the severity of the acute 
Q-fever infecƟ on appears a predictor of long-term reduced health status.
No uniformity exists regarding opƟ mal treatment for QFS. Results from RCTs using long-
term anƟ bioƟ cs are not available, and the available studies all suﬀ er from several important 
limitaƟ ons, such as the lack of a clear QFS descripƟ on, the inclusion of paƟ ents with a symptom 
duraƟ on of 1-4 months, and the inclusion of paƟ ents with posiƟ ve C. burneƟ i PCR at baseline, 
possibly indicaƟ ng chronic Q-fever, and can therefore not be generalized. As the evidence 
of beneﬁ cial anƟ bioƟ c treatment in QFS paƟ ents lacks, it should not be prescribed for QFS 
paƟ ents. The recommended treatment aŌ er diagnosis of QFS in the Dutch QFS guideline is 
based on CFS literature, and consists of CBT and, if available GET. The eﬀ ecƟ veness of these 
treatments in QFS has not been proven yet. A randomised placebo-controlled trial in order 
to evaluate the eﬃ  cacy of both long-term doxycycline and CBT in QFS paƟ ents is currently 
performed [42]. Treatment should at least focus on the provision of medical care, physical 
rehabilitaƟ on and addiƟ onal psychological support [81]. Furthermore, physicians should be 
aware of accompanying complaints, especially depressive thoughts, which require treatment 
at an early stage [29]. AlternaƟ ve treatments were only eﬀ ecƟ ve in one case-report and are 
therefore not recommended. Finally, the prognosis of QFS paƟ ents is unclear regardless if 
treated or not.
In conclusion, the occurrence and long-term persistence of faƟ gue following acute Q-fever, 
generally referred to as QFS, has major health-related consequences. InformaƟ on on aeƟ ol-
ogy, prevenƟ on, treatment, and prognosis of QFS is underrepresented in the internaƟ onal 
literature. In order to facilitate comparison of ﬁ ndings, and as a plaƞ orm for future preferably 
prospecƟ ve studies, we propose a uniform deﬁ niƟ on of QFS and the use of uniform measure-
ment tools. In addiƟ on, in order to facilitate comparison of long-term sequelae following 
several infecƟ ous agents, and as a plaƞ orm for further preferably prospecƟ ve studies, an in-
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ternaƟ onal collaboraƟ on and a research agenda are desirable with regard to micro-organisms 
known for causing post-infecƟ ve faƟ gue, in which C. burneƟ i should undoubtedly be included.
ACKNOWLEDGEMENTS
The authors would like to acknowledge René Spijker, medical informaƟ on retrieval specialist, 
for his assistance with the search strategy in Pubmed, Embase, and PsycInfo, and Lieke Wield-
ers, PhD, for sharing her knowledge on performing systemaƟ c reviews, especially the quality 
assessment of arƟ cles. Furthermore, the authors would like to thank Teske Schoﬀ elen, MD 
PhD, for her criƟ cal evaluaƟ on as a third review author.
REFERENCES
1. Kaplan MM, Bertagna P. The geographical distribuƟ on of Q fever. BulleƟ n of the World Health Organiza-
Ɵ on. 1955;13(5):829-60. PubMed PMID: 13284560; PubMed Central PMCID: PMC2538086.
2. NaƟ onal InsƟ tute for Public Health and the Environment. Available : hƩ p://www.rivm.nl/Onderwerpen/
Q/Q_koorts.
3. HatcheƩ e TF, Hayes M, Merry H, Schlech WF, Marrie TJ. The eﬀ ect of C. burneƟ i infecƟ on on the 
quality of life of paƟ ents following an outbreak of Q fever. Epidemiol Infect. 2003;130(3):491-5. Epub 
2003/06/27. PubMed PMID: 12825734; PubMed Central PMCID: PMCPmc2869986.
4. Leung-Shea C, Danaher PJ. Q fever in members of the United States armed forces returning from Iraq. 
Clin Infect Dis. 2006;43(8):E77-E82. PubMed PMID: WOS:000240666200030.
5. Ledina D, Bradaric N, Milas I, Ivic I, Brncic N, Kuzmicic N. Chronic faƟ gue syndrome aŌ er Q fever. Med 
Sci Monit. 2007;13(7):Cs88-92. Epub 2007/06/30. PubMed PMID: 17599032.
6. Arashima Y, Kato K, Komiya T, Kumasaka K, Matsukawa Y, Murakami M, et al. Improvement of chronic 
nonspeciﬁ c symptoms by long-term minocycline treatment in Japanese paƟ ents with Coxiella burneƟ i 
infecƟ on considered to have post-Q fever faƟ gue syndrome. Intern Med. 2004;43(1):49-54. Epub 
2004/02/18. PubMed PMID: 14964579.
7. Wildman MJ, Smith EG, Groves J, Beaƫ  e JM, Caul EO, Ayres JG. Chronic faƟ gue following infecƟ on by 
Coxiella burneƟ i (Q fever): ten-year follow-up of the 1989 UK outbreak cohort. QJM. 2002;95(8):527-
38. Epub 2002/07/30. PubMed PMID: 12145392.
8. Marmion BP, Shannon M, Maddocks I, Storm P, Penƫ  la I. Protracted debility and faƟ gue aŌ er acute Q 
fever. Lancet. 1996;347(9006):977-8. Epub 1996/04/06. PubMed PMID: 8598796.
9. Ayres JG, Flint N, Smith EG, Tunnicliﬀ e WS, Fletcher TJ, Hammond K, et al. Post-infecƟ on faƟ gue syn-
drome following Q fever. QJM. 1998;91(2):105-23. Epub 1998/05/14. PubMed PMID: 9578893.
10. Oosterheert JJ, Kampschreur L, Hoepelman AI. [FaƟ gue aŌ er Q fever: nothing new]. Nederlands Tijd-
schriŌ  voor Geneeskunde. 2012;156(48):A5474. Epub 2012/11/30. PubMed PMID: 23191975.
11. van Loenhout JA, van Tiel HH, van den Heuvel J, Vercoulen JH, Bor H, van der Velden K, et al. Serious 
long-term health consequences of Q-fever and Legionnaires’ disease. J Infect. 2014. Epub 2014/01/29. 
doi: 10.1016/j.jinf.2014.01.004. PubMed PMID: 24468188.
12. Hickie I, Davenport T, Wakeﬁ eld D, Vollmer-Conna U, Cameron B, Vernon SD, et al. Post-infecƟ ve and 
chronic faƟ gue syndromes precipitated by viral and non-viral pathogens: prospecƟ ve cohort study. BMJ 
192  |  Chapter 9
(Clin Res ed). 2006;333(7568):575. Epub 2006/09/05. doi: 10.1136/bmj.38933.585764.AE. PubMed 
PMID: 16950834; PubMed Central PMCID: PMCPmc1569956.
13. Tempelmann C, Prins J, Koopmans C. Economical consequences of the Q fever outbreak [in Dutch], SEO 
Econ. Res. (2011) 2011-2015.
14. Ayres JG, Smith EG, Flint N. Protracted faƟ gue and debility aŌ er acute Q fever. Lancet. 
1996;347(9006):978-9. Epub 1996/04/06. PubMed PMID: 8598797.
15. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroﬀ  A. The Chronic FaƟ gue Syndrome: 
A Comprehensive Approach to Its Deﬁ niƟ on and Study. Ann Intern Med. 1994;121(12):953-9. doi: 
10.7326/0003-4819-121-12-199412150-00009.
16. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al. IdenƟ ﬁ caƟ on of ambiguiƟ es 
in the 1994 chronic faƟ gue syndrome research case deﬁ niƟ on and recommendaƟ ons for resoluƟ on. 
BMC Health Serv Res. 2003;3(1):25. doi: 10.1186/1472-6963-3-25. PubMed PMID: 14702202; PubMed 
Central PMCID: PMC317472.
17. NaƟ onal InsƟ tute for Public Health and the Environment. Dutch guideline Q fever faƟ gue syndrome 
(QFS) [in Dutch] 2012. Available from: hƩ p://www.rivm.nl/dsresource?objecƟ d=rivmp:118226&type=
org&disposiƟ on=inline.
18. Vollmer-Conna U, Cameron B, Hadzi-Pavlovic D, Singletary K, Davenport T, Vernon S, et al. PosƟ nfecƟ ve 
faƟ gue syndrome is not associated with altered cytokine producƟ on. Clin Infect Dis. 2007;45(6):732-5. 
doi: hƩ p://dx.doi.org/10.1086/520990. PubMed PMID: 2007442464.
19. Penƫ  la IA, Harris RJ, Storm P, Haynes D, Worswick DA, Marmion BP. Cytokine dysregulaƟ on in the 
post-Q-fever faƟ gue syndrome. QJM. 1998;91(8):549-60. Epub 1999/01/20. PubMed PMID: 9893758.
20. Harris RJ, Storm PA, Lloyd A, Arens M, Marmion BP. Long-term persistence of Coxiella burneƟ i in the 
host aŌ er primary Q fever. Epidemiol Infect. 2000;124(3):543-9. Epub 2000/09/12. PubMed PMID: 
10982079; PubMed Central PMCID: PMCPmc2810941.
21. Marmion BP, Storm PA, Ayres JG, Semendric L, Mathews L, Winslow W, et al. Long-term persistence of 
Coxiella burneƟ i aŌ er acute primary Q fever. QJM. 2005;98(1):7-20. Epub 2004/12/31. doi: 10.1093/
qjmed/hci009. PubMed PMID: 15625349.
22. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-OƩ awa Scale (NOS) for 
assessing the quality of nonrandomised studies in meta-analyses 2008.  Available from: hƩ p://www.
ohri.ca/programs/clinical_epidemiology/oxford.asp.
23. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological 
quality of economic evaluaƟ ons: Consensus on Health Economic Criteria. Int J Technol Assess Health 
Care. 2005;21(2):240-5. PubMed PMID: 15921065.
24. Moga C, Guo B, Schopﬂ ocher D, Harstall C. Development of a quality appraisal tool for case series 
studies using a modiﬁ ed Delphi technique; 2012.
25. van Loenhout JA, Paget WJ, Sandker GW, Hautvast JL, van der Velden K, Vercoulen JH. Assessing health 
status and quality of life of Q-fever paƟ ents: The Nijmegen Clinical Screening Instrument versus the 
Short Form 36. Health Qual Life Outcomes. 2013;11(1). doi: hƩ p://dx.doi.org/10.1186/1477-7525-11-
112.
26. Scadding JG. FaƟ gue syndromes. QJM. 1999;92(5):293-4. Epub 2000/01/01. PubMed PMID: 10615486.
27. Raoult D. Chronic Q fever: expert opinion versus literature analysis and consensus. J Infect. 
2012;65(2):102-8. Epub 2012/04/28. doi: 10.1016/j.jinf.2012.04.006. PubMed PMID: 22537659.
28. Arashima Y, Yakubo S, Nagaoka H, Komiya T, Murakami M, Nakayama T, et al. A paƟ ent in whom treat-
ment for coxiella burneƟ i infecƟ on ameliorated a depressive state and thoughts of impending death. 
InternaƟ onal Medical Journal. 2012;19(1):65-6. PubMed PMID: 2012223501.
29. Yakubo S, Ueda Y, Tanekura N, Arashima Y, Nakayama T, Komiya T, et al. The ﬁ rst case of a paƟ ent suﬀ er-
ing from Coxiella burneƟ i infecƟ on aƩ empƟ ng suicide arising from a state of depression. InternaƟ onal 
Medical Journal. 2012;19(4):312-3. PubMed PMID: 2012700928.
FaƟ gue Following Acute Q-Fever  |  193
9
30. Arashima Y, Yakubo S, Ueda Y, Munemura T, Komiya T, Isa H, et al. A ﬁ rst case of asthma thought to 
be caused by coxiella burneƫ   infecƟ on. InternaƟ onal Medical Journal. 2013;20(6):699-700. PubMed 
PMID: 2014054225.
31. Brooke RJ, van Lier A, Donker GA, W VDH, Kretzschmar ME. Comparing the impact of two concurrent 
infecƟ ous disease outbreaks on The Netherlands populaƟ on, 2009, using disability-adjusted life years. 
Epidemiol Infect. 2014:1-10. Epub 2014/01/31. doi: 10.1017/s0950268813003531. PubMed PMID: 
24476696.
32. van Asseldonk MA, Prins J, Bergevoet RH. Economic assessment of Q fever in the Netherlands. Prev Vet 
Med. 2013;112(1-2):27-34. Epub 2013/07/23. doi: 10.1016/j.prevetmed.2013.06.002. PubMed PMID: 
23866818.
33. Marmion BP, Harris RJ, Storm PA, Semendric L. Q fever: sƟ ll a mysterious disease. QJM. 2002;95(12):832-
3. Epub 2002/11/28. PubMed PMID: 12454328.
34. Wildman MJ, Ayres JG. Q fever: sƟ ll a mysterious disease. QJM. 2002;95(12):833-4. Epub 2003/01/15. 
PubMed PMID: 12524714.
35. Harvey-SuƩ on PL. Post-Q fever syndrome. Med J Aust. 1995;162(3):168. Epub 1995/02/06. PubMed 
PMID: 7854246.
36. Sukocheva OA, Marmion BP, Storm PA, Lockhart M, Turra M, Graves S. Long-term persistence aŌ er acute 
Q fever of non-infecƟ ve Coxiella burneƟ i cell components, including anƟ gens. QJM. 2010;103(11):847-
63. Epub 2010/07/20. doi: 10.1093/qjmed/hcq113. PubMed PMID: 20639288.
37. Marmion BP, Sukocheva O, Storm PA, Lockhart M, Turra M, Kok T, et al. Q fever: persistence of anƟ genic 
non-viable cell residues of Coxiella burneƟ i in the host--implicaƟ ons for post Q fever infecƟ on faƟ gue 
syndrome and other chronic sequelae. QJM. 2009;102(10):673-84. Epub 2009/06/27. doi: 10.1093/
qjmed/hcp077. PubMed PMID: 19556396.
38. Raoult D. Q fever: sƟ ll a mysterious disease. QJM. 2002;95(8):491-2. Epub 2002/07/30. PubMed PMID: 
12145387.
39. Iwakami E, Arashima Y, Kato K, Komiya T, Matsukawa Y, Ikeda T, et al. Treatment of chronic faƟ gue 
syndrome with anƟ bioƟ cs: pilot study assessing the involvement of Coxiella burneƟ i infecƟ on. Intern 
Med. 2005;44(12):1258-63. Epub 2006/01/18. PubMed PMID: 16415546.
40. Yakubo S, Ueda Y, Arashima Y. Long-term absence from school of a boy suﬀ ering severe general Malaise 
from coxiella burneƟ i infecƟ on. InternaƟ onal Medical Journal. 2013;20(6):688-90. PubMed PMID: 
2014054222.
41. Yakubo S, Yakubo S, Ueda Y, Tanekura N, Arashima Y, Munemura T, et al. Kampo Formula Shakuyaku-
kanzo-To Alleviates SensaƟ on of Muscle Spasm in Coxiella burneƟ i InfecƟ on. InternaƟ onal Medical 
Journal. 2013;20(2):218-20. PubMed PMID: 2012154829.
42. Keijmel SP, Delsing CE, Sprong T, Bleijenberg G, van der Meer JW, Knoop H, et al. The Qure study: Q 
fever faƟ gue syndrome--response to treatment; a randomized placebo-controlled trial. BMC Infect Dis. 
2013;13:157. Epub 2013/03/30. doi: 10.1186/1471-2334-13-157. PubMed PMID: 23536997; PubMed 
Central PMCID: PMCPmc3620935.
43. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline 
development, reporƟ ng and evaluaƟ on in health care. CMAJ. 2010;182(18):E839-42. Epub 2010/07/07. 
doi: 10.1503/cmaj.090449. PubMed PMID: 20603348; PubMed Central PMCID: PMC3001530.
44. Shannon M. The post Q fever faƟ gue syndrome: an epidemiological study (dissertaƟ on). Adelaide: 
University of Adelaide; 1992.
45. BenneƩ  BK, Hickie IB, Vollmer-Conna US, Quigley B, Brennan CM, Wakeﬁ eld D, et al. The relaƟ onship 
between faƟ gue, psychological and immunological variables in acute infecƟ ous illness. Aust N Z J Psy-
chiatry. 1998;32(2):180-6. Epub 1998/05/20. PubMed PMID: 9588296.
46. Kadota Y, Cooper G, Burton AR, Lemon J, Schall U, Lloyd A, et al. Autonomic hyper-vigilance in post-
infecƟ ve faƟ gue syndrome. Biol Psychol. 2010;85(1):97-103. doi: hƩ p://dx.doi.org/10.1016/j.biopsy-
cho.2010.05.009. PubMed PMID: 2010421837.
194  |  Chapter 9
47. Galbraith S, Cameron B, Li H, Lau D, Vollmer-Conna U, Lloyd AR. Peripheral blood gene expression 
in posƟ nfecƟ ve faƟ gue syndrome following from three diﬀ erent triggering infecƟ ons. J Infect Dis. 
2011;204(10):1632-40. Epub 2011/10/04. doi: 10.1093/infdis/jir612. PubMed PMID: 21964398.
48. Zhang L, Gough J, Christmas D, MaƩ ey DL, Richards SC, Main J, et al. Microbial infecƟ ons in eight ge-
nomic subtypes of chronic faƟ gue syndrome/myalgic encephalomyeliƟ s. J Clin Pathol. 2010;63(2):156-
64. Epub 2009/12/04. doi: 10.1136/jcp.2009.072561. PubMed PMID: 19955554; PubMed Central 
PMCID: PMCPmc2921262.
49. Hussain-Yusuf H, Islam A, Healy B, Lockhart M, Nguyen C, Sukocheva O, et al. An analysis of Q fever pa-
Ɵ ents 6 years aŌ er an outbreak in Newport, Wales, UK. QJM. 2012;105(11):1067-73. Epub 2012/07/10. 
doi: 10.1093/qjmed/hcs119. PubMed PMID: 22771556.
50. Helbig KJ, Heatley SL, Harris RJ, Mullighan CG, Bardy PG, Marmion BP. VariaƟ on in immune response 
genes and chronic Q fever. Concepts: preliminary test with post-Q fever faƟ gue syndrome. Genes Im-
mun. 2003;4(1):82-5. Epub 2003/02/22. doi: 10.1038/sj.gene.6363912. PubMed PMID: 12595908.
51. Helbig K, Harris R, Ayres J, Dunckley H, Lloyd A, Robson J, et al. Immune response genes in the post-
Q-fever faƟ gue syndrome, Q fever endocardiƟ s and uncomplicated acute primary Q fever. QJM. 
2005;98(8):565-74. Epub 2005/06/16. doi: 10.1093/qjmed/hci086. PubMed PMID: 15955794.
52. Kato K, Arashima Y, Asai S, Furuya Y, Yoshida Y, Murakami M, et al. DetecƟ on of Coxiella burneƟ i speciﬁ c 
DNA in blood samples from Japanese paƟ ents with chronic nonspeciﬁ c symptoms by nested polymerase 
chain reacƟ on. FEMS Immunol Med Microbiol. 1998;21(2):139-44. Epub 1998/07/31. PubMed PMID: 
9685003.
53. Reilly S, Northwood JL, Caul EO. Q fever in Plymouth, 1972-88. A review with parƟ cular reference to 
neurological manifestaƟ ons. Epidemiol Infect. 1990;105(2):391-408. Epub 1990/10/01. PubMed PMID: 
2209742; PubMed Central PMCID: PMCPmc2271878.
54. Ayres JG, Wildman M, Groves J, Ment J, Smith EG, Beaƫ  e JM. Long-term follow-up of paƟ ents 
from the 1989 Q fever outbreak: no evidence of excess cardiac disease in those with faƟ gue. QJM. 
2002;95(8):539-46. Epub 2002/07/30. PubMed PMID: 12145393.
55. Ikuta K, Yamada T, Shimomura T, Kuratsune H, Kawahara R, Ikawa S, et al. DiagnosƟ c evaluaƟ on of 2’, 
5’-oligoadenylate synthetase acƟ viƟ es and anƟ bodies against Epstein-Barr virus and Coxiella burneƟ i 
in paƟ ents with chronic faƟ gue syndrome in Japan. Microbes Infect. 2003;5(12):1096-102. Epub 
2003/10/14. PubMed PMID: 14554250.
56. Thomas HV, Thomas DR, Salmon RL, Lewis G, Smith AP. Toxoplasma and coxiella infecƟ on and psy-
chiatric morbidity: a retrospecƟ ve cohort analysis. BMC Psychiatry. 2004;4:32. Epub 2004/10/20. doi: 
10.1186/1471-244x-4-32. PubMed PMID: 15491496; PubMed Central PMCID: PMCPmc526777.
57. Limonard GJ, Nabuurs-Franssen MH, Weers-Pothoﬀ  G, Wijkmans C, Besselink R, Horrevorts AM, et al. 
One-year follow-up of paƟ ents of the ongoing Dutch Q fever outbreak: clinical, serological and echocar-
diographic ﬁ ndings. InfecƟ on. 2010;38(6):471-7. Epub 2010/09/22. doi: 10.1007/s15010-010-0052-x. 
PubMed PMID: 20857313; PubMed Central PMCID: PMCPmc3003145.
58. Limonard GJ, Peters JB, Nabuurs-Franssen MH, Weers-Pothoﬀ  G, Besselink R, Groot CA, et al. Detailed 
analysis of health status of Q fever paƟ ents 1 year aŌ er the ﬁ rst Dutch outbreak: a case-control study. 
QJM. 2010;103(12):953-8. Epub 2010/08/31. doi: 10.1093/qjmed/hcq144. PubMed PMID: 20802011.
59. Morroy G, Peters JB, van Nieuwenhof M, Bor HH, Hautvast JL, van der Hoek W, et al. The health status 
of Q-fever paƟ ents aŌ er long-term follow-up. BMC Infect Dis. 2011;11:97. Epub 2011/04/20. doi: 
10.1186/1471-2334-11-97. PubMed PMID: 21501483; PubMed Central PMCID: PMCPmc3110112.
60. Piraino B, Vollmer-Conna U, Lloyd AR. GeneƟ c associaƟ ons of faƟ gue and other symptom domains of 
the acute sickness response to infecƟ on. Brain Behav Immun. 2012;26(4):552-8. Epub 2012/01/10. doi: 
10.1016/j.bbi.2011.12.009. PubMed PMID: 22227623.
61. Strauss B, Loschau M, Seidel T, Stallmach A, Thomas A. Are faƟ gue symptoms and chronic faƟ gue syn-
drome following Q fever infecƟ on related to psychosocial variables? J Psychosom Res. 2012;72(4):300-
4. Epub 2012/03/13. doi: 10.1016/j.jpsychores.2012.01.010. PubMed PMID: 22405225.
FaƟ gue Following Acute Q-Fever  |  195
9
62. Morroy G, Bor HH, Polder J, Hautvast JL, van der Hoek W, Schneeberger PM, et al. Self-reported sick 
leave and long-term health symptoms of Q-fever paƟ ents. Eur J Public Health. 2012;22(6):814-9. Epub 
2012/02/09. doi: 10.1093/eurpub/cks003. PubMed PMID: 22315459.
63. Kremers MN, Janssen R, Wielders CC, Kampschreur LM, Schneeberger PM, NeƩ en PM, et al. Correla-
Ɵ ons between peripheral blood coxiella burneƟ i DNA load, interleukin-6 levels, and C-reacƟ ve protein 
levels in paƟ ents with acute Q fever. Clin Vaccine Immunol. 2014;21(4):484-7. doi: hƩ p://dx.doi.
org/10.1128/CVI.00715-13. PubMed PMID: 2014239787.
64. van Dam S, van Loenhout JA, Peters JB, Rietveld A, Paget WJ, Akkermans RP, et al. A cross-secƟ onal 
study to assess the long-term health status of paƟ ents with lower respiratory tract infecƟ ons, including 
Q fever. Epidemiol Infect. 2014:1-7. Epub 2014/03/15. doi: 10.1017/s0950268814000417. PubMed 
PMID: 24625631.
65. van Loenhout JA, Wielders CC, Morroy G, Cox MJ, van der Hoek W, Hautvast JL, et al. Severely im-
paired health status of non-noƟ ﬁ ed Q fever paƟ ents leads to an underesƟ maƟ on of the true burden 
of disease. Epidemiol Infect. 2015:1-8. Epub 2015/01/15. doi: 10.1017/s0950268814003689. PubMed 
PMID: 25582890.
66. van Loenhout JA, Hautvast JL, Akkermans RP, Donders NC, Vercoulen JH, Paget WJ, et al. Work parƟ cipa-
Ɵ on in Q-fever paƟ ents and paƟ ents with Legionnaires’ disease: A 12-month cohort study. Scand J 
Public Health. 2015;43(3):294-301. doi: 10.1177/1403494815571030. PubMed PMID: 25724468.
67. van Loenhout JA, Hautvast JL, Vercoulen JH, Akkermans RP, Wijkmans CJ, van der Velden K, et al. Q-fever 
paƟ ents suﬀ er from impaired health status long aŌ er the acute phase of the illness: results from a 
24-month cohort study. J Infect. 2015;70(3):237-46. doi: 10.1016/j.jinf.2014.10.010. PubMed PMID: 
25452036.
68. Powell O. “Q” fever: clinical features in 72 cases. Aust Ann Med. 1960;9:214-23. PubMed PMID: 
13737616.
69. van Woerden HC, Healy B, Llewelyn MB, MaƩ hews IP. A nested case control study demonstraƟ ng 
increased chronic faƟ gue six years aŌ er a Q fever outbreak. Microbiol Res. 2011;2(e19):69-72. doi: 
10.4081/mr.2011.e19.
70. Marmion B. A guide to Q fever and Q fever vaccinaƟ on. Australia: CSL Biotherapies; 2009. 125 p.
71. Ware Jr. JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the 
scoring and staƟ sƟ cal analysis of SF-36 health proﬁ le and summary measures: summary of results from 
the Medical Outcomes Study. Med Care. 1995;33(4 Suppl):AS264-79. PubMed PMID: 7723455.
72. Peters JB, Daudey L, Heijdra YF, Molema J, Dekhuijzen PN, Vercoulen JH. Development of a baƩ ery 
of instruments for detailed measurement of health status in paƟ ents with COPD in rouƟ ne care: the 
Nijmegen Clinical Screening Instrument. Qual Life Res. 2009;18(7):901-12. doi: 10.1007/s11136-009-
9502-2. PubMed PMID: 19543807; PubMed Central PMCID: PMC2724638.
73. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, et al. ProducƟ on of pro-inﬂ amma-
tory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 
2004;34(7):1289-97. doi: hƩ p://dx.doi.org/10.1017/S0033291704001953. PubMed PMID: 2004-
21862-015.
74. Castell BD, Kazantzis N, Moss-Morris RE. CogniƟ ve Behavioral Therapy and Graded Exercise for Chronic 
FaƟ gue Syndrome: A Meta-Analysis. Clin Psychol-Sci Pr. 2011;18(4):311-24. doi: 10.1111/j.1468-
2850.2011.01262.x. PubMed PMID: WOS:000298355100004.
75. Malouﬀ  JM, Thorsteinsson EB, Rooke SE, Bhullar N, SchuƩ e NS. Eﬃ  cacy of cogniƟ ve behavioral therapy 
for chronic faƟ gue syndrome: a meta-analysis. Clin Psychol Rev. 2008;28(5):736-45. doi: 10.1016/j.
cpr.2007.10.004. PubMed PMID: 18060672.
76. Gielissen MF, Verhagen S, Witjes F, Bleijenberg G. Eﬀ ects of cogniƟ ve behavior therapy in severely 
faƟ gued disease-free cancer paƟ ents compared with paƟ ents waiƟ ng for cogniƟ ve behavior therapy: 
a randomized controlled trial. J Clin Oncol. 2006;24(30):4882-7. doi: 10.1200/JCO.2006.06.8270. 
PubMed PMID: 17050873.
196  |  Chapter 9
77. Voet N, Bleijenberg G, Hendriks J, de Groot I, Padberg G, van Engelen B, et al. Both aerobic exercise and 
cogniƟ ve-behavioral therapy reduce chronic faƟ gue in FSHD: an RCT. Neurology. 2014;83(21):1914-22. 
doi: 10.1212/WNL.0000000000001008. PubMed PMID: 25339206.
78. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled 
trial of cogniƟ ve behavior therapy for mulƟ ple sclerosis faƟ gue. Psychosom Med. 2008;70(2):205-13. 
doi: 10.1097/PSY.0b013e3181643065. PubMed PMID: 18256342.
79. Working Group of the Royal Australasian College of Physicians. Chronic faƟ gue syndrome. Clinical 
pracƟ ce guidelines--2002. Med J Australia. 2002;176 Suppl:S23-56. PubMed PMID: 12056987.
80. Drachler MD, Leite JCD, Hooper L, Hong CS, Pheby D, Nacul L, et al. The expressed needs of people with 
Chronic FaƟ gue Syndrome/Myalgic EncephalomyeliƟ s: A systemaƟ c review. BMC Public Health. 2009;9. 
doi: Artn 458. 10.1186/1471-2458-9-458. PubMed PMID: WOS:000273144200001.
81. Hickie I, Lloyd A, Wakeﬁ eld D, Ricci C. Is there a posƟ nfecƟ on faƟ gue syndrome? Australian Family 
Physician. 1996;25(12):1847-52. Epub 1996/12/01. PubMed PMID: 9009004.
82. DiƩ ner AJ, Wessely SC, Brown RG. The assessment of faƟ gue: A pracƟ cal guide for clinicians and re-
searchers. J Psychosom Res. 2004;.56(2):pp. doi: 10.1016/S0022-3999%2803%2900371-4 15016573. 
PubMed PMID: 2004-12308-002.
83. Vercoulen J, Swanink C, Fennis J, Galama J, van der Meer J, Bleijenberg G. Dimensional assessment of 
chronic faƟ gue syndrome. J Psychosom Res. 1994;38(5):383 - 92. PubMed PMID: doi:10.1016/0022-
3999(94)90099-X.
84. Chalder T, Berelowitz G, Pawlikowska T, WaƩ s L, Wessely S, Wright D, et al. Development of a faƟ gue 
scale. J Psychosom Res. 1993;37(2):147-53. PubMed PMID: 8463991.
85. Bergner M, BobbiƩ  RA, Carter WB, Gilson BS. The Sickness Impact Proﬁ le - Development and Final 
Revision of a Health-Status Measure. Med Care. 1981;19(8):787-805. doi: Doi 10.1097/00005650-
198108000-00001. PubMed PMID: ISI:A1981MD41200001.
86. Smith G. Q fever outbreak in Birmingham, UK. Lancet. 1989;2(8662):557. PubMed PMID: 2570248.
87. Smith DL, Ayres JG, Blair I, Burge PS, Carpenter MJ, Caul EO, et al. A large Q fever outbreak in the West 
Midlands: clinical aspects. Respiratory Medicine. 1993;87(7):509-16. PubMed PMID: 8265838.
88. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic faƟ gue and 
chronic faƟ gue syndrome: a prospecƟ ve primary care study. Am J Public Health. 1997;87(9):1449-55. 
PubMed PMID: 9314795; PubMed Central PMCID: PMC1380968.
89. HatcheƩ e TF, Hudson RC, Schlech WF, Campbell NA, HatcheƩ e JE, Ratnam S, et al. Goat-associated Q fe-
ver: a new disease in Newfoundland. Emerg Infect Dis. 2001;7(3):413-9. doi: 10.3201/eid0703.010308. 
PubMed PMID: 11384518; PubMed Central PMCID: PMC2631794.
90. Holmes GP, Kaplan JE, Gantz NM, Komaroﬀ  AL, Schonberger LB, Straus SE, et al. Chronic faƟ gue syn-
drome: a working case deﬁ niƟ on. Ann Intern Med. 1988;108(3):387-9. PubMed PMID: 2829679.
91. Reid S, Chalder T, Cleare A, Hotopf M, Wessely S. Chronic faƟ gue syndrome. BMJ (Clinical Research ed). 
2000;320(7230):292-6. PubMed PMID: 10650029; PubMed Central PMCID: PMC1117488.
92. Hadzi-Pavlovic D, Hickie IB, Wilson AJ, Davenport TA, Lloyd AR, Wakeﬁ eld D. Screening for prolonged 
faƟ gue syndromes: validaƟ on of the SOFA scale. Soc Psych Psych Epid. 2000;35(10):471-9. doi: DOI 
10.1007/s001270050266. PubMed PMID: WOS:000165107600006.
93. Kerr JR, Burke B, PeƩ y R, Gough J, Fear D, MaƩ ey DL, et al. Seven genomic subtypes of chronic faƟ gue 
syndrome/myalgic encephalomyeliƟ s: a detailed analysis of gene networks and clinical phenotypes. J 
Clin Pathol. 2008;61(6):730-9. doi: 10.1136/jcp.2007.053553. PubMed PMID: 18057078.
94. Kerr JR, PeƩ y R, Burke B, Gough J, Fear D, Sinclair LI, et al. Gene expression subtypes in paƟ ents 
with chronic faƟ gue syndrome/myalgic encephalomyeliƟ s. J Infect Dis. 2008;197(8):1171-84. doi: 
10.1086/533453. PubMed PMID: 18462164.
FaƟ gue Following Acute Q-Fever  |  197
9
95. Kaushik N, Fear D, Richards SC, McDermoƩ  CR, Nuwaysir EF, Kellam P, et al. Gene expression in peripheral 
blood mononuclear cells from paƟ ents with chronic faƟ gue syndrome. J Clin Pathol. 2005;58(8):826-32. 
doi: 10.1136/jcp.2005.025718. PubMed PMID: 16049284; PubMed Central PMCID: PMC1770875.
96. Wessely S. Chronic faƟ gue: Symptom and syndrome. Ann Intern Med. 2001;134(9):838-43. PubMed 
PMID: WOS:000168543100007.
97. Wegdam-Blans MC, Nabuurs-Franssen MN, Horrevorts AM, Peeters MF, Schneeberger PM, Bijlmer 
HA. Laboratory diagnosis of acute Q fever [in Dutch]. Nederlands TijdschriŌ  voor Geneeskunde. 
2010;154:A2388. PubMed PMID: Medline:20858325.
98. Gilsdorf A, Kroh C, Grimm S, Jensen E, Wagner-Wiening C, Alpers K. Large Q fever outbreak due to sheep 
farming near residenƟ al areas, Germany, 2005. Epidemiol Infect. 2008;136(8):1084-7. PubMed PMID: 
Medline:17892631.
99. van Woerden HC, Mason BW, Nehaul LK, Smith R, Salmon RL, Healy B, et al. Q fever outbreak in in-
dustrial seƫ  ng. Emerg Infect Dis. 2004;10(7):1282-9. doi: 10.3201/eid1007.030536. PubMed PMID: 
15324550; PubMed Central PMCID: PMC3323322.
100. Wegdam-Blans M, Kampschreur L, Delsing C, Bleeker-Rovers C, Sprong T, van Kasteren M, et al. Chronic 
Q fever: review of the literature and a proposal of new diagnosƟ c criteria. J Infect. 2012;64:247 - 59. 
PubMed PMID: doi:10.1016/j.jinf.2011.12.014.
101. van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, et al. Q fever in the 
Netherlands: an update on the epidemiology and control measures. Eurosurveillance. 2010;15(12). 
PubMed PMID: 20350500.
102. Dijkstra F, van der Hoek W, Wijers N, Schimmer B, Rietveld A, Wijkmans CJ, et al. The 2007-2010 Q 
fever epidemic in The Netherlands: characterisƟ cs of noƟ ﬁ ed acute Q fever paƟ ents and the asso-
ciaƟ on with dairy goat farming. FEMS Immunol Med Microbiol. 2012;64(1):3-12. doi: 10.1111/j.1574-
695X.2011.00876.x. PubMed PMID: 22066649.
103. van Loenhout JA, Paget WJ, Vercoulen JH, Wijkmans CJ, Hautvast JL, van der Velden K. Assessing the 
long-term health impact of Q-fever in the Netherlands: a prospecƟ ve cohort study started in 2007 on 
the largest documented Q-fever outbreak to date. BMC Infect Dis. 2012;12(280). doi: hƩ p://dx.doi.
org/10.1186/1471-2334-12-280. PubMed PMID: 2012706082.
104. European Union. Amending Decision 2002/253/EC laying down case deﬁ niƟ ons for reporƟ ng communi-
cable disease s to the Community network under Decision No. 2119/98/EC of the European Parliament 
and of the Council. Oﬃ  cial Journal of the European Union. 2008.
105. Keijmel SP, Morroy G, Delsing CE, Bleijenberg G, Bleeker-Rovers CP, Timen A. [Persistent faƟ gue fol-
lowing Q fever]. Nederlands TijdschriŌ  voor Geneeskunde. 2012;156(48):A5258. Epub 2012/11/30. 
PubMed PMID: 23191971.
198  |  Chapter 9
SUPPLEMENTARY FIGURES AND TABLES
S1 Figure
SecƟ on/topic # Checklist item
Reported 
on page #
TITLE
Title 1 IdenƟ fy the report as a systemaƟ c review, meta-analysis, or both. 172
ABSTRACT
Structured 
summary
2 Provide a structured summary including, as applicable: background; 
objecƟ ves; data sources; study eligibility criteria, parƟ cipants, and 
intervenƟ ons; study appraisal and synthesis methods; results; limitaƟ ons; 
conclusions and implicaƟ ons of key ﬁ ndings; systemaƟ c review registraƟ on 
number.
172
INTRODUCTION
RaƟ onale 3 Describe the raƟ onale for the review in the context of what is already 
known.
173
ObjecƟ ves 4 Provide an explicit statement of quesƟ ons being addressed with reference 
to parƟ cipants, intervenƟ ons, comparisons, outcomes, and study design 
(PICOS).
173
METHODS
Protocol and 
registraƟ on
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registraƟ on informaƟ on including 
registraƟ on number.
173-4
Eligibility criteria 6 Specify study characterisƟ cs (e.g., PICOS, length of follow-up) and report 
characterisƟ cs (e.g., years considered, language, publicaƟ on status) used as 
criteria for eligibility, giving raƟ onale.
174-5
InformaƟ on 
sources
7 Describe all informaƟ on sources (e.g., databases with dates of coverage, 
contact with study authors to idenƟ fy addiƟ onal studies) in the search and 
date last searched.
173-4
Search 8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.
173-4
Study selecƟ on 9 State the process for selecƟ ng studies (i.e., screening, eligibility, included in 
systemaƟ c review, and, if applicable, included in the meta-analysis).
173-5
Data collecƟ on 
process
10 Describe method of data extracƟ on from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and conﬁ rming 
data from invesƟ gators.
173-5
Data items 11 List and deﬁ ne all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumpƟ ons and simpliﬁ caƟ ons made.
173-5
Risk of bias 
in individual 
studies
12 Describe methods used for assessing risk of bias of individual studies 
(including speciﬁ caƟ on of whether this was done at the study or outcome 
level), and how this informaƟ on is to be used in any data synthesis.
173-5
Summary 
measures
13 State the principal summary measures (e.g., risk raƟ o, diﬀ erence in means). 173-5
Synthesis of 
results
14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.
Not 
applicable
FaƟ gue Following Acute Q-Fever  |  199
9
SecƟ on/topic # Checklist item
Reported on 
page #
Risk of bias across 
studies
15 Specify any assessment of risk of bias that may aﬀ ect the cumulaƟ ve 
evidence (e.g., publicaƟ on bias, selecƟ ve reporƟ ng within studies).
173-5
AddiƟ onal 
analyses
16 Describe methods of addiƟ onal analyses (e.g., sensiƟ vity or subgroup 
analyses, meta-regression), if done, indicaƟ ng which were pre-
speciﬁ ed.
Not applicable
RESULTS
Study selecƟ on 17 Give numbers of studies screened, assessed for eligibility, and included 
in the review, with reasons for exclusions at each stage, ideally with a 
ﬂ ow diagram.
176-7
Study 
characterisƟ cs
18 For each study, present characterisƟ cs for which data were extracted 
(e.g., study size, PICOS, follow-up period) and provide the citaƟ ons.
Supplementary 
tables
Risk of bias within 
studies
19 Present data on risk of bias of each study and, if available, any outcome 
level assessment (see item 12).
176-7
Results of 
individual studies
20 For all outcomes considered (beneﬁ ts or harms), present, for each 
study: (a) simple summary data for each intervenƟ on group (b) eﬀ ect 
esƟ mates and conﬁ dence intervals, ideally with a forest plot.
176-89
Synthesis of 
results
21 Present results of each meta-analysis done, including conﬁ dence 
intervals and measures of consistency.
Not applicable
Risk of bias across 
studies
22 Present results of any assessment of risk of bias across studies (see 
Item 15).
176-7
AddiƟ onal 
analysis
23 Give results of addiƟ onal analyses, if done (e.g., sensiƟ vity or subgroup 
analyses, meta-regression [see Item 16]).
Not applicable
DISCUSSION
Summary of 
evidence
24 Summarize the main ﬁ ndings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).
189-90
LimitaƟ ons 25 Discuss limitaƟ ons at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of idenƟ ﬁ ed research, reporƟ ng 
bias).
189-90
Conclusions 26 Provide a general interpretaƟ on of the results in the context of other 
evidence, and implicaƟ ons for future research.
189-90
FUNDING
Funding 27 Describe sources of funding for the systemaƟ c review and other 
support (e.g., supply of data); role of funders for the systemaƟ c review.
See ﬁ nancial 
disclosure 
secƟ on of 
the online 
submission 
system
From: Moher D, LiberaƟ  A, Tetzlaﬀ  J, Altman DG, The PRISMA Group (2009). Preferred ReporƟ ng 
Items for SystemaƟ c Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097
200  |  Chapter 9
S1 Table. Overview of study populaƟ ons and used deﬁ niƟ ons
Included 
arƟ cles Study populaƟ ons and used deﬁ niƟ ons
1960, O. 
Powell [68]
1-2 yrs post AQF (AQF conﬁ rmed by demonstraƟ on CFT to C.b. with either a rise from zero to ≥1:32, or a 
Ɵ tre in a single specimen of ≥1:256 in paƟ ents admiƩ ed to hospital or suspected of infecƟ on late in the 
illness) from Princess Alexandra Hospital, Brisbane. No deﬁ niƟ on for QFS or faƟ gue
1990, S. 
Reilly [53]
All AQF cases diagnosed and monitored by the Public Health Laboratory in Plymouth between 1972 and 
1988 out of FUO, respiratory infecƟ ons, CNE, and hepaƟ Ɵ s cases. Clinical and serological status assessed in 
1989. AQF: ≥fourfold rise in phase II Ɵ tre, or by a stable phase II Ɵ tre ≥80 if there was strong clinical evidence 
of AQF. Past infecƟ on: evidence of past exposure to C.b. by single or sustained phase II Ɵ tres ≥10 to ≤40, 
with QF not being considered to be causally related to the presenƟ ng complaint. No deﬁ niƟ on for faƟ gue
1995, P. 
Harvey-
SuƩ on [35]
No study populaƟ on or QFS deﬁ niƟ on
1996, B. 
Marmion [8]
5-14 yrs post laboratory-proven AQF (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II 
anƟ bodies), QFS deﬁ ned as: 1) incapacitaƟ ng faƟ gue requiring prolonged rest aŌ er simple tasks; 2) nausea, 
persistent headache; 3) feeling feverish with profuse, odoriferous sweats at night, usually afebrile; 4) myalgia 
in any muscle group; 5) intermiƩ ent fasciculaƟ on of muscle ﬁ bres and muscle tenderness on palpaƟ on; 6) 
arthralgia without swelling, in any joint including costochondrals; 7) ethanol intolerance compared with 
capacity before AQF; and 8) interrupted sleep paƩ erns, excessive and unreasonable irritability, unreliable 
short-term memory, and poor concentraƟ on. Less frequent complaints: bloaƟ ng, irritable bowel syndrome, 
nasal and bronchial congesƟ on, blurred vision, bright light intolerance, and enlargement and pain in lymph 
nodes. Deﬁ niƟ on CFS: according to the 1994 internaƟ onal CFS criteria [15]
1996, J. Ayres 
[14]
6 yrs post AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II anƟ bodies), no 
QFS deﬁ niƟ on, but rather descripƟ on of complaints being signiﬁ cantly more prevalent in past QF cases 
i.c.w. controls: joint pains, sleep disturbance, cough, sweaƟ ng, irritability, chest pain, breathlessness, and 
dizziness
1998, J. Ayres 
[9]
5 yrs post AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II anƟ bodies), no QFS 
deﬁ niƟ on, but rather descripƟ on of complaints being signiﬁ cantly more prevalent in past QF cases i.c.w. 
controls: faƟ gue, sweaƟ ng, breathlessness on exerƟ on, blurred vision, with symptom severity in QF cases 
being higher for faƟ gue, blurred vision, sweaƟ ng, memory deterioraƟ on, joint pains and headaches
1998, B. 
Bennet [45]
PIFS paƟ ents from DIOS or from the University Health Service at the University of New South Wales whose 
symptoms have been present ≤4 wks
1998, K. Kato 
[52]
PaƟ ents with chronic nonspeciﬁ c symptoms, such as faƟ gue, joint aches, sleep disturbance, night sweats, 
myalgia aﬀ ecƟ ng various muscle groups, nausea, persistent headache, and so on, without diagnosis or 
treatment history of QF and living in close contact with animals, presented between March 1996 and April 
1997 to the Department of Internal Medicine and PsychosomaƟ c Medicine, Nihon University Health Science 
Centre. Healthy controls: without/few complaints, who received annual examinaƟ ons at the same hospital
1998, I. 
Penƫ  la [19]
Deﬁ niƟ on QFS paƟ ents: 1) severe incapacitaƟ ng faƟ gue ≥6 mo post AQF, with symptom score >100; 2) 
presence of myalgia and arthralgia; and 3) abnormal sweats, parƟ cularly at night. In addiƟ on, most paƟ ents 
had other symptoms such as inappropriate exhausƟ on on minor exerƟ on, muscle fasciculaƟ on, headaches, 
bright light intolerance, ethanol intolerance, interrupted and unrefreshing sleep paƩ erns, irraƟ onal 
irritability, loss of libido, depression, impairment mental concentraƟ on and short-term memory. Resolving 
QFS: recruited in similar way aŌ er several yrs observaƟ on, but symptom score dropped from values >100 to 
≤95. QF without QFS: 6 mo post AQF without complex of symptoms and low symptom score (1-35)
1999, J. 
Scadding 
[26]
No study populaƟ on or QFS deﬁ niƟ on
2000, R. 
Harris [20]
Deﬁ niƟ on of QFS paƟ ents: conform [19]. Controls: conform [19]
2002, J. Ayres 
[54]
10 yrs post laboratory-proven AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II 
anƟ bodies). Controls: no serological evidence of past exposure to C.b. Deﬁ niƟ on faƟ gue: according to the 
1994 internaƟ onal CFS criteria [15, 88]
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2002, M. 
Wildman [7]
10 yrs post laboratory-proven AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II 
anƟ bodies). Deﬁ niƟ on faƟ gue: score ≥4 using the tradiƟ onal scoring system for the faƟ gue quesƟ onnaire 
[84]. Deﬁ niƟ on ICF: faƟ gued and describing faƟ gue >50% of the Ɵ me for 6 mo. Deﬁ niƟ on CFS: ICF and 
funcƟ onal impairment and ≥4 addiƟ onal symptoms according to the 1994 internaƟ onal diagnosƟ c criteria 
[15]. Controls: no serological evidence of past exposure to C.b.
2002, D. 
Raoult [38]
Deﬁ niƟ on QFS paƟ ent: residual asthenia following QF at 6 mo post AQF
2002, B. 
Marmion 
[33]
No study populaƟ on or QFS deﬁ niƟ on
2002, M. 
Wildman 
[34]
No study populaƟ on or QFS deﬁ niƟ on. Deﬁ niƟ on faƟ gue: according to the 1994 internaƟ onal CFS criteria 
[15, 88]
2003, T. 
HatcheƩ e [3]
3 and 27 mo post AQF [89], no QFS deﬁ niƟ on. Controls: without AQF during same outbreak cohort
2003, K. 
Helbig [50]
Deﬁ niƟ on QFS paƟ ents: conform [19]. Recovered QFS: conform [19]
2003 K. Ikuta 
[55]
CFS based on the 1988 CDC working case deﬁ niƟ on [90] and the Ministry of Health and Welfare of Japan, 
from ToƩ ori University Hospital, Yonago, and from Osaka University Hospital, Osaka, Japan. Healthy controls: 
from ToƩ ori University Hospital Yonago
2004, Y. 
Arashima [6]
Deﬁ niƟ on QFS paƟ ents: prolonged nonspeciﬁ c complaints, with general faƟ gue of unknown origin, or 
headache, slightly elevated body temperature (37-37,5˚C), arthralgia, or myalgia, with C.b. seroposiƟ ve 
deﬁ ned by IgMII ≥1:32 or IgGII ≥1:128 (or ≥1:64 if anƟ body for B. henselae was negaƟ ve) and/or detectable 
C.b. DNA, for 3 mo Ɵ ll 4 yrs, between July and November 2001 from the Department of Internal Medicine 
of the Nihon University School of Medicine, Tokyo
2004, H. 
Thomas [56]
8 yrs post recruitment in 1991 from a random sample of farmers drawn from the Ministry of Agriculture, 
Fisheries and Food June Agricultural Census lists of agricultural holdings, with C.b. seroposiƟ vity deﬁ ned by 
IgGII ≥1:32. No QFS deﬁ niƟ on
2005, B. 
Marmion 
[21]
Deﬁ niƟ on UK cases: 12 yrs post laboratory-proven AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 
4-fold rise in phase II anƟ bodies). Deﬁ niƟ on faƟ gue: conform [7]. Deﬁ niƟ on Australian QFS cases: conform 
[19, 20], 9 mo-5 yrs post AQF. Deﬁ niƟ on faƟ gue: according to the 1994 internaƟ onal CFS criteria [15]
2005, K. 
Helbig [51]
Deﬁ niƟ on QFS paƟ ents: as in [19, 21]. Deﬁ niƟ on AQF with asymptomaƟ c recovery: 12 yrs post laboratory-
proven AQF [86, 87] (AQF deﬁ ned as a CFT Ɵ tre of ≥1:256 or a 4-fold rise in phase II anƟ bodies), with 
complete recovery without QFS or other chronic sequel. Deﬁ niƟ on QIE: clinical evidence of endocardiƟ s 
by observaƟ on of vegetaƟ ons on ultrascan or on histopathological examinaƟ on of the diseased valve, and 
a compaƟ ble serological proﬁ le deﬁ ned by IgGI and II >320, low or no IgM and IgAI ≥160, and PCR posiƟ ve 
examinaƟ on of valve vegetaƟ on specimens and in some instances by isolaƟ on of C.b. in cell culture or 
laboratory animals, Caucasians mainly from New South Wales and Queensland
2005, E. 
Iwakami [39]
Deﬁ niƟ on CFS paƟ ents: according to the 1994 internaƟ onal CFS criteria [15, 91], in combinaƟ on with 
proven C.b. infecƟ on deﬁ ned by IgG ≥1:128 (or ≥1:64 if B. henselae was negaƟ ve), or IgM ≥1:32, and/or 
detectable C.b. DNA, for 8 mo Ɵ ll 11 yrs. Deﬁ niƟ on QFS paƟ ents: nonspeciﬁ c complaints such as CF, slightly 
elevated body temperature, headache, arthralgia and myalgia of unknown origin for several mo or longer, 
but not meeƟ ng the 1994 internaƟ onal CFS criteria, in combinaƟ on with a conﬁ rmed C.b. infecƟ on deﬁ ned 
by IgG ≥1:128 (or ≥1:64 if B. henselae was negaƟ ve), or IgM ≥1:32, and/or detectable C.b. DNA by n-PCR, 
regardless of the presence or absence of pre-exisƟ ng infecƟ on, for 1 mo Ɵ ll 10 yrs
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2006, I. 
Hickie [12]
PaƟ ents from DIOS with symptoms ≤6 weeks assessed at 3 and 6 wks, and 3 and 12 mo post AI, without 
pre-exisƟ ng medical disorders or drug use likely to be associated with prolonged faƟ gue. Provisional PIFS: 
if SOMA scores at all Ɵ me points up to and including 3 mo exceeded the established threshold score 
[92]. Conﬁ rmed PIFS: CFS at 6 mo post AI according to the 1994 internaƟ onal CFS criteria [15]. Controls: 
recovered promptly from the same infecƟ on
2007, D. 
Ledina [5]
Deﬁ niƟ on QFS paƟ ents: between January 2000 and December 2004 at Split University Hospital, CroaƟ a. 1) 
12 mo post AQF complaints of morning faƟ gue, disrupted sleep, headache, prolonged faƟ gue >24 hours 
post exerƟ on, muscle pain, persistent slightly elevated body temperature, without CQF, meeƟ ng the 1994 
internaƟ onal CFS criteria [15]. 2) 2 mo post AQF no symptoms, than start neck pain with 6 mo post AQF start 
of faƟ gue, insomnia, headache, sweaƟ ng, unrefreshing sleep, for 12 mo, meeƟ ng the 1994 internaƟ onal 
CFS criteria [15] with posiƟ ve ELISA IgG 1.6 and IgA 1.4. 3) 4 mo post AQF start symptoms of faƟ gue, 
disrupted sleep, headaches, muscle and joint pain, for 7 mo, meeƟ ng the 1994 internaƟ onal CFS criteria 
[15], with posiƟ ve ELISA IgG 2.4 and IgA 1.5
2007, U. 
Vollmer-
Conna [18]
PIFS paƟ ents from DIOS assessed at 1, 2, 3, 6, and 12 mo post AI, with conﬁ rmed PIFS if symptoms persisted 
beyond 6 mo with a score of ≥3 at all Ɵ me points on the empirically derived subscale SOMA, without 
alternaƟ ve explanaƟ ons for ongoing illness and meeƟ ng the 1994 internaƟ onal CFS criteria [15]
2009, B. 
Marmion 
[37]
Samples from 11 paƟ ents ≥12 yrs post laboratory-proven AQF [86, 87], of whom 1 paƟ ents had slightly 
elevated body temperature, late-stage QIE
2009, L. 
Zhang [48]
Deﬁ niƟ on CFS/ME: idiopathic CFS/ME according to the 1994 internaƟ onal CFS criteria [15], from Bristol, 
London, and New York, and CFS/ME from [93, 94]. Deﬁ niƟ on Q-CFS/ME: CFS/ME according to the 1994 
internaƟ onal CFS criteria [15] triggered by laboratory documented QF, from Birmingham. Deﬁ niƟ on 
endogenous depression: fulﬁ lled DSM-IV criteria, from Bristol and surrounding area. Deﬁ niƟ on healthy 
blood donors: from Dorset NaƟ onal Blood Service [95]. Excluded were psychiatric diseases, smoking previous 
yr, alcohol or drugs abuse, current use or ≤3 mo of anƟ bioƟ cs, steroids, cytotoxic drugs or anƟ depressant
2010, Y. 
Kadota [46]
PIFS paƟ ents from DIOS or from a terƟ ary referral assessment clinic at a public teaching hospital in Sydney, 
and paƟ ents’ current symptom proﬁ les had to fulﬁ ll the 1994 internaƟ onal CFS criteria [15]
2010, O. 
Sukocheva 
[36]
Samples from paƟ ents 12 yrs post laboratory-proven AQF [86, 87], classiﬁ caƟ on of paƟ ents into clinical 
groupings according to asymptomaƟ c recovery or presence of QFS with or without other co-morbidity [7, 
96], with a chosen subset from 1) recGr3, AQF with asymptomaƟ c recovery; 2) QFSGr5, AQF followed by 
QFS without co-morbidity; 3) QFSGr6, AQF followed by QFS with faƟ gue-associated co-morbidity
2010, G. 
Limonard 
[58]
12 mo post laboratory-proven AQF (AQF deﬁ ned as any inhabitant of the outbreak cluster area who 
presented with compaƟ ble clinical symptoms and a posiƟ ve IFA serology, with an IgMII and IgGII ≥1:64 or 
seroconversion with 4-fold rise in anƟ body Ɵ tre during FU). Controls: from neighbourhood of QF paƟ ent 
without QF history, with negaƟ ve QF serology
2010, G. 
Limonard 
[57]
Post laboratory-proven AQF (AQF deﬁ ned as any inhabitant of the outbreak cluster area who presented 
with ≥1 compaƟ ble clinical symptoms (fever, faƟ gue, chills, headache, myalgia, sweats, cough) and the 
demonstraƟ on of C.b. infecƟ on, as evidence by: 1) seroconversion or 4-fold rise in anƟ body Ɵ tre using 
CFT in samples taken ≥14 days apart; 2) presence of IFA IgMII and IgGII ≥1:64; or 3) a posiƟ ve serum PCR) 
assessed at baseline, 3, 6, 12 mo. Deﬁ niƟ on CQF: any inhabitant of outbreak cluster area with clinical enƟ ty 
compaƟ ble with endocardiƟ s, vascular infecƟ on, osteoarƟ cular infecƟ on, chronic hepaƟ Ɵ s, or pregnancy, 
with an IgGI ≥800, for ≥6 mo post AQF
2011, G. 
Morroy [59]
12-26 mo post AQF (AQF according to the Dutch noƟ ﬁ caƟ on criteria [97] deﬁ ned as a laboratory 
conﬁ rmaƟ on of QF with a seroconversion or a 4-fold rise in anƟ body Ɵ tre between 2 subsequent tests 
with 2-4 wks Ɵ me interval using CFT or IFA, and clinical presentaƟ on of fever, pneumonia or hepaƟ Ɵ s, 
≥18 yrs, noƟ ﬁ ed in 2007/2008. Excluded: unknown onset of QF infecƟ on, incomplete quesƟ onnaires and 
quesƟ onnaires completed by another person
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2011, H. van 
Woerden 
[69]
6 yrs post AQF (AQF deﬁ ned as those who had clinical symptoms and serological evidence of AQF as 
demonstrated by an IgMII ≥80, or a fourfold rise on sequenƟ al CFT in 2002). Deﬁ niƟ on controls: who 
worked in the same factory but had no symptoms of AQF and no serological evidence of infecƟ on with no 
IgM, no CFT and no IgGI or IgGII at the Ɵ me of the outbreak
2011, S. 
Galbraith 
[47]
Caucasian PIFS paƟ ents from DIOS with unexplained illness persisƟ ng ≥6 mo with a score of ≥3 at all Ɵ me 
points on the empirically derived subscale SOMA, without alternaƟ ve explanaƟ ons for ongoing illness and 
meeƟ ng the 1994 internaƟ onal CFS criteria [15]. Controls: recovered promptly from the same infecƟ on
2012, B. 
Piraino [60]
Caucasian adult PIFS paƟ ents from DIOS [12] assessed at baseline, 2-3 wks, 4-6 wks, followed by 3-mo 
interval unƟ l 12 mo post AI
2012, B. 
Strauss [61]
2 yrs post laboratory-proven AQF [98]. Controls: without registered indicator for QF infecƟ on, from same 
general pracƟ Ɵ oners as study paƟ ents
2012, G. 
Morroy [62]
12-26 mo post AQF (AQF according to the Dutch noƟ ﬁ caƟ on criteria [97] deﬁ ned as a laboratory 
conﬁ rmaƟ on of QF and clinical presentaƟ on with fever, pneumonia or hepaƟ Ɵ s, noƟ ﬁ ed in 2007/2008)
2012, Y. 
Arashima 
[28]
Deﬁ niƟ on QFS paƟ ent: 3 mo post AI with general faƟ gue, slightly elevated body temperature (37˚C or higher), 
cough, night sweats, arthralgia, noise in his ears, taste disturbance, and headache, without abnormaliƟ es 
in physical examinaƟ on, laboratory examinaƟ on including cultures and addiƟ onal tests (X-rays, abdominal 
ultrasound, echocardiography, treadmill exercise test), but with posiƟ ve n-PCR for C.b., IgGII 1:64
2012, D. 
Raoult [27]
No study populaƟ on or QFS deﬁ niƟ on
2012, H. 
Hussain-
Yusuf [49]
PaƟ ents 6 yrs post serological evidence of AQF in 2002 [99]. Controls: worked in the same factory but were 
serologically negaƟ ve for QF at the Ɵ me of the outbreak
2012, J. 
Oosterheert 
[10]
No study populaƟ on or QFS deﬁ niƟ on
2012, S. 
Yakubo [29]
Deﬁ niƟ on QFS paƟ ents: general faƟ gue, nausea, stomach pain, abnormal sensaƟ on in the mouth, sore 
throat, and trouble sleeping, with IgGI 1:256
2013, S. 
Keijmel [42]
Deﬁ niƟ on QFS paƟ ents: according to the Dutch guideline on QFS [17], referred to Radboud university 
medical center, Nijmegen, the Netherlands; adults (non-pregnant, non-lactaƟ ng), ≥18 yrs, with laboratory-
proven AQF since 2007 and/or posiƟ ve serology ﬁ ƫ  ng a past infecƟ on with C.b., and being severely faƟ gued 
(CIS faƟ gue ≥35) for ≥6 mo, and being disabled because of faƟ gue (SIP total score ≥450), with a reference 
to AQF and absence of faƟ gue before the episode of AQF or a signiﬁ cant increase ever since. Excluded: CQF 
[100], AQF in the presence of risk factors for developing CQF necessitaƟ ng prophylacƟ c use of doxycycline, 
pregnancy or unwillingness to use eﬀ ecƟ ve contracepƟ ves during the study, imminent death, inability to 
give informed consent, allergy or intolerance to doxycycline, somaƟ c or psychiatric illness explaining chronic 
faƟ gue, current enrolment in other invesƟ gaƟ onal drug trials or receiving invesƟ gaƟ onal agents, receiving or 
having received AB >4 wks potenƟ ally acƟ ve against C.b., use of barbiturates, phenytoin, or carbamazepine, 
moderate or severe liver disease, current engagement in legal procedure for ﬁ nancial beneﬁ ts
2013, S. 
Yakubo [41]
Deﬁ niƟ on QFS paƟ ent: 6 yrs post AI with general malaise, spasm leŌ  hand, slightly elevated body 
temperature, without abnormaliƟ es in physical examinaƟ on, laboratory examinaƟ on including pharyngeal 
culture and addiƟ onal tests (chest X-ray, X-ray of larynx/pharynx/ears and paranasal sinuses, ECG, abdominal 
ultrasound, brain CT, EEG), with negaƟ ve n-PCR for C.b., IgMI and IgMII <1:16, IgGI <1:16, IgGII 1:32. Six mo 
aŌ er presentaƟ on IgGI 1:128
2013, M. van 
Asseldonk 
[32]
All noƟ ﬁ ed, hospitalised, deceased and non-reported cases of QF, determined from [2] and [101]
2013, J. van 
Loenhout 
[25]
12 mo post AQF, paƟ ents ≥18 yrs diagnosed with QF in 2010 and 2011, who fulﬁ lled the Dutch noƟ ﬁ caƟ on 
criteria for QF [102] were eligible for parƟ cipaƟ on
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S1 Table. Overview of study populaƟ ons and used deﬁ niƟ ons (conƟ nued)
Included 
arƟ cles Study populaƟ ons and used deﬁ niƟ ons
2013, S. 
Yakubo [40]
Deﬁ niƟ on QFS paƟ ent: 2 mo post AI with severe faƟ gue, general malaise, arthralgia, myalgia, persistent 
slightly elevated body temperature (around 37˚C), whole-body lassitude, without abnormaliƟ es in physical 
examinaƟ on, laboratory examinaƟ on including a pharyngeal culture and addiƟ onal tests (chest X-ray, ECG), 
but with posiƟ ve n-PCR for C.b., without posiƟ ve anƟ bodies
2013, R. 
Brooke [31]
QF noƟ ﬁ ed paƟ ents with onset symptoms between 1 January 2009 and 31 December 2013. A(H1N1)
pdm09 noƟ ﬁ ed paƟ ents, reﬂ ected by inﬂ uenza-like-illness registraƟ on from the Dutch SenƟ nel General 
PracƟ ce Network for inﬂ uenza-like-illness from NIVEL Netherlands InsƟ tute for Health Services Research 
between 27 April 2009 and 26 April 2010
2013, Y. 
Arashima 
[30]
Deﬁ niƟ on QFS paƟ ents: 18 mo post AI with general faƟ gue, cough, dyspnoea, sputum, breathing 
diﬃ  culty, slightly elevated body temperature, headache, poor appeƟ te, copious sweaƟ ng, night sweaƟ ng, 
nausea, vomiƟ ng, palpitaƟ ons, and dizziness, without abnormaliƟ es on physical examinaƟ on, laboratory 
examinaƟ on (besides slight liver dysfuncƟ on), but with posiƟ ve n-PCR for C.b., IgMII 1:16, IgGII 1:128
2014, M. 
Kremers [63]
Post laboratory-proven AQF (AQF according to the Dutch noƟ ﬁ caƟ on criteria [97] deﬁ ned as symptomaƟ c 
paƟ ents with posiƟ ve PCR for C.b. DNA in serum samples before the development of an IgMII anƟ body 
response measured by IFA or ELISA), between April 2009 and August 2009, and assessment 4 yrs post AQF, 
all who were sƟ ll alive, ≥18 yrs and of whom a 12 mo FU sample was present
2014, J. van 
Loenhout 
[11]
Deﬁ niƟ on QF study populaƟ on [103]: noƟ ﬁ ed paƟ ents 1 yr post AQF in 2010 and 2011 (AQF according to 
the Dutch noƟ ﬁ caƟ on criteria deﬁ ned as a laboratory conﬁ rmaƟ on of QF with a seroconversion or a 4-fold 
rise in IgG anƟ body Ɵ tre in a paired serum sample with ≥2 wks Ɵ me interval using CFT or IFA, presence of 
IgMII anƟ bodies, posiƟ ve PCR or culture in blood or respiratory material, presence of phase I anƟ bodies, 
combined with a clinical presentaƟ on with fever, pneumonia or hepaƟ Ɵ s, an onset of illness within previous 
90 days [102], and ≥18 yrs. Deﬁ niƟ on Legionnaires disease study populaƟ on: noƟ ﬁ ed paƟ ents, 1 yr post 
Legionnaires’ disease in 2010 (Legionnaires’ disease according to the Dutch noƟ ﬁ caƟ on criteria deﬁ ned as 
matching clinical symptoms, usually pneumonia, conﬁ rmed by at least 1 but preferably 2 of the laboratory 
diagnosƟ c test: isolaƟ on of Legionella-species from respiratory secreƟ ons or blood; Legionella pneumophila-
anƟ gen in urine by radio-immuno-assay, ELISA, or immuno-chromatographic assay; Legionella-species by 
PCR in clinical material; signiﬁ cant Ɵ tre of IgM by ELISA; signiﬁ cant Ɵ tre elevaƟ on of anƟ bodies. Healthy 
controls: via adverƟ sements in local newspapers in the city of Nijmegen area. Excluded controls: underlying 
respiratory illness
2014, A. van 
Dam [64]
10-19 mo post LRTI as diagnosed by general pracƟ Ɵ oner between 1 May 2009 and 30 September 2009 in 
provinces of Northern Brabant and Gelderland, categorized into following ICPC groups: acute bronchiƟ s, 
inﬂ uenza, pneumonia, and other LRTI who were iniƟ ally tested for QF, ≥18 yrs and ≤75 yrs. Deﬁ niƟ on QF 
posiƟ ve: LRTI paƟ ents with posiƟ ve diagnosƟ c tests by either PCR, IFA, or CFT
2015, J. van 
Loenhout 
[67]
Over a period of 24 mo (assessed at 3, 6, 9, 12, 18 and 24 mo) post laboratory-proven AQF in 2010 and 2011 
(AQF according to the Dutch noƟ ﬁ caƟ on criteria [102]), ≥18 yrs
2015, J. van 
Loenhout 
[65]
Deﬁ niƟ on noƟ ﬁ ed QF paƟ ents: 4 yrs post laboratory-proven AQF in 2007 and 2008 (AQF according to the 
EU case deﬁ niƟ on [104] with laboratory criteria (isolaƟ on of C.b. from clinical specimen; detecƟ on of C.b. 
nucleid acid in clinical specimen; C.b. speciﬁ c anƟ body response (IgGII or IgMII)), epidemiological criteria 
(exposure to common source; animal to human transmission), and clinical criteria (fever, pneumonia and/
or hepaƟ Ɵ s), onset of disease <90 days, ≥18 yrs. Deﬁ niƟ on non-noƟ ﬁ ed QF paƟ ents: 4 yrs post laboratory-
proven QF in 2008 and 2009 (according to the EU case deﬁ niƟ on, but only fulﬁ lling the laboratory criteria 
and not the clinical criteria of fever, pneumonia or hepaƟ Ɵ s), onset of disease <90 days, ≥18 yrs
2015, J. van 
Loenhout 
[66]
Deﬁ niƟ on QF study populaƟ on [103]: noƟ ﬁ ed paƟ ents assessed 3, 6, 9 and 12 mo post laboratory-proven 
AQF in 2010 and 2011 (AQF according to the Dutch noƟ ﬁ caƟ on criteria), ≥18 yrs. Deﬁ niƟ on Legionnaires 
disease study populaƟ on [103]: noƟ ﬁ ed paƟ ents 12 mo post Legionnaires’ disease in 2010 (Legionnaires’ 
disease according to the Dutch noƟ ﬁ caƟ on criteria)
AbbreviaƟ ons: AI= Acute infecƟ on, AQF= Acute Q-fever, B. henselae= Bartonella henselae, C.b.= Coxiella burneƟ i, CDC= 
Centres for Disease Control and PrevenƟ on, CF= Chronic faƟ gue, CFS(/ME)= Chronic faƟ gue syndrome (/myeloencephali-
Ɵ s), CFT= Complement ﬁ xaƟ on test, CIS= Checklist Individual Strength, CNE= Culture negaƟ ve endocardiƟ s, CQF= Chronic 
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Q-fever, DIOS= Dubbo InfecƟ on Outcomes Study, cohort study of subjects ≥16 yrs followed from the onset of a 
conﬁ rmed and documented AI due to EBV; C.b.; or RRV ≤6 wks post AI unƟ l complete recovery, DSM-IV= DiagnosƟ c 
StaƟ sƟ cal Manual of Mental Disorders, EBV= Epstein-Barr virus, ECG= Electrocardiography, ELISA= enzyme-linked im-
munﬂ uorsorbent assay, EU= European Union, FU= Follow-up, FUO= Fever of unknown origin, I.c.w.= In comparison 
with, ICF= Idiopathic chronic faƟ gue, ICPC= InternaƟ onal classiﬁ caƟ on of primary care, IFA= Immunoﬂ uorescence 
assay, IgA= AnƟ -phase IgA, IgG= AnƟ -phase IgG, IgGI= AnƟ -phase IgG I Ɵ tre, IgGII= AnƟ -phase IgG II Ɵ tre, IgM= AnƟ -
phase IgM, IgMI= AnƟ -phase IgM I Ɵ tre, IgMII= AnƟ -phase IgM II Ɵ tre, LRTI= Lower respiratory tract infecƟ on, Mo= 
Month(s), (n-)PCR= (nested-) Polymerase chain reacƟ on, PIF(S)= Post-infecƟ ve faƟ gue (syndrome), Q-CFS(/ME)= 
Q-fever induced chronic faƟ gue syndrome (/myeloencephaliƟ s), QF= Q-fever, QF(F)S= Q-fever faƟ gue syndrome, or 
Post-Q-fever chronic faƟ gue syndrome, or Post-Q-fever debility syndrome, or PQFS= Post-(acute)Q-fever (faƟ gue) 
syndrome, (Q)IE= (Q-fever induced) InfecƟ ve endocardiƟ s, Ref= Reference, RRV= Ross River virus, SIP= Sickness Im-
pact Proﬁ le, SOMA= Empirically derived subscale of the SPHERE, used to record PIFS or illness duraƟ on. This reliably 
predicts disability and reﬂ ects paƟ ents’ and doctors’ reports of reasons for presentaƟ on to primary care. Scores ≥3 
represents a clinically-signiﬁ cant faƟ gue state, UK= United Kingdom, Wks= Weeks, Yr(s)= Year(s)
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S2 Table. Domain diagnosis
Ref
Country, yr study, 
period and duraƟ on Study type
PaƟ ents, controls, characterisƟ cs, co-
morbidity* Tool intervenƟ on 
1999, J. 
Scadding [26]
Country unknown, 
1999. DuraƟ on study 
NA
PO, 
comment on 
[19]
No paƟ ents/controls. CharacterisƟ cs and 
co-morbidity: NR
NA NA
2012, D. 
Raoult [27]
France, 2012 PO, 
comment on 
[100]
No paƟ ents/controls. CharacterisƟ cs and 
co-morbidity: NR. Focus on CQF
NA NA
2012, J. 
Ooster-heert 
[10]
Netherlands, 2012 PO, 
comment on 
[105]
No paƟ ents/controls. CharacterisƟ cs and 
co-morbidity: NR. Focus on terminology of 
faƟ gue following QF
NA NA
2013, J. van 
Loen-hout 
[25]
Netherlands, 2011-
2012, single mea-
surement 12 mo post 
illness onset
CoS 309 AQF paƟ ents, no controls. To assess 
use of NCSI and SF-36 in providing a 
detailed assessment of health status 
of QF paƟ ents and to evaluate which 
subdomains measure unique aspects of 
health status
NCSI, SF-36 NA
* Deﬁ niƟ on of used study populaƟ on in arƟ cles explained in a diﬀ erent table, including deﬁ niƟ ons of QFS and/or 
faƟ gue is applicable. Main informaƟ on is on diagnosis. Some arƟ cles also contain relevant informaƟ on on other 
domains: A= AeƟ ology, B/D= Background/descripƟ ve, P/T= PrevenƟ on/therapy
AbbreviaƟ ons: AI= Acute infecƟ on, AQF= Acute Q-fever, CF= Chronic faƟ gue, CFS= Chronic faƟ gue syndrome, CoS= 
Cohort study, CQF= Chronic Q-fever, Mo= Month(s), NA= Not applicable, NCSI= Nijmegen clinical screening instru-
ment, originally developed to provide a detailed assessment of health status of COPD paƟ ents. It combines a number 
of exisƟ ng health status quesƟ onnaires, NOS= Newcastle–OƩ awa Scale: S= selecƟ on (maximum of 4 stars), C= com-
parability (maximum of 2 stars), O= outcome (maximum of 3 stars); ★: star earned; ☆: item not applicable, NR= Not 
reported, PIF(S)= Post-infecƟ ve faƟ gue (syndrome), PO= Personal opinion, PQFS= Post-(acute)Q-fever (faƟ gue) syn-
drome, QA= Quality assessment, QF= Q-fever, QF(F)S= Q-fever faƟ gue syndrome, Ref= Reference, SF-36= The Short 
Form (36) Health Survey, a paƟ ent-reported survey of paƟ ent health to assess quality of life of paƟ ents, funcƟ onal 
impairment and reduced health related quality of life, Yr(s)= Year(s)
FaƟ gue Following Acute Q-Fever  |  207
9
Outcome Conclusions/recommendaƟ ons
Other 
domain
QA (NOS)
S C O
CFS, deﬁ ned in clinical-descripƟ ve terms, should convey no 
causal implicaƟ on; when there is convincing evidence of a 
causal factor, the case belongs to a causally-deﬁ ned subset 
of this syndrome. PQFS conforms to this desideratum
If mechanisms of complaints and speciﬁ c 
therapeuƟ c approaches are unknown, the term 
PQFS/QFS should be used as this leaves no 
doubt that ﬁ ndings are relevant to a CFS subset
NA NA
NA CF is a non-speciﬁ c subjecƟ ve state, not a 
speciﬁ c symptom of QF; no treatment is 
currently eﬀ ecƟ ve, it is not a diagnosƟ c problem. 
Some paƟ ents with faƟ gue have high anƟ body 
Ɵ tres, others not
NA NA
NA Important to underline and recognise PIFS. 
New terminology QFS not useful; PIF described 
for many infecƟ ous diseases; not causaƟ ve 
micro-organism, but disease severity correlates 
with symptom duraƟ on post AI. Can lead to 
culƟ vaƟ on, aƩ racƟ ng paƟ ents with other 
intenƟ ons then geƫ  ng beƩ er, ↑ healthcare 
costs
NA NA
NCSI: ↓ intercorrelaƟ ons subdomains. 4 subdomains 
showed conceptual similarity (SubjecƟ ve Pulmonary 
Symptoms, SubjecƟ ve Impairment and Dyspnoea EmoƟ ons, 
and between FaƟ gue and Health Related Quality of Life) 
with ≥1 SF-36 subdomain (Vitality and General Health, and 
between Vitality and Mental Health and Social FuncƟ oning) 
and vice versa
Both NCSI and SF-36 can be used to measure 
health status in QF paƟ ents. Combining NCSI 
and 4 SF-36 subdomains (Role Physical, Bodily 
Pain, Social FuncƟ oning, Role EmoƟ onal), is 
preferred to obtain a detailed overview
NA 






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S3 Table. Domain background/descripƟ ve
Ref
Country, yr study, 
period and duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
1960, O. 
Powell [68]
Australia, 1958 July-
1959 June
Observa-
Ɵ onal pros. 
CoS
AQF paƟ ents (n=72, all ♂), describe clinical features 
and FU
NR NA
1990, S. 
Reilly [53]
UK, 1972-1988, 
study period 16 yrs
Observa-
Ɵ onal pros. 
CoS
Seroprevalence C.b. assessed aŌ er tesƟ ng all 
FUO, respiratory infecƟ ons, CNE, and hepaƟ Ɵ s 
cases. Co-morbidity: NR. Time baseline (AQF) to 
measurement complaints NR
CFT, IFA (selected 
cases)
NA
1995, P. 
Harvey-
SuƩ on [35]
Australia, yr NR POB N unknown. PQDS or PQCFS. No control group NA NA
1996, B. 
Marmion 
[8]
Australia, 1995. 
Study period: 5-14 
yrs post AQF in 
1981-89
CC Post AQF laboratory proven (n=39) with QFS, 
skin-test /anƟ body negaƟ ve vaccinated (n=39), 
skin-test or anƟ body posiƟ ve without QF history 
(39), seronegaƟ ve (n=39). Controls matched (sex, 
≤10 yrs age). Co-morbidity: NR
54-item 
quesƟ onnaire 
based on 
symptoms
NA
1996, J. 
Ayres [14]
UK, 1995. Study 
period 6 yrs post 
AQF
CC QF paƟ ents (n=83, 70 ♂) vs. matched (age, 
sex) controls (n=26). Co-morbidity: NR. Assess 
prevalence chronic symptoms 6 yrs post AQF
QuesƟ onnaire as 
in [8]
NA
1998, J. 
Ayres [9]
UK, 1994. Study 
period: 5 yrs post 
AQF
CC 71 symptomaƟ c C.b. (mean age 55, 81.7% ♂, 
32.4% current smokers). Matched (sex, age, 
ethnicity) controls: 142 (55 yrs, 81.7% ♂, 16.9% no 
febrile illness needing medical aƩ enƟ on April-July 
1989). Asses CFS symptoms prevalence post AQF
Modiﬁ ed 
quesƟ onnaire [8], 
including VAS per 
symptom
NA
1998, K. 
Kato [52]
Japan, March 
1996-April 1997. 
Period: NA. Single 
blood samples
CC 52 paƟ ents (13 ♂, mean age 41 SD15, range 9-74): 
faƟ gue 77%, feeling feverish 44%, joint aches/ 
myalgia 70%, headache 56%, cough/sore throat 
42%; duraƟ on 4.9 yrs SD1.0, range 0.5-22. 52 
healthy controls (35 ♂, mean age 52, SD10, range 
38-82), and 70 cord blood samples
n-PCR NA
2002, M. 
Wildman [7]
UK, 1999 CC 10 yrs post C.b. outbreak. 80 matched controls 
(sex, age, and smoking) random 2 local general 
pracƟ Ɵ oners (mean age 55.4, SD11.7, 68 ♂). 108 
Q-exposed cases (mean age 55.6, SD11.8, 68 
♂) last contacted 1989/1994. Exclusion controls 
serology posiƟ ve C.b. 77 matched pairs analysed. 
Aim: had subjects involved in West Midlands 1989 
outbreak ↑ faƟ gue i.c.w. non-exposed controls 10 
yrs later
11-item faƟ gue 
quesƟ onnaire, 
GHQ, CIS-R. MOS, 
SDQ. Laboratory 
test C.b., spirome-
try, ECG, shuƩ le 
walk, incremen-
tal exercise test
NA
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Outcome Conclusions/recommendaƟ ons
Other 
domain
QA (CR or NOS)
S C O
ProporƟ on of cases convalescence prolonged, with undue faƟ gue, 
setback up on moderate exerƟ on, poor appeƟ te, and occasional 
headache. 15/61 returned to work >6 wks post AQF, 12 >8wks. 
Mean period oﬀ  work: 0-29 yrs 29 days, 30-49 yrs 45 days, 50-69 yrs 
68 days. Total amount of Ɵ me on workers’ compensaƟ on payment 
2013 days
Conﬁ rms previous observaƟ ons that 
convalescence is more protracted in elderly
NA 


103 C.b. infecƟ ons: 46 AQF, 5 CQF, 52 past infecƟ ons. Details 
61 cases (46 AQF, 5 CQF, 10 past infecƟ ons). Outcome AQF: 
57% uncomplicated, 4% prolonged faƟ gue (duraƟ on unknown), 
11% underlying malignancy, 9% neurological sequelae, 9% 
persistent chest symptoms, 9% hepaƟ c dysfuncƟ on. Outcome 
previous infecƟ on: 10% prolonged faƟ gue, 10% depression, 10% 
lymphadenopathy, 20% sarcoidosis, 10% polyarthriƟ s nodosa
QF remains unpredictable, with a propensity to 
follow a protracted course. Prolonged serological 
and clinical surveillance of all QF cases is 
suggested
NA 




ObservaƟ on of bradycardia in PQDS paƟ ents Bradycardia may be a sign of PQDS NA NA
CombinaƟ ons faƟ gue, night sweats, myalgia, fasciculaƟ on, with 
various minor symptoms more common in post AQF group, in 
18-48% depending on number and mix of symptoms used for QFS 
deﬁ niƟ on. Met CFS CDC criteria: 11/39 post AQF, 0/39 vaccinees, 
0/39 other controls
InterpretaƟ ons range from compensaƟ on-driven 
through psychogenic perpetuaƟ on of original 
symptoms/depression, to chronic immune 
sƟ mulaƟ on. Hypothesis persistence C.b./its 
anƟ gens causes dysregulaƟ on macrophage/T-
lymphocyte axis with aberrant monokine and 
lymphokine producƟ on mediaƟ ng symptoms
Diag,
A







QF group: 66% faƟ gue, 69% joint aches, 65% sleep disturbance, 
59% cough, 53% sweats, irritability 54%, chest pain 51%, 
breathlessness 49%, headaches 47%, dizziness 39%, blurred vision 
34%, alcohol intolerance 33%. ↑ Prevalence cases i.c.w. controls: 
joint pains, sleep disturbance, cough, sweats, irritability, chest pain, 
breathlessness, dizziness. No diﬀ erence prevalence faƟ gue, blurred 
vision, headaches, alcohol intolerance
Findings support view that chronic PQFS exists 
which is in many ways similar to CFS
NA 






QF symptom prevalence: signiﬁ cant ↑ faƟ gue, sweaƟ ng, blurred 
vision, breathlessness on exerƟ on (especially non-smokers) than 
controls. QF cases symptom severity: ↑ faƟ gue, blurred vision, 
sweaƟ ng, memory ↓, joint pains and headaches. 42.3% QF cases 
and 26% controls had CFS according to CDC criteria (p=0.025, 
post-hoc)
A syndrome characterized by undue faƟ gue, 
breathlessness on exerƟ on, excessive sweaƟ ng 
and blurred vision post C.b. infecƟ on, persists 
yrs. Deﬁ ning quesƟ onnaire based syndrome due 
to QF is dangerous, objecƟ ve measures needed. 
Mechanism elusive, subclinical cardiomyopathy/
autonomic dysfuncƟ on suggested
NA 






Physical examinaƟ on. CFS: 17/52 C.b. posiƟ ve, ampliﬁ caƟ on 438-bp 
fragments n-PCR. 52 controls 5/52 and 2/70 cord blood samples 
posiƟ ve n-PCR. Mean age paƟ ents posiƟ ve n-PCR 42, SD14, range 
9-67. EsƟ mated duraƟ on faƟ gue 77%, feeling feverish 53%, joint 
aches/myalgia 70%, headache 41%, cough/sore throat 47% was 4.0 
yrs SD1.2. PosiƟ ve raƟ o paƟ ents nonspeciﬁ c complaints ↑ i.c.w. 
healthy controls (p<0.05) and cord blood (p<0.001)
High prevalence C.b. infecƟ on adult paƟ ents 
with long term, nonspeciﬁ c complaints i.c.w. 
healthy controls, and possible existence chronic 
post AQF syndrome in Japan. Results appear to 
support the report of [8] and QFS concept
NA 



108 Q-exposed, 64.8% faƟ gue, 34.3% ICF vs. controls 36.3% and 
15.0%. 77 matched pairs: faƟ gue Q-exposed vs. controls: 64.9% 
vs. 35.1%, p<0.0001. ICF in 32.5% Q-exposed and 14.3% controls, 
p=0.01. 46.8% GHQ cases Q-exposed vs. 23.4% controls, p=0.004. 
Matched analysis: faƟ gue 66.7% Q-exposed, 34.7% controls, 
p<0.001, ICF 34.7% Q-exposed vs. 13.9% controls, p=0.004. CFS 
19.4% Q-exposed vs. 4.2% controls. p=0.003. 47.2% Q-exposed had 
GHQ vs. 23.6% controls, p=0.004
C.b. cases exposed in 1989 had more faƟ gue 
than controls, some fulﬁ lled CFS criteria. 
Uncertain if this is due to ongoing anƟ gen 
persistence or to psychological eﬀ ects of 
prolonged medical follow-up
A 







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S3 Table. Domain background/descripƟ ve (conƟ nued)
Ref
Country, yr study, 
period and duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2002, B. 
Marmion 
[33]
Australia, 2002. 
DuraƟ on study NA
PO, comment 
on [38]
No paƟ ents/controls. CharacterisƟ cs and co-
morbidity: NR
NA NA
2002, M. 
Wildman 
[34]
UK, 2002. DuraƟ on 
study NA
PO, comment 
on [38]
No paƟ ents/controls. CharacterisƟ cs and co-
morbidity: NR
CFS study 
group’s 1994 
CDC deﬁ niƟ on; 
3 faƟ gue levels 
with ↑ seve-rity: 
(i) faƟ gue, (ii) 
idiopathic CF, and 
(iii) CFS
NA
2003, T. 
HatcheƩ e 
[3]
Canada, yr study 
NR, study period: 
1999-2001
CoS Post AQF (n=33), controls without AQF during 
same outbreak cohort (n=24). CharacterisƟ cs and 
co-morbidity NR. To follow eﬀ ect of AQF on quality 
of life of paƟ ents 3 and 27 mo post AQF
QuesƟ onnaires 
on nature and 
duraƟ on of 
symptoms, SF-36
NA
2004, H. 
Thomas 
[56]
UK, 1999. Study 
period March-July 
1999
CC Random sample farmers (n= 425). Test 
seroprevalence T. gondii and C.b., and associaƟ on 
T. gondii, slow reacƟ on and poor concentraƟ on, 
and between C.b. and persistent faƟ gue, and 
associaƟ on organisms with depression/ depressive 
ideas. DuraƟ on infecƟ on unknown
CIS-R, venous 
blood
NA
2006, I. 
Hickie [12]
Australia, (sub study 
DIOS), yr study NR
CoS N=253; 68 EBV (mean age 22, range 16-49, 57% 
♀), 60 RRV (mean age 40, range 18-69, 45% ♀), 
43 C.b. (mean age 40, range 16-73, 14% ♀), 82 
not conﬁ rmed (mean age 38, range 16-77, 44% 
♀). Control of faƟ gue: baseline, 3 and 6 wks, 3 and 
12 mo post AI. Excluded; hypothyroidism/primary 
sleep-/psychiatric disorders. Controls (age and sex 
matched) recovered from AI at 6 mo
SPHERE, SOMA 
Laboratory 
and clinical 
examinaƟ on
NA
2010, G. 
Limonard 
[58]
Netherlands, 2008 CC 54 post AQF paƟ ents (61.1% ♂, mean age 53.1, 
SD14.2, co-morbidity 40.7%, current smoker 
44.4%). 23 seronegaƟ ve neighbourhood controls 
(sex matched, age ±10 yrs) (42.3% ♂, mean age 
53.6, SD9.7, co-morbidity 39.1%, current smoker 
26.1). Asses health status 1 yr post AQF
NCSI NA
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Other 
domain
QA  (CR or NOS)
S C O
Previous report [20] did not claim persistent infecƟ on to cause 
PQFS. SubstanƟ al proporƟ on AQF paƟ ents have QFS-like symptoms 
to QFS (milder version of acute phase symptoms without fever) 
for 6-9 mo post AQF and then recover. ±8-10% exhibit similar 
symptoms and do not reach immune/other homeostasis ≥1 yr
SystemaƟ c FU AQF paƟ ents needed, as 8-10% 
not recover ≥2 yrs post AQF
NA NA
Findings in faƟ gue prevalence study [7] diﬀ ers from 5-10% found by 
others [38]. However, prevalence of faƟ gue in UK’s general pracƟ ce 
populaƟ on is 38% vs. 36.3% in controls [7]. Idiopathic CF: 18.3% 
general pracƟ ce vs. 15% in [7]
Lack explicit measurement instruments make 
comparison faƟ gue between studies impossible. 
Increased faƟ gue scores in QF exposed cohort 
were measured with standardized and well-
validated instru-ments, permiƫ  ng replicaƟ on. 
FaƟ gue measurement is essenƟ al and should be 
standardized to compare studies
NA NA
3 mo post AQF only General Health scores of C.b. infected were 
↓ than controls (p=0.03). 27 mo post AQF scores 5/8 domains 
and physical/mental summary scales ↓ i.c.w. controls. 27 mo post 
AQF 52% C.b. infected sƟ ll reported symptoms, incl. 7 with iniƟ ally 
resolved symptoms 3 mo post AQF. Of 3 C.b. infected symptoms 
resolved at 27 mo, who iniƟ ally had persistent symptoms. ↓ scores 
General Health, Mental Health, Vitality and physical summary scales 
in those with persistent symptoms i.c.w. no symptoms. No iniƟ al 
symptoms nor anƟ bioƟ c treatment of AQF predicƟ ve for developing 
persistent symptoms post AQF
Post C.b. infecƟ on symptoms can persist >2 
yrs with signiﬁ cant quality of life impact. Data 
reﬂ ect further evidence of QFFS. Diﬀ erences 
may reﬂ ect socioeconomic, physiological/ 
psychological eﬀ ects of being labelled with QF 
rather than true post-infecƟ ous sequelae
A 





15% relevant faƟ gue levels, 5% concentraƟ on problems, 5% 
depressive ideas, 4% depression, 6% general psychiatric morbidity. 
Seroprevalence: 45% T. gondii, ↑ with age, no gender diﬀ erences; 
31% C.b., no associaƟ on age/gender. 46 seroposiƟ ve for both. 
Neither infecƟ on associated clinical relevant faƟ gue, concentraƟ on 
problems, depression, depressive ideas/overall psychiatric morbidity 
i.c.w. seronegaƟ ve individuals, not associated ↑ risk psychiatric 
outcome aŌ er age and sex adjustment. ↑ % C.b. seronegaƟ ve 
psychiatric symptoms i.c.w. seroposiƟ ve
No evidence T. gondii/C.b. infecƟ ons associated 
with neuropsychiatric morbidity, in parƟ cular 
poor concentraƟ on/faƟ gue
NA 




Provisional PIFS case rate 35% at 6 wks, 27% at 3 mo, 12% at 6 mo, 
and 9% at 12 mo, regardless of the infecƟ ve agent, age, gender 
or psychiatric disorders. Conﬁ rmed PIFS: 28 cases (14 ♂, 14 ♀, 
mean age 37, range 17-63); 5 EBV, 3 QF, 13 RRV, 8 unconﬁ rmed 
infecƟ ons. I.c.w. all parƟ cipant, no diﬀ erence in age/sex. I.c.w. 
controls, comparable: premorbid psychiatric diagnosis, intercurrent 
psychiatric disorders. Conﬁ rmed PIFS: median score acute sickness 
factor rapidly ↓ to zero, for faƟ gue, musculoskeletal pain and 
neurocogniƟ ve disturbance remained ↑
Pro-inﬂ ammatory cytokines do not remain ↑ in 
PIFS. Key risk factor PIFS is severity acute illness; 
not demographic, psychological (premorbid/
intercurrent psychiatric disorders) factors
A 





C.b. cases scored 1 yr post AQF signiﬁ cantly worse for all 
subdomains of symptoms. 52% cases clinically signiﬁ cant faƟ gue vs. 
26% controls. Abnormal faƟ gue score QF paƟ ents 74% vs. controls 
48%. Severe levels resp. 52% vs. 26%. NCSI scores of 11 seroposiƟ ve 
and 23 seronegaƟ ve controls not diﬀ erent for 8 subdomains health 
status
Sustained ↓ in health status 1 yr post AQF. 
NCSI scores from seroposiƟ ve controls without 
clinical QF history comparable with seronegaƟ ve 
controls, suggesƟ ng that clinical expression of 
AQF is essenƟ al in subsequent sustained ↓ 
health status
A 







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Country, yr study, 
period and duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2010, G. 
Limonard 
[57]
Netherlands, yr 
study NR. Study 
period 2007-2008
CoS 85 AQF paƟ ents (62% ♂, mean age 49 (18-80)). 
No controls. Co-morbidity: n=26 (6 cardiovascular, 
3 pulmonary, 1 neurological, 4 rheumatological, 1 
haematological, 3 depression, 5 diabetes, 3 other). 
HospitalisaƟ on: 24 AQF paƟ ents
Post AQF: 
history, physical 
examinaƟ on (6, 
12 mo), IFA, CFT 
(baseline, 3, 6, 
12 mo). Single 
transthoracic 
echocardiography
NA
2011, G. 
Morroy [59]
Netherlands, study 
period 2008-2011
CC 515 noƟ ﬁ ed QF paƟ ents (2007 and 2008) with 
known 1st day of illness (mean age 50.4 and 51.8 
yrs, 60% ♂, 57.2 % co-morbidity) vs. healthy 
individuals (n=65) and severe COPD paƟ ents 
(n=128) assessed 12-26 mo post AQF
NCSI NA
2011, 
HC van 
Woerden 
[69]
UK, yr study 2008 Nested-CC 32 post AQF 6 yrs post outbreak Newport Wales, 
2002 (mean age 50.18, SD 9.85). 13 controls (mean 
age 53.57, SD 8.86). Assess if i) CF ii) depression, 
and iii) ↓ physical funcƟ oning were more common 
in AQF paƟ ents 2002 i.c.w. controls
C.b. IFA, PHQ-9, 
Chalder FaƟ gue 
scale, GHQ
NA
2012, B. 
Strauss [61]
Germany, yr study 
NR
CC 84 post C.b. 2 yrs post Jena outbreak 2005 (mean 
age 48.4, SD15.2, ♀ 49%). 85 controls (mean age 
49.3, SD16.8, ♀ 61% same general pracƟ Ɵ oner 
not controlled C.b.). To invesƟ gate if faƟ gue/CF 
and/or CFS more frequent in C.b. infected vs. non-
infected controls, and contrast QF paƟ ents with /
without faƟ gue symptoms related to somatoform 
symptoms, hypochondrial worries/beliefs, 
psychosocial complaints and social support
MFI 20, SF-12, 
CDC-SI, SOMS, 
WI, OQ-45, 
F-Sozu K14, mini-
DIPS
NA
2012, G. 
Morroy [62]
Netherlands, yr 
study: 2008-2011, 
duraƟ on: 2007-2010
CoS 515 noƟ ﬁ ed AQF, known 1st day of illness in 2007 
or 2008 (mean age resp. 50.4 and 51.8; 60% ♂, 
57.2% with co-morbidity) FU 12 or 26 mo post AQF. 
QuanƟ ﬁ caƟ on of sick leave post AQF and long-term 
symptoms
NCSI and open 
quesƟ ons 
regarding work
NA
2012, Y. 
Arashima 
[28]
Japan, yr study NR CR ♂ 46 yrs, general faƟ gue, slightly elevated body 
temperature, night sweats, noise in ears, taste 
disturbance, headache, cough. Result: depressed 
with thoughts of death. Disease period 3 mo 
earlier. Co-morbidity: high-level depression (SDS 
65) aŌ er start symptoms. PS 6. IgMI, IgMII, and IgGI 
negaƟ ve, IgGII 1:64, n-PCR serum posiƟ ve
PS, SDS, n-PCR, 
IFA
Minocycline 1 
mo 200 mg/d, 
switched to 
100mg/d 
(to-tal 3 mo). 
AnƟ depres-
sant p.o.
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Post AQF 59% persistent symptoms at 6 mo and 30% at 12 mo FU. 
Self-reported faƟ gue iniƟ ally 69%, at 6 mo 52%, at 12 mo 26%. No 
CQF. 59% had cardiac valvulopathy. ↑ anƟ body Ɵ tres up to 3 mo, 
and ↓ in the following 9 mo
Screening echocardiography is no longer 
standard post AQF. At 6 mo faƟ gue is the most 
common complaint. Further studies needed 
with a control group to assess health status
NA 


 

Abnormal faƟ gue score 58.9% QF paƟ ents, of which 43.5% severe. 
Similar scores for parƟ cipants older and younger than 50 yrs. I.c.w. 
healthy controls (12.3% faƟ gue) QF paƟ ents scored signiﬁ cantly 
worse but beƩ er than COPD controls for subdomain faƟ gue. 
HospitalisaƟ on, heart and lung disease, arthriƟ s and depression 
signiﬁ cantly inﬂ uence degree of faƟ gue
Sustained ↓ in health status 12-26 mo post AQF 
regardless of age. Policy makers ought to take 
this into account when considering measures to 
curb the extensive outbreak. HospitalisaƟ on and 
co-morbidity predictors ↓ health status. More 
aƩ enƟ on needed prevenƟ on and treatment 
long-term consequences
A 






Chalder FaƟ gue scores cases signiﬁ cantly ↑ (P=0.047). PHQ-9 
and GHQ scores equal i.c.w. controls. CS analysis relaƟ onship IgGII 
in 2008 and Chalder FaƟ gue scores (P=0.004) and PHQ-9 scores 
(0.049). Longitudinal associaƟ on AQF and CF 6 yrs later. CS analysis 
relaƟ onship depression scores (PHQ-9) and posiƟ ve QF serology
CF more common 6 yrs later in QF posiƟ ve 
paƟ ents. Possible relaƟ onship ↑ C.b. IgGII, 
symptoms CF and depression. High anƟ body 
levels may indicate ↑ responder status rather 
than presence micro-organism. Points up the 
desirability trial anƟ bioƟ c treatment in QFS
P/T 





Post C.b. more faƟ gue symptoms and CF i.c.w. controls (54.8 vs. 
20%, 32.1 vs. 4.7%). Not more CFS criteria (1 paƟ ent each group). 
C.b. with faƟ gue symptoms had signiﬁ cantly ↑ scores SOMS, WI, ↑ 
psychosocial complaints with OQ-45. Health Related Quality of Life 
QF group ↓ than controls
FaƟ gue symptoms common among QF paƟ ents. 
No ↑ CFS prevalence among QF paƟ ents. 
CombinaƟ on faƟ gue and other psychosocial 
symptoms support biopsychological aeƟ ology. 
CBT might be opƟ onal for prolonged faƟ gue post 
QF for those with psychological distress
A, P/T 





Post AQF 39.6% more 1 mo absent work. HospitalisaƟ on during 
AQF, smoking and heart disease independent risk factors for long-
term sick leave. At 12-26 mo post AQF 9.3% unable to funcƟ on 
at pre QF levels due to faƟ gue and ↓ concentraƟ on. >30% not 
fully resumed daily acƟ viƟ es; 80.8% due to faƟ gue, 4.9% due to 
respiratory problems. 12-26 mo post AQF 40% reported health 
complaints; faƟ gue 19.8%, diﬃ  culty concentraƟ ng 9.5%, muscle 
pain 9.0%, night sweats 7.9%, eye problems 3.8%
QF has considerable impact on producƟ vity 
and perceived health status. HospitalisaƟ on, 
indicator of AQF severity, was a predictor for 
long-term sick leave and faƟ gue
NA 




<1-2 weeks treatment, arthralgia and slightly elevated body 
temperature ↓, other symptoms improved. At compleƟ on, clinical 
symptoms almost resolved. IgMI, IgMII, IgGI, IgGII all negaƟ ve, 
n-PCR negaƟ ve. PS 1. SDS 47. 1 yr FU: no exacerbaƟ ons
PQFS is associated with depression. Minocycline 
seems eﬀ ecƟ ve. Carefully monitor depression 
in PQFS
Diag, A, 
P/T
-/-, +, ++, ++, ++, 
NA, +/-, -/-
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Country, yr study, 
period and duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2012, S. 
Yakubo [29]
Japan, yr study NR CR ♂ 53 yrs, past QF infecƟ on, general faƟ gue, nausea, 
stomach pain, abnormal oral sensaƟ on, sore throat, 
trouble sleeping. Co-morbidity: depression
SDS AnƟ de-pres-
sant, C.b. 
anƟ bi-oƟ c
2013, 
M. van 
As-seldonk 
[32]
Netherlands, 2012. 
Study period: 2007-
2011
Economic 
evalua-Ɵ on
No paƟ ents/controls. Co-morbidity and 
characterisƟ cs: NR. Assess economic impact QF 
outbreak in the Netherlands, clarify costs-beneﬁ ts 
control campaign, quanƟ fy and compare costs 
livestock sector, human health costs and disease 
burden. ±25% post AQF who seek medical 
aƩ enƟ on expected to have CFS. Recovery period 
CFS 5-10 yrs (calculated with 7.5 yrs, working 50% 
contract Ɵ me). Disability rate/weight factor: 0.14. 
3.000 Euro/noƟ ﬁ ed case
DALY (YLD, YLL). 
DeterminisƟ c 
socio-economic 
model
NA
2013, R. 
Brooke [31]
Netherlands, yr 
study NR. Study 
period Jan 2009-Apr 
2010. DuraƟ on 
study NA
Burden of 
disease study
QF noƟ ﬁ caƟ ons Jan 2009-Dec 2009 (1407 ♂, 906 
♀) vs. inﬂ uenza noƟ ﬁ caƟ ons Apr 2009-Apr 2010 
(1219 ♂, 1508 ♀). CorrecƟ on for underreporƟ ng 
QF (factor 12.6) and inﬂ uenza (factor 4.4 to 5.6)
YLD, YLL (2009 
Dutch life 
expectancy), 
DALYs, BCoDE 
comparison 2 
infecƟ ous disease 
outbreaks
NA
2013, Y. 
Arashima 
[30]
Japan, yr study NR CR ♀ 31 yrs, general faƟ gue, cough, dyspnoea, slightly 
elevated body temperature, headache, dizziness, 
poor appeƟ te, copious sweaƟ ng, night sweaƟ ng, 
nausea, vomiƟ ng, palpitaƟ ons. QFS (IgMII 1:16, 
IgGII 1:128, n-PCR posiƟ ve) 18 mo post URTI, no 
result anƟ bioƟ c treatment. Bronchial asthma 1 mo 
post URTI, 3 mo steroid inhaler, no improvement. 
Co-morbidity: moderate/greater depression (SDS 
54). Suicide aƩ empt
PS, SDS, n-PCR, 
IFA
Steroid 
inhaler 3 mo. 
Minocycline 
200mg/d post 
diagno-sis 
QFS
2014, J. van 
Loen-hout 
[11]
Netherlands, yr 
study NR. Study 
period: 2011-2012, 
single measurement 
12 mo post onset of 
illness
CC QF paƟ ents (n=309, 53.7% ♂, mean age 49.9 
(13.8), current smoker 28.8%, pre-exisƟ ng health 
problems 40.6%, hospitalised 36.6%) vs. Legionella 
paƟ ents (n=190, 68.9% ♂, mean age 61.1 (11.5), 
current smoker 37.4%, pre-exisƟ ng health 
problems 59.5%, hospitalised 61.1%), and QF group 
matched (age, gender) healthy controls (normal 
lung funcƟ on, n=121, 55.4% ♂, mean age 51.4)). 
Assess and compare health status paƟ ents 1 yr post 
QF/Legionella
NCSI, SF-36 NA
2014, A. van 
Dam [64]
Netherlands, 2009-
2011, inclusion 
1st May-30th 
September 2009
CC 50 QF seroposiƟ ve LRTI (mean age 48.1, SD14.3) 
vs. 32 QF seronegaƟ ve LRTI paƟ ents (mean age 
57.2, SD14.4); 18-75 yrs. Comparable gender 
(60% vs. 50% ♂), current smoking (40% vs. 30%), 
hospitalisaƟ on during LRTI (10% vs. 7%), co-
morbidity (42% vs. 56%). QF posiƟ ve: more oŌ en 
pneumonia i.c.w. QF negaƟ ve. Assess if LRTI due to 
QF has higher health status impairment i.c.w. other 
LRTIs 15 mo post AI
NCSI (compleƟ on 
10-19 mo post 
LRTI, mean 15 
mo). QF posiƟ ve 
tested with PCR, 
IFA or CFT
NA
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Depression triggered by C.b. led to suicide Treat C.b. with anƟ bioƟ c. Check for depression, 
if present treat aggressive. Consider psychiatrist 
early. SDS is useful in these cases
Diag P/T -/-, +/-, +/-, +/-, 
+/-, NA -,
-/-
Total disease burden 2462 DALY, of which CFS 1481 DALY, CQF 806 
DALY. Income losses accumulate over Ɵ me due to long duraƟ on paid 
sick leave. Treatment costs: <2% total human health costs. Using 
extreme upper and lower bounds; CFS 30% of cases, duraƟ on ≥10 
yrs, disability weight 0.20, 18.167 Euro/DALY; CFS in 20% of cases, 
duraƟ on ≥5 yrs, disability weight 0.10; 87.602 Euro/DALY
Most long-term beneﬁ ts implemented control 
programme reduced disease burden and human 
health costs. Majority short-term intervenƟ on 
costs in dairy goat sector. EsƟ mated: total loss 
in public sector: 222 Million Euro; total loss 307 
Million Euro. EsƟ mated burden human health 
2462 DALY’s 2007-2011. CFS most prominent 
burden
NA 16/19 checklist 
items posiƟ ve **
QF: 5797 DALYs, 1771 from acute illness, 4027 from sequelae. PIFS 
57% total burden, mainly 45-49 age group. Inﬂ uenza: 24484 DALYs, 
3033 from sequelae. Total no DALYs due to inﬂ uenza higher than 
QF, but on per case basis QF more severe. QF is 8.28x worse than 
inﬂ uenza regarding composite health measures due to long-term 
sequelae up to 10 yrs post AI
IntervenƟ on prioriƟ zaƟ on for QF should target 
immediate intervenƟ ons for containment and 
support of long-term sequelae. Long-term 
sequelae contribute a high burden of disease
NA NA
At least 3 mo minocycline: improvement generalized symptoms and 
bronchial asthma. PS 1. n-PCR negaƟ ve. IgMII 1:16, IgGII 1:16. FU 
9 mo post treatment: bronchial asthma and faƟ gue disappeared. 
Depression alleviated
C.b. can cause bronchial asthma and should 
be considered when resistant to standard 
treatment accompanied by slightly elevated 
body temperature or general faƟ gue. Be aware 
of suicide aƩ empts
Diag, P/T -/-, ++, ++, ++, ++, 
NA, +/-, -/-
Worse score QF vs. Legionella paƟ ents on subdomains faƟ gue 
(60.2% vs. 50.0%, i.c.w. 2.5% healthy controls), General Quality 
of Life (50.0% vs. 42.6%), Role Physical. Adjustment confounders: 
only Role Physical remained diﬀ erent. In both QF and Legionella: 
proporƟ on severely aﬀ ected paƟ ents ↑ i.c.w. controls
Certain infecƟ ous illnesses are followed by long 
term impaired health status, including PICF. 
QF and Legionella paƟ ents are aﬀ ected on ≥1 
aspects health status, especially faƟ gue, General 
Quality of Life, Role Physical. Impact QF seems 
higher than from Legionella. Health staﬀ  need 
to be aware of this impact in order to provide 
adequate care
NA 





QF posiƟ ve LRTI: severely aﬀ ected General Quality of Life (40%) 
and faƟ gue (40%), QF negaƟ ve LRTI: faƟ gue (64%) and subjecƟ ve 
pulmonary symptoms (35%). 40% QF posiƟ ve and 56% QF negaƟ ve 
severely aﬀ ected on >1 subdomain. No diﬀ erence health status 
scores QF posiƟ ve and QF negaƟ ve LRTI paƟ ents for all subdomains 
except subjecƟ ve pulmonary symptoms
Large group LRTI paƟ ents aﬀ ected >1 aspect of 
health status 15 mo post LRTI. LiƩ le diﬀ erence 
in health status QF posiƟ ve and QF negaƟ ve 
LRTI paƟ ents. General pracƟ Ɵ oners ought to 
be aware of long-term health problems in LRTI 
paƟ ents in general
NA 







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2015, J. van 
Loen-hout 
[67]
Netherlands, study 
period: 2010-2013, 
FU at 3, 6, 9, 12, 18, 
and 24 mo post AQF
CoS 336 post AQF paƟ ents (in 2010-2011, 54.8% 
♂, mean age 48.5, SD13.9, co-morbidity 
39.7%), comparison NCSI scores matched (age, 
gender) healthy controls. To assess health status 
progression of QF paƟ ents over 24-mo period, and 
idenƟ fy inﬂ uencing factors
NCSI (3, 12, 
18, and 24 
mo), SF-36, 
quesƟ onnaires
NA
2015, J. 
van Loen-
hout[65]
Netherlands, yr 
study 2011-2013, 
Single measurement 
4 yrs post AQF
CC 448 noƟ ﬁ ed post AQF (2007-2008, 57.6% ♂, mean 
age 54.4, SD12.4, co-morbidity 51.1%) vs. 193 
symptomaƟ c non-noƟ ﬁ ed post QF (2008-2009, 
45.1% ♂, mean age 50.2, SD15.3, co-morbidity 
52.6%), vs. healthy controls. To compare long-term 
health status noƟ ﬁ ed and non-noƟ ﬁ ed QF paƟ ents
NCSI NA
2015, J. van 
Loen-hout 
[66]
Netherlands, yr 
study NR. Study 
period: 2010-2012, 
FU 3, 6, 9 and 12 
mo post AQF, 12 mo 
post AI Legionella
CoS, with 
partly CC
336 QF, 190 Legionella paƟ ents. Assess (progress 
of) work parƟ cipaƟ on of QF paƟ ents up to 12 mo 
post AQF, idenƟ fy associated factors, and compare 
work parƟ cipaƟ on between QF and Legionella 
paƟ ents 12 mo post AI
QuesƟ onnaire 3, 
6, 9 and 12 mo 
post AQF, ADIQ 
at 12 mo both 
groups
NA
*Deﬁ niƟ on of used study populaƟ on in arƟ cles explained in a diﬀ erent table, including deﬁ niƟ ons of QFS and/or faƟ gue is applicable. 
Main informaƟ on in this table is on background/descripƟ ve. Some arƟ cles also contain relevant informaƟ on on other domains: Diag= 
Diagnosis, A= AeƟ ology, P/T= PrevenƟ on/therapy
** Quality assessment economic evaluaƟ on study was assessed using the ‘Evers checklist’ [23]
AbbreviaƟ ons: ADIQ= Acceptance of Disease and Impairments QuesƟ onnaire, to assess the diﬀ erent stages of the grieving process due to 
the infecƟ on that paƟ ents underwent, AI= Acute infecƟ on, AQF= Acute Q-fever, BCoDE= Burden of Communicable Diseases in Europe proj-
ect, aƩ ributes DALYs of an infecƟ ous disease to the year the acute infecƟ on occurs. This allows for the aƩ ribuƟ on of long-term sequelae, 
which may generate a higher number of DALYs, to the causaƟ ve infecƟ on rather than only the iniƟ al acute illness, C.b.= Coxiella burneƟ i, 
CBT= CogniƟ ve behavioural therapy, CC= Case-control study, CDC= Centres for Disease Control and PrevenƟ on, CDC-SI= German version 
of the CDC-Symptom Inventory. The inventory asks in detail for 11 symptoms that commonly accompany CFS. These symptoms have to be 
described with respect to their intensity and frequency related to the last months, CF= Chronic faƟ gue, CFS= Chronic faƟ gue syndrome, 
CFT= Complement ﬁ xaƟ on test, CIS-R=Revised Clinical Interview Schedule to assess the symptoms of neuroƟ c psychopathology in the week 
prior to interview. The CIS-R is made up of 14 secƟ ons, each covering a parƟ cular area of neuroƟ c symptoms. Summed scores from all 14 
secƟ ons range from 0-57, the overall threshold for clinically signiﬁ cant psychiatric morbidity is 12, CNE= Culture negaƟ ve endocardiƟ s, CoS= 
Cohort study, CQF= Chronic Q-fever, CR= Case-report, CS= Cross-secƟ onal, DALY= A composite health measure that represents one lost year 
of healthy life between the current health status and that of an ideal health situaƟ on. Calculated as the sum of YLD for incident cases and 
the YLL due to premature death, DIOS= Dubbo InfecƟ on Outcomes Study, cohort study of subjects ≥16 yrs followed from the onset of a 
conﬁ rmed and documented AI due to EBV; C.b.; or RRV ≤6 wks post AI unƟ l complete recovery, EBV= Epstein-Barr virus, ECG= Electrocar-
diography, F-Sozu K14= To assess social support, a 14-item quesƟ onnaire resulƟ ng in a total score describing the quality and quanƟ ty of a 
person’s social support, FU= Follow-up, FUO= Fever of unknown origin, GHQ= General health quesƟ onnaire, 12-item quesƟ onnaire to de-
tect current cases of psychiatric co-morbidity, I.c.w.= In comparison with, ICF= Idiopathic chronic faƟ gue, IFA= Immunoﬂ uorescence assay, 
IgGI= AnƟ -phase IgG I Ɵ tre, IgGII= AnƟ -phase IgG II Ɵ tre, IgMI= AnƟ -phase IgM I Ɵ tre, IgMII= AnƟ -phase IgM II Ɵ tre, LRTI= Lower respiratory 
tract infecƟ on, MFI 20= German version of the MulƟ dimensional FaƟ gue Inventory, a commonly used 20-item quesƟ onnaire indicaƟ ng 
diﬀ erent dimensions of faƟ gue, Mini-DIPS= DiagnosƟ c interview, a short form of the diagnosƟ c interview of psychological disorders, Mo= 
Month(s), MOS= Medical outcome study 20-item quesƟ onnaire, used to deﬁ ne funcƟ onal impairment in the construcƟ on of the CFS deﬁ ni-
Ɵ on, NA= Not applicable, NCSI= Nijmegen clinical screening instrument, originally developed to provide a detailed assessment of health 
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Outcome Conclusions/recommendaƟ ons
Other 
domain
QA  (CR or NOS)
S C O
Signiﬁ cant linear improvement over Ɵ me in 9/12 health status 
subdomains. Severely aﬀ ected: faƟ gue 73.0% at 3 mo, 60.0% at 12 
mo, 37.0% at 24 mo (vs. 2.5% healthy reference group), General 
Quality of Life 42.2% at 3 mo, 50.2% at 12 mo, 33.7% at 24 mo 
(vs. 19.8% healthy reference group). For 3 most severely aﬀ ected 
subdomains (faƟ gue, General Quality of Life, Role Physical): females, 
young adults, pre-exisƟ ng health problems, at baseline were 
associated with ↓ long-term health status
Despite linear improvement over Ɵ me, >1/3 
paƟ ents had ↓ health status at 24 mo. Results 
suggest that psychological distress is not an 
important factor in explaining ↑ faƟ gue levels
A 





NoƟ ﬁ ed: more ♂, ↑ age vs. non-noƟ ﬁ ed. Equal proporƟ ons 
followed addiƟ onal treatment for long-lasƟ ng health eﬀ ects of QF, 
but addiƟ on anƟ bioƟ c treatment slightly ↑ in noƟ ﬁ ed paƟ ents. In 
both groups: faƟ gue (noƟ ﬁ ed 50.5% vs. non-noƟ ﬁ ed 54.6%) and 
quality of life (noƟ ﬁ ed 42.3% vs. non-noƟ ﬁ ed 44.4%) most severely 
aﬀ ected subdomains. No diﬀ erence long-term health status noƟ ﬁ ed 
vs. non-noƟ ﬁ ed, paƟ ents scored worse all subdomains i.c.w. healthy 
controls
Long-term health status is not determined by 
symptoms during acute QF. LiƩ le improvement 
health status between 1 and 4 yrs post AQF. 
ImplicaƟ on 2007-2009 Dutch QF outbreak 
underesƟ mated if only considering noƟ ﬁ ed 
paƟ ents. True burden of disease due to QF 
outbreak is larger
A 




↓ ProporƟ on QF paƟ ents with ↓ work parƟ cipaƟ on, 45% at 3 mo 
to 19% at 12 mo (vs. 15% Legionella paƟ ents at 12 mo). Median 
proporƟ on reducƟ on hours worked stable over Ɵ me. ↑ ProporƟ on 
paƟ ents not reporƟ ng symptoms up to 12 mo. No symptoms at 12 
mo: QF 44% vs. 57% Legionella. Most frequent symptoms at 12 mo 
QF: faƟ gue, concentraƟ on/memory problems, headache (all 24%), 
and muscle pain 23%. Legionella: concentraƟ on/ memory problems 
(21%), faƟ gue, respiratory pro-blems, joint pains (13%). Grieving 
process: QF ↑ score denial and resistance, ↓ acceptance i.c.w. 
Legionella. QF; associated factors ↓ work parƟ cipaƟ on: symptoms, 
↑ level sorrow, former smoker (i.c.w. never smoked), no alcohol 
consumpƟ on, following treatment for long-term health eﬀ ects. 
Median Ɵ me to full return to work in QF group <3 mo
Almost 1/5 QF paƟ ent and 1/6 Legionella paƟ ent 
↓ work parƟ cipaƟ on at 12 mo. OccupaƟ onal 
and insurance physicians need to be aware of 
long-term impact of QF and Legionella on work 
parƟ cipaƟ on. SuggesƟ on; undergoing QF leads 
to grief process similar to progressive disease, 
underlining the severity of sequelae due to QF
NA 





status of COPD paƟ ents. It combines a number of exisƟ ng health status quesƟ onnaires, NOS= Newcastle–OƩ awa Scale: S= selecƟ on (maximum of 
4 stars), C= comparability (maximum of 2 stars), O= outcome (maximum of 3 stars); ★: star earned; ☆: item not applicable, N/No= Number (of), 
(n-)PCR= (nested-) Polymerase chain reacƟ on, NR= Not reported, OQ-45= OQ-45, to measure psychological symptoms and general impairment. 
It is a common symptom inventory used in many psychotherapy studies to reﬂ ect total impairment, social as well as interpersonal distress and 
impairment of social role performance, PHQ-9= a self-administered subset of the PRIMA-MD diagnosƟ c instrument for common mental disorders 
to assess symptoms severity of depression, PICF= Post-infecƟ ous chronic faƟ gue, PIF(S)= Post-infecƟ ve faƟ gue (syndrome), P.o.= Oral, PO= Personal 
opinion, POB= Personal observaƟ on, PQCFS= Post-Q-fever chronic faƟ gue syndrome, PQDS= Post-Q-fever debility syndrome, PQFS= Post-(acute)
Q-fever (faƟ gue) syndrome, Pros.= ProspecƟ ve, PS= Performance status score (range 0-9), which reﬂ ects the grade of faƟ gue/malaise to assess the 
severity of CFS, QA-CR= Quality assessment; for CR no quality checklists are available. Therefore, the following eight criteria for quality assessment 
were determined; addressing an appropriate and clearly focused quesƟ on, representaƟ ve populaƟ on, descripƟ on of the survey method or data 
collecƟ on, outcome measures deﬁ ned, outcome measures described, response rate reported and results valid and applicable to the paƟ ent group 
targeted. The arƟ cles scores on these items: -/-, -, +/-, +, or ++, based on the CoordinaƟ on of Cancer Clinical PracƟ ce Guidelines in Europe criteria, 
QF= Q-fever, QF(F)S= Q-fever faƟ gue syndrome, Ref= Reference, RRV= Ross River virus, SD= Standard deviaƟ on, SDS= Self-raƟ ng depression scale, 
consisƟ ng of 20 quesƟ ons, score per quesƟ on: 1-4 points, SDQ= SomaƟ c Discomfort QuesƟ onnaire, a checklist of 25 somaƟ c symptoms, as somaƟ c 
symptoms are important minor symptoms in the construcƟ on of CFS deﬁ niƟ on, SF-12= The Short Form (12) Health Survey, SF-36= The Short Form 
(36) Health Survey, a paƟ ent-reported survey of paƟ ent health to assess quality of life of paƟ ents, funcƟ onal impairment and reduced health 
related quality of life, SOMA= Empirically derived subscale of the SPHERE, used to record PIFS or illness duraƟ on. This reliably predicts disability 
and reﬂ ects paƟ ents’ and doctors’ reports of reasons for presentaƟ on to primary care. Scores ≥3 represents a clinically-signiﬁ cant faƟ gue state. 
Provisional PIFS: SOMA scores ≥3 at all Ɵ me points up ≤3 months. Conﬁ rmed PIFS: symptoms persisted >6 months, and alternaƟ ve explanaƟ ons for 
ongoing illness was excluded, SOMS= Screening for Somatoform Disorders, a 53-item quesƟ onnaire assessing symptoms common for somatoform 
and somaƟ saƟ on disorder leading to the calculaƟ on of diﬀ erent indices, SPHERE= SomaƟ c and Psychological Health Report, to assess a wide range 
of physical and psychological symptoms, including severity and duraƟ on of symptoms, T. gondii= Toxoplasma gondii, UK= United Kingdom, URTI= 
Upper respiratory tract infecƟ on, VAS= Visual analogue score, 10cm scale to quanƟ fy symptom severity, Wks= Weeks, WI= Whiteley Index, to mea-
sure the paƟ ents’ tendency for hypochondriacal worries and beliefs, YLD= Number of years lost due to disability: number of incident cases x aver-
age duraƟ on of the disease x weight factor that reﬂ ects the severity of the disease on a scale from 0 (perfect health) to 1 (dead), YLL= Years of Life 
Lost due to premature death; number of deaths caused by the disease x standard life expectancy at the age at which death occurs, Yr(s)= Year(s)
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S4 Table. Domain aeƟ ology
Ref
Country, yr 
study, period and 
duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
1998, B. 
Bennet 
[45]
Australia, yr study 
NR (sub study 
DIOS). Study 
period NR
Pros. CoS 17 EBV, 8 QF, 5 RRV (82% ♂, mean age 29 
(15-77)). Explore longitudinal relaƟ onships 
between physical and psychological symptoms 
and immunological factors during peak illness 
(symptoms <4 wks before presentaƟ on) and 
recovery phase (2 and 4 wks aŌ er baseline) of AI 
(EBV, C.b., and RRV)
Baseline: interview, 
POMS, GHQ, SOFA, 
CIDI, DTH skin 
response. At 2 wks: 
interview, POMS, 
GHQ, SOFA. At 4 wks: 
interview, POMS, GHQ, 
SOFA, DTH test
NA
1998, I. 
Penƫ  la 
[19]
Australia, yr 
study NR. Single 
measure-ment 
study
CC 18 QFS paƟ ents (mean age 39 (33-45), symptom 
score >100, mean 145 (133-157)). 27 controls; 6 
resolving QFS (symptom score <100, mean age 
39 (31-48)), 5 past AQF (>6 mo) without QFS 
(symptom score 15 (1-35), mean age 39 (25-54)), 
8 QF skin test - vaccinated (mean age 44 (31-56), 
symptom score 7 (1-13)), 8 QF - healthy controls 
(mean age 32 (23-40), symptom score 5 (1-9)). 
Mean age groups equal. Asses cytokine release 
paƩ erns PBMC sƟ mulated with QF (phase I and 
II), measles anƟ gens and PHA, in 72-h culture
Interview; clinical 
history, presence, 
frequency, and 
intensity of 16 minor 
and major QFS 
symptoms scored on 
linear numerical scale 
1-20. Analysis of: IL-1, 
IL-2, IL-4, IL-5, IL-6, 
IL-10, IFNy, TNFa, TNFb 
and TGFB
NA
2000, R. 
Harris [20]
Australia, yr study 
NR. Study period 
NR. Mean period 
sampling 37 mo 
post AI (2 aŌ er 9 
mo, remainder 
aŌ er ≥12)
CC QFS (n=29); 18 from [19], 11 addiƟ onal with QFS 
post AQF. PBMC (n=29), liver biopsy (n=14), BMA 
(n=20). Controls from [19]. PBMC: paƟ ents no 
QFS post AQF (n=5); post-vaccinaƟ on (n=7), C.b. 
seronegaƟ ve healthy controls without CFS (n=6). 
BMA (n=6) of paƟ ents with diseases other than 
QF. PosiƟ ve PCR controls; QIE or recrudescent 
infecƟ on in pregnancy (n=10)
PCR (target IS1111a), 
several primer sets in 
convenƟ onal PCR and 
TaqMan PCR system
NA
2002, J. 
Ayres [54]
UK, 1999. Study 
period 10 yrs post 
AQF
Nested CC N=85 C.b.-exposed (85.6% ♂, mean age 54.7, 
SD12.0, co-morbidity 29.4%) vs. n=75 matched 
(sex & smoking) QF seronegaƟ ve controls 
(86.7% ♂, mean age 55.3, SD11.4, co-morbidity 
29.3%). Determine if persistent faƟ gue post AQF 
represents sub-clinical cardiomyopathy
QuesƟ onnaires, 
12-lead ECG, 
echocardiography, 
spirometry, shuƩ le 
walk distance, MUGA 
scan (only in subset)
NA
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Outcome Conclusions/recommendaƟ ons
Other 
domain
QA (NOS)
S C O
Baseline: faƟ gue and malaise most common symptoms. 
Depressive and anxiety symptoms not prominent. 46% 
cases no DTH skin response, indicaƟ ve of impaired cell-
mediated immunity. Over 4 wk period, improvement 
somaƟ c and psychological symptoms, but 63% 
remained faƟ gue. Most symptoms improved; somaƟ c 
changes notable in faƟ gue and malaise, rather than 
psychological (anxiety and depression). Psychological 
changes due to changes in percepƟ on faƟ gue and 
vigour. ↓ reported faƟ gue correlated with ↑ DTH skin 
response (indicaƟ ng relaƟ on between faƟ gue and cell-
mediated immunity) and GHQ scores
FaƟ gue commonly remains a prominent complaint 
at 4 wks. ResoluƟ on of faƟ gue is associated 
with improvement in cell-mediated immunity, 
supporƟ ng an immunological basis for PIF
NA 





Aberrant cytokine release paƩ erns of PBMC QFS 
paƟ ents sƟ mulated with QF anƟ gens; ↑ IL-6 release 
(mean 502 pg/ml, i.c.w. 47-53 pg/ml in other groups, 
p=0.018). Mean PBMC response of QFS to PHA ↑ than 
controls, not signiﬁ cant. 72% QFS paƟ ents: IL-6 release 
values >100 pg/ml; 66pg/ml max value for 95% CI of 
control groups. QFS ↓ IL-2 responders with QF anƟ gens 
(p=0.014), but equal IL-2 release post PHA sƟ mulaƟ on. 
QFS: ↑ IFNy responders (p=0.0008); no diﬀ erence 
median [IFNy] released (p=0.14). IL-1 ↑ on PHA 
sƟ mulaƟ on PBMC from QFS than controls (p=0.03), no 
diﬀ erence with QF anƟ gens. >IL-5 responders among 
QFS with QF anƟ gens. CorrelaƟ on IL-6 in condiƟ oned 
medium, total symptom score, and scores other key 
symptoms. In QFS: persistent IL-6 upregulaƟ on, no 
Ɵ me-correlaƟ on with AQF
Hypothesis: cytokine deregulaƟ on due to chronic 
immune sƟ mulaƟ on and modulaƟ on by persistent 
C.b./anƟ gens. Aberrant IL-6 response not claimed 
to explain QFS pathogenesis. IL-6 might contribute 
to QFS symptomatology. QFS development 
appears to require cellular immune response 
against C.b. anƟ gens. A speculaƟ ve unifying 
concept is that QFS and QIE represent diﬀ erent 
poles of dysfuncƟ onal cell-mediated immunity 
response to C.b. QFS paƟ ents have posiƟ ve 
LMR to QF anƟ gens, greatly ↑ IL-6 release 
paƩ erns from PBMC, IFNy upregulated, but IL-2 
downregulated. FaƟ gue can be intermiƩ ent 
(relapsing) or conƟ nuous in QFS
Diag, 
B/D




 


C.b. detecƟ on in QFS: PBMC 5/29, liver biopsy 2/14, 
BMA 13/20. In PBMC: no QFS 0/5, vaccinated 0/7, 
seronegaƟ ve 0/6. In BMA: other diseases 0/6. PCR 
posiƟ ve in QIE/placenƟ Ɵ s 10/10
C.b. DNA in bone marrow 0.75-5 yrs post AQF 
infecƟ on unveils new QF pathology state. C.b. 
live/dead/other bio-enƟ Ɵ es not deﬁ ned. PaƩ ern 
suggesƟ ve paucibaccillary infecƟ on presumably 
under immune control, but not eliminated. 
Supports previous reports relaƟ onship QFS, 
cytokine dysregulaƟ on and immunomodulaƟ on 
from C.b. persistence. Bone marrow could be 
focus crypƟ c infecƟ on which might seed other 
sides. Before drawing conclusions on QFS, 
invesƟ gate bone marrow in more paƟ ents with/
without QFS/other sequelae
Diag 





68.2% C.b. cases faƟ gue any duraƟ on, 42.4% faƟ gue 
excluding co-morbidity. 20% CDC-deﬁ ned CFS vs. 
5.3% controls, 8.2% excluding co-morbidity vs. 0% 
controls. Normal ECG’s 76.5% cases, 69.3% controls, no 
diﬀ erences. Echocardiography: controls ↓ fracƟ onal 
shortening. FaƟ gued vs. non-faƟ gued QF cases: 
comparable echocardiography, ECG, shuƩ le walk 
distances, pack years smoking. Normal MUGA scan 6 
C.b. cases (CDC-deﬁ ned CFS without co-morbidity)
Findings do not support the existence of a sub-
clinical cardiomyopathy in paƟ ents with faƟ gue 
aŌ er AQF, therefore not explaining breathlessness 
and faƟ gue. Chronic heart disease following AQF is 
rare and limited to IE
B/D 







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S4 Table. Domain aeƟ ology (conƟ nued)
Ref
Country, yr 
study, period and 
duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2002, D. 
Raoult [38]
France, 2002. 
DuraƟ on study NA
PO No paƟ ents/controls. CharacterisƟ cs and co-
morbidity: NR
NA NA
2003, K. 
Helbig [50]
Australia, yr 
study NR. Single 
measurement 
study
CC 23 acƟ ve/recovered QFS, 42 controls Red Cross 
blood donors, all Caucasians. To compare 
variability in phenotype distribuƟ on among range 
of cytokine and accessory immune response 
genes in PQFS and controls
Genotyping within 
NRAMP1 gene, HLA 
typing for HLA-DR and 
HLA-B; 25 polymorphic 
variants 14 genes 
analysed
NA
2003, K. 
Ikuta [55]
Japan, yr study 
NR. Single 
measurement 
study
CC 44 CFS (H1: 22 CFS, 14 ♂, 23-61 yrs; H2: 22 CFS, 
17 ♂, 20-46 yrs), 38 healthy controls (20 ♂, 20-59 
yrs). To invesƟ gate associaƟ on viral infecƟ ons 
with CFS and 2-5AS acƟ vity in PBMC in Japan in 2 
hospitals (H1, H2) diﬀ erent areas
C.b., IFA IgGII posiƟ ve 
Ɵ tre ≥1:64
NA
2005, B. 
Marmion 
[21]
Australia and 
UK, 2001, study 
period NR
CC (case 
follow-up 
study)
C.b. posiƟ ve UK cases (n=92) 12 yr post AQF 
(Birmingham 1989, n=92 blood samples, n=91 
PBMC, n=35 BMA), Australian cases (n=29) 9 
mo-5 yrs post AQF (n=29 blood samples and 
PBMC, n=20 BMA, n=14 liver biopsy) with CFS 
(CDC-criteria). To compare prevalence infecƟ on 
markers between cohorts
I. C.b. PCR (directed 
against several targets 
in the genome) DNA 
detecƟ on PBMC and 
bone mar-row, II. 
CFT, IFA Phase I & II, 
III. isolaƟ on C.b. cell 
cultures of mice - PCR 
posiƟ ve
NA
2005, K. 
Helbig [51]
Australia and 
UK, yr NR, study 
duraƟ on NR
CC (gene-Ɵ c 
asso-ciaƟ on)
31 QFS paƟ ents vs. uncomplicated recovery up 
to 12 yrs post AQF (n=22) vs. QIE (n=22, mean 
age 57, range 29-78, Ɵ me lag infecƟ on-IE 8.8 yrs, 
SD12, range 2-40) i.c.w. standard control panels 
general populaƟ on. To compare frequencies of 
allelic polymorphisms in immune response genes 
in diﬀ erent QF paƟ ent groups
Whole blood, DNA 
extracƟ on, HLA typing, 
microsatellite typing, 
SNP analysis
NA
2007, U. 
Vollmer-
Conna [18]
Australia, 1999 
(sub study DIOS); 
12 mo collecƟ on 
period. Appraisal 
1, 2, 3, 6, 12 mo 
post AI
Pros. CoS 22 PIFS paƟ ents (11 EBV, 6 RRV, 5 C.b.) vs. 42 
aged-matched controls who recovered <6 wks of 
EBV (n=17), RRV (n=14), and QF (n=11). Analysis 
inﬂ uence PIFS status on symptom severity and 
cytokine producƟ on i.c.w. controls
SPHERE, BDQ. SOMA 
score ≥3 to record PIFS
NA
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Outcome Conclusions/recommendaƟ ons
Other 
domain
QA (NOS)
S C O
6 mo post AQF 5-10% residual asthenia, very few >1 yr. 
SubjecƟ ve symptoms diﬃ  cult to quanƟ fy. CF: diﬃ  cult 
to deﬁ ne, with diﬀ erent prevalence. Unknown if CF 
psychological in origin/directly caused by bacterium. 
Might reﬂ ect observaƟ onal bias, C.b. strain or cultural 
diﬀ erences, or geneƟ c suscepƟ bility
Amplicon producƟ on PCR in peripheral blood 
CF paƟ ents needs conﬁ rmaƟ on. New tools 
might allow to examine aeƟ ology incompletely 
understood diseases caused by intracellular 
bacteria
B/D NA
No signiﬁ cant variaƟ on frequency individual SNP 
paƟ ents and controls, but more variants diﬀ ering 
from wild type in paƟ ents i.c.w. controls, p=0.025. 
Diﬀ erences allelic frequencies HLA-DR, signiﬁ cant ↑ 
frequency HLA-DR11 in QFS, but not HLA-B. Phenotype 
frequencies SNP in genes not signiﬁ cantly diﬀ erent 
from controls. VariaƟ on allele distribuƟ on QFS and 
controls INFy di-nucleoƟ de repeat. IFNy genes; ↑ 
prevalence homozygous state IFNy allele 2 in intron 1 
in QFS
Possible geneƟ c role expression overt chronic 
manifestaƟ ons, e.g. individual variaƟ on C.b. 
immune response. Given complexity of geneƟ c 
control of immune system, a simple 1-to-1 
relaƟ on between QFS expression/other chronic 
complicaƟ on QF and a parƟ cular polymorphic 
variaƟ on in a cytokine or immune control gene is 
unlikely. Eﬀ ects are more likely mulƟ genic
Diag 


 
2-5AS acƟ vity: 19 (mean 2.23) in H1, 7 (mean 0.91) in 
H2, 4 in controls (mean 0.74). Diﬀ erences H1 and H2, 
and H1 and controls (p<0.01). No diﬀ erence H2 and 
controls. IFNa similar in few CFS paƟ ents and controls. 
No relaƟ onship 2-5AS and IFNa posiƟ vity. EBV anƟ -EA-
IgG anƟ bodies in 9% and 32%in H1 and H2. IgG C.b. 
posiƟ ve 6/22 H1, 0/22 H2, 1/9 controls. No diﬀ erence 
C.b. posiƟ ve H1 and controls/paƟ ents H2 and controls. 
No correlaƟ on 2-5AS acƟ vity and C.b. Ɵ tres (p>0.05)
2-5AS acƟ vity ↑ PBMC CFS paƟ ents. CFS may 
be associated EBV/C.b. ↑ 2-5AS suggests 
immunological dysfuncƟ ons with virus infecƟ ons 
in CFS. No relaƟ on Ɵ tres C.b. and 2-5AS acƟ viƟ es. 
2-5AS acƟ vity changed from posiƟ ve to negaƟ ve in 
1 CFS paƟ ent when C.b. anƟ bodies disap-peared, 
suggests C.b. associaƟ on 2-5AS acƟ vity some 
CFS paƟ ents. Imply 2-5AS in some CFS paƟ ents 
acƟ vated by other mechanisms, in addiƟ on to 
EBV and C.b.
NA 



Both groups remained seroposiƟ ve irrespecƟ ve clinical 
state. C.b. genomic DNA detected by PCR in 65% of 
BMA from Australian vs. 88% Birmingham paƟ ents. No 
C.b. isolated from PCR posiƟ ve samples
Results indicate more complex interacƟ on 
between host-regulated, persistent carriage of 
C.b. and disease. An addiƟ onal variable factor of 
host regulaƟ on of cellular immune response must 
determine levels of persistence and symptomaƟ c 
outcomes. Hypothesis: in QF without sequelae, 
process largely conﬁ ned to bone marrow. In QFS, 
modulaƟ on by the paƟ ent’s immunogeneƟ c 
background causes ↑ levels of C.b. genomes in 
bone marrow and ↑ shedding into peripheral 
blood
Diag 



Signiﬁ cant diﬀ erences between 3 groups. QFS paƟ ents 
diﬀ ered from QIE, the uncomplicated and controls 
in frequency of HLA-DRB1*11 and 2/2 genotype of 
IFNy intron 1 microsatellite. Carriage HLA DRB1*11 
allele associated with ↓ IFNy and IL-2 responses from 
PBMC. QIE showed diﬀ erences in IL-10 promoter 
microsatellites R and G, and ↑ frequency TNFa 
receptor II 196R polymorphism. QF paƟ ents with 
uncomplicated recovery, diﬀ ered from those with QFS/
QIE, but similar in allelic frequencies to control panels
Conclusions C.b., parvovirus B19 infecƟ on and 
CFS studies suggest that ‘idiopathic’ CFS paƟ ents 
from the wider populaƟ on, away from outbreaks/
occupaƟ onally exposed groups, are unlikely 
to have laboratory evidence of infecƟ on with 
the same infecƟ ve agent. A common immuno-
geneƟ cally determined failure of cytokine 
homeostasis to infecƟ ve agents with the capacity 
to persist long in hosts is more likely
Diag 


 
No group diﬀ erences cytokine levels. Severity 
symptoms ↓ in Ɵ me. ↑ Age associated with ↑ 
musculoskeletal pain and neurocogniƟ ve disturbance. 
PIFS stereotyped post diﬀ erent triggers, with equal 
acute-phase cytokine producƟ on. Psychological/ 
microbial factors not predicƟ ve PIFS. PIFS: ↑ mean no. 
bed-days acute phase, and more days “out of role”
Ongoing producƟ on IL-1b, IL-2, IL-4, IL-6, IL-10, 
IL-12, TNFa and INFy have no role in PIFS. Evidence 
against hypothesis associaƟ ng prolonged faƟ gue 
with altered cytokine levels. AI triggers, not drives 
symptoms. PIFS can persist wks to mo
B/D   
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Ref
Country, yr 
study, period and 
duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2009, B. 
Marmion 
[37]
Australia and UK, 
yr study NR
Laboratory 
case study
10 Birmingham (1989) C.b. PCR posiƟ ve and 1 
IE. To retest PCR posiƟ ve samples with more 
sensiƟ ve methods for viable C.b. and C.b. cell 
components anƟ gen and speciﬁ c LPS ≥12 yrs post 
AQF, and re-interpret previous results. Review 
literature for a concept of immunomodulatory 
complex generated by current studies
3 SCID mice; spleen 
and liver examinaƟ on 
by PCR (targets 
COM1 and IS1111a 
sequences), IFA
InoculaƟ on 
paƟ ent 
sam-ples in 
SCID mice for 
60 d
2009, L. 
Zhang [48]
United Kingdom, 
yr study and 
period NR. Single 
measurement 
study
CC 117 paƟ ents idiopathic CFS/ME; 6 Q-CFS/
ME. Controls: endogenous depression (n=14), 
blood donors (n=29). AƩ empt to reproduce 
genomic subtypes CFS/ME (with disƟ nct: SF-36, 
clinical phenotypes, severity and geographical 
distribuƟ on), determine speciﬁ city signature CFS/
ME, and test associaƟ ons CFS/ME subtype and 
infecƟ on by determining expression levels 88 
human genes
Chalder FaƟ gue Scale, 
SF-36, SomaƟ c and 
Psychological Health 
Report, PSQ, McGill 
Pain QuesƟ onnaire, 
PAXgene blood 
RNA kit, micro-
spectrophoto-metry, 
qPCR
NA
2010, Y. 
Kadota 
[46]
Australia, 1999 
(sub study 
DIOS); single 
measurement
Pros. CC 23 PIFS paƟ ents (9 RRV, 7 EBV, 4 QF, 3 viral 
infecƟ on unknown origin) vs. 25 matched 
(age, sex, BMI, acƟ vity levels) healthy controls. 
EvaluaƟ on associaƟ on of PIFS with bidirecƟ onal 
autonomic signalling disturbance
Pulse oximeter, pain 
test algometer, Stroop 
task, SPHERE, SOMA 
K10, BDQ, DS14
NA
2010, O. 
Sukoche-va 
[36]
Australia, yr study 
NR, duraƟ on NR
CC 
(laboratory 
case study)
No paƟ ents/controls. Samples post AQF 
paƟ ents (Birmingham, 1989), 3 groups; recGr3: 
asymptomaƟ c recovery post AQF. QFSGr5: QFS, 
no co-morbidity. QFSGr6: QFS faƟ gue associated 
co-morbidity. 12 yrs post outbreak, groups 
sampled C.b. anƟ body, blood leucocytes, PCR 
on BMA. PCR posiƟ ve samples (bone marrow, 
PBMC, or aorƟ c valve specimens) 10 paƟ ents 
from subsets inoculated intraperitoneal NOD/
SCID mice. Control animals received blood PCR 
negaƟ ve, seronegaƟ ve controls. To isolate living 
C.b. to ascertain pathological eﬀ ects, retest and 
determine nature residual C.b. cell components
Cell culture assay, 
PCR (target COM1 
and IS1111a), CBA, 
skin granuloma 
test in guinea 
pigs, immunoche-
mistry,histoche-mistry, 
image acquisiƟ on
InoculaƟ on 
paƟ ent sam-
ples in NOD/
SCID mice, 
FU for infec-
Ɵ on evidence 
and presence 
DNA and 
speciﬁ c 
anƟ -gens 
in spleen 
and liver 
macrophages
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All paƟ ents’ specimens including heart valve with 
endocardiƟ s were infecƟ on negaƟ ve in SCID mice. Mice 
spleens and livers PCR negaƟ ve. Spleen secƟ ons of all 
specimens showed Coxiella anƟ gen LPS complex by IFA
Long-term persistence non-infecƟ ve, 
biodegradable immunomodulatory complex 
traces genomic DNA. Immuno-modulatory 
complex survival >12 yrs, in 1 paƟ ent 70 yrs, 
implies repeated passage macrophages ↓ 
regulaƟ on biodegrading funcƟ on. Systemic 
symptoms QFS may reﬂ ect wide distribuƟ on 
parasiƟ zed mononuclear phagocytes. QFS follows 
clinical overt infecƟ on, rarely subclinical infecƟ on
NA NA
In CFS/ME diﬀ erenƟ al expression conﬁ rmed for all 
88 genes. 8 genomic CFS/ME subtypes with marked 
diﬀ erences global funcƟ oning, clinical symptoms, 
severity levels and geographical distribuƟ on. Q-CFS/
ME similar paƩ erns gene expression in peripheral 
blood to idiopathic CFS/ME, and markedly diﬀ erent 
from normal group. 5/6 Q-CFS/ME paƟ ents clustered 
in subtype A, but no subtype-speciﬁ c relaƟ onships 
found with C.b. anƟ bodies. Evidence subtype-speciﬁ c 
relaƟ onships EBV and enterovirus. Gene expression 
in endogenous depression similar to normal controls, 
except ↑ regulaƟ on 5 genes (APP, CREBBP, GNAS, 
PDCD2, and PDCD6). Q-CFS/ME paƟ ents ↑ McGill Pain 
QuesƟ onnaire scores i.c.w. other groups. SF-36 ↑, 
Mental and physical faƟ gue, and SPHERE scores ↓ i.c.w. 
all groups, except normal blood
Q-CFS/ME had similar paƩ erns gene expression as 
idiopathic CFS/ME
Diag, 
B/D





PIFS paƟ ents: ↑ symptoms in general, faƟ gue related, 
or psychological distress, more days not fulﬁ lling normal 
roles past mo, ↑ experience negaƟ ve emoƟ ons, ↑ 
reporƟ ng funcƟ onal impairment daily acƟ viƟ es, ↑ 
resƟ ng heartbeat, ↑ sensiƟ vity to physiological signals. 
RelaƟ on between heartbeat discriminaƟ on accuracy 
and pressure pain sensiƟ vity. Diﬀ erent heart rate 
paƩ ern in response to ongoing mental stressors
PIFS: ↑ interocepƟ ve sensiƟ vity (with strong 
symptoms correlaƟ on), disƟ nct paƩ ern cardiac 
response; evidence physiological hyper-vigilance 
and response inﬂ exibility. ↑ ResƟ ng heart rate 
with ↓ heart rate variability: ↓ parasym-pathic 
drive. Autonomic dysfuncƟ on involves both 
disturbance processing incoming homeostaƟ c 
informaƟ on, and altered reacƟ vity to stressors
B/D   


Culture samples 10 QF paƟ ents NOD/SCID mice, 12 
yrs post AQF no viable C.b. No AI induced. Complexes 
material C.b. anƟ gens found in mouse spleens, 
signiﬁ cantly higher amounts in samples QFS, also in 
bone marrow and liver in all cases. Immunomodu-
latory complex sƟ mulate cytokine release in mice and 
THP-1 macrophages, and to provoke inﬂ ammatory 
reacƟ on on intradermal injecƟ on into skin of QF 
hyperimmunized guinea pigs (with Qvax). QFSGr5 
and 6: weight ↓ 1st week post inoculaƟ on, later 
recovered and steady weight gain consistent with 
absence infecƟ on. All mouse spleen specimens PCR 
negaƟ ve (1:100 diluƟ ons). Despite absence acƟ ve 
infecƟ on, changes: moderate spleen enlargement 
QFSgr5 and 6 i.c.w. controls (p<0.05), no massive 
splenomegaly by live C.b. SecƟ ons mouse spleens with 
variable amounts aggregates stained to detect speciﬁ c 
anƟ gen, also in NOD/SCID mouse bone marrow and 
liver inoculated with QFS specimens. C.b. anƟ gens 
no correlaƟ on low levels C.b., suggests complexes 
to represent incompletely degraded cell material. 
C.b. anƟ gens localized in spleen phagocytes, and C.b. 
immunomodulatory complex in lysosomes mouse 
splenocytes. L-6/IL-10 raƟ o and ↑ level IL-10 might 
signal important role in facilitaƟ ng survival non-
degraded bacterial material
In QFS viable, infecƟ ve C.b. are rarely, if ever, 
isolated from PBMC or bone marrow, but complex 
of anƟ gen and Phase 1 LPS (immunomodulatory 
com-plex) is regularly present. This non-infec-Ɵ ve 
complex of C.b. anƟ gens survives in host and 
provokes aberrant humoral and cell-mediated 
immunity responses – a possi-ble pathogenic link 
between iniƟ al infec-Ɵ on and PQFFS. Diﬀ erent 
responses between endocardiƟ s, asymptomaƟ c/ 
recovered and QFS paƟ ents considered due 
to immunogeneƟ c diﬀ erences in handling 
immunomodulatory complex and cytokine 
responses. HypotheƟ cal pathogeneƟ c sequence 
QFS; overt clinical QF and immunogeneƟ c 
polymorphism --> defecƟ ve anƟ gen clearance 
(immune-modulatory complex persistence) --> 
persistent cell-mediated immunity and cytokine 
dysregulaƟ on --> cytokine-mediated somaƟ c gene 
modulaƟ on --> QFS
NA NA
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Country, yr 
study, period and 
duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool intervenƟ on 
2011, S. 
Galbraith 
[47]
Australia, yr study 
NR (sub study 
DIOS). Study 
period: baseline 
measure (T1 0<6 
wks), T2 6<12 
wks, T3 3<9 mo 
or >9 mo, T4 >12 
mo, FU aŌ er 2 and 
4 wks
Longitudinal, 
nested CC
Caucasians with PIFS (n=18; EBV, RRV, C.b.) 
(mean age: 40, SD18 years). Matched (age, sex 
& infecƟ on type) controls (n=18) who recovered 
promptly (mean age: 39, SD16). 11 ♂ per group. 
127 samples analysed, 3-4 Ɵ me points/subject. 
In longitudinally collected samples peripheral 
blood transcriptomes studied for gene expression 
paƩ erns in PIFS paƟ ents and controls. Diﬀ erenƟ al 
expression sought between early illness and 
late recovery (within-subject comparison), PIFS 
cases and recovered controls (between subjects 
comparison), and genes correlated with end 
phenotypes derived by principal components 
analysis (between-cohorts)
Microarray and 
conﬁ rmatory qPCR. 
SPHERE, SOMA
NA
2012, B. 
Piraino 
[60]
Australia, yr 
study NR (sub 
study DIOS). 
Study period 
NR. Baseline, FU 
2-3wks, 4-6wks, 
3-mo interval unƟ l 
12 mo post AI
CoS Caucasians (mean age 34.2, 49% ♀), <6 wks post 
AI (n=296), EBV, RRV, QF. Princi-pal components 
analysis acute phase, self-report symptom data to 
empirically derived indices faƟ gue, pain, neuro-
cogniƟ ve diﬃ  culƟ es, mood disturbance, overall 
illness severity. Apply endophenotype concept 
to clinical dataset describing symptom domains 
of acute sickness response post viral/non-viral 
pathogens, and validaƟ on by showing associaƟ on 
with SNP in cytokine genes (IL-6, TNFa, IFNy, 
IL-10)
SPHERE (and SOMA), 
PSC, BDQ, principal 
component analysis, 
NanoDropR ND-1000 
(DNA quanƟ ﬁ caƟ on), 
Sequenom 
MassARRAY® 
(genotyping of SNP)
NA
2012, H. 
Hussain-
Yusuf [49]
UK, 2008 CC Cohort 211 UK factory workers C.b.-exposed 
2002. FU 6 yrs post outbreak, comparison QF 
serology, presence viable C.b., its DNA and faƟ gue 
in post AQF cases (n=38, 3 uncertain serology 
2002) vs. seronegaƟ ve, same outbreak (n=14). 
Assess if C.b. anƟ gens (immunomodulatory 
complex) remain undegraded in some post AQF, 
with abnormal cytokine proﬁ le causing ongoing 
faƟ gue
Chalder FaƟ gue Scale, 
qPCR (com1 gene) 
on PBMC and VERO 
cultures (detect C.b. 
DNA), IFA, SCID mice 
inocula-Ɵ on (detect 
viable C.b.)
NA
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23 genes with modest diﬀ erenƟ al expression (0.6-2.3-
fold change) in within-subject comparisons of early, 
symptomaƟ c Ɵ me points with late, recovered Ɵ me 
points. Modest diﬀ erences 63 genes, in CS comparison 
cases-controls 6 mo post AI in regression model. 223 
genes correlated with individual symptom domains. 
qPCR conﬁ rmed 33/45 genes, none consistent across 
cohorts. Within subject comparison: 12 subjects (5 
with QF) T1 SOMA scores ≥3, T4 SOMA scores <3. No 
genes with adjusted signiﬁ cance <0.05. RelaƟ ve lack 
variance gene expression levels over ≥12 mo. Between 
subject comparisons: 17 cases (6 QF), 11 controls 
(2 QF). No genes with adjusted signiﬁ cance <0.05. 
QF subjects predominantly ♂ and older. 13 genes 
adjusted signiﬁ cance <0.05, 1 (CYBA) associated with 
faƟ gue in 2 of 3 infecƟ ve cohorts (EBV, QF). Analysis 
idenƟ ﬁ ed illness severity, faƟ gue and neurocogniƟ ve 
disturbance, correlated for EBV and QF cohorts. 
CorrelaƟ on test: 96 genes unadjusted signiﬁ cant at 5% 
for EBV and QF for severity, 93 for faƟ gue symptom 
domain, 106 for neurocogniƟ ve disturbance. Repeated 
correlaƟ on analysis: no genes correlated for EBV and 
QF in associaƟ on with severity, faƟ gue, neurocogniƟ ve 
disturbance
Several infecƟ ons trigger PIFS, which share key 
illness characterisƟ cs with each other and CFS. 
Previous CS CC studies of CFS suggested unique 
gene expression signature in peripheral blood 
samples. Although illness characterisƟ cs of PIFS 
paƟ ents have more similariƟ es than diﬀ erences, 
no reliable peripheral blood gene expression 
correlate is evident. No genes consistently 
associated with illness. CFS incidence closely 
comparable between EBV, RRV, C.b. Lack of 
coherent set of gene expression correlates across 
cohorts argues against validity of previously 
proposed signatures for PIFS or CFS. PIFS likely to 
be truly post-infecƟ ve, un-associated with ongoing 
acƟ ve replicaƟ on of triggering agent
NA 







Individual symptom indices correlated with overall 
severity and funcƟ onal status. Domain scores stable 
over Ɵ me within subjects, but varied between subjects 
with same infecƟ on, and across infecƟ on sub-cohorts. 
Overall illness severity may have been comparable in 
some subjects, relaƟ ve contribuƟ ons from individual 
symptom domains making up the illness complex varied 
between these subjects. T allele IFNy+874T/A SNP best 
predictor of ↑ faƟ gue. ♀ more likely grouped in ↑ 
faƟ gue extreme. C allele of IL-10-592C/A SNP exerted 
protecƟ ve eﬀ ect on neurocogniƟ ve diﬃ  culƟ es. A allele 
IL-10-592 SNP and G allele IL-6-174G/C SNP associated 
↑ mood disturbance
Acute illness response has discrete symptoms 
including faƟ gue with unique geneƟ c associaƟ ons. 
Study oﬀ ers new pathophysiological inside faƟ gue 
states. Illness severity phenotype not dependent 
on age/sex/infecƟ on subtype. Robust correlaƟ on 
between illness severity and reported disability 
in AI. ♀ over represented in high severity group 
faƟ gue, mood disturbance, neurocogniƟ ve 
diﬃ  culƟ es
NA 




18% became seronegaƟ ve, remainder 10 phase I, 
21 phase I en II anƟ bodies. 29% controls became 
seroposiƟ ve. No paƟ ent/control PBMC contained viable 
C.b./DNA. No viable C.b. in PMBC tested in cell culture 
and SCID mice inoculaƟ on. Chalder FaƟ gue Scale score 
aŌ er 6 yrs (n=11): 4 signiﬁ cant faƟ gue, 4 some, 3 not 
faƟ gued. No relaƟ onship between faƟ gue levels and 
serology, nor with presence of viable C.b./DNA
6 yrs post AQF, some paƟ ents became 
seronegaƟ ve but none contained viable C.b./DNA 
in their PBMC. CorrelaƟ on PQFF and persistent 
DNA could not be examined. A more sensiƟ ve 
DNA assays or more invasive sampling needed to 
test hypothesis. IgGII most useful to test past QF 
exposure
B/D 





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2014, M. 
Kremers 
[63]
Netherlands, yr 
study 2013-2014. 
Study period: 
April- August 
2009, FU 4 yrs 
post AQF
CoS 102 seronegaƟ ve PCR posiƟ ve, symptomaƟ c, AQF 
paƟ ents (64.7% ♂, mean age 48, SD16, range 
17-85); 24 hospitalised. 93 FU 3, 6 or 12 mo for 
IFA IgGI and II. NCSI 4 yrs post AQF (n=58). Assess 
if ↑ CRP AQF coincides with ↑ IL-6 and if levels 
correlate with C.b. DNA load and disease severity, 
expressed by hospital admission and faƟ gue 
development
NCSI, PCR (Ct value), 
IFA, CRP, IL-6
NA
* Deﬁ niƟ on of used study populaƟ on in arƟ cles explained in a diﬀ erent table, including deﬁ niƟ ons of QFS and/or faƟ gue 
is applicable. Main informaƟ on is on aeƟ ology. Some arƟ cles also contain relevant informaƟ on on other domains: Diag= 
Diagnosis, B/D= Background/descripƟ ve, P/T= PrevenƟ on/therapy
AbbreviaƟ ons: 2-5AS= 2’,5’-oligoadenylate synthetase, AI= Acute infecƟ on, AQF= Acute Q-fever, BDQ= Brief Disability Ques-
Ɵ onnaire, assessment of the impact of illness on funcƟ onal capacity, and days out of role quanƟ ﬁ ed the days over the past 
months the respondent was unable to carry out usual daily acƟ viƟ es fully, BMA= Bone marrow aspirate, BMI= Body Mass 
Index, C.b.= Coxiella burneƟ i, CBA= Cytometric bead array, uses the sensiƟ vity of ampliﬁ ed ﬂ uorescence detecƟ on by ﬂ ow 
cytometry to measure soluble analytes (e.g. interleukins) in a parƟ cle-based immunoassay, CC= Case-control study, CDC= 
Centres for Disease Control and PrevenƟ on, CF= Chronic faƟ gue, CFS(/ME)= Chronic faƟ gue syndrome (/myeloencephaliƟ s), 
CFT= Complement ﬁ xaƟ on test, CIDI= Composite internaƟ onal diagnosƟ c interview to screen for any history of depression, 
anxiety or somaƟ saƟ on disorder. This computerised program formulates ICD-10 and DSM-III-R diagnoses and records cur-
rent as well as pre-exisƟ ng psychiatric morbidity, CoS= Cohort study, CRP= C-reacƟ ve protein, CS= Cross-secƟ onal, DIOS= 
Dubbo InfecƟ on Outcomes Study, cohort study of subjects ≥16 yrs followed from the onset of a conﬁ rmed and documented 
AI due to EBV; C.b.; or RRV ≤6 wks post AI unƟ l complete recovery, DS14= Distressed personality scale, assessment of 
negaƟ ve aﬀ ecƟ vity (an enduring tendency to experience negaƟ ve emoƟ ons) and trait social inhibiƟ on (the tendency to 
feel inhibited, tense, and insecure when with others), DTH= Delayed-type hypersensiƟ vity, to assess cell-mediated immune 
funcƟ on in vivo, EBV= Epstein-Barr virus, ECG= Electrocardiography, FU= Follow-up, GHQ= General health quesƟ onnaire, 12-
item quesƟ onnaire to detect current cases of psychiatric co-morbidity, I.c.w.= In comparison with, IFA= Immunoﬂ uorescence 
assay, IFN= Interferon, IgG= AnƟ -phase IgG, IgGI= AnƟ -phase IgG I Ɵ tre, IgGII= AnƟ -phase IgG II Ɵ tre, IL= Interleukin, IS= 
InserƟ on sequence, K10= Kessler 10, to assess current psychological distress, LMR= Lymphocyte mitogenic responses, LPS= 
Lipopolysaccharide, Mo= Month(s), MUGA scan= MulƟ  Gated AcquisiƟ on Scan (gated cardiac radio-nuclide scans), a Ɵ me-
proven nuclear medicine test to evaluate the funcƟ on of the right and leŌ  ventricles of the heart, allowing informed diag-
nosƟ c intervenƟ on in heart failure, NA= Not applicable, NCSI= Nijmegen clinical screening instrument, originally developed 
to provide a detailed assessment of health status of COPD paƟ ents. It combines a number of exisƟ ng health status ques-
Ɵ onnaires, NOS= Newcastle–OƩ awa Scale: S= selecƟ on (maximum of 4 stars), C= comparability (maximum of 2 stars), O= 
outcome (maximum of 3 stars); ★: star earned; ☆: item not applicable, N/No= Number (of), (n-)PCR= (nested-) Polymerase 
chain reacƟ on, NR= Not reported, Pain test algometer= For pressure pain threshold test to measure pain sensiƟ vity, PBMC= 
Peripheral blood mononuclear cells, PHA= phytohaemaggluƟ nin, PIF(S)= Post-infecƟ ve faƟ gue (syndrome), PO= Personal 
opinion, POMS= Proﬁ le of Mood States to assess current mood status. This instrument includes 7 subscales: ‘faƟ gue’, ‘de-
pression’, ‘anxiety’, ‘vigour’, ‘anger’, ‘friendliness’, and ‘confusion’, PQFF= Post-Q-fever faƟ gue, PQF(F)S= Post-(acute)Q-fever 
(faƟ gue) syndrome, Pros.= ProspecƟ ve, PSC= Physical Symptoms Checklist, consisƟ ng of 51 symptom items, PSQ= PiƩ s-
burgh Sleep QuesƟ onnaire, to assess sleep abnormaliƟ es, QA = Quality assessment, Q-CFS(/ME)= Q-fever induced chronic 
faƟ gue syndrome (/myeloencephaliƟ s), QF= Q-fever, QF(F)S= Q-fever faƟ gue syndrome, (Q)IE= (Q-fever induced) InfecƟ ve 
endocardiƟ s, Ref= Reference, RRV= Ross River virus, SCID= Severe combined immunodeﬁ ciency, SD= Standard deviaƟ on, 
SF-36= The Short Form (36) Health Survey, a paƟ ent-reported survey of paƟ ent health to assess quality of life of paƟ ents, 
funcƟ onal impairment and reduced health related quality of life, SNP= Single nucleoƟ de polymorphism, SOFA= Schedule 
of FaƟ gue and Anergy to idenƟ fy cases of chronic faƟ gue syndrome. The subject rates 10 items on a 4-point scale. Subjects 
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92 paƟ ents ↑ IL-6, 101 ↑ CRP during AQF. Signiﬁ cant 
weak negaƟ ve correlaƟ on C.b. DNA loads, IL-6 and CRP, 
signiﬁ cant moderate-strong posiƟ ve correlaƟ on IL-6 
and CRP. Hospitalised paƟ ents: ↑ IL-6 and CRP than 
the non-hospitalised, C.b. DNA load equal. NCSI: 58 
respondents, 34 abnormal outcome (58.6%) mild and 
severe faƟ gue. No diﬀ erence in Ct values, CRP and IL-6 
in AQF between paƟ ents with normal outcome and 
abnormal outcome subdomain faƟ gue
CorrelaƟ on IL-6 and CRP in AQF points to immune 
acƟ vaƟ on pathway in which IL-6 induces CRP. 
Diﬀ erences IL-6 and CRP between hospitalised vs. 
the non-hospitalised despite idenƟ cal DNA load 
suggest an important role for host factors. ↑ IL-6 
and CRP seems predicƟ ve of more severe disease. 
No support that IL-6 or CRP levels during AQF are 
prognosƟ c for faƟ gue development
NA 



who score ≥3 items as ‘a good part of the Ɵ me’ or ‘most of the Ɵ me’ are classiﬁ ed as cases of ‘faƟ gue/neurasthenia’, SOMA= 
Empirically derived subscale of the SPHERE, used to record PIFS or illness duraƟ on. This reliably predicts disability and reﬂ ects 
paƟ ents’ and doctors’ reports of reasons for presentaƟ on to primary care. Scores ≥3 represents a clinically-signiﬁ cant faƟ gue 
state. Provisional PIFS: SOMA scores ≥3 at all Ɵ me points up ≤3 months. Conﬁ rmed PIFS: symptoms persisted >6 months, and 
alternaƟ ve explanaƟ ons for ongoing illness was excluded. SPHERE= SomaƟ c and Psychological Health Report, to assess a wide 
range of physical and psychological symptoms, including severity and duraƟ on of symptoms, Stroop task= To assess cardiac re-
sponse, TGFB= Transforming growth factor beta, TNF= Tumor necrosis factor, UK= United Kingdom, Wks= Weeks, Yr(s)= Year(s)
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S5 Table. Domain prevenƟ on/therapy
Ref
Country, yr 
study, period and 
duraƟ on Study type PaƟ ents, controls, characterisƟ cs, co-morbidity* Tool
2004, Y. 
Arashima [6]
Japan, yr study NR. 
Period: Jul-Nov 
2001, baseline, 4, 
8 and 12 wks post 
start treatment
CoS 20 QFS paƟ ents (3 ♂, mean age 34.6±5.7) with subjecƟ ve 
symptoms (duraƟ on 20.8±3.3 mo, range 3 mo-4 yrs): 
faƟ gue (20/20), slightly elevated body temperature 
(17/20), arthralgia or myalgia (10/20), headache (12/20), 
cough or sore throat (16/20), ↑ sweaƟ ng (10/20), and 
gastrointesƟ nal symptoms (13/20). To address presence 
post QFS in Japan, and evaluaƟ on of minocycline for post 
QFS in changes in subjecƟ ve symptoms, C.b. anƟ body 
Ɵ tres and C.b. DNA. No controls
QuesƟ onnaires (assess 
severity of subjecƟ ve 
symptoms), PS score, 
IFA, n-PCR. AnƟ bioƟ c 
side eﬀ ects evaluated by 
interview and laboratory 
examinaƟ on results
2005, E. 
Iwakami 
[39]
Japan, May 
2001-March 2003. 
Period: baseline, 3 
mo treatment
CoS 4/8 CFS paƟ ents (2 ♂; 1 with IgGII 1:128; 3 with C.b. 
DNA posiƟ ve); mean age 29, SD4, range 23-33, duraƟ on 
complaints: 52.0 mo, SD55.3, range 8 mo-11 yrs. FaƟ gue 
(PS score 7±1.2), slightly elevated body temperature, 
headache, arthralgia/myalgia (100%), cough/sore throat 
(75%). 54 QFS paƟ ents (10 ♂) posiƟ ve C.b. DNA (n=34), 
IgMII ≥1:32 (n=15)/IgGII ≥1:128 (n=34); mean age 38, 
SD16, range 11-77, duraƟ on complaints: 21.1 mo, SD24.3, 
range 1 mo-10 yrs. FaƟ gue (PS score 5.3±2.4), slightly 
elevated body temperature (100%), headache (63%). 
To explore C.b. in CFS by anƟ bioƟ c treatment, monitor 
symptom changes, PCR and C.b. anƟ bodies
n-PCR, C.b. anƟ bodies 
iniƟ al examinaƟ on and 3 
mo aŌ er start treatment. 
QuesƟ onnaire survey, PS
2007, D. 
Ledina [5]
CroaƟ a, yr study 
NR, study period: 
2000-2004
Case-
series
N=3 post AQF with PQFS. 2 ♂ (34 and 30 yrs), 1 ♀ (30 yrs). 
IniƟ al treatment AQF: erythromycin and gentamycine 2 
wks (n=1), doxycycline 2 wks (n=2). Emphasize existence 
and incidence CFS post AQF according to CDC CFS criteria, 
and show eﬀ ects anƟ bioƟ c treatment in QFS
QuesƟ onnaires before 
and aŌ er treatment for 
subjecƟ ve symptoms. 
Noted in 4 degrees 
absent-severe
2013, S. 
Keijmel [42]
Netherlands, yr 
study: 2011-2015
RCT proto-
col
ObjecƟ ve: include 180 QFS paƟ ents, ♂ and ♀. EvaluaƟ on 
of eﬃ  cacy of long-term doxycycline and CBT in QFS-
paƟ ents
CIS; SIP total score, total 
score SCL-90, C.b. PCR and 
serology
2013, S. 
Yakubo [41]
Japan, yr study NR CR ♀ 71 yrs, 6 yrs post AI with general malaise, spasm leŌ  
hand, slightly elevated body temperature. Co-morbidity: 
NR. NegaƟ ve n-PCR for C.b., IgMI and IgMII <1:16, IgGI 
<1:16, IgGII 1:32
n-PCR, IFA
2013, S. 
Yakubo [40]
Japan, yr study NR CR ♂ 13 yrs, faƟ gue and severe malaise, slightly elevated body 
temperature, arthralgia, myalgia, lassitude, disease period 
2 mo earlier. Extended period no school aƩ endance. Co-
morbidity: NR. IFA IgMII and IgGII negaƟ ve, n-PCR posiƟ ve
n-PCR, IFA
FaƟ gue Following Acute Q-Fever  |  229
9
IntervenƟ on Outcome
Conclusions/
recommendaƟ ons
Other 
domain
QA (CR or NOS)
S C O
3 mo: minocycline 
100mg/d (n=18)/ 
erythromycin 400mg/d 
(n=1)/ levoﬂ oxacin 
200mg/d (n=1)
No leucocytosis or ↑ ESR. Slightly ↑ CRP 5 
paƟ ents. All 7 who had been DNA posiƟ ve, 
became negaƟ ve with improvement subjecƟ ve 
symptoms. IgM and IgG anƟ bodies became 
negaƟ ve post treatment. Clinical picture all 
paƟ ents improved: general faƟ gue (20/20), 
↓ body temperature (12/17), gastrointesƟ nal 
symptoms (10/13) and headache (9/12). PS 
score related to faƟ gue unchanged in 2 mo, 
but ﬁ nally ↓, PS scores ↑
Minocycline administraƟ on 
useful for improving chronic 
nonspeciﬁ c symptoms 
considered to be post QFS, 
and should be ﬁ rst-line drug 
for QFS. ObservaƟ ons may 
reﬂ ect existence of live C.b. 
in QFS paƟ ents
Diag, B/D 





3 mo: minocycline 
100mg/d (n=29)/ 
doxycycline 100mg/d 
(n=26)/levoﬂ oxacin 
200mg/d (n=3)
All 58 paƟ ents tested C.b. aŌ er treatment; 
all n-PCR posiƟ ves became negaƟ ve. CFS 
group (n=4): no improvement PS (p=0.422), 
no diﬀ erence pre- and post-treatment 
temperatures (p=0.07) or headache (p=0.39) 
scores. QFS group: PS scores improved 
(p<0.001), temperature (p<0.001) and 
headache scores ↓ (p<0.001) post treatment
Possibility direct involvement 
C.b. pathological state CFS 
low. Diﬀ erent response to 
tetracycline suggest direct 
C.b. involvement pathological 
state QFS. Latent C.b. 
infecƟ on not involved either 
onset CFS or appearance 
symptoms
Diag, B/D 



Case 1: 9 mo doxycycline 
200mg/d + ciproﬂ oxacin 
1000mg/d. Case 2: 
ciproﬂ oxacin 1000mg/d 
2 mo, then doxycycline 
200mg/d 4 mo. Case 3: 1 
mo corƟ costeroids, then 3 
mo doxycycline
Case 1: sƟ ll faƟ gue aŌ er physical acƟ vity 
(disappears aŌ er 30 min rest) and low 
intensity headache. Muscle pain and slightly 
elevated body temperature disappeared. No 
criteria CFS post-treatment. Case 2: regression 
symptoms, except minor headache. No criteria 
CFS post-treatment. Case 3: sƟ ll faƟ gued, 
disrupted sleep, headache, muscle and joint 
pains, sƟ ll fulﬁ ls CFS criteria post treatment
Results prolonged 
anƟ bioƟ c treatment CFS 
inconsistent. DiagnosƟ c 
criteria and therapeuƟ c 
recommendaƟ ons for PQFS 
require further invesƟ gaƟ on
Diag, B/D 9/18 criteria **
24 wks of: placebo, 
doxycycline 200 mg/d, 
or CBT
SƟ ll treaƟ ng paƟ ents NA Diag NA
Kampo formula Tsumura 
Shakuyaku-Kanzo-To 
granules (7,5g/d) 3 mo
AlleviaƟ on of sƟ ﬀ ness in hand and arm aŌ er 
2 days treatment, symptom disappeared 
completely. 6 mo aŌ er start treatment 
reappearance sƟ ﬀ ness and IgGI 1:128
QFS may feature intermiƩ ent 
muscle spasms, ameliora-
ted by Shakuyaku-Kanzo-To 
granules, warrants further 
research
NA -/-, -,
+, +, +, NA, -/-, -/-
Kampo formula Tsumura 
Hochu-ekki-To granules 
(7,5mg/d) 1 mo, then 
erythromycin 800mg/d 
1 mo, then doxycycline 
200mg/d 1 mo, then 
erythromycin 800mg/d at 
least 6 mo
Slight improvement 1 mo post erythromycin, 
none post doxycycline, fever stopped aŌ er 
long-term erythromycin, general malaise 
conƟ nued. Improvement aŌ er conƟ nued 
treatment
Consider C.b. as possible 
cause in cases of long-term 
school absence due to 
severe malaise similar to that 
caused by CFS
Diag, B/D -/-, +,
-/-, +/-, +/-, NA, 
+/-, -/-
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* Deﬁ niƟ on of used study populaƟ on in arƟ cles explained in a diﬀ erent table, including deﬁ niƟ ons of QFS 
and/or faƟ gue is applicable. Main informaƟ on is on prevenƟ on/therapy. Some arƟ cles also contain relevant 
informaƟ on on other domains: Diag= Diagnosis, B/D= Background/descripƟ ve, A= AeƟ ology
** Quality assessment for case-series was performed with a quality appraisal tool making use of 18 criteria 
with a considered acceptable quality if at least 14 criteria were scored (≥70%) [24]
AbbreviaƟ ons: AI= Acute infecƟ on, AQF= Acute Q-fever, C.b.= Coxiella burneƟ i, CBT= CogniƟ ve behavioural 
therapy, CDC= Centre of Disease Control, CFS= Chronic faƟ gue syndrome, CIS= subscale faƟ gue of the Checklist 
Individual Strength, to indicate the level of faƟ gue experienced in the previous two weeks, measured with eight 
items on a seven-point Likert-scale (range 8–56), CoS= Cohort study, CRP= C-reacƟ ve protein, CR= Case-report, 
ESR= Erythrocyte sedimentaƟ on rate, IFA= Immunoﬂ uorescence assay, IgG= AnƟ -phase IgG, IgGII= AnƟ -phase IgG 
II Ɵ tre, IgM= AnƟ -phase IgM, IgMII= AnƟ -phase IgM II Ɵ tre, Mo= Month(s), NA= Not applicable, NOS= Newcastle–
OƩ awa Scale: S= selecƟ on (maximum of 4 stars), C= comparability (maximum of 2 stars), O= outcome (maximum of 
3 stars); ★: star earned; ☆: item not applicable, N/No= Number (of), (n-)PCR= (nested-) Polymerase chain reacƟ on, 
NR= Not reported, PQFS= Post-(acute)Q-fever (faƟ gue) syndrome, PS= Performance status score (range 0-9), which 
reﬂ ects the grade of faƟ gue/malaise to assess the severity of CFS, QA-CR= Quality assessment; for CR no quality 
checklists are available. Therefore, the following eight criteria for quality assessment were determined; addressing 
an appropriate and clearly focused quesƟ on, representaƟ ve populaƟ on, descripƟ on of the survey method or data 
collecƟ on, outcome measures deﬁ ned, outcome measures described, response rate reported and results valid 
and applicable to the paƟ ent group targeted. The arƟ cles scores on these items: -/-, -, +/-, +, or ++, based on the 
CoordinaƟ on of Cancer Clinical PracƟ ce Guidelines in Europe criteria, RCT= Randomised controlled trial, QF(F)S= 
Q-fever faƟ gue syndrome, Ref= Reference, SCL-90= Symptom Checklist 90, to measure the level of psychological 
distress, consisƟ ng of 90 items scored on a ﬁ ve-point Likert-scale (range 90-450), SD= Standard deviaƟ on, SIP= 
Sickness Impact Proﬁ le, to measure the level of funcƟ onal impairment. A total score is derived out of the scores on 
the subscales: sleep-rest, household, mobility, social interacƟ ons, walking, alertness and intellectual funcƟ oning, 
work, and recreaƟ on, Wks= Weeks, Yr(s)= Year(s)
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S6 Table. Grey literature 
Ref
Country, yr 
study, period 
and duraƟ on
Docu-
ment PaƟ ents, controls, characterisƟ cs, co-morbidity Tool
1992, M. 
Shannon 
[1]
Australia, yr 
study NR, 
study period 
NR
Thesis AbaƩ oir workers (n=117), immune status assessed 1981-1986. 
Group of clinical history AQF and serology CFT Phase I and II, and 
IFA (n=39). All either ↑ CFT anƟ body Ɵ tre and/raised IFA IgM 
as indicaƟ on current QF. Unexposed comparison cohort (n=39): 
vaccinated and non-vaccinated (seroposiƟ ves without clinical history 
AQF). Occurrence infecƟ on not noted
C.b. CFT, IFA, 
quesƟ onnaires
2009, B. 
Marmion 
[2]
Australia and 
UK, yr study 
NR, study 
period NR
Book 
(chap-ter)
No paƟ ents/controls. CharacterisƟ cs and co-morbidity: NR. 
Experience from several studies
NA
2011, C. 
Tempel-
man [3]
Netherlands, 
yr study 2011
Report on 
eco-nomic 
evalua-
Ɵ on
Economic costs –human and veterinary Dutch QF outbreak 2007-
2010 assessed with 4024 noƟ ﬁ caƟ on AQF. AssumpƟ ons: 25% 
(n=503) AQF get QFS duraƟ on 5-10 yrs. Results: quality of life ↓, 
assumed period sick leave 5-10 yrs, producƟ vity 50% ↓. AssumpƟ on 
60% of those with QFS were gainfully employed
Interviews, public 
data outbreak
2012 
Guideline 
working 
group on 
QFS [4]
Netherlands, 
yr study 2011-
2012
Guideline Achieve uniformity diagnosis and treatment QFS QFS and CFS 
literature and 
mulƟ discipline-ry 
consensus
These documents contain relevant informaƟ on for the domains: Diag= Diagnosis, B/D= Background/
descripƟ ve, A= AeƟ ology, P/T= PrevenƟ on/therapy. Main domain indicated in bolt
AbbreviaƟ ons: ALT= Alanin aminotransferase, AQF= Acute Q-fever, BMI= body mass index, C.b.= Coxi-
ella burneƟ i, CBT= CogniƟ ve behavioural therapy, CFS= Chronic faƟ gue syndrome, CFT= complement 
ﬁ xaƟ on test, CK= creaƟ ne kinase, CRP= C-reacƟ ve protein, CQF= chronic Q-fever, ESR= Erythrocyte 
sedimentaƟ on rate, IFA= Immunoﬂ uorescence assay, IL= Interleukin, Mo= Month(s), NA= Not applica-
ble, NR= Not reported, QF= Q-fever, QF(F)S= Q-fever faƟ gue syndrome, Ref= Reference, TSH= thyroid 
sƟ mulaƟ ng hormone, Yr(s)= Year(s)
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Outcome/advice Conclusions/recommendaƟ ons Domains QA
Deﬁ niƟ on QFS; laboratory proven, clinically manifest QF, commences within 
12 mo of illness, duraƟ on ≥6 mo. 5 major symptoms; 1. faƟ gue of 2-≥7dys, 
≥6x/yr conƟ nuously with some absence from work, 2. malaise – as above 
except work, 3. muscle twitches/ fasciculaƟ ons, 4. nausea ≥6x/yr, 5. abnormal 
sweaƟ ng ≥10x/yr, might be accompanied by other symptoms. Most subjects 
healthy before AQF regarding depression. Mental problems; depression, 
lack of concentraƟ on, impairment short memory, mood lability, altered 
sleep paƩ ern following AQF. Some general pracƟ Ɵ oners stated that tricyclic 
anƟ depressants were beneﬁ cial. 30-40 cases/1000 abaƩ oir workers/yr, each 
costs 2-88.000 in medical care and loss of wages, endocardiƟ s 50-10.000/yr, 
QFS 20-50.000/yr. DuraƟ on QFS 6 mo-20 yrs
Approximately 23% develops QFS 
post overt AQF. No grounds to dismiss 
QFS as a psychiatric depressive 
illness. AeƟ ology is unclear, might 
be due to immune sƟ mulaƟ on and a 
disordered funcƟ on of the lymphocyte-
macrophage interacƟ on. Same 
pathways to mood change may be 
involved in depression and QFS and 
altered by chemotherapy
B/D,
P/T
NA
Start oŌ en 6 mo-1 yr post AQF. Symptoms complex not limited to faƟ gue, also 
nausea, headache, night sweats, myalgia, arthralgia, fasciculaƟ ons, painful 
lymph nodes, disturbed sleep paƩ ern, anger, ↓ concentraƟ on, mental acuity 
↓. DuraƟ on: >1 yr, oŌ en 5-10 yrs. AnƟ gens in samples SCID mice, cellular 
immune response heightened, cytokine dysregulaƟ on: IL-6 ↑, IL-10, IL-2 ↓, 
low fever. Pathogenesis; no consensus. Bacteraemia restricted by humoral 
and cell-mediated immunity, by product clearing C.b. DNA containing 
components with an immunomodulatory eﬀ ect. Cell-mediated immunity and 
dendriƟ c cells causing dysregulaƟ on, cytokines and other immune mediators 
give rise to symptoms
In Australia QFS is the most common 
chronic sequel of AQF aﬀ ecƟ ng 10-15% 
of paƟ ents. It usually follows AQF and 
rarely if ever subclinical infecƟ on
B/D,
A
NA
QFS duraƟ on 5-10 yrs costs ↓ quality of life 55.6-104.7 million euros. Costs of 
sick-leave due to QFS are not separately presented but together with CQF and 
therefore not menƟ oned
Economic costs due to QF outbreak are 
considerable as the course of disease 
especially due to QFS is protracted 
and reﬂ ected in ↓ quality of life, ↓ 
producƟ vity, and ↓ income
 B/D NA
QFS deﬁ niƟ on: severe faƟ gue causing signiﬁ cant disabiliƟ es daily life ≥6 
mo, reference to lab conﬁ rmed AQF, not caused by somaƟ c/psychiatric 
co-morbidity, faƟ gue absent before AQF/signiﬁ cantly ↑ since. Diagnosis on 
history, physical and laboratory examinaƟ on excluding other causes of faƟ gue 
(including ESR, CRP, CK, TSH, leukocytes with diﬀ erenƟ aƟ on, creaƟ nine, 
alkaline phosphatase, ALT, glucose, ferriƟ n, urinary sediment). Cave diagnosis 
in case of morbid obesity (BMI>40) or substance abuse. Impossible to 
diagnose QFS in case of: depression/depression preceded current symptoms, 
schizophrenia, psychoses, any type demenƟ a, eaƟ ng disorders, unless 
resolved ≥5 yrs
Advice paƟ ents ≤6 mo post AQF: i) stay 
mentally/physically acƟ ve, adjust pace 
if necessary; ii) alternate acƟ viƟ es, 
also within acƟ viƟ es; iii) keep fulﬁ lling 
daily role; iv) keep steady sleep-
wake paƩ ern; v) avoid focussing on 
faƟ gue; vi) focus on feasible acƟ viƟ es, 
appreciate accomplishments. Advice 
CBT/GET aŌ er QFS diagnosis. GET 
might be an addiƟ onal treatment 
strategy
Diag, B/D, 
A, P/T
NA
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SUMMARISING DISCUSSION 
Chapter 2 is descripƟ ve; sketches the Q-fever outbreak from 2007 to 2010 and provides 
general informaƟ on on C. burneƟ i diagnosis, sequels of infecƟ on and veterinary control 
measures.
Part I. Serological screening for chronic Q-fever
Chapter 3, Large regional diﬀ erences in serological follow-up of Q-fever paƟ ents in the 
Netherlands
Previous knowledge on this subject
Acute Q-fever may progress to chronic Q-fever in about 2% [1] of paƟ ents. Serological follow-
up of acute Q-fever paƟ ents is essenƟ al in order to idenƟ fy and ensure Ɵ mely treatment of 
chronic Q-fever [2-4]. However, naƟ onal or internaƟ onal guidelines on serological follow-up 
were not available at the Ɵ me of the Dutch epidemic.
The Municipal Health Service (MHS) Hart voor Brabant received informaƟ on from pa-
Ɵ ents and health professionals, suggesƟ ng that not all Q-fever paƟ ents received serological 
follow-up and that there might be regional diﬀ erences in follow-up procedures.
The aim of the study and what was examined
The aim of this study was to invesƟ gate the extent to which acute Q-fever paƟ ents received 
serological follow-up, idenƟ fy regional diﬀ erences in the organisaƟ on, knowledge and prac-
Ɵ ces among medical pracƟ Ɵ oners regarding serological follow-up.
We used data of 3,198 paƟ ents diagnosed with acute infecƟ on by three Laboratories of 
Medical Microbiology (LMM) in the province of Noord-Brabant between 2007 and 2009. One 
LMM oﬀ ered acƟ ve follow-up by sending paƟ ents a reminder while the other two LMMs only 
tested at the physicians’ request. The follow-up rate of the two systems was compared. In 
addiƟ on, the knowledge regarding Q-fever of 209/501 general pracƟ Ɵ oners (GPs) and 32/112 
medical specialists was invesƟ gated with a quesƟ onnaire.
What this study adds
• The serological follow-up of acute Q-fever paƟ ents, among the three laboratories ranged 
from 25% to 95% [5].
• Up to 95% of paƟ ents responded to acƟ ve recall for serological follow-up
• If recall depended on GPs/specialists, 25% of paƟ ents received serological follow-up.
• Two thirds of GPs and specialists correctly idenƟ ﬁ ed risk groups for chronic Q-fever.
• 35% of GPs and 22% of medical specialists never requested serological follow-up.
• 63% of GPs and 45% of specialists assumed that an MHS or LMM organized serological 
follow-up.
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RecommendaƟ ons as a consequence of this study
• AcƟ ve recall of paƟ ents by a LMM ensures the best follow-up rate for Q-fever. AcƟ ve recall 
could also be considered for other infecƟ ous diseases that require serological follow-up. 
It is advisable to discuss with laboratories, medical pracƟ Ɵ oners and paƟ ent organisaƟ ons 
or groups what recall system could work best in a given situaƟ on.
• Provide every paƟ ent diagnosed with acute Q-fever an explanatory leaﬂ et on the impor-
tance of serological follow-up and laboratory forms with dates for follow-up. This could be 
done by the health care provider/assistant.
• Incorporate recommendaƟ ons for serological follow-up in naƟ onal guidelines.
Chapter 4, Strategies for early detecƟ on of chronic Q-fever; a systemaƟ c review
Previous knowledge on this subject
InternaƟ onal literature suggested at least two serologic tests (at three and six months) during 
the ﬁ rst year aŌ er an episode of acute Q-fever [3, 4, 6]. In 2008 Dutch authors [7] advised 
tests at three, six, and twelve months aŌ er diagnosis. Three years later, disƟ nguishing be-
tween low and high risk paƟ ents was suggested for serological follow-up tests: for the ﬁ rst 
group once at nine months, and for the second group at three, six, nine, and twelve months 
[8]. RecommendaƟ ons from individual studies on follow-up and screening strategies for early 
detecƟ on of chronic Q-fever exist but internaƟ onal guidelines were not available.
The aim of this study and what was examined
The aim of this study was to assess the evidence base for diﬀ erent follow-up and screening 
strategies for early detecƟ on of chronic Q-fever. Criteria for those at risk of a chronic infec-
Ɵ on, frequency, opƟ mum Ɵ ming, intervals, and duraƟ on of follow-up were also considered.
By conducƟ ng a systemaƟ c literature review, all relevant literature available from PubMed 
or Embase up to 17 October 2012 was assessed which resulted in the inclusion of 20 arƟ cles.
What this study adds and its recommendaƟ ons
• There was no consensus in deﬁ niƟ ons or follow-up strategy. Most studies suggested 
serological follow-up of acute Q-fever but informaƟ on on Ɵ ming, frequency and duraƟ on 
was inconsistent.
• Only acute Q-fever paƟ ents with a clinical indicaƟ on of a cardiac valve abnormality should 
be subjected to echocardiography.
• Provide frequent, e.g. every three months, serological and clinical follow-up for acute 
Q-fever paƟ ents with known risk factors. Provide follow-up  once during the ﬁ rst year – 
but aŌ er three months for example at 6 or nine months- for those without a known risk 
factor.
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• Establish naƟ onal and internaƟ onal guidelines on the serological and clinical follow-up of 
acute Q-fever paƟ ents.
• Consider in outbreak situaƟ ons serological screening of risk groups for chronic Q-fever 
for C. burneƟ i.
Chapter 5, PopulaƟ on Screening for chronic Q-fever seven years aŌ er a major outbreak
Previous knowledge on this subject
In 2007, 25% of sampled inhabitants of Herpen, the ﬁ rst Dutch village aﬀ ected by the Q-fever 
outbreak, were seroposiƟ ve [9]. Between 2007 and 2010 this village was in the proximity of 
four C. burneƟ i posiƟ ve goat farms. Two of these farms had C. burneƟ i induced aborƟ ons in 
April 2007 and May 2008. The closest farm was in the village and the furthest six kilometres 
away from the village centre.
An immune ﬂ uorescence assay (IFA) IgG anƟ body Ɵ tre phase I ≥1:1,024 during follow-up 
is an important marker of chronic infecƟ on [8].
The aim of the study and what was examined
Seven years aŌ er the outbreak started, we measured the serological C. burneƟ i status of 
inhabitants of the village Herpen in order to idenƟ fy chronic Q-fever infecƟ ons including 
those that occurred aŌ er an asymptomaƟ c C. burneƟ i infecƟ on. This in order to oﬀ er Ɵ mely 
treatment to those with chronic Q-fever and assess whether large-scale populaƟ on screening 
elsewhere in the outbreak area is warranted.
The serological C. burneƟ i status of 1,517 adult inhabitants (>70% response) was mea-
sured with the Immuno Fluorescence Assay (IFA). An IFA cut-oﬀ  of IgG phase I or II of ≥1:64 
indicated a past C. burneƟ i infecƟ on. ParƟ cipants with an IgG phase I ≥1:512 [10] were con-
sidered at risk for chronic Q-fever and referred for clinical examinaƟ on to conﬁ rm or reject 
this diagnosis.
What this study adds
• Seven years aŌ er the outbreak began, 513/1,517 (34%) parƟ cipants had anƟ bodies 
against C. burneƟ i.
• Of the parƟ cipants that were IFA posiƟ ve in 2007, 17% seroreverted and had become 
seronegaƟ ve by 2014. Taking this into account approximately 41% of parƟ cipants were 
esƟ mated to have been infected with C. burneƟ i.
• Six parƟ cipants, 1.2% of seroposiƟ ves, had an IgG I ≥1:512. All were PCR negaƟ ve. Two had 
been diagnosed previously with chronic Q-fever. The other four were clinically examined. 
One of these four parƟ cipants, a male >65 years, with an increased erythrocyte sedi-
mentaƟ on rate, renal insuﬃ  ciency, diabetes mellitus type 2, and a cardiac murmur , was 
diagnosed with chronic Q-fever. He had no episode of acute Q-fever in his medical history.
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• Of the 69 parƟ cipants with known cardiovascular risk factors, 16 (23%) were IFA-posiƟ ve. 
Three had received the Q-fever vaccine, while 13 were naturally infected. Two of these 13 
parƟ cipants (15%) developed chronic Q-fever.
• Screening the general adult populaƟ on of Herpen seven years aŌ er the beginning of an 
outbreak idenƟ ﬁ ed one individual (1/1,517) with previously undetected chronic Q-fever.
RecommendaƟ ons as a consequence of this study
• Screen paƟ ents with known cardiovascular risk factors for chronic Q-fever, for C. burneƟ i 
infecƟ on as soon as an outbreak is detected and vaccinate the innate.
• Beware of seroreversion. Realise that negaƟ ve C. burneƟ i serology (IFA) does not rule 
out a previous infecƟ on. Take this into account when vaccinaƟ ng high risk groups against 
Q-fever.
• GPs in a high incidence area ought to be aware that chronic Q-fever can develop aŌ er an 
a-symptomaƟ c C. burneƟ i infecƟ on.
• General populaƟ on screening for chronic Q-fever, seven years aŌ er the beginning of an 
outbreak, appears to have a low yield.
Discussion part I
It is essenƟ al that individuals diagnosed with acute Q-fever are informed about the risk of 
developing chronic Q-fever and the importance of serological follow up and that they also 
receive this follow up [5] especially during the ﬁ rst year aŌ er infecƟ on [10]. Informed paƟ ents 
could request this follow-up when not oﬀ ered by their health care provider. During the Dutch 
outbreak serological tesƟ ng within one year aŌ er acute Q-fever, detected 98% [10] of chronic 
Q-fever paƟ ents.
The delay between development and diagnosis of chronic Q-fever aŌ er asymptomaƟ c 
infecƟ on is unknown. Chronic Q-fever can be detected years [4, 11] aŌ er the iniƟ al infecƟ on 
in the absence of screening. Undetected chronic Q-fever cases are likely to have been the ini-
Ɵ ally symptomaƟ c infected that did not seek medical care or did not receive proper follow-up 
aŌ er the acute episode or those with an iniƟ al asymptomaƟ c infecƟ on. Of all chronic Q-fever 
cases, registered in the Dutch database – the minority- 38% recalled an acute Q-fever episode 
[12]. Follow-up of asymptomaƟ c or undiagnosed C. burneƟ i infecƟ ons and or screening those 
with an undiagnosed risk factor in order to idenƟ fy chronic Q-fever is impossible. PopulaƟ on 
screening [13], years aŌ er a large outbreak, required a considerable eﬀ ort and investment 
and had a small yield [13].
Immediate openness about a Q-fever outbreak and informing medical pracƟ Ɵ oners’ 
and the general public about serological follow-up and possible long-term complicaƟ ons, 
together with an acƟ ve serological follow-up system is essenƟ al for Ɵ mely idenƟ ﬁ caƟ on of 
chronic Q-fever. That way both the public and the GP will not only be aware of acute Q-fever 
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infecƟ ons during an outbreak but might be more vigilant in the future regarding chronic 
Q-fever. There was a limited vaccinaƟ on campaign aŌ er the outbreak in 2011. The percent-
age of the at risk for chronic Q-fever that were vaccinated is low [4] (see also Chapter 5). It is 
unclear if this is due to the selecƟ on procedure of the treaƟ ng medical doctor or if paƟ ents 
decided against vaccinaƟ on. Again, informing both medical doctors and the populaƟ on in an 
outbreak area might enable those at risk to make their own informed choice.
Part II. The health status especially faƟ gue and work aŌ er a C. burneƟ i 
infecƟ on
Chapter 6, Self-reported sick leave and long-term health symptoms of Q-fever paƟ ents
Previous knowledge on this subject
NaƟ onal or internaƟ onal studies, on sick leave or the ability to work at individual or Q-fever 
paƟ ent group level, were unavailable in 2009 through searching Pubmed.
The MHS Hart voor Brabant repeatedly received quesƟ ons from occupaƟ onal health phy-
sicians, GPs, medical specialists and paƟ ents regarding the post Q-fever impact on persisƟ ng 
symptoms in parƟ cular faƟ gue and consequences for work.
The aim of the study and what was examined
The objecƟ ve was to assess the frequency and duraƟ on of sick leave, symptoms and associ-
ated risk factors, 12 to 26 months aŌ er an episode of acute Q-fever. The study populaƟ on 
consisted of all 870 acute Q-fever paƟ ents, noƟ ﬁ ed by the MHS ‘Hart voor Brabant’ and 
‘Brabant Zuid-Oost’ with a ﬁ rst day of illness in 2007 or 2008. The MHS ‘Hart voor Brabant’ 
sent paƟ ents noƟ ﬁ ed in 2007 a quesƟ onnaire in February 2009 (13–26 months aŌ er the 
onset of acute Q-fever) while this was one year aŌ er onset of illness for those noƟ ﬁ ed in 
2008. The response rate was 64% (n=556).
What this study adds
• AŌ er acute Q-fever, 40% of the gainfully employed were longer than one month absent 
from work.
• AŌ er 12 to 26 months: 9% of those that resumed work were unable to funcƟ on at pre 
Q-fever levels, mainly due to faƟ gue and concentraƟ on problems.
• Almost a third of parƟ cipants did not fully resume daily acƟ viƟ es.
• AŌ er 12 to 26 months, 40% of parƟ cipants reported perceived Q-fever related health 
complaints namely: faƟ gue 20%, diﬃ  culty concentraƟ ng 10%, muscle pain 9%, and night-
Ɵ me sweaƟ ng 8%.
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RecommendaƟ ons as a consequence of this study
OccupaƟ onal health professionals, GPs, medical specialists and policy makers need to be 
aware, informed and instructed on how to deal with these long-term personal and societal 
(including work) consequences.
Chapter 7, The health status of Q-fever paƟ ents aŌ er long-term follow-up
Previous knowledge on this subject
Dutch studies oŌ en used the validated Nijmegen Clinical Screening Instrument (NCSI) to 
assess the sub-domains of the health status [14]. FaƟ gue is a separate sub-domain of this 
instrument. Several studies reported on prolonged faƟ gue aŌ er acute Q-fever [15-25].
The aim of the study and what was examined
The aim of this study was to provide a detailed assessment of the health status of noƟ ﬁ ed 
Q-fever paƟ ents 12 to 26 months aŌ er the onset of illness in 2007 or 2008. This was in order 
to assist clinicians and paƟ ents to beƩ er understand the natural course and predictors of an 
aﬀ ected health status aŌ er acute Q-fever.
The study populaƟ on, method and response rate are described in Chapter 6. The health 
status and its sub-domains were assessed with the NCSI. Control groups were healthy indi-
viduals (n= 65) and Chronic ObstrucƟ ve Pulmonary Disease paƟ ents (COPD) (n= 128).
What this study adds
• 12 to 26 month aŌ er onset of illness 7 of 8 NCSI sub-domains of acute and noƟ ﬁ ed Q-fever 
paƟ ents were impaired in comparison to healthy controls.
• Almost 60% of paƟ ents reported abnormal faƟ gue of which 44% was severe.
• The general quality of life was in 45% of cases severely aﬀ ected.
• HospitalisaƟ on in the acute phase was signiﬁ cantly related to abnormal long-term behav-
ioural impairment, health related quality of life and subjecƟ ve symptoms.
RecommendaƟ ons as a consequence of this study
• Inform medical doctors of these detrimental long-term outcomes to enable them to 
understand and support these paƟ ents and refer them to specialist care e.g. a Q-fever 
experƟ se centre.
• Develop treatment guidelines for aﬀ ected paƟ ents, GPs and medical specialists.
• Policy makers need to take the long-term burden of infecƟ ous diseases into account, 
when considering measures to control outbreaks.
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Chapter 8, The health status of a village populaƟ on, seven years aŌ er a major Q-fever 
outbreak
Previous knowledge on this subject
From 2010 onwards, informaƟ on on the long-term health status post Q-fever, assessed with 
the NCSI, became available from several Dutch studies [22-26]. One year aŌ er onset of illness 
74% of paƟ ents (n=54) reported abnormal faƟ gue [22].
Seven years aŌ er the outbreak started the MHS Hart voor Brabant conƟ nued to receive 
quesƟ ons from occupaƟ onal health physicians, GPs, medical specialists and paƟ ents regard-
ing the long-term post Q-fever impact on the health status and parƟ cular faƟ gue.
The aim of the study and what was examined
The aim of the ‘Q-Herpen-II’ study was to assess the presence of C. burneƟ i anƟ bodies in 
relaƟ on to the health status with an emphasis on faƟ gue. All 2,161 adult inhabitants (≥18 
years of age) of the village Herpen (postal code 5373) were invited to ﬁ ll in a quesƟ onnaire 
including the NCSI and donate blood in January or March 2014. A C. burneƟ i IFA IgG phase I 
or II Ɵ tre ≥1:64 was considered posiƟ ve. The response rate was 71% (1,534/2,161).
What this study adds
• Seven years aŌ er the start of the outbreak there was no signiﬁ cant diﬀ erence in faƟ gue 
levels between parƟ cipants with and without C. burneƟ i anƟ bodies.
• Regardless of the IFA status 38% of parƟ cipants reported faƟ gue including 23% with 
severe faƟ gue. The IFA status was not an independent risk factor for faƟ gue.
• Seven years aŌ er symptomaƟ c acute Q-fever followed by a naƟ onal noƟ ﬁ caƟ on [27], 63% 
(n=31/49) of parƟ cipants reported faƟ gue including 47% severe faƟ gue.
• AŌ er a mild or asymptomaƟ c infecƟ on that had not been noƟ ced by the parƟ cipant nor 
fulﬁ lled the noƟ ﬁ caƟ on criteria [27], 33% (n=150/451) reported faƟ gue including 20% 
severe faƟ gue.
• FaƟ gue aŌ er a C. burneƟ i infecƟ on seemed to occur primarily in the group with 
symptomaƟ c acute Q-fever who as a result fulﬁ lled the naƟ onal noƟ ﬁ caƟ on criteria [27].
• Knowledge of or belief in a previous infecƟ on did not inﬂ uence the level of faƟ gue.
• There was no correlaƟ on between the C. burneƟ i IFA Ɵ tre and the level of faƟ gue.
RecommendaƟ ons as a consequence of this study
• One ought to be cauƟ ous to aƩ ribute faƟ gue to a C. burneƟ i infecƟ on. Other morbidiƟ es 
that could cause faƟ gue should be -as far as possible - excluded ﬁ rst.
• Inquire or check the paƟ ents ﬁ le for the severity of the iniƟ al infecƟ on.
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• Aim to idenƟ fy in future research what pathogenic mechanisms determine the long-term 
diﬀ erences in faƟ gue between iniƟ ally symptomaƟ c (noƟ ﬁ ed) and mild or asymptomaƟ c 
C. burneƟ i infecƟ ons.
Chapter 9, FaƟ gue following acute Q-fever: a systemaƟ c literature review
Previous knowledge on this subject
Post InfecƟ on FaƟ gue Syndromes (PIFS) [16, 17] can occur aŌ er infecƟ ons [18] such as Bor-
relia burgdorferi [19], Legionella pneumophila [24], Epstein Barr and Ross River virus [18].
In Australia Q- fever faƟ gue syndrome (QFS) is the most common chronic sequel of acute 
Q-fever and aﬀ ects 10-15% of paƟ ents [20]. Protracted faƟ gue aŌ er acute Q-fever can last 10 
[17, 21] to 20 years [28] and can present with accompanying symptoms that resemble [16] 
the Chronic FaƟ gue Syndrome (CFS).
Hypotheses on aeƟ ology were contradictory [29] and varied from altered cytokine pro-
ducƟ on [30], development of symptoms determined by host and geneƟ c factors [30-32], to 
the perpetuaƟ on of symptoms due to psychogenic factors and behaviour [33]. Opinions on 
possible treatment of QFS varied [34-36], and quesƟ ons exisƩ ed regarding prevenƟ on and 
prognosis.
The aim of the study and what was examined
Recurrent quesƟ ons regarding the deﬁ niƟ on, background/descripƟ on, aeƟ ology, prognosis, 
prevenƟ on and treatment of faƟ gue aŌ er a C. burneƟ i infecƟ on led to a systemaƟ c review 
(SR). Through a SR all relevant available literature on these subjects searched with PubMed, 
Embase and PsycInfo up to 26 May 2015 was assessed, resulƟ ng in the inclusion of 61 arƟ cles.
What this study adds
• A chronological overview of available literature on faƟ gue aŌ er a C. burneƟ i infecƟ on up 
to 26 May 2015, organised in deﬁ niƟ on, aeƟ ology, background, prognosis and treatment.
• Uniform internaƟ onal deﬁ niƟ ons of long-term post infecƟ on faƟ gue or QFS were unavail-
able, and assessment/measurement tools diﬀ ered between studies, which aﬀ ects the 
interpretaƟ on of diagnosis, prevalence, aeƟ ology, prognosis and choice of treatment.
• Only the Dutch QFS guideline provided a step by step plan to diagnose QFS.
• Commonly reported symptoms accompanying faƟ gue following C. burneƟ i infecƟ on were 
musculoskeletal complaints, neurocogniƟ ve symptoms, sleeping problems, headaches, 
blurred vision, increased (night) sweaƟ ng, respiratory complaints, and mood disorders.
• FaƟ gue following acute Q-fever carries a large burden of disease and has a major negaƟ ve 
impact on the health status of paƟ ents with signiﬁ cant economic implicaƟ ons. The major-
ity of paƟ ents returned to work within the ﬁ rst 12 months aŌ er acute Q-fever, although 
up to 20% reported reduced work parƟ cipaƟ on.
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• AeƟ ology: the role of geneƟ c variaƟ ons in host immune responses in QFS was contradic-
tory and might result from individual immune responses to C. burneƟ i rather than from a 
geneƟ c signature. Cytokine dysregulaƟ on mediaƟ ng symptoms in QFS may originate from 
immunomodulatory complexes of non-viable undegraded C. burneƟ i DNA or its anƟ gens 
but results were contradictory.
• A predictor for post-infecƟ ve faƟ gue, including QFS: was the severity of the acute Q-fever 
episode. Neither psychological nor microbial factors were predictors.
• Treatment: no randomized controlled trials (RCT’s) were performed, and available data 
are scarce and inconsistent. The Dutch QFS guideline suggests that CogniƟ ve Behavioural 
Treatment (CBT) and Graded Exercise Therapy (GET) might reduce faƟ gue in paƟ ents with 
QFS although evidence is lacking.
RecommendaƟ ons as a consequence of this study
• InternaƟ onal consensus is needed to determine the deﬁ niƟ on of PIFS and the use of a 
tool to measure it. Not only Q-fever but also other infecƟ ous diseases that can lead to 
this syndrome should be considered. In the absence of such internaƟ onal consensus the 
most recent detailed descripƟ on and diagnosis formulated in the Dutch QFS guideline 
[36] would suﬃ  ce.
• Only prospecƟ ve, clinical studies and treatment trials such as the Qure study [37] might 
answer quesƟ ons regarding deﬁ niƟ on, prognosis, treatment and outcome of faƟ gue aŌ er 
an infecƟ on with C. burneƟ i.
• Aim to idenƟ fy in future research the pathogenic mechanism that determines the dif-
ference in faƟ gue outcome between symptomaƟ c and mild or asymptomaƟ c C. burneƟ i 
infecƟ ons.
Discussion part II
It is important to use a validated and uniform tool to assess post-infecƟ ve faƟ gue, including 
QFS. InteresƟ ngly when paƟ ents were asked if they were faƟ gued, 8% answered posiƟ vely 
(Chapter 6). When assessed with the NCSI the same study populaƟ on of acute Q-fever pa-
Ɵ ents reported 60% abnormal faƟ gue of which 44% was severe (Chapter 7). This large diﬀ er-
ence emphasises the importance of a standardised tool for any comparison.
In future studies, control groups should be appropriate and serologically tested for 
C. burneƟ i anƟ bodies. IniƟ ally our control groups consisted of healthy controls (Chapter 7) 
that had not visited a specialist 6 months prior to recruitment and were thus healthier than 
the general populaƟ on. The other control group (Chapter 7) consisted of COPD paƟ ents. 
PaƟ ents had suﬀ ered an episode of acute Q-fever followed by registraƟ on by the MHS and 
naƟ onal noƟ ﬁ caƟ on. The two control groups were not serologically tested for C. burneƟ i 
anƟ bodies. The populaƟ on study (Chapter 8) is however a realisƟ c representaƟ on of the 
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populaƟ on, furthermore every parƟ cipant was serologically tested for C. burneƟ i anƟ bodies. 
This study provided the unique opportunity to compare those with past acute Q-fever, mild, 
unnoƟ ced or asymptomaƟ c C. burneƟ i infecƟ ons, and seronegaƟ ves which led to unexpected 
but more realisƟ c ﬁ ndings. Our ﬁ nding that the health status and level of faƟ gue at group 
level was similar for seroposiƟ ves and seronegaƟ ves was comparable with a small study of 
Limonard et al. [23]. Limonard described that the health status of C. burneƟ i seroposiƟ ve 
(n=11) and seronegaƟ ve controls (n=23) was similar. Our large study had enough power to 
corroborate this point. It also conﬁ rmed previous observaƟ ons that faƟ gue usually follows 
acute Q-fever and rarely if ever subclinical infecƟ on [20].
AŌ er the results from the studies described in Chapters 6 and 7 were released the MHS 
Hart voor Brabant urged for a standardised approach of those who suﬀ ered long-term faƟ gue 
aŌ er acute Q-fever. This led to the mulƟ disciplinary QFS guideline [36]. The paƟ ent organiza-
Ɵ on Q-uesƟ on was represented in the working group. This led to collaboraƟ on of the paƟ ent 
organisaƟ on in design of the Q-Herpen II PopulaƟ on study and in dispersal of the outcomes 
in laymen’s terms.
The full impact of the outbreak including work related factors will be further invesƟ gated 
in the study “ImpaQt” [38], a meta- analysis that will amongst other studies include data from 
three of our studies (Chapters 6,7 and 8).
Conclusions
Through a series of studies we answered quesƟ ons regarding screening for chronic Q-fever 
and assessed the health status including faƟ gue aŌ er a C. burneƟ i infecƟ on.
The main lessons learnt regarding serological screening for chronic Q-fever are:
• Following diagnosis, serological follow-up has a high compliance when organised cen-
trally. When informed as to the why and Ɵ ming of the follow-up, paƟ ents are perfectly 
able to make a choice in their own best interest by presenƟ ng for screening. Follow-up 
dependent on the iniƟ aƟ ve of the treaƟ ng medical doctor is inadequate.
• Serological follow-up at 3,6,9 and 12 months is indicated for groups at high risk for a 
chronic infecƟ on while screening once within 12 months might be suﬃ  cient for others.
• General populaƟ on screening for chronic Q-fever years aŌ er an outbreak in a high inci-
dence area, has a low yield and is not advisable. Instead, known cardiovascular risk groups 
for chronic Q-fever should be screened and vaccinated if applicable as soon as there is an 
outbreak in their residenƟ al area.
The main lessons learnt regarding the health status are:
• 12 to 26 months aŌ er acute Q-fever paƟ ents had an aﬀ ected health status, especially 
faƟ gue. This was reﬂ ected in both a reduced ability to work and performance of daily 
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acƟ viƟ es. As the outbreak was very large this had socio-economic implicaƟ ons for af-
fected individuals, their families and communiƟ es.
• Seven years aŌ er the start of the outbreak, the IFA status, at populaƟ on level, was not an 
independent risk factor for an impaired health status or faƟ gue. The long-term diﬀ erence 
in health status between symptomaƟ c, mild and asymptomaƟ c casus regarding faƟ gue is 
noƟ ceable. Although this seemed a diﬃ  cult message to convey, it was well received by 
the general public.
• We found no unanimous answers to quesƟ ons regarding the deﬁ niƟ on, diagnosis, 
aeƟ ology, prognosis and best treatment of faƟ gue aŌ er a Q-fever infecƟ on. The main 
reason being diﬀ erences in deﬁ niƟ ons and tools used to assess the level of faƟ gue.
Although the Q-fever outbreak stopped, the long-term sequels of C. burneƟ i infecƟ ons sƟ ll 
require aƩ enƟ on. It is conceivable that new outbreaks will occur in other countries. Les-
sons learnt from our studies may beneﬁ t both outbreak management and the aŌ er care of 
paƟ ents.
It is essenƟ al to engage paƟ ents and paƟ ent organisaƟ ons at an early stage during an 
outbreak and be transparent, regardless of the content of the message. This builds trust and 
empowers paƟ ents. This is especially important in rural and semi-rural areas with intensive 
animal husbandry acƟ viƟ es and fear of the general public of yet another outbreak of a zoo-
nosis.
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SAMENVATTENDE DISCUSSIE 
Hoofdstuk 2 is descripƟ ef, beschrijŌ  de 2007 - 2010 Q-koorts uitbraak en geeŌ  algemene informaƟ e 
over de diagnose van C. burneƟ i, gevolgen van infecƟ e en veterinaire maatregelen.
Deel I. Serologische screening voor chronische Q-koorts.
Hoofdstuk 3, Grote regionale verschillen in serologische follow-up van paƟ ënten met 
Q-koorts in Nederland
Kennis over dit onderwerp
Ongeveer 2% [1] van paƟ ënten met acute Q-koorts ontwikkelt chronische Q-koorts. Serolo-
gische follow-up van paƟ ënten met acute Q-koorts is essenƟ eel voor het herkennen en Ɵ jdig 
behandelen van chronische Q-koorts [2-4]. Tijdens de Nederlandse Q-koorts uitbraak werd 
geen naƟ onale richtlijn voor serologische follow-up van acute Q-koorts opgesteld.
De gemeenschappelijke gezondheidsdienst (GGD) Hart voor Brabant, ontving informaƟ e 
van paƟ ënten en gezondheidszorg personeel dat niet alle Q-koorts paƟ ënten serologische 
follow-up ontvingen en dat er mogelijk regionale verschillen waren in de follow-up procedure.
Het doel van het onderzoek en wat onderzocht werd
Het doel van dit onderzoek was nagaan in welke mate paƟ ënten met acute Q-koorts sero-
logische follow-up kregen en regionale verschillen in de organisaƟ e van follow-up, kennis en 
gedrag van behandelaars met betrekking tot serologische follow-up, inventariseren.
Tijdens dit onderzoek gebruikten wij data van 3.198 paƟ ënten met een acute infecƟ e tus-
sen 2007 en 2009 gediagnosƟ ceerd, door een van de drie Laboratoria Medische Microbiolo-
gie (LMM) in Noord-Brabant. Eén LMM bood paƟ ënten acƟ eve follow-up, door paƟ ënten een 
herinnering voor bloedafname te sturen. Terwijl de andere twee LMM alleen een serologisch 
test uitvoerden, na aanvraag van een arts. Het follow-up percentage van de twee systemen 
werd vergeleken. De kennis van serologische follow-up van Q-koorts van 209/501 huisartsen 
(HA) en 32/112 medische specialisten werd onderzocht d.m.v. een vragenlijst.
Wat deze studie toevoegt
• De serologische follow-up van paƟ ënten met acute Q-koorts toonde een grote variaƟ e 
tussen de drie laboratoria en liep uiteen van 25% tot 95% [5].
• Tot 95% van paƟ ënten, volgde een acƟ eve oproep voor serologisch testen op.
• Wanneer de oproep alleen aĬ ing van de HA/specialist, ontving 25% van paƟ ënten sero-
logische follow-up.
• Twee derde van HA en specialisten idenƟ ﬁ ceerde risicogroepen voor chronische Q-koorts 
correct.
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• 35% van de HA en 22% van de medische specialisten vroegen nooit serologische follow-
up aan.
• 63% van de HA en 45% van de medische specialisten namen aan dat serologische follow-
up na acute Q-koorts georganiseerd werd door een GGD of een LMM.
Aanbevelingen als gevolg van deze studie
• Een acƟ eve oproep van paƟ ënten door een LMM resulteert in het hoogste serologische 
follow-up percentage voor Q-koorts. Overweeg acƟ eve oproep ook voor andere infecƟ e-
ziekten waarbij serologische follow-up nodig is. Bespreek met laboratoria, behandelaars, 
paƟ ëntenorganisaƟ es of paƟ ëntengroepen welk oproepsysteem het beste kan werken in 
een gegeven situaƟ e.
• Geef iedere paƟ ënt met acute Q-koorts een folder met uitleg over het belang van se-
rologische follow-up en laboratoriumformulieren met follow-up data. De behandelaar/
assistent kan dit laatste uitvoeren.
• Includeer aanbevelingen m.b.t. serologische follow-up in een naƟ onale richtlijn.
Hoofdstuk 4, Strategieën voor vroegsignalering van chronisch Q-koorts; een 
systemaƟ sch literatuur onderzoek
Kennis over dit onderwerp
De internaƟ onale literatuur suggereerde minimaal twee serologische testen (drie en zes 
maanden) het eerste jaar na acute Q-koorts [3,4,6]. In 2008 adviseerden Nederlandse 
auteurs [7] om drie, zes, en twaalf maanden na de diagnose te testen. Drie jaar later, was 
de suggesƟ e om voor serologische follow-up laag en hoog risico paƟ ënten voor chronische 
Q-koorts te onderscheiden [8]. De eerste groep éénmalig te testen na negen maanden en de 
tweede groep na drie, zes, negen en twaalf maanden [8]. Er zijn studies met aanbevelingen 
over follow-up en screeningsstrategieën voor de vroege signalering van chronische Q-koorts 
maar geen internaƟ onale richtlijnen.
Het doel van het onderzoek en wat onderzocht werd
Het doel van de studie was de evidenƟ e van verschillende follow-up en screeningsstrategieën 
voor de vroegsignalering van chronische Q-koorts nagaan. Hierbij werd rekening gehouden 
met criteria voor een hoog risico voor een chronische infecƟ e, de frequenƟ e en Ɵ ming, het 
interval en de duur van follow-up.
Tijdens een systemaƟ sche literatuur onderzoek werd alle relevante literatuur, beschikbaar 
via PubMed of Embase tot 17 oktober 2012, doorgenomen. Dit resulteerde in de inclusie van 
20 publicaƟ es.
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Wat deze studie toevoegt en aanbevelingen
• Een consensus over de deﬁ niƟ e van follow-up strategie ontbreekt. De meeste studies 
suggereerden serologische follow-up van acute Q-koorts paƟ ënten maar informaƟ e over 
het moment, frequenƟ e en de duur waren inconsistent.
• Alleen acute Q-koorts paƟ ënten met de klinische indicaƟ e van een cardiale klep abnorma-
liteit behoren echocardiograﬁ e te krijgen.
• Geef paƟ ënten na acute Q-koorts met een bekende risicofactor frequente serologische 
en klinische follow-up. Voor paƟ ënten zonder risicofactor volstaat éénmalige follow-up 
Ɵ jdens het eerste jaar maar wel na drie maanden b.v. 6 of 9 maanden.
• Kom tot naƟ onale en internaƟ onale richtlijnen m.b.t. de klinische en serologische follow-
up van acute Q-koorts.
• Overweeg in uitbraak situaƟ es serologische screening van hoog risicogroepen op 
C. burneƟ i.
Hoofdstuk 5, PopulaƟ escreening voor chronische Q-koorts zeven jaar na een grote 
uitbraak
Kennis over dit onderwerp
In 2007, waren 25% van de onderzochte inwoners van Herpen, het eerste Nederlandse dorp 
met een Q-koorts uitbraak, seroposiƟ ef [9]. In de nabijheid van dit dorp waren tussen 2007 
en 2010 vier geitenbedrijven C. burneƟ i posiƟ ef. Hiervan hadden twee bedrijven C. burneƟ i 
geïnduceerde abortussen in april 2007 en mei 2008. Eén bedrijf lag in het dorp en het verste 
lag op zes kilometer afstand van het dorpscentrum.
Een immunoﬂ uorescenƟ e test (IFA) IgG anƟ body Ɵ ter fase I ≥1:1.024 Ɵ jdens follow-up is 
een belangrijke marker voor een chronische infecƟ e [8].
Het doel van het onderzoek en wat onderzocht werd
De serologische C. burneƟ i status van inwoners van Herpen werd zeven jaar na het begin van 
de uitbraak onderzocht om chronische Q-koorts op te sporen, ook na een asymptomaƟ sche 
infecƟ e. Het doel van dit onderzoek was personen met chronische Q-koorts Ɵ jdig behandelen 
en de noodzaak inschaƩ en van grootschalige screening in andere uitbraakgebieden.
De serologische C. burneƟ i status van 1.517 volwassen bewoners (71% respons) werd 
nagegaan met de IFA. De IFA aŅ apwaarde van IgG fase I of II ≥1:64 wees op een doorge-
maakte C. burneƟ i infecƟ e. Deelnemers met een IgG fase I ≥1:512 [10] werden beschouwd als 
risicovol voor chronische Q-koorts. Zij werden voor nader klinisch onderzoek verwezen om 
deze diagnose al dan niet te sluiten.
254  |  Chapter 10
Wat deze studie toevoegt
• Bijna 34% (513/1.517) van de deelnemers was zeven jaar na het begin van de uitbraak, 
C. burneƟ i seroposiƟ ef.
• 17% van de in 2007 IFA posiƟ eve deelnemers seroconverteerden en waren seronegaƟ ef 
in 2014. De inschaƫ  ng is daarom dat 41% van de deelnemers een C. burneƟ i infecƟ e 
doormaakten.
• Van zes deelnemers, 1,2% van de seroposiƟ even, was de IgGI Ɵ ter ≥1:512. Allen waren 
PCR negaƟ ef. Twee van deze deelnemers kregen al eerder de diagnose chronische Q-
koorts. De overige vier werden klinisch onderzocht. Eén van hen, een man ouder dan 
65 jaar, met een toegenomen erythrocyten sedimentaƟ e snelheid, renale insuﬃ  ciënƟ e, 
diabetes mellitus type 2, en een cardiale ruis, kreeg de diagnose chronische Q-koorts. 
AnamnesƟ sch had hij geen acute Q-koorts episode doorgemaakt.
• Van de 69 deelnemers die bekend waren met cardiovasculaire risicofactoren, bleken 
16 (23%) IFA-posiƟ ef. Bij drie deelnemers was dit na Q-koorts vaccinaƟ e, terwijl 13 op 
natuurlijke wijze geïnfecteerd werden. Twee van deze 13 deelnemers (15%) ontwikkelden 
chronische Q-koorts.
• Het screenen van de algemene volwassen populaƟ e van Herpen, zeven jaar na het begin 
van de uitbraak, idenƟ ﬁ ceerde één nieuw (1/1.517) geval van chronische Q-koorts.
Aanbevelingen
• Screen paƟ ënten bekend met cardiovasculaire risicofactoren voor chronische Q-koorts, 
voor C. burneƟ i zodra een uitbraak is vastgesteld en vaccineer deze onbeschermde risico-
groep.
• Houdt rekening met seroreversie. NegaƟ eve C. burneƟ i serologie (IFA) sluit een eerdere 
infecƟ e niet uit. Overweeg dit bij de vaccinaƟ e van hoog risicogroepen.
• Huisartsen in een hoog incidenƟ e gebied dienen zich te realiseren dat chronische Q-
koorts zich ook kan ontwikkelen na het doormaken van een asymptomaƟ sche C. burneƟ i 
infecƟ e.
• Algemene populaƟ escreening voor chronische Q-koorts, zeven jaar na het begin van een 
uitbraak, lijkt weinig op te leveren.
Discussie deel I.
Het is essenƟ eel dat iedereen met de diagnose acute Q-koorts informaƟ e ontvangt over chro-
nische Q-koorts, het belang van serologische follow-up en deze follow-up krijgt [5], vooral 
Ɵ jdens het eerste jaar na de infecƟ e [10]. Geïnformeerde paƟ ënten kunnen de behandelaar 
verzoeken om serologische follow-up wanneer deze niet wordt aangeboden. Tijdens de Q-
koorts uitbraak in Nederland, bleek dat het serologisch testen van acute Q-koorts paƟ ënten 
Ɵ jdens het eerste jaar, 98% [10] van chronische Q-koorts al opspoorde.
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De Ɵ jd tussen de ontwikkeling van chronische Q-koorts en de diagnose na een asympto-
maƟ sche infecƟ e is onbekend. Chronische Q-koorts kan [4,11] jaren na de infecƟ e opgespoord 
worden wanneer men niet eerder screent. In geval van niet opgespoorde chronische Q-koorts 
gaat het vaak om aanvankelijk symptomaƟ sche paƟ ënten die geen medische hulp zochten of 
geen follow-up ontvingen. Of personen die een asymptomaƟ sche infecƟ e doormaakten. Van 
alle in de Nederlandse databank geregistreerde gevallen van chronische Q-koorts, kan een 
minderheid van 38%, zich een episode van acute Q-koorts herinneren [12]. Het opvolgen 
van asymptomaƟ sche of niet gediagnosƟ ceerde C. burneƟ i infecƟ es en of het screenen van 
personen met een hoog risico voor chronische Q-koorts – om chronische Q koorts vast te 
stellen, is onmogelijk. Het screenen van een populaƟ e [13], jaren na een grote uitbraak, vergt 
een forse inspanning en investering en leverde weinig op.
Onmiddellijke openheid over een Q-koorts uitbraak in een regio met informaƟ e aan de 
bevolking en behandelaars over serologisch screenen en de mogelijke lange termijn com-
plicaƟ es, samen met een acƟ ef serologisch follow-up systeem is essenƟ eel om chronische 
Q-koorts snel te herkennen. Zowel de bevolking als behandelaars zijn zich dan niet alleen 
bewust van acute Q-koorts Ɵ jdens een uitbraak maar ook opleƩ end in de toekomst met 
betrekking tot chronische Q-koorts.
De Q-koorts vaccinaƟ ecampagne in 2011, na de uitbraak was beperkt. Het percentage 
personen met een risicofactor voor chronische Q-koorts dat gevaccineerd werd is laag [4] (zie 
hoofdstuk 5). Het is onduidelijk of dit een gevolg is van de selecƟ eprocedure van de behan-
deld arts of dat paƟ ënten zelf besloten zich niet te laten vaccineren. Ook hier is het belangrijk 
om zowel artsen als de populaƟ e in een uitbraakgebied te informeren zodat personen met 
een risicofactor hun eigen geïnformeerde keuze kunnen maken.
Deel II. De gezondheidsstatus in het bijzonder vermoeidheid en 
ziekteverzuim na een C. burneƟ i infecƟ e
Hoofdstuk 6, Zelf gerapporteerd ziekteverzuim en lange termijn symptomen van 
Q-koorts
Kennis over dit onderwerp
NaƟ onale of internaƟ onale studies, over ziekteverzuim en de mogelijkheid tot werken waren 
in 2009 niet beschikbaar via Pubmed.
De GGD Hart voor Brabant ontving regelmaƟ g vragen van bedrijfsartsen, huisartsen, me-
dische specialisten en paƟ ënten over de impact van Q-koorts op aanhoudende symptomen, 
in het bijzonder vermoeidheid en consequenƟ es voor werk.
Het doel van het onderzoek en wat onderzocht werd
Het doel was om de frequenƟ e en duur van ziekteverzuim, symptomen en geassocieerde 
risicofactoren 12 tot 26 maanden na acute Q-koorts, na te gaan. De studiepopulaƟ e bestond 
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uit alle 870 paƟ ënten met acute Q-koorts en een eerste ziektedag in 2007 or 2008 die gemeld 
werden door de GGDen ‘Hart voor Brabant’ and ‘Brabant Zuid-Oost’. De GGD ‘Hart voor Bra-
bant’ stuurde paƟ ënten die in 2007 gemeld werden in februari 2009 een vragenlijst (13–26 
maanden na de eerste ziektedag). Voor paƟ ënten die in 2008 gemeld werden, was dit een 
jaar na aanvang van de symptomen. De respons was 64% (n=556).
Wat deze studie toevoegt
• Na acute Q-koorts, was het ziekteverzuim van 40% van werknemers langer dan één 
maand.
• Na 12 tot 26 maanden kon 9% van de werknemers die hun werk hervaƩ en niet meer op 
hetzelfde niveau funcƟ oneren als voor acute Q-koorts. Dit was voornamelijk het gevolg 
van vermoeidheid of concentraƟ eproblemen.
• Bijna één derde van de deelnemers kon de dagelijkse acƟ viteiten niet volledig hervaƩ en.
• Na 12 tot 26 maanden rapporteerden 40% van de deelnemers klachten die zij als een 
gevolg van de Q-koorts infecƟ e zagen. Deze klachten waren vermoeidheid 20%, concen-
traƟ eproblemen 10%, spierpijn 9%, en nachtzweten 8%.
Aanbevelingen
• Bedrijfsartsen, huisartsen, medische specialisten en beleidsmakers dienen zich bewust 
te zijn, geïnformeerd en geïnstrueerd te worden hoe om te gaan met deze lange termijn 
consequenƟ es voor het individu die ook hun weerslag hebben op maatschappelijk niveau.
Hoofdstuk 7, De gezondheidsstatus van Q-koorts paƟ ënten na lange termijn opvolging
Kennis over dit onderwerp
Nederlandse studies gebruiken vaak het gevalideerde Nijmegen Clinical Screening Instrument 
(NCSI) om de verschillende subdomeinen van de gezondheidsstatus na te gaan [14]. Ver-
moeidheid is een apart subdomein van dit instrument. Verschillende internaƟ onale studies 
beschrijven vermoeidheid na acute Q-koorts [15-25].
Het doel van het onderzoek en wat onderzocht werd
Het doel van deze studie is 12 tot 26 maanden na acute Q-koorts de gezondheidsstatus in 
detail nagaan van de door de GGD in 2007 en 2008 gemelde paƟ ënten. Dit om clinici en 
paƟ ënten een beter inzicht te geven in het natuurlijk verloop en de voorspellers van de 
gezondheidsstatus na acute Q-koorts.
De studiepopulaƟ e, methode en respons zijn beschreven in hoofdstuk 6. De gezond-
heidsstatus met de verschillende subdomeinen werden vastgesteld d.m.v. de NCSI. Con-
trolegroepen waren gezonde individuen (n= 65) en paƟ ënten met Chronische ObstrucƟ eve 
Pulmonaire Disease (COPD) (n= 128).
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Wat deze studie toevoegt
• 12 tot 26 maanden na aanvang van de acute Q-koorts waren 7 van de 8 subdomeinen van 
de NCSI signiﬁ cant aangedaan ten opzichte van de gezonde controlegroep.
• Bijna 60% van de Q-koorts paƟ ënten rapporteerde vermoeidheid waarvan 44% ernsƟ ge.
• Bij 45% van de Q-koorts paƟ ënten was de algemene kwaliteit van leven ernsƟ g aange-
daan.
• PaƟ ënten die Ɵ jdens de episode van acute Q-koorts gehospitaliseerd werden, rappor-
teerden signiﬁ cant vaker lange termijn; gedragsmaƟ ge beperkingen, een verminderde 
gezondheid gerelateerde kwaliteit van leven en subjecƟ eve symptomen.
Aanbevelingen
• Informeer artsen over deze lange termijn gevolgen zodat zij paƟ ënten beter kunnen 
begrijpen en ondersteunen en hen verwijzen naar specialisƟ sche zorg b.v. een Q-koorts 
experƟ se centrum.
• Ontwikkel behandelrichtlijnen voor aangedane paƟ ënten en behandelaars.
• Beleidsmakers dienen deze lange termijn ziektelast te overwegen bij besluitvorming over 
controlemaatregelen bij uitbraken.
Hoofdstuk 8, De gezondheidsstatus van een dorpspopulaƟ e, zeven jaar na een grote 
Q-koorts uitbraak
Kennis over dit onderwerp
Vanaf 2010, werd informaƟ e van verschillende Nederlandse studies [22-26] over de lange 
termijn gevolgen van de gezondheidsstatus na acute Q-koorts, gemeten met het NCSI be-
schikbaar. Eén jaar na het begin van de klachten rapporteerden 74% van deze paƟ ënten 
(n=54) abnormale vermoeidheid [22].
Zeven jaar na het begin van de uitbraak ontving de GGD Hart voor Brabant nog vragen van 
bedrijfsartsen, andere medici en paƟ ënten over de lange termijn gevolgen van Q-koorts op 
de gezondheidsstatus en in het bijzonder vermoeidheid.
Het doel van het onderzoek en wat onderzocht werd
Het doel van de ‘Q-Herpen-II’ studie was de relaƟ e tussen de aanwezigheid van C. burneƟ i 
anƟ lichamen en de gezondheidsstatus met de nadruk op vermoeidheid nagaan. Alle 2.161 
volwassen inwoners (18 jaar en ouder) van het dorp Herpen (postcode 5373) kregen een 
uitnodiging voor: het invullen van een vragenlijst, waar de NCSI deel van uit maakte en een 
bloedafname in januari of maart 2014. Een IFA IgG fase I of II Ɵ ter ≥1:64 werd gezien als 
posiƟ ef. De respons was 71% (1.534/2.161).
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Wat deze studie toevoegt
• Zeven jaar na het begin van de uitbraak was er geen signiﬁ cant verschil in de mate van 
vermoeidheid tussen deelnemers met en zonder C. burneƟ i anƟ lichamen.
• OnaĬ ankelijk van de IFA status rapporteerden 38% van de deelnemers vermoeidheid 
waarvan 23% ernsƟ ge. De IFA status was geen onaĬ ankelijke risicofactor voor vermoeid-
heid.
• Na het doormaken van symptomaƟ sche acute Q-koorts gevolgd door een naƟ onale mel-
ding [27] was zeven jaar later 63% (n=31/49) van de deelnemers vermoeid, waarvan 47% 
ernsƟ g.
• Na een milde of asymptomaƟ sche infecƟ e die door de betrokkene niet was opgemerkt en 
niet voldeed aan de meldingscriteria [27] rapporteerde 33% (n=150/451) vermoeidheids-
klachten waarvan 20% ernsƟ ge.
• Vermoeidheid na een infecƟ e met C. burneƟ i lijkt zich voornamelijk te beperken tot de 
groep met symptomaƟ sche acute Q-koorts die als gevolg daarvan voldeed aan de naƟ o-
nale meldingscriteria [27].
• Het maakte voor de mate van moeheid niet uit of deelnemers al dan niet op de hoogte 
waren van hun uitslag of dachten dat ze deze infecƟ e doormaakten.
• De C. burneƟ i IFA Ɵ ter en de mate van vermoeidheid waren niet gerelateerd.
Aanbevelingen
• Betracht voorzichƟ gheid bij het verklaren van vermoeidheid door een doorgemaakte 
C. burneƟ i infecƟ e. Andere morbiditeit die vermoeidheid kan veroorzaken dient (voor 
zover mogelijk) eerst uitgesloten te worden.
• Vraag of ga in het paƟ ëntendossier na wat de ernst van de aanvankelijke infecƟ e was.
• Ga in toekomsƟ g onderzoek na welk pathogeen mechanisme bepalend is voor het verschil 
in de lange termijn mate van vermoeidheid tussen symptomaƟ sche (genoƟ ﬁ ceerde) en 
milde of asymptomaƟ sche C. burneƟ i infecƟ es.
Hoofdstuk 9, Vermoeidheid na acute Q-koorts: een systemaƟ sch literatuuronderzoek
Kennis over dit onderwerp
Post infecƟ euze vermoeidheidssyndromen (PIVS) [16,17] kunnen ook ontstaan na andere in-
fecƟ es [18] door bijvoorbeeld Borrelia burgdorferi [19], Legionella pneumophila [24] Epstein 
Barr en Ross River virus [18].
In Australia is het Q-koorts vermoeidheidssyndroom (QVS) het meest voorkomende chro-
nische gevolg van acute Q koorts dat bij 10-15% van paƟ ënten voorkomt [20]. Langdurige 
vermoeidheid na een acute Q-koorts episode kan 10 [17,21] tot 20 jaar [28] aanhouden 
en gepaard gaan met symptomen die lijken op het chronische vermoeidheidssyndroom 
(CVS) [16]. Hypothesen m.b.t. de eƟ ologie [29] waren tegenstrijdig en varieerden van een 
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verstoorde cytokine producƟ e [30], ontwikkeling van symptomen bepaalt door gastheer en 
geneƟ sche factoren [30-32], tot het in standhouden van klachten door psychogene factoren 
en gedrag [33]. Meningen over de mogelijke behandeling van QVS verschilden [34-36]. Daar-
naast bestonden er vragen over prevenƟ e en prognose.
Het doel van het onderzoek en wat onderzocht werd
Terugkerende vragen over de deﬁ niƟ e, achtergrond/beschrijving, eƟ ologie, prognoses, pre-
venƟ e en behandeling van vermoeidheid na een C. burneƟ i infecƟ e resulteerden in een sys-
temaƟ sch literatuuronderzoek. Alle relevante beschikbare literatuur over deze onderwerpen 
tot 26 mei 2015 werd gezocht met behulp van PubMed, Embase and PsycInfo en resulteerde 
in de inclusie van 61 arƟ kelen.
Wat deze studie toevoegt
• Een chronologisch overzicht van alle beschikbare literatuur tot 26 mei 2015, over 
vermoeidheid na infecƟ e met C. burneƟ i, georganiseerd in de onderwerpen deﬁ niƟ e, 
eƟ ologie, achtergrond, prognose en behandeling.
• Een uniforme internaƟ onale deﬁ niƟ e van lange termijn post infecƟ euze vermoeidheid 
(PIV) of QVS was niet beschikbaar. Doordat de meeƟ nstrumenten en methoden ver-
schilden tussen studies, beïnvloedde dit de interpretaƟ e van de diagnosis, prevalenƟ e, 
eƟ ologie, prognoses en behandelkeuze.
• De Nederlandse QVS richtlijn was het enige document met een stappenplan voor de 
diagnose QVS.
• Dikwijls gerapporteerde klachten die samengaan met vermoeidheid na een Q-koorts in-
fecƟ e waren: musculoskeletaire klachten, neurocogniƟ eve symptomen, slaapproblemen, 
hoofdpijn, wazig zicht, toegenomen (nacht) zweten, respiratoire klachten, en stemmings-
stoornissen.
• Vermoeidheid na acute Q-koorts heeŌ  een grote ziektelast en negaƟ eve impact op de 
gezondheidsstatus van paƟ ënten en hierdoor economische implicaƟ es. De meerderheid 
van paƟ ënten werkten weer binnen 12 maanden na acute Q-koorts, maar bijna 20% rap-
porteerde afgenomen werk parƟ cipaƟ e.
• EƟ ologie: de rol van geneƟ sche variaƟ e in de gastheer immuun-reacƟ e bij QVS was tegen-
strijdig en kan een gevolg zijn van individuele immuunreacƟ es op C. burneƟ i in plaats van 
geneƟ sche kenmerken. Cytokine disregulaƟ e die symptomen in QVS beïnvloeden kunnen 
een gevolg zijn van immunomodulatoire complexen van niet levend niet afgebroken 
C. burneƟ i DNA of anƟ genen, maar resultaten waren tegenstrijdig.
• Een voorspeller voor PIVS inclusief QVS: was de ernst van de acute Q-koorts. Psychologi-
sche of microbiologische factoren waren geen voorspellers.
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• Behandeling: gerandomiseerd vergelijkende onderzoeken (RCT’s) werden niet uitgevoerd, 
de weinige beschikbare data waren inconsistent. De Nederlandse QVS richtlijn suggereert 
dat CogniƟ eve Gedrags Therapie (CGT) en Graded Exercise Therapy (GET) vermoeidheid 
in paƟ ënten met QVS kunnen reduceren maar bewijs hiervoor ontbreekt.
Aanbevelingen
• Een internaƟ onale consensus is nodig voor het vaststellen van de deﬁ niƟ e PIVS even-
als uniforme instrumenten. Behalve Q-koorts moet men rekening houden met andere 
infecƟ eziekten die kunnen lijden tot dit syndroom. Zolang een dergelijke internaƟ onale 
consensus ontbreekt, geeŌ  de Nederlandse QVS richtlijn [36] de meest recente gedetail-
leerde descripƟ e en diagnose en is als zodanig bruikbaar.
• Alleen prospecƟ eve, klinische studies en behandel trials zoals de Qure-studie [37] kunnen 
mogelijk antwoord geven op vragen m.b.t. de deﬁ niƟ e, prognose, behandeling en de 
gevolgen voor vermoeidheid na een C. burneƟ i infecƟ e.
• ToekomsƟ g onderzoek dient het pathogene mechanisme dat een rol speelt in de mate van 
vermoeidheid tussen symptomaƟ sche en milde of asymptomaƟ sche C. burneƟ i infecƟ es 
na te gaan.
Discussie deel II
Het gebruik van een gevalideerd uniform instrument om PIVS, inclusief QFS na te gaan is 
essenƟ eel. Acht procent van paƟ ënten gaf aan dat zij vermoeid waren als deze vraag werd 
gesteld (Hoofdstuk 6). Dezelfde studiepopulaƟ e rapporteerde 60% abnormale vermoeidheid 
waarvan 44% ernsƟ g bij invullen van de NCSI (Hoofdstuk7). Dit grote verschil illustreert en 
benadrukt het belang van het gebruik van een gestandaardiseerd instrument voor enige 
vergelijking.
In toekomsƟ ge studies, hoort de controlegroep zorgvuldig gekozen en serologisch getest 
te worden op C. burneƟ i anƟ lichamen. Aanvankelijk bestond de controlegroep uit gezonde 
personen (Hoofdstuk 7) die de afgelopen maanden geen specialist bezochten en daarom 
gezonder waren dan de algemene populaƟ e. De andere controlegroep bestond uit personen 
met COPD (Hoofdstuk 7). PaƟ ënten hadden acute Q-koorts doorgemaakt, waren geregis-
treerd door de GGD en naƟ onaal gemeld. De twee controlegroepen werden niet serologisch 
getest op aanwezigheid van C. burneƟ i anƟ lichamen. De populaƟ estudie (Hoofdstuk 8) is 
wel een realisƟ sche weergave van de volwassen populaƟ e en iedere deelnemer werd se-
rologische getest op C. burneƟ i anƟ lichamen. Deze studie bood de unieke kans om acute 
Q-koorts, milde, onopgemerkte en asymptomaƟ sche C. burneƟ i infecƟ es te vergelijken met 
seronegaƟ even, wat resulteerde in onverwachte maar meer realisƟ sche bevindingen. De 
bevinding dat de gezondheidsstatus en de mate van vermoeidheid vergelijkbaar was tussen 
sero- posiƟ eve en negaƟ eve deelnemers kwam overeen met een kleine studie van Limonard 
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et al. [23]. Limonard beschreef dat de gezondheidsstatus van C. burneƟ i seroposiƟ eve (n=11) 
en negaƟ eve (controles) (n=23) vergelijkbaar was. Onze grote studie (Hoofdstuk 8) had 
voldoende power om dit punt te conﬁ rmeren. Het bevesƟ gde ook de eerdere veronderstel-
lingen dat vermoeidheid in het algemeen ontstaat na acute Q-koorts en zeer zelden na een 
subklinische infecƟ e [20].
Nadat de resultaten van de studies beschreven in hoofdstuk 6 and 7 openbaar werden 
drong de GGD Hart voor Brabant aan op een gestandaardiseerde benadering van personen 
met langdurige vermoeidheid na acute Q-koorts. De mulƟ disciplinaire QVS richtlijn [36] 
ontstond mede als gevolg hiervan. De paƟ ëntenorganisaƟ e Q-uesƟ on nam acƟ ef deel aan 
de werkgroep van deze richtlijn. Zo ontstond een samenwerking met Q-uesƟ on die o.a. 
resulteerde in een bijdrage aan de vormgeving van de “Q-Herpen II” populaƟ estudie en het 
bekendmaken van de resultaten in lekentaal.
De volle impact van de uitbraak, inclusief werk gerelateerde factoren, zal onderzocht 
worden in de studie “ImpaQt” [38], een meta-analyse, die naast andere studies ook data van 
de drie hier beschreven studies in hoofdstukken 6, 7 en 8 includeert.
Conclusies
Via een reeks studies was het mogelijk vragen met betrekking tot het screenen voor chroni-
sche Q-koorts en de gezondheidsstatus inclusief vermoeidheid na een infecƟ e met C. burneƟ i, 
te beantwoorden.
De belangrijkste lessen met betrekking tot serologische screening voor chronische 
Q-koorts zijn:
• Centraal georganiseerde serologische follow-up heeŌ  een hoge respons. PaƟ ënten die 
geïnformeerd worden over de redenen en momenten van follow-up zijn goed in staat om 
een eigen keuze te maken. Dit uit zich in een hoog percentage paƟ ënten dat zich screent. 
Follow-up wordt onvoldoende geïniƟ eerd door behandelaars.
• Serologische follow-up op 3, 6, 9 en12 maanden is geïndiceerd voor hoog risicogroepen 
voor chronische Q-koorts. Eenmalig screenen binnen 12 maanden na de acute infecƟ e 
kan voldoende zijn voor anderen.
• Een algemene populaƟ escreening voor chronische Q-koorts, zeven jaar na een uitbraak 
in een hoog incidenƟ e gebied, levert weinig op en is niet aanbevolen. In plaats hiervan 
is screenen op C. burneƟ i anƟ lichamen van bekende cardiovasculaire risicogroepen voor 
chronische Q-koorts een opƟ e. Dit dient te gebeuren zodra er een uitbraak is. VaccinaƟ e 
dient zo snel mogelijk uitgevoerd te worden als van toepassing.
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De belangrijkste lessen m.b.t. de gezondheidsstatus zijn:
• 12 tot 26 maanden na acute Q-koorts hadden deelnemers een aangedane gezondheids-
status met vooral vermoeidheid. Zij rapporteerden zowel een afname in de uitvoer van 
hun werk als hun dagelijkse acƟ viteiten. Omdat de uitbraak groot was had dit socio-eco-
nomische implicaƟ es voor de betrokken individuen, hun families en gemeenschappen.
• De IFA status was zeven jaar na de uitbraak, op populaƟ e niveau, geen onaĬ ankelijke 
risicofactor voor een slechtere gezondheidsstatus of vermoeidheid. Met betrekking tot 
vermoeidheid is het verschil tussen acute Q-koorts, milde en asymptomaƟ sche infecƟ es 
opvallend. Deze schijnbaar moeilijke boodschap werd goed ontvangen door het algemene 
publiek.
• Eenduidige antwoorden op vragen m.b.t. de deﬁ niƟ e, diagnose, eƟ ologie, prognose en 
de beste behandeling van vermoeidheid na Q-koorts waren niet beschikbaar. De belang-
rijkste reden was de verschillen in deﬁ niƟ es en instrumenten die gebruikt werden om de 
mate van vermoeidheid vast te stellen.
De Q-koorts uitbraak in Nederland is gestopt. Nu vragen vooral de lange termijn complica-
Ɵ es van C. burneƟ i infecƟ es aandacht. Het is goed mogelijk dat nieuwe uitbraken in andere 
landen ontstaan. Anderen kunnen dan proﬁ teren van de hier geleerde lessen. Dit kan het 
uitbraakmanagement en de nazorg van paƟ ënten ten goede komen.
OnaĬ ankelijk van de boodschap, is het essenƟ eel om paƟ ënten en paƟ ëntenorganisaƟ es 
in een vroeg stadium van een uitbraak te betrekken, en transparant te zijn. Zo bouwt men 
vertrouwen op en geeŌ  paƟ ënten kennis en macht. Dit is bijzonder belangrijk in rurale en 
semi-rurale gebieden met intensieve veehouderij en de angst van de bevolking voor een 
volgende zoönose uitbraak.
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DANKWOORD 
Mooi dat wetenschappelijk onderzoek deel uitmaakt van de opleiding arts maatschappij en 
gezondheid. Van idee tot publiceerbaar arƟ kel in 56 dagen, is een goede stok achter de deur.
Het onderzoek begon als een economische studie. Johan Polder1, jij gaf aan: “als je denkt 
dat je het kan - doen!”. Onze gesprekken inspireerden mij. Je maakte alƟ jd Ɵ jd vrij om mij 
een zetje te geven. Juriaan Prins2, onvermoeibaar stopte je veel uren in de kostenstudie. Een 
openbaring al die berekeningen. Dank voor alle inzet en uitleg.
Hans Bor3, vanaf het begin was je betrokken bij mijn onderzoeken. Jouw uitleg en advies 
over datamanagement en analyse waren een ontdekkingsreis in de wereld van de bio-
staƟ sƟ ek, aan de hand van een geduldige bescheiden leermeester. Jij gaf telkens aan: “maak 
er een promoƟ etraject van“. Hans, dank voor dit alles, dit manuscript is het resultaat!
Van de GGD en het team infecƟ eziektebestrijding dank ik een ieder die mijn promoƟ e-
traject mogelijk maakte, faciliteerde en/of mij een warm hart toedroeg. Jos van der Sande, 
jij gaf mij de ruimte te promoveren en streek de kreukels glad. Jou dank ik in het bijzonder 
voor jouw benaderbaarheid, spitsvondigheid en vertrouwen in mij. ClemenƟ ne Wijkmans, jij 
vertegenwoordigde de GGD Hart voor Brabant en het onderzoek Ɵ jdens vele overleggen en 
uren.
Twee promotoren. Wat een luxe! Koos van der Velden, je laveerde succesvol tussen de 
klippen door en glimlachte om en tegen de beren op de weg. Roel CouƟ nho, wereldreiziger 
met een overvolle agenda. En toch die snelle, vakkundige reacƟ e. Commentaar, recht voor 
z’n raap alƟ jd open voor discussie. Wat bevrijdend! Wim van de Hoek, steeds wist je tekst 
waar ik op vastliep vlot te trekken. Wim, ik ben dankbaar dat ik op jouw Q-koorts kennis en 
netwerk mocht mee liŌ en. De promoƟ e overleggen gaven mij nieuwe inzichten en de impuls 
om door te zeƩ en. Deze discussies, het relaƟ veren en de dosis humor mis ik.
Malou, Paula, Mandy, Anne, Zindia, Jelle en Karen, als stagiaires maakten jullie bijdragen 
deze onderzoeken mogelijk. De samenwerking was ﬁ jn en ook voor mij leerzaam.
Lieke Wielders en Joris van Loenhout, ﬁ jn om ad hoc met jullie van gedachten te wisselen 
over onderzoeke. Dank voor alle steun en advies Ɵ jdens dit hele promoƟ eproces.
De lijst van medeauteurs van deze mulƟ disciplinaire onderzoeken is lang. De samenwer-
king met ieder van jullie was voor mij een leerzaam voorrecht. Peter Schneeberger5, omdat je 
eind of medeauteur van op één na alle arƟ kelen in dit proefschriŌ  noem ik jou als enige apart. 
1Gezondheidseconoom RIVM en Tranzo, 2Econometrist bij Sociaal Economisch Onderzoek en nu het 
UWV, 3BiostaƟ sƟ cus bij de academische werkplaats AMPHI, 4toenmalig hoofd team algemene gezond-
heidszorg GGD Hart voor Brabant nu GGD Nederland, 5arts-medisch microbioloog in het Jeroen Bosch 
Ziekenhuis. 
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Peter, dank dat je jouw aanstekelijke enthousiasme, onderzoeksideeën en enorme vakkennis 
deelde. Jouw commentaar was wervelend snel, tussen drie telefoontjes door, inspirerend, 
soms crypƟ sch en stof tot nadenken.
De paƟ ëntenvereniging Q-uesƟ on was toenemend betrokken bij de onderzoeken. Van 
concept idee tot de communicaƟ e van resultaten aan deelnemers. Michel van de Bergh, Nel-
leke Maathuis en Ria van Son, jullie vragen, en vertaling naar onderzoeksdeelnemers waren 
een essenƟ ële bijdrage. Dank voor jullie gedreven inzet.
Wat mooi de opƟ male samenwerking van zoveel vrijwilligers van vele organisaƟ es bij 
de uitvoer van Q-Herpen-II in 2014. Het voelde voor mij en ik hoop ook voor jullie als een 
feestje....
Dank aan alle studiedeelnemers. Dankzij jullie ingevulde vragenlijsten (soms bijna boek-
werken) en soms bloeddonaƟ es werden deze onderzoeken mogelijk.
Koos Jaap van Zwieten6 toen de deuren van de Radboud Universiteit Nijmegen (RU) voor 
mij, een vierdejaars student geneeskunde uit Suriname in 1984 dicht bleven (behalve voor 
het eerste studiejaar) vond jij een ingang bij de Universiteit Leuven. Daar ben ik jou alƟ jd 
dankbaar voor gebleven. Ik nam mij in 1984 voor nooit meer voet in de RU te zeƩ en. Het is 
daarom bijzonder dat ik juist hier promoveer.
Tijdens dit promoƟ etraject kon ik dankzij AMPHI niet om de RU heen, dat een warm nest 
bleek. Dank aan een ieder die hier aan bijdroeg.
Het thuisfront moest de afgelopen jaren afzien. Zeker als moeders oa weer geen bood-
schappen deed, niet kookte, geen Ɵ jd had en laat thuiskwam. Benjamin, je moest het maar 
rechtbreien. Gelukkig stelde je grenzen-“enough Ɵ me on the confuser @£&!”. Juist nu “het” 
af is en ik er weer helemaal “ben” vliegen jullie, Alia en Savana uit. Ik kan deze jaren niet 
inhalen maar weet dat jullie voor mij alƟ jd op de eerste plaats staan.
6Emeritus professor Geneeskunde en Levenswetenschappen, Universiteit van Hasselt.
About the author  |  271
11
ABOUT THE AUTHOR 
Gabriella Morroy commenced her study of Medicine in 1979 in Surinam, South America. 
The military coup in 1982 led to the closure of the University in Surinam and an exodus of 
students. Gabriella travelled to Europe in 1983. In 1988 she obtained her medical diploma 
from the Catholic University of Leuven, Belgium aŌ er her last internship at the Department 
of InfecƟ ous Diseases in Avicenne Hospital, in Rabat, Morocco.
AŌ er compleƟ ng her medical studies, Gabriella worked for six months at the Department 
of InfecƟ ous Diseases at the Municipal Health Service (MHS) in Amsterdam, and a similar 
period at the NaƟ onal InsƟ tute for Public Health and the Environment (RIVM). Gabriella 
completed eight missions with Médecins Sans FronƟ ères (MSF) France and Holland in Africa 
and the Middle East. Tasks ranged from curaƟ ve care, to the training of Community Health 
Workers, Water and SanitaƟ on Oﬃ  cers and TradiƟ onal Midwives; to the coordinaƟ on of 
large vaccinaƟ on campaigns and the management of refugee camps, to the rehabilitaƟ on of 
hospitals and outpaƟ ent services.
In 1991 Gabriella obtained her Diploma in Tropical Medicine and Hygiene from the InsƟ -
tute of Tropical Medicine in Liverpool. From 1992 to 1996 Gabriella worked as the country 
representaƟ ve for the Tropical InsƟ tute of Antwerp on a Sexually TransmiƩ ed InfecƟ on In-
tervenƟ on Research Programme with the WHO CollaboraƟ ve group in Nairobi, Kenya. From 
1997 onwards Gabriella worked as a Medical Consultant in East Africa and was a co-founder 
and Community Health Director of Wildlife Works, Kenya hƩ p://www.wildlifeworks.com/.
In 2001, Gabriella moved with her partner and two daughters from Kenya to the Nether-
lands. IniƟ ally Gabriella worked at the MHS Noord West Veluwe in Harderwijk, fulﬁ lling a wide 
range of duƟ es from Social Medical Advice, to Environmental Health and InfecƟ ous Diseases. 
From 2003 onwards she worked at the Department of InfecƟ ous Diseases of the MHS Hart 
voor Brabant in ‘s-Hertogenbosch. In 2010 Gabriella won the MoƟ vaƟ on Prize for Original 
and Applied Research awarded by the NaƟ onal InsƟ tute of Public Health (NSPOH) and be-
came registered as a Medical Consultant Communicable Disease Control. Since mid-2012 
she combines work at the MHS with a part Ɵ me PhD posiƟ on at the Academic CollaboraƟ ve 
Centre (AMPHI) at the Radboud University, Nijmegen.
Gabriella is a member of the Dutch board of InfecƟ ous Diseases (NVIB) and secretary of 
its EducaƟ on Commission.
StarƟ ng in 2011 Gabriella completed three years of the Hatha Yoga teachers’ course at 
Saswitha a Teaching InsƟ tute for Yoga and Philosophy (Bilthoven the Netherlands). Since 
2012 she is an elected Regional RepresentaƟ ve (Region Middle North and East Brabant) of 
the Diabetes OrganisaƟ on of the Netherlands (Diabetes Vereniging Nederland).
272  |  CHAPTER 11
LIST OF PUBLICATIONS 
Morroy G, Keijmel SP, Delsing CE, Bleijenberg G, Langendam M, Timen A, Bleeker-Rovers CP
FaƟ gue Following Acute Q-Fever: a SystemaƟ c Literature Review. PLoS ONE, 2016. 11(5): 
e0155884. DOI:10.1371/journal.pone.0155884
Morroy G, van der Hoek W,Nanver ZD, Schneeberger PM, Bleeker-Rovers CP,Van der Velden 
J, CouƟ nho RA.The health status of a village populaƟ on, seven years aŌ er a major Q-fever 
outbreak. Epidemiology and infecƟ on, 2015, 1-10. DOI:10.1017/S0950268815002472.
Morroy G, van der Hoek W, Albers J, CouƟ nho RA, Bleeker-Rovers CP, Schneeberger PM. 
PopulaƟ on Screening for Chronic Q-Fever Seven Years aŌ er a Major Outbreak. PloS ONE, 
2015. 10(7), e0131777. DOI:10.1371/journal.pone.0131777
Van Loenhout JA, Wielders CC, Morroy G, Cox MJ, Van der Hoek W, Hautvast JL, Paget WJ, 
Van der Velden J. Severely impaired health status of non-noƟ ﬁ ed Q-fever paƟ ents leads to an 
underesƟ maƟ on of the true burden of disease. Epidemiology and infecƟ on, 2015. 1-8.
Wielders CC, van Loenhout JA, Morroy G, Rietveld A, Notermans DW, Wever PC, HM Renders, 
CAP Leenders, Wim van der Hoek, Schneeberger PM. Long-Term Serological Follow-Up of 
Acute Q-Fever PaƟ ents aŌ er a Large Epidemic. PloS one, 2015. 10(7), e0131848.
Morroy G, Wielders CC, Kruisbergen MJ, van der Hoek W, Marcelis JH, Wegdam-Blans MC, CJ 
Wijkmans, Schneeberger PM. Large regional diﬀ erences in serological follow-up of q Fever pa-
Ɵ ents in the Netherlands. PloS ONE, 2013, 8(4), e60707. DOI:10.1371/journal.pone.0060707.
Wielders CC, Morroy G, Wever PC, CouƟ nho RA, Schneeberger PM, & Hoek W. Strategies for 
early detecƟ on of chronic Q fever: a systemaƟ c review. European journal of clinical invesƟ ga-
Ɵ on, 2013. 43(6), 616-639. DOI:10.1111/eci.12073.
van der Hoek W, Morroy G, Renders NH, Wever PC, Hermans MH, Leenders AC, & Schnee-
berger PM. Epidemic Q fever in humans in the Netherlands. In Coxiella burneƟ i: Recent 
Advances and New PerspecƟ ves in Research of the Q Fever Bacterium (pp. 329-364). 2012 
Springer Netherlands.
List of publicaƟ ons  |  273
11
Morroy G, Prins J, Bergevoet R, Schneeberger P, Bor HHJ, Van Der Hoek W, J Hautvast, CJ 
Wijkmans, JB Peters. & Polder JJ. Of goats and humans; the societal costs of the Dutch Q fever 
saga. InternaƟ onal Journal of InfecƟ ous Diseases, 2012,16, e266.
Morroy G, Bor HH, Polder J, Hautvast JL, Van Der Hoek W, Schneeberger PM, & Wijkmans CJ. 
Self-reported sick leave and long-term health symptoms of Q-fever paƟ ents. European Journal 
of Public Health.2012; 22(6) 814–819 DOI: 10.1093/eurpub/cks003
Morroy G, Peters JB, van Nieuwenhof M, Bor HH, Hautvast JL, van der Hoek W, CJ Wijkmans & 
Vercoulen JH. The health status of Q-fever paƟ ents aŌ er long-term follow-up. BMC infecƟ ous 
diseases, 2011, 11(1), 97. DOI:10.1186/1471-2334-11-97
Keijmel SP and Morroy G, Delsing CE, Bleijenberg G, Bleeker-Rovers CP, & Timen A(2011). 
[Persistent faƟ gue following Q fever]. Nederlands Ɵ jdschriŌ  voor geneeskunde, 156(48), 
A5258-A5258.
Dijkstra F, Riphagen-Dalhuisen J, Wijers N, Hak E, van der Sande MAB, Morroy G, PM Schnee-
berger, B Schimmer, DW Notermans & Van der Hoek W. AnƟ bioƟ c therapy for acute Q fever 
in The Netherlands in 2007 and 2008 and its relaƟ on to hospitalizaƟ on. Epidemiology and 
infecƟ on, 2011,139(09), 1332-1341.
Schimmer B, Morroy G, Dijkstra F, Schneeberger PM, Weers-Pothoﬀ  G, Timen A, Wijkmans C 
& Van Der Hoek W. Large ongoing Q fever outbreak in the south of The Netherlands, 2008. 
Euro surveillance: bulleƟ n Européen sur les maladies transmissibles.2008. European com-
municable disease bulleƟ n, 13(31).
Van Steenbergen JE, Morroy G, Groot CA, Ruikes FG, Marcelis JH, & Speelman P. [An outbreak 
of Q fever in The Netherlands--possible link to goats]. Nederlands Ɵ jdschriŌ  voor geneeskunde. 
2007. 151(36), 1998-2003.
Karagiannis I, Morroy G, Rietveld A, Horrevorts AM, Hamans M, Francken P, Schimmer B. Q 
fever outbreak in the Netherlands: a preliminary report. Euro Surveill.2007.12(Pt 32), 3247.
Other subjects
De GiusƟ  M, Marinelli L, Aurigemma C, Tuﬁ  D, Mannocci A, Solimini AG, C Marzuillo, Morroy G 
& La Torre G. Prevalence of Staphylococcus aureus colonizaƟ on and anƟ bioƟ c suscepƟ bility: 
A survey among biomedical students. Public health.2013 127(4), 392-394.
274  |  CHAPTER 11
Bruggeman I, Morroy G, van Hoeven-Dekkers S, & Weel A. INFECTIEZIEKTEN EN ARBEID. 
TijdschriŌ  voor bedrijfs-en verzekeringsgeneeskunde, 2012. 20(3), 115-119.
Ladbury G, Morroy G, Hoeven-Dekkers SV, Botermans C, Veelenturf C, BasƟ aens M, Cees van 
Abeelen & Wijkmans C. An outbreak of scabies in mulƟ ple linked healthcare seƫ  ngs in The 
Netherlands. InfecƟ on Control.2012. 33(10), 1047-1050.
Heijne JC, Teunis P, Morroy G, Wijkmans C, Oostveen S, Duizer E, Mirjam Kretzschmar & Wall-
inga J. Enhanced hygiene measures and norovirus transmission during an outbreak. Emerging 
infecƟ ous diseases. 2009. 15(1), 24.
Friesema IHM, Vennema H, Heijne JCM, de Jager CM, Morroy G, van den Kerkhof JHTC, 
EJM de Coster, BA Wolters, HLG ter Waarbeek, EB Fanoy, PFM Teunis, R van der Linde & van 
Duynhoven YTHP. Norovirus outbreaks in nursing homes: the evaluaƟ on of infecƟ on control 
measures. Epidemiology and InfecƟ on.2009. 137(12), 1722-1733.
Huijsdens XW, Janssen M, Renders NH, Leenders A, Van Wijk P, van Santen-Verheuvel MG, 
Jolanda Koel van-Driel, & Morroy G. Methicillin-resistant Staphylococcus aureus in a beauty 
salon, the Netherlands. Emerging infecƟ ous diseases.2008.14(11), 1797.
Morroy G, Renders NHM, & Timen A. Een cluster van PVl-posiƟ eve community associated-
MRSA rond een schoonheidsspecialiste. InfecƟ eziekten BulleƟ n.2007. 18(7), 232-233.
Dillingh SJ, Jira P, Morroy G, Wolters B, Beutler J, & Schneeberger PM. [Two paƟ ents with 
Hantavirus infecƟ on in The Netherlands; substanƟ al increase in incidence in neighbouring 
countries]. Nederlands Ɵ jdschriŌ  voor geneeskunde.2006.150(23), 1303-1306.
Duizer E, Timen A, Morroy G, & de Roda Husman AM. Norovirus outbreak at an internaƟ onal 
scout jamboree in the Netherlands, July-August 2004: internaƟ onal alert. Euro Surveill, 2004. 
8(33), 2523.
van der Sande M, Ruijs H, Cools H, Meijer A, van der Plas S, & Morroy G. Inﬂ uenza uitbraken in 
verpleeghuizen 2004–2005. TijdschriŌ  voor VerpleeghuisGeneeskunde.2005. 30(4), 125-128.


 CHAPTER 12
Fact sheet Q-fever
12

Fact sheet Q-fever  |  279
12
FACT SHEET Q-FEVER
The bacterium Coxiella burneƟ i
In 1937, Derrick ﬁ rst described an outbreak of febrile illness in abaƩ oir workers in Queensland, 
Australia. The causaƟ ve pathogen was unknown and he called the symptom complex Q-fever 
(Q for query). The pathogen was independently isolated by Burnet from a paƟ ent via a guinea 
pig (Australia) and Cox in Ɵ cks (USA). IniƟ ally named RickeƩ sia burneƟ i the pathogen was 
renamed Coxiella burneƟ i (C. burneƟ i), in order to honour both Cox and Burnet. Q-fever is a 
zoonosis caused by C. burneƟ i a Gram negaƟ ve obligate intracellular highly resistant bacte-
rium, with a worldwide occurrence, except New Zealand. DomesƟ c ruminants are the main 
reservoir, although rodents, birds and arthropods can also be infected.
IncubaƟ on period
The incubaƟ on period varies from two to 48 days but is on average 14 to 24 days.
Transmission
InfecƟ on of humans occurs mainly aŌ er inhalaƟ on of contaminated aerosols. During the 
Dutch outbreak the risk of infecƟ on was increased up to 5 km around goat farms that had 
experienced aborƟ on storms due to C burneƟ i. C. burneƟ i is highly infecƟ ous as one organism 
can cause infecƟ on.
Pathogenesis
The inhaled bacteriae are phagocyƟ sed by alveolar macrophages in the lungs. Infected mac-
rophages transport C. burneƟ i through the blood stream. Cellular and humoral immunologi-
cal responses are both involved in the defence.
Clinical expression
IniƟ al infecƟ on
The majority approx. 60% of infected individuals are asymptomaƟ c. The clinical manifesta-
Ɵ ons of the 40% symptomaƟ c individuals vary from mild ﬂ u like symptoms with fever and 
headache to more severe manifestaƟ ons in the remaining 20% with atypical pneumonia. 
Peri- and myo cardiƟ s, meningiƟ s and meningo encephaliƟ s, disorientaƟ on, vascular and 
osteoarƟ cular infecƟ ons are among the many diﬀ erent manifestaƟ ons. In the Netherlands, 
pneumonia was a common presentaƟ on of acute Q-fever while hepaƟ Ɵ s was rarely observed. 
In general the infecƟ on is self-limiƟ ng aŌ er one to two weeks.
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Long-term sequels
1. Chronic Q-fever
AŌ er a symptomaƟ c or asymptomaƟ c infecƟ on with C. burneƟ i the immune system might be 
unable to clear the infecƟ on. The infecƟ on might ﬂ are up and cause a chronic infecƟ on. Chronic 
Q-fever develops in approximately 2% of Q-fever infecƟ ons and can be detected months—or 
even years—aŌ er the iniƟ al infecƟ on, which was either symptomaƟ c or asymptomaƟ c. Risk 
factors include pre-exisƟ ng cardiac valvulopathy, vascular graŌ , aneurysm, immuno-suppres-
sion and pregnancy. Chronic Q-fever is the most serious complicaƟ on of Q-fever and can lead 
to endocardiƟ s, an infected aneurysm or vascular graŌ , causing high morbidity and mortality 
even if opƟ mal and Ɵ mely treatment is received. Chronic Q-fever is not noƟ ﬁ able, therefore 
precise numbers are unavailable; however, up to May 2012, 284 paƟ ents were voluntarily 
registered into a database as part of a research project run by the University Medical Center 
Utrecht. For early detecƟ on of chronic Q-fever, paƟ ents should have at least one serological 
examinaƟ on and a clinical evaluaƟ on within one year following the acute infecƟ on.
2. FaƟ gue aŌ er Q-fever
FaƟ gue can persist aŌ er Q-fever, accompanied by a host of other a speciﬁ c symptoms such 
as headache, disturbed sleep, night sweats, myalgia, arthralgia and blurred vision. Some 
call this syndrome the Q-fever FaƟ gue Syndrome (QFS) but there are no uniform diagnosƟ c 
criteria. Similar post infecƟ ous faƟ gue syndromes (PIFS) are described aŌ er other infecƟ ons 
for example with River Ross virus, Epstein-Barr virus and Legionella pneumophila. Although 
the aeƟ ology of QFS remains unknown, factors such as geneƟ c predisposiƟ on, the hosts’ 
immune response, the severity of the acute illness and or biopsychology could play a role. 
Five to ten years aŌ er the onset of illness up to 68% of paƟ ents report faƟ gue of which QFS 
may be up to 42%.
Treatment
The ﬁ rst choice of treatment for acute Q-fever is doxycycline (200mg/day for 14 days), whereas 
chronic Q-fever needs to be treated with 18-24 months of doxycycline in combinaƟ on with 
hydroxychloroquine. The most eﬀ ecƟ ve treatment for QFS has not been established.
Diagnosis
During approximately the ﬁ rst two weeks aŌ er the onset of illness C. burneƟ i DNA may be de-
tected with a Polymerase Chain ReacƟ on (PCR) test. As the anƟ body response starts aŌ er one 
to two weeks, the PCR becomes negaƟ ve and serology is the only way to diagnose infecƟ on. 
Common tests are; the complement ﬁ xaƟ on test (CFT), the Enzyme-Linked Immunosorbent 
Assay (ELISA) and the indirect immunoﬂ uorescence assay (IFA). The IFA is considered the 
reference method, with IgG phase II anƟ gen Ɵ tres larger than IgG phase I during the acute 
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phase of illness. In early acute sera, IgM phase II Ɵ tres may be higher and appear even sooner 
than IgG phase II. In general seroconversion or a fourfold Ɵ tre increase are diagnosƟ c for 
recent infecƟ ons.
NoƟ ﬁ caƟ on and the Q-fever outbreak in the Netherlands
In the Netherlands Q-fever became noƟ ﬁ able in 1975. Annually an average of 17 cases was 
noƟ ﬁ ed. NoƟ ﬁ caƟ on criteria used at the beginning of the outbreak in 2007 were: a laboratory 
conﬁ rmaƟ on and matching clinical symptoms. In July 2008 noƟ ﬁ caƟ on criteria were changed 
to; the presence of fever, pneumonia or hepaƟ Ɵ s plus a laboratory conﬁ rmaƟ on and noƟ ﬁ ed 
to the MHS within 90 days following the onset of illness. At least one of the following labora-
tory criteria also had to be met: an IFA or a Complement FixaƟ on Test (CFT) seroconversion or 
fourfold or larger C. burneƟ i IgG-anƟ body Ɵ tre increase in paired sera (minimally two weeks 
apart) or presence of IgM-Phase II anƟ bodies or a posiƟ ve C. burneƟ i PCR (unless the sample 
is from a paƟ ent with chronic Q-fever).
From 2007-2010 the largest described Q-fever outbreak ever took place in the Nether-
lands. In this period, 4,026 cases were noƟ ﬁ ed. The esƟ maƟ on is that 10 to 12 Ɵ mes more 
people became infected. These data are based on seroprevalence data and informaƟ on 
from the blood bank in a high incidence area. This is not surprising as most infecƟ ons were 
asymptomaƟ c and some symptomaƟ c cases might not have been diagnosed or did not ﬁ t 
the noƟ ﬁ caƟ on criteria. See ﬁ gure 1 for the geographical spread of the outbreak in Ɵ me and 
ﬁ gure 2 for the number of noƟ ﬁ caƟ ons in Ɵ me.
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Figure 1.Incidence of noƟ ﬁ ed Q-fever cases per municipality per year.
Figure 2.Municipal Health service Q-fever noƟ ﬁ caƟ ons n= 4.220 from 2007 up to 2014 according to 
month and year of noƟ ﬁ caƟ on, by Hart voor Brabant and other Municipal Health services.
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